0	The	_	_	O
1	addition	_	_	O
2	of	_	_	O
3	mTOR	_	_	O
4	inhibitor	_	_	O
5	everolimus	_	_	O
6	(	_	_	O
7	EVE	_	_	O
8	)	_	_	O
9	to	_	_	O
10	exemestane	_	_	O
11	(	_	_	O
12	EXE	_	_	O
13	)	_	_	O
14	was	_	_	O
15	evaluated	_	_	O
16	in	_	_	O
17	an	_	_	O
18	international	_	_	O
19	,	_	_	O
20	phase	_	_	O
21	3	_	_	O
22	study	_	_	O
23	(	_	_	O
24	BOLERO	_	_	O
25	-	_	_	O
26	2	_	_	O
27	)	_	_	O
28	in	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	hormone	_	_	O
32	-	_	_	O
33	receptor	_	_	O
34	-	_	_	O
35	positive	_	_	O
36	(	_	_	O
37	HR	_	_	O
38	(	_	_	O
39	+	_	_	O
40	)	_	_	O
41	)	_	_	O
42	breast	_	_	O
43	cancer	_	_	O
44	refractory	_	_	O
45	to	_	_	O
46	letrozole	_	_	O
47	or	_	_	O
48	anastrozole	_	_	O
49	.	_	_	O

50	The	_	_	O
51	safety	_	_	O
52	and	_	_	O
53	efficacy	_	_	O
54	of	_	_	O
55	anticancer	_	_	O
56	treatments	_	_	O
57	may	_	_	O
58	be	_	_	O
59	influenced	_	_	O
60	by	_	_	O
61	ethnicity	_	_	O
62	(	_	_	O
63	Sekine	_	_	O
64	et	_	_	O
65	al	_	_	O
66	.	_	_	O

67	in	_	_	O
68	Br	_	_	O
69	J	_	_	O
70	Cancer	_	_	O
71	99	_	_	O
72	:	_	_	O
73	1757	_	_	O
74	-	_	_	O
75	62	_	_	O
76	,	_	_	O
77	2008	_	_	O
78	)	_	_	O
79	.	_	_	O

80	Safety	_	_	O
81	and	_	_	O
82	efficacy	_	_	O
83	results	_	_	O
84	from	_	_	O
85	Asian	_	_	O
86	versus	_	_	O
87	non	_	_	O
88	-	_	_	O
89	Asian	_	_	O
90	patients	_	_	O
91	in	_	_	O
92	BOLERO	_	_	O
93	-	_	_	O
94	2	_	_	O
95	are	_	_	O
96	reported	_	_	O
97	.	_	_	O

98	Patients	_	_	O
99	were	_	_	O
100	randomized	_	_	O
101	(	_	_	O
102	2	_	_	O
103	:	_	_	O
104	1	_	_	O
105	)	_	_	O
106	to	_	_	O
107	10	_	_	O
108	mg	_	_	O
109	/	_	_	O
110	day	_	_	O
111	EVE	_	_	O
112	+	_	_	O
113	EXE	_	_	O
114	or	_	_	O
115	placebo	_	_	O
116	(	_	_	O
117	PBO	_	_	O
118	)	_	_	O
119	+	_	_	O
120	EXE	_	_	O
121	.	_	_	O

122	Primary	_	_	O
123	endpoint	_	_	O
124	was	_	_	O
125	progression	_	_	O
126	-	_	_	O
127	free	_	_	O
128	survival	_	_	O
129	(	_	_	O
130	PFS	_	_	O
131	)	_	_	O
132	.	_	_	O

133	Secondary	_	_	O
134	endpoints	_	_	O
135	included	_	_	O
136	overall	_	_	O
137	survival	_	_	O
138	,	_	_	O
139	response	_	_	O
140	rate	_	_	O
141	,	_	_	O
142	clinical	_	_	O
143	benefit	_	_	O
144	rate	_	_	O
145	,	_	_	O
146	and	_	_	O
147	safety	_	_	O
148	.	_	_	O

149	Of	_	_	O
150	143	_	_	O
151	Asian	_	_	O
152	patients	_	_	O
153	,	_	_	O
154	98	_	_	O
155	received	_	_	O
156	EVE	_	_	O
157	+	_	_	O
158	EXE	_	_	O
159	and	_	_	O
160	45	_	_	O
161	received	_	_	O
162	PBO	_	_	O
163	+	_	_	O
164	EXE	_	_	O
165	.	_	_	O

166	Treatment	_	_	B-Premise
167	with	_	_	I-Premise
168	EVE	_	_	I-Premise
169	+	_	_	I-Premise
170	EXE	_	_	I-Premise
171	significantly	_	_	I-Premise
172	improved	_	_	I-Premise
173	median	_	_	I-Premise
174	PFS	_	_	I-Premise
175	versus	_	_	I-Premise
176	PBO	_	_	I-Premise
177	+	_	_	I-Premise
178	EXE	_	_	I-Premise
179	among	_	_	I-Premise
180	Asian	_	_	I-Premise
181	patients	_	_	I-Premise
182	by	_	_	I-Premise
183	38	_	_	I-Premise
184	%	_	_	I-Premise
185	(	_	_	I-Premise
186	HR	_	_	I-Premise
187	=	_	_	I-Premise
188	0	_	_	I-Premise
189	.	_	_	I-Premise

190	62	_	_	I-Premise
191	;	_	_	I-Premise
192	95	_	_	I-Premise
193	%	_	_	I-Premise
194	CI	_	_	I-Premise
195	,	_	_	I-Premise
196	0	_	_	I-Premise
197	.	_	_	I-Premise

198	41	_	_	I-Premise
199	-	_	_	I-Premise
200	0	_	_	I-Premise
201	.	_	_	I-Premise

202	94	_	_	I-Premise
203	)	_	_	I-Premise
204	.	_	_	I-Premise

205	Median	_	_	B-Premise
206	PFS	_	_	I-Premise
207	was	_	_	I-Premise
208	also	_	_	I-Premise
209	improved	_	_	I-Premise
210	among	_	_	I-Premise
211	non	_	_	I-Premise
212	-	_	_	I-Premise
213	Asian	_	_	I-Premise
214	patients	_	_	I-Premise
215	by	_	_	I-Premise
216	59	_	_	I-Premise
217	%	_	_	I-Premise
218	(	_	_	I-Premise
219	HR	_	_	I-Premise
220	=	_	_	I-Premise
221	0	_	_	I-Premise
222	.	_	_	I-Premise

223	41	_	_	I-Premise
224	;	_	_	I-Premise
225	95	_	_	I-Premise
226	%	_	_	I-Premise
227	CI	_	_	I-Premise
228	,	_	_	I-Premise
229	0	_	_	I-Premise
230	.	_	_	I-Premise

231	33	_	_	I-Premise
232	-	_	_	I-Premise
233	0	_	_	I-Premise
234	.	_	_	I-Premise

235	50	_	_	I-Premise
236	)	_	_	I-Premise
237	.	_	_	I-Premise

238	Median	_	_	B-Premise
239	PFS	_	_	I-Premise
240	duration	_	_	I-Premise
241	among	_	_	I-Premise
242	EVE	_	_	I-Premise
243	-	_	_	I-Premise
244	treated	_	_	I-Premise
245	Asian	_	_	I-Premise
246	patients	_	_	I-Premise
247	was	_	_	I-Premise
248	8	_	_	I-Premise
249	.	_	_	I-Premise

250	48	_	_	I-Premise
251	versus	_	_	I-Premise
252	4	_	_	I-Premise
253	.	_	_	I-Premise

254	14	_	_	I-Premise
255	months	_	_	I-Premise
256	for	_	_	I-Premise
257	PBO	_	_	I-Premise
258	+	_	_	I-Premise
259	EXE	_	_	I-Premise
260	,	_	_	I-Premise
261	and	_	_	I-Premise
262	7	_	_	I-Premise
263	.	_	_	I-Premise

264	33	_	_	I-Premise
265	versus	_	_	I-Premise
266	2	_	_	I-Premise
267	.	_	_	I-Premise

268	83	_	_	I-Premise
269	months	_	_	I-Premise
270	,	_	_	I-Premise
271	respectively	_	_	I-Premise
272	,	_	_	I-Premise
273	in	_	_	I-Premise
274	non	_	_	I-Premise
275	-	_	_	I-Premise
276	Asian	_	_	I-Premise
277	patients	_	_	I-Premise
278	.	_	_	I-Premise

279	The	_	_	B-Premise
280	most	_	_	I-Premise
281	common	_	_	I-Premise
282	grade	_	_	I-Premise
283	3	_	_	I-Premise
284	/	_	_	I-Premise
285	4	_	_	I-Premise
286	adverse	_	_	I-Premise
287	events	_	_	I-Premise
288	(	_	_	I-Premise
289	stomatitis	_	_	I-Premise
290	,	_	_	I-Premise
291	anemia	_	_	I-Premise
292	,	_	_	I-Premise
293	elevated	_	_	I-Premise
294	liver	_	_	I-Premise
295	enzymes	_	_	I-Premise
296	,	_	_	I-Premise
297	hyperglycemia	_	_	I-Premise
298	,	_	_	I-Premise
299	and	_	_	I-Premise
300	dyspnea	_	_	I-Premise
301	)	_	_	I-Premise
302	occurred	_	_	I-Premise
303	at	_	_	I-Premise
304	similar	_	_	I-Premise
305	frequencies	_	_	I-Premise
306	in	_	_	I-Premise
307	Asian	_	_	I-Premise
308	and	_	_	I-Premise
309	non	_	_	I-Premise
310	-	_	_	I-Premise
311	Asian	_	_	I-Premise
312	patients	_	_	I-Premise
313	.	_	_	I-Premise

314	Grade	_	_	B-Premise
315	1	_	_	I-Premise
316	/	_	_	I-Premise
317	2	_	_	I-Premise
318	interstitial	_	_	I-Premise
319	lung	_	_	I-Premise
320	disease	_	_	I-Premise
321	occurred	_	_	I-Premise
322	more	_	_	I-Premise
323	frequently	_	_	I-Premise
324	in	_	_	I-Premise
325	Asian	_	_	I-Premise
326	patients	_	_	I-Premise
327	.	_	_	I-Premise

328	Quality	_	_	B-Premise
329	of	_	_	I-Premise
330	life	_	_	I-Premise
331	was	_	_	I-Premise
332	similar	_	_	I-Premise
333	between	_	_	I-Premise
334	treatment	_	_	I-Premise
335	arms	_	_	I-Premise
336	in	_	_	I-Premise
337	Asian	_	_	I-Premise
338	patients	_	_	I-Premise
339	.	_	_	I-Premise

340	Adding	_	_	B-Claim
341	EVE	_	_	I-Claim
342	to	_	_	I-Claim
343	EXE	_	_	I-Claim
344	provided	_	_	I-Claim
345	substantial	_	_	I-Claim
346	clinical	_	_	I-Claim
347	benefit	_	_	I-Claim
348	in	_	_	I-Claim
349	both	_	_	I-Claim
350	Asian	_	_	I-Claim
351	and	_	_	I-Claim
352	non	_	_	I-Claim
353	-	_	_	I-Claim
354	Asian	_	_	I-Claim
355	patients	_	_	I-Claim
356	with	_	_	I-Claim
357	similar	_	_	I-Claim
358	safety	_	_	I-Claim
359	profiles	_	_	I-Claim
360	.	_	_	I-Claim

361	This	_	_	B-Claim
362	combination	_	_	I-Claim
363	represents	_	_	I-Claim
364	an	_	_	I-Claim
365	improvement	_	_	I-Claim
366	in	_	_	I-Claim
367	the	_	_	I-Claim
368	management	_	_	I-Claim
369	of	_	_	I-Claim
370	postmenopausal	_	_	I-Claim
371	women	_	_	I-Claim
372	with	_	_	I-Claim
373	HR	_	_	I-Claim
374	(	_	_	I-Claim
375	+	_	_	I-Claim
376	)	_	_	I-Claim
377	/	_	_	I-Claim
378	HER2	_	_	I-Claim
379	(	_	_	I-Claim
380	-	_	_	I-Claim
381	)	_	_	I-Claim
382	advanced	_	_	I-Claim
383	breast	_	_	I-Claim
384	cancer	_	_	I-Claim
385	progressing	_	_	I-Claim
386	on	_	_	I-Claim
387	nonsteroidal	_	_	I-Claim
388	aromatase	_	_	I-Claim
389	inhibitors	_	_	I-Claim
390	,	_	_	I-Claim
391	regardless	_	_	I-Claim
392	of	_	_	I-Claim
393	ethnicity	_	_	I-Claim
394	.	_	_	I-Claim


0	Most	_	_	O
1	patients	_	_	O
2	with	_	_	O
3	glioblastoma	_	_	O
4	are	_	_	O
5	older	_	_	O
6	than	_	_	O
7	60	_	_	O
8	years	_	_	O
9	,	_	_	O
10	but	_	_	O
11	treatment	_	_	O
12	guidelines	_	_	O
13	are	_	_	O
14	based	_	_	O
15	on	_	_	O
16	trials	_	_	O
17	in	_	_	O
18	patients	_	_	O
19	aged	_	_	O
20	only	_	_	O
21	up	_	_	O
22	to	_	_	O
23	70	_	_	O
24	years	_	_	O
25	.	_	_	O

26	We	_	_	O
27	did	_	_	O
28	a	_	_	O
29	randomised	_	_	O
30	trial	_	_	O
31	to	_	_	O
32	assess	_	_	O
33	the	_	_	O
34	optimum	_	_	O
35	palliative	_	_	O
36	treatment	_	_	O
37	in	_	_	O
38	patients	_	_	O
39	aged	_	_	O
40	60	_	_	O
41	years	_	_	O
42	and	_	_	O
43	older	_	_	O
44	with	_	_	O
45	glioblastoma	_	_	O
46	.	_	_	O

47	Patients	_	_	O
48	with	_	_	O
49	newly	_	_	O
50	diagnosed	_	_	O
51	glioblastoma	_	_	O
52	were	_	_	O
53	recruited	_	_	O
54	from	_	_	O
55	Austria	_	_	O
56	,	_	_	O
57	Denmark	_	_	O
58	,	_	_	O
59	France	_	_	O
60	,	_	_	O
61	Norway	_	_	O
62	,	_	_	O
63	Sweden	_	_	O
64	,	_	_	O
65	Switzerland	_	_	O
66	,	_	_	O
67	and	_	_	O
68	Turkey	_	_	O
69	.	_	_	O

70	They	_	_	O
71	were	_	_	O
72	assigned	_	_	O
73	by	_	_	O
74	a	_	_	O
75	computer	_	_	O
76	-	_	_	O
77	generated	_	_	O
78	randomisation	_	_	O
79	schedule	_	_	O
80	,	_	_	O
81	stratified	_	_	O
82	by	_	_	O
83	centre	_	_	O
84	,	_	_	O
85	to	_	_	O
86	receive	_	_	O
87	temozolomide	_	_	O
88	(	_	_	O
89	200	_	_	O
90	mg	_	_	O
91	/	_	_	O
92	m	_	_	O
93	(	_	_	O
94	2	_	_	O
95	)	_	_	O
96	on	_	_	O
97	days	_	_	O
98	1	_	_	O
99	-	_	_	O
100	5	_	_	O
101	of	_	_	O
102	every	_	_	O
103	28	_	_	O
104	days	_	_	O
105	for	_	_	O
106	up	_	_	O
107	to	_	_	O
108	six	_	_	O
109	cycles	_	_	O
110	)	_	_	O
111	,	_	_	O
112	hypofractionated	_	_	O
113	radiotherapy	_	_	O
114	(	_	_	O
115	34	_	_	O
116	·	_	_	O
117	0	_	_	O
118	Gy	_	_	O
119	administered	_	_	O
120	in	_	_	O
121	3	_	_	O
122	·	_	_	O
123	4	_	_	O
124	Gy	_	_	O
125	fractions	_	_	O
126	over	_	_	O
127	2	_	_	O
128	weeks	_	_	O
129	)	_	_	O
130	,	_	_	O
131	or	_	_	O
132	standard	_	_	O
133	radiotherapy	_	_	O
134	(	_	_	O
135	60	_	_	O
136	·	_	_	O
137	0	_	_	O
138	Gy	_	_	O
139	administered	_	_	O
140	in	_	_	O
141	2	_	_	O
142	·	_	_	O
143	0	_	_	O
144	Gy	_	_	O
145	fractions	_	_	O
146	over	_	_	O
147	6	_	_	O
148	weeks	_	_	O
149	)	_	_	O
150	.	_	_	O

151	Patients	_	_	O
152	and	_	_	O
153	study	_	_	O
154	staff	_	_	O
155	were	_	_	O
156	aware	_	_	O
157	of	_	_	O
158	treatment	_	_	O
159	assignment	_	_	O
160	.	_	_	O

161	The	_	_	O
162	primary	_	_	O
163	endpoint	_	_	O
164	was	_	_	O
165	overall	_	_	O
166	survival	_	_	O
167	.	_	_	O

168	Analyses	_	_	O
169	were	_	_	O
170	done	_	_	O
171	by	_	_	O
172	intention	_	_	O
173	to	_	_	O
174	treat	_	_	O
175	.	_	_	O

176	This	_	_	O
177	trial	_	_	O
178	is	_	_	O
179	registered	_	_	O
180	,	_	_	O
181	number	_	_	O
182	ISRCTN81470623	_	_	O
183	.	_	_	O

184	342	_	_	O
185	patients	_	_	O
186	were	_	_	O
187	enrolled	_	_	O
188	,	_	_	O
189	of	_	_	O
190	whom	_	_	O
191	291	_	_	O
192	were	_	_	O
193	randomised	_	_	O
194	across	_	_	O
195	three	_	_	O
196	treatment	_	_	O
197	groups	_	_	O
198	(	_	_	O
199	temozolomide	_	_	O
200	n	_	_	O
201	=	_	_	O
202	93	_	_	O
203	,	_	_	O
204	hypofractionated	_	_	O
205	radiotherapy	_	_	O
206	n	_	_	O
207	=	_	_	O
208	98	_	_	O
209	,	_	_	O
210	standard	_	_	O
211	radiotherapy	_	_	O
212	n	_	_	O
213	=	_	_	O
214	100	_	_	O
215	)	_	_	O
216	and	_	_	O
217	51	_	_	O
218	of	_	_	O
219	whom	_	_	O
220	were	_	_	O
221	randomised	_	_	O
222	across	_	_	O
223	only	_	_	O
224	two	_	_	O
225	groups	_	_	O
226	(	_	_	O
227	temozolomide	_	_	O
228	n	_	_	O
229	=	_	_	O
230	26	_	_	O
231	,	_	_	O
232	hypofractionated	_	_	O
233	radiotherapy	_	_	O
234	n	_	_	O
235	=	_	_	O
236	25	_	_	O
237	)	_	_	O
238	.	_	_	O

239	In	_	_	B-Premise
240	the	_	_	I-Premise
241	three	_	_	I-Premise
242	-	_	_	I-Premise
243	group	_	_	I-Premise
244	randomisation	_	_	I-Premise
245	,	_	_	I-Premise
246	in	_	_	I-Premise
247	comparison	_	_	I-Premise
248	with	_	_	I-Premise
249	standard	_	_	I-Premise
250	radiotherapy	_	_	I-Premise
251	,	_	_	I-Premise
252	median	_	_	I-Premise
253	overall	_	_	I-Premise
254	survival	_	_	I-Premise
255	was	_	_	I-Premise
256	significantly	_	_	I-Premise
257	longer	_	_	I-Premise
258	with	_	_	I-Premise
259	temozolomide	_	_	I-Premise
260	(	_	_	I-Premise
261	8	_	_	I-Premise
262	·	_	_	I-Premise
263	3	_	_	I-Premise
264	months	_	_	I-Premise
265	[	_	_	I-Premise
266	95	_	_	I-Premise
267	%	_	_	I-Premise
268	CI	_	_	I-Premise
269	7	_	_	I-Premise
270	·	_	_	I-Premise
271	1	_	_	I-Premise
272	-	_	_	I-Premise
273	9	_	_	I-Premise
274	·	_	_	I-Premise
275	5	_	_	I-Premise
276	;	_	_	I-Premise
277	n	_	_	I-Premise
278	=	_	_	I-Premise
279	93	_	_	I-Premise
280	]	_	_	I-Premise
281	vs	_	_	I-Premise
282	6	_	_	I-Premise
283	·	_	_	I-Premise
284	0	_	_	I-Premise
285	months	_	_	I-Premise
286	[	_	_	I-Premise
287	95	_	_	I-Premise
288	%	_	_	I-Premise
289	CI	_	_	I-Premise
290	5	_	_	I-Premise
291	·	_	_	I-Premise
292	1	_	_	I-Premise
293	-	_	_	I-Premise
294	6	_	_	I-Premise
295	·	_	_	I-Premise
296	8	_	_	I-Premise
297	;	_	_	I-Premise
298	n	_	_	I-Premise
299	=	_	_	I-Premise
300	100	_	_	I-Premise
301	]	_	_	I-Premise
302	,	_	_	I-Premise
303	hazard	_	_	I-Premise
304	ratio	_	_	I-Premise
305	[	_	_	I-Premise
306	HR	_	_	I-Premise
307	]	_	_	I-Premise
308	0	_	_	I-Premise
309	·	_	_	I-Premise
310	70	_	_	I-Premise
311	;	_	_	I-Premise
312	95	_	_	I-Premise
313	%	_	_	I-Premise
314	CI	_	_	I-Premise
315	0	_	_	I-Premise
316	·	_	_	I-Premise
317	52	_	_	I-Premise
318	-	_	_	I-Premise
319	0	_	_	I-Premise
320	·	_	_	I-Premise
321	93	_	_	I-Premise
322	,	_	_	I-Premise
323	p	_	_	I-Premise
324	=	_	_	I-Premise
325	0	_	_	I-Premise
326	·	_	_	I-Premise
327	01	_	_	I-Premise
328	)	_	_	I-Premise
329	,	_	_	I-Premise
330	but	_	_	I-Premise
331	not	_	_	I-Premise
332	with	_	_	I-Premise
333	hypofractionated	_	_	I-Premise
334	radiotherapy	_	_	I-Premise
335	(	_	_	I-Premise
336	7	_	_	I-Premise
337	·	_	_	I-Premise
338	5	_	_	I-Premise
339	months	_	_	I-Premise
340	[	_	_	I-Premise
341	6	_	_	I-Premise
342	·	_	_	I-Premise
343	5	_	_	I-Premise
344	-	_	_	I-Premise
345	8	_	_	I-Premise
346	·	_	_	I-Premise
347	6	_	_	I-Premise
348	;	_	_	I-Premise
349	n	_	_	I-Premise
350	=	_	_	I-Premise
351	98	_	_	I-Premise
352	]	_	_	I-Premise
353	,	_	_	I-Premise
354	HR	_	_	I-Premise
355	0	_	_	I-Premise
356	·	_	_	I-Premise
357	85	_	_	I-Premise
358	[	_	_	I-Premise
359	0	_	_	I-Premise
360	·	_	_	I-Premise
361	64	_	_	I-Premise
362	-	_	_	I-Premise
363	1	_	_	I-Premise
364	·	_	_	I-Premise
365	12	_	_	I-Premise
366	]	_	_	I-Premise
367	,	_	_	I-Premise
368	p	_	_	I-Premise
369	=	_	_	I-Premise
370	0	_	_	I-Premise
371	·	_	_	I-Premise
372	24	_	_	I-Premise
373	)	_	_	I-Premise
374	.	_	_	I-Premise

375	For	_	_	B-Premise
376	all	_	_	I-Premise
377	patients	_	_	I-Premise
378	who	_	_	I-Premise
379	received	_	_	I-Premise
380	temozolomide	_	_	I-Premise
381	or	_	_	I-Premise
382	hypofractionated	_	_	I-Premise
383	radiotherapy	_	_	I-Premise
384	(	_	_	I-Premise
385	n	_	_	I-Premise
386	=	_	_	I-Premise
387	242	_	_	I-Premise
388	)	_	_	I-Premise
389	overall	_	_	I-Premise
390	survival	_	_	I-Premise
391	was	_	_	I-Premise
392	similar	_	_	I-Premise
393	(	_	_	I-Premise
394	8	_	_	I-Premise
395	·	_	_	I-Premise
396	4	_	_	I-Premise
397	months	_	_	I-Premise
398	[	_	_	I-Premise
399	7	_	_	I-Premise
400	·	_	_	I-Premise
401	3	_	_	I-Premise
402	-	_	_	I-Premise
403	9	_	_	I-Premise
404	·	_	_	I-Premise
405	4	_	_	I-Premise
406	;	_	_	I-Premise
407	n	_	_	I-Premise
408	=	_	_	I-Premise
409	119	_	_	I-Premise
410	]	_	_	I-Premise
411	vs	_	_	I-Premise
412	7	_	_	I-Premise
413	·	_	_	I-Premise
414	4	_	_	I-Premise
415	months	_	_	I-Premise
416	[	_	_	I-Premise
417	6	_	_	I-Premise
418	·	_	_	I-Premise
419	4	_	_	I-Premise
420	-	_	_	I-Premise
421	8	_	_	I-Premise
422	·	_	_	I-Premise
423	4	_	_	I-Premise
424	;	_	_	I-Premise
425	n	_	_	I-Premise
426	=	_	_	I-Premise
427	123	_	_	I-Premise
428	]	_	_	I-Premise
429	;	_	_	I-Premise
430	HR	_	_	I-Premise
431	0	_	_	I-Premise
432	·	_	_	I-Premise
433	82	_	_	I-Premise
434	,	_	_	I-Premise
435	95	_	_	I-Premise
436	%	_	_	I-Premise
437	CI	_	_	I-Premise
438	0	_	_	I-Premise
439	·	_	_	I-Premise
440	63	_	_	I-Premise
441	-	_	_	I-Premise
442	1	_	_	I-Premise
443	·	_	_	I-Premise
444	06	_	_	I-Premise
445	;	_	_	I-Premise
446	p	_	_	I-Premise
447	=	_	_	I-Premise
448	0	_	_	I-Premise
449	·	_	_	I-Premise
450	12	_	_	I-Premise
451	)	_	_	I-Premise
452	.	_	_	I-Premise

453	For	_	_	B-Premise
454	age	_	_	I-Premise
455	older	_	_	I-Premise
456	than	_	_	I-Premise
457	70	_	_	I-Premise
458	years	_	_	I-Premise
459	,	_	_	I-Premise
460	survival	_	_	I-Premise
461	was	_	_	I-Premise
462	better	_	_	I-Premise
463	with	_	_	I-Premise
464	temozolomide	_	_	I-Premise
465	and	_	_	I-Premise
466	with	_	_	I-Premise
467	hypofractionated	_	_	I-Premise
468	radiotherapy	_	_	I-Premise
469	than	_	_	I-Premise
470	with	_	_	I-Premise
471	standard	_	_	I-Premise
472	radiotherapy	_	_	I-Premise
473	(	_	_	I-Premise
474	HR	_	_	I-Premise
475	for	_	_	I-Premise
476	temozolomide	_	_	I-Premise
477	vs	_	_	I-Premise
478	standard	_	_	I-Premise
479	radiotherapy	_	_	I-Premise
480	0	_	_	I-Premise
481	·	_	_	I-Premise
482	35	_	_	I-Premise
483	[	_	_	I-Premise
484	0	_	_	I-Premise
485	·	_	_	I-Premise
486	21	_	_	I-Premise
487	-	_	_	I-Premise
488	0	_	_	I-Premise
489	·	_	_	I-Premise
490	56	_	_	I-Premise
491	]	_	_	I-Premise
492	,	_	_	I-Premise
493	p	_	_	I-Premise
494	<	_	_	I-Premise
495	0	_	_	I-Premise
496	·	_	_	I-Premise
497	0001	_	_	I-Premise
498	;	_	_	I-Premise
499	HR	_	_	I-Premise
500	for	_	_	I-Premise
501	hypofractionated	_	_	I-Premise
502	vs	_	_	I-Premise
503	standard	_	_	I-Premise
504	radiotherapy	_	_	I-Premise
505	0	_	_	I-Premise
506	·	_	_	I-Premise
507	59	_	_	I-Premise
508	[	_	_	I-Premise
509	95	_	_	I-Premise
510	%	_	_	I-Premise
511	CI	_	_	I-Premise
512	0	_	_	I-Premise
513	·	_	_	I-Premise
514	37	_	_	I-Premise
515	-	_	_	I-Premise
516	0	_	_	I-Premise
517	·	_	_	I-Premise
518	93	_	_	I-Premise
519	]	_	_	I-Premise
520	,	_	_	I-Premise
521	p	_	_	I-Premise
522	=	_	_	I-Premise
523	0	_	_	I-Premise
524	·	_	_	I-Premise
525	02	_	_	I-Premise
526	)	_	_	I-Premise
527	.	_	_	I-Premise

528	Patients	_	_	B-Premise
529	treated	_	_	I-Premise
530	with	_	_	I-Premise
531	temozolomide	_	_	I-Premise
532	who	_	_	I-Premise
533	had	_	_	I-Premise
534	tumour	_	_	I-Premise
535	MGMT	_	_	I-Premise
536	promoter	_	_	I-Premise
537	methylation	_	_	I-Premise
538	had	_	_	I-Premise
539	significantly	_	_	I-Premise
540	longer	_	_	I-Premise
541	survival	_	_	I-Premise
542	than	_	_	I-Premise
543	those	_	_	I-Premise
544	without	_	_	I-Premise
545	MGMT	_	_	I-Premise
546	promoter	_	_	I-Premise
547	methylation	_	_	I-Premise
548	(	_	_	I-Premise
549	9	_	_	I-Premise
550	·	_	_	I-Premise
551	7	_	_	I-Premise
552	months	_	_	I-Premise
553	[	_	_	I-Premise
554	95	_	_	I-Premise
555	%	_	_	I-Premise
556	CI	_	_	I-Premise
557	8	_	_	I-Premise
558	·	_	_	I-Premise
559	0	_	_	I-Premise
560	-	_	_	I-Premise
561	11	_	_	I-Premise
562	·	_	_	I-Premise
563	4	_	_	I-Premise
564	]	_	_	I-Premise
565	vs	_	_	I-Premise
566	6	_	_	I-Premise
567	·	_	_	I-Premise
568	8	_	_	I-Premise
569	months	_	_	I-Premise
570	[	_	_	I-Premise
571	5	_	_	I-Premise
572	·	_	_	I-Premise
573	9	_	_	I-Premise
574	-	_	_	I-Premise
575	7	_	_	I-Premise
576	·	_	_	I-Premise
577	7	_	_	I-Premise
578	]	_	_	I-Premise
579	;	_	_	I-Premise
580	HR	_	_	I-Premise
581	0	_	_	I-Premise
582	·	_	_	I-Premise
583	56	_	_	I-Premise
584	[	_	_	I-Premise
585	95	_	_	I-Premise
586	%	_	_	I-Premise
587	CI	_	_	I-Premise
588	0	_	_	I-Premise
589	·	_	_	I-Premise
590	34	_	_	I-Premise
591	-	_	_	I-Premise
592	0	_	_	I-Premise
593	·	_	_	I-Premise
594	93	_	_	I-Premise
595	]	_	_	I-Premise
596	,	_	_	I-Premise
597	p	_	_	I-Premise
598	=	_	_	I-Premise
599	0	_	_	I-Premise
600	·	_	_	I-Premise
601	02	_	_	I-Premise
602	)	_	_	I-Premise
603	,	_	_	I-Premise
604	but	_	_	I-Premise
605	no	_	_	I-Premise
606	difference	_	_	I-Premise
607	was	_	_	I-Premise
608	noted	_	_	I-Premise
609	between	_	_	I-Premise
610	those	_	_	I-Premise
611	with	_	_	I-Premise
612	methylated	_	_	I-Premise
613	and	_	_	I-Premise
614	unmethylated	_	_	I-Premise
615	MGMT	_	_	I-Premise
616	promoter	_	_	I-Premise
617	treated	_	_	I-Premise
618	with	_	_	I-Premise
619	radiotherapy	_	_	I-Premise
620	(	_	_	I-Premise
621	HR	_	_	I-Premise
622	0	_	_	I-Premise
623	·	_	_	I-Premise
624	97	_	_	I-Premise
625	[	_	_	I-Premise
626	95	_	_	I-Premise
627	%	_	_	I-Premise
628	CI	_	_	I-Premise
629	0	_	_	I-Premise
630	·	_	_	I-Premise
631	69	_	_	I-Premise
632	-	_	_	I-Premise
633	1	_	_	I-Premise
634	·	_	_	I-Premise
635	38	_	_	I-Premise
636	]	_	_	I-Premise
637	;	_	_	I-Premise
638	p	_	_	I-Premise
639	=	_	_	I-Premise
640	0	_	_	I-Premise
641	·	_	_	I-Premise
642	81	_	_	I-Premise
643	)	_	_	I-Premise
644	.	_	_	I-Premise

645	As	_	_	O
646	expected	_	_	O
647	,	_	_	O
648	the	_	_	B-Premise
649	most	_	_	I-Premise
650	common	_	_	I-Premise
651	grade	_	_	I-Premise
652	3	_	_	I-Premise
653	-	_	_	I-Premise
654	4	_	_	I-Premise
655	adverse	_	_	I-Premise
656	events	_	_	I-Premise
657	in	_	_	I-Premise
658	the	_	_	I-Premise
659	temozolomide	_	_	I-Premise
660	group	_	_	I-Premise
661	were	_	_	I-Premise
662	neutropenia	_	_	I-Premise
663	(	_	_	I-Premise
664	n	_	_	I-Premise
665	=	_	_	I-Premise
666	12	_	_	I-Premise
667	)	_	_	I-Premise
668	and	_	_	I-Premise
669	thrombocytopenia	_	_	I-Premise
670	(	_	_	I-Premise
671	n	_	_	I-Premise
672	=	_	_	I-Premise
673	18	_	_	I-Premise
674	)	_	_	I-Premise
675	.	_	_	I-Premise

676	Grade	_	_	B-Premise
677	3	_	_	I-Premise
678	-	_	_	I-Premise
679	5	_	_	I-Premise
680	infections	_	_	I-Premise
681	in	_	_	I-Premise
682	all	_	_	I-Premise
683	randomisation	_	_	I-Premise
684	groups	_	_	I-Premise
685	were	_	_	I-Premise
686	reported	_	_	I-Premise
687	in	_	_	I-Premise
688	18	_	_	I-Premise
689	patients	_	_	I-Premise
690	.	_	_	I-Premise

691	Two	_	_	B-Premise
692	patients	_	_	I-Premise
693	had	_	_	I-Premise
694	fatal	_	_	I-Premise
695	infections	_	_	I-Premise
696	(	_	_	I-Premise
697	one	_	_	I-Premise
698	in	_	_	I-Premise
699	the	_	_	I-Premise
700	temozolomide	_	_	I-Premise
701	group	_	_	I-Premise
702	and	_	_	I-Premise
703	one	_	_	I-Premise
704	in	_	_	I-Premise
705	the	_	_	I-Premise
706	standard	_	_	I-Premise
707	radiotherapy	_	_	I-Premise
708	group	_	_	I-Premise
709	)	_	_	I-Premise
710	and	_	_	I-Premise
711	one	_	_	I-Premise
712	in	_	_	I-Premise
713	the	_	_	I-Premise
714	temozolomide	_	_	I-Premise
715	group	_	_	I-Premise
716	with	_	_	I-Premise
717	grade	_	_	I-Premise
718	2	_	_	I-Premise
719	thrombocytopenia	_	_	I-Premise
720	died	_	_	I-Premise
721	from	_	_	I-Premise
722	complications	_	_	I-Premise
723	after	_	_	I-Premise
724	surgery	_	_	I-Premise
725	for	_	_	I-Premise
726	a	_	_	I-Premise
727	gastrointestinal	_	_	I-Premise
728	bleed	_	_	I-Premise
729	.	_	_	I-Premise

730	Standard	_	_	B-Claim
731	radiotherapy	_	_	I-Claim
732	was	_	_	I-Claim
733	associated	_	_	I-Claim
734	with	_	_	I-Claim
735	poor	_	_	I-Claim
736	outcomes	_	_	I-Claim
737	,	_	_	I-Claim
738	especially	_	_	I-Claim
739	in	_	_	I-Claim
740	patients	_	_	I-Claim
741	older	_	_	I-Claim
742	than	_	_	I-Claim
743	70	_	_	I-Claim
744	years	_	_	I-Claim
745	.	_	_	I-Claim

746	Both	_	_	B-Claim
747	temozolomide	_	_	I-Claim
748	and	_	_	I-Claim
749	hypofractionated	_	_	I-Claim
750	radiotherapy	_	_	I-Claim
751	should	_	_	I-Claim
752	be	_	_	I-Claim
753	considered	_	_	I-Claim
754	as	_	_	I-Claim
755	standard	_	_	I-Claim
756	treatment	_	_	I-Claim
757	options	_	_	I-Claim
758	in	_	_	I-Claim
759	elderly	_	_	I-Claim
760	patients	_	_	I-Claim
761	with	_	_	I-Claim
762	glioblastoma	_	_	I-Claim
763	.	_	_	I-Claim

764	MGMT	_	_	B-Claim
765	promoter	_	_	I-Claim
766	methylation	_	_	I-Claim
767	status	_	_	I-Claim
768	might	_	_	I-Claim
769	be	_	_	I-Claim
770	a	_	_	I-Claim
771	useful	_	_	I-Claim
772	predictive	_	_	I-Claim
773	marker	_	_	I-Claim
774	for	_	_	I-Claim
775	benefit	_	_	I-Claim
776	from	_	_	I-Claim
777	temozolomide	_	_	I-Claim
778	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	toxicities	_	_	O
3	,	_	_	O
4	functional	_	_	O
5	outcomes	_	_	O
6	,	_	_	O
7	and	_	_	O
8	health	_	_	O
9	-	_	_	O
10	related	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	associated	_	_	O
15	with	_	_	O
16	concurrent	_	_	O
17	chemoradiation	_	_	O
18	therapy	_	_	O
19	(	_	_	O
20	CRT	_	_	O
21	)	_	_	O
22	in	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	head	_	_	O
26	and	_	_	O
27	neck	_	_	O
28	cancer	_	_	O
29	.	_	_	O

30	Prospective	_	_	O
31	and	_	_	O
32	retrospective	_	_	O
33	outcomes	_	_	O
34	study	_	_	O
35	.	_	_	O

36	Tertiary	_	_	O
37	care	_	_	O
38	institution	_	_	O
39	.	_	_	O

40	Participants	_	_	O
41	in	_	_	O
42	the	_	_	O
43	longitudinal	_	_	O
44	Outcomes	_	_	O
45	Assessment	_	_	O
46	Project	_	_	O
47	whose	_	_	O
48	head	_	_	O
49	and	_	_	O
50	neck	_	_	O
51	cancer	_	_	O
52	was	_	_	O
53	treated	_	_	O
54	with	_	_	O
55	CRT	_	_	O
56	between	_	_	O
57	February	_	_	O
58	1	_	_	O
59	,	_	_	O
60	2000	_	_	O
61	,	_	_	O
62	and	_	_	O
63	March	_	_	O
64	1	_	_	O
65	,	_	_	O
66	2007	_	_	O
67	(	_	_	O
68	n	_	_	O
69	=	_	_	O
70	104	_	_	O
71	)	_	_	O
72	.	_	_	O

73	Patients	_	_	O
74	prospectively	_	_	O
75	provided	_	_	O
76	functional	_	_	O
77	and	_	_	O
78	health	_	_	O
79	-	_	_	O
80	related	_	_	O
81	quality	_	_	O
82	of	_	_	O
83	life	_	_	O
84	information	_	_	O
85	,	_	_	O
86	including	_	_	O
87	data	_	_	O
88	from	_	_	O
89	the	_	_	O
90	1	_	_	O
91	-	_	_	O
92	year	_	_	O
93	and	_	_	O
94	most	_	_	O
95	current	_	_	O
96	follow	_	_	O
97	-	_	_	O
98	up	_	_	O
99	visits	_	_	O
100	.	_	_	O

101	Medical	_	_	O
102	records	_	_	O
103	were	_	_	O
104	reviewed	_	_	O
105	to	_	_	O
106	determine	_	_	O
107	toxicity	_	_	O
108	and	_	_	O
109	survival	_	_	O
110	rates	_	_	O
111	.	_	_	O

112	Well	_	_	O
113	-	_	_	O
114	defined	_	_	O
115	acute	_	_	O
116	and	_	_	O
117	late	_	_	O
118	toxicities	_	_	O
119	;	_	_	O
120	functional	_	_	O
121	outcomes	_	_	O
122	(	_	_	O
123	diet	_	_	O
124	,	_	_	O
125	dentition	_	_	O
126	,	_	_	O
127	tracheostomies	_	_	O
128	)	_	_	O
129	;	_	_	O
130	head	_	_	O
131	and	_	_	O
132	neck	_	_	O
133	cancer	_	_	O
134	-	_	_	O
135	specific	_	_	O
136	,	_	_	O
137	general	_	_	O
138	health	_	_	O
139	,	_	_	O
140	and	_	_	O
141	depression	_	_	O
142	outcomes	_	_	O
143	;	_	_	O
144	and	_	_	O
145	survival	_	_	O
146	rates	_	_	O
147	.	_	_	O

148	Most	_	_	O
149	patients	_	_	O
150	had	_	_	O
151	oropharyngeal	_	_	O
152	or	_	_	O
153	laryngeal	_	_	O
154	tumors	_	_	O
155	(	_	_	O
156	87	_	_	O
157	.	_	_	O

158	5	_	_	O
159	%	_	_	O
160	)	_	_	O
161	and	_	_	O
162	advanced	_	_	O
163	-	_	_	O
164	stage	_	_	O
165	disease	_	_	O
166	(	_	_	O
167	75	_	_	O
168	.	_	_	O

169	0	_	_	O
170	%	_	_	O
171	)	_	_	O
172	.	_	_	O

173	Approximately	_	_	B-Premise
174	one	_	_	I-Premise
175	-	_	_	I-Premise
176	half	_	_	I-Premise
177	had	_	_	I-Premise
178	hematologic	_	_	I-Premise
179	toxicities	_	_	I-Premise
180	and	_	_	I-Premise
181	toxicity	_	_	I-Premise
182	-	_	_	I-Premise
183	related	_	_	I-Premise
184	treatment	_	_	I-Premise
185	delays	_	_	I-Premise
186	.	_	_	I-Premise

187	Approximately	_	_	B-Premise
188	one	_	_	I-Premise
189	-	_	_	I-Premise
190	quarter	_	_	I-Premise
191	had	_	_	I-Premise
192	neurotoxicities	_	_	I-Premise
193	and	_	_	I-Premise
194	/	_	_	I-Premise
195	or	_	_	I-Premise
196	ototoxicites	_	_	I-Premise
197	,	_	_	I-Premise
198	moist	_	_	I-Premise
199	desquamation	_	_	I-Premise
200	,	_	_	I-Premise
201	pneumonia	_	_	I-Premise
202	,	_	_	I-Premise
203	nausea	_	_	I-Premise
204	and	_	_	I-Premise
205	vomiting	_	_	I-Premise
206	requiring	_	_	I-Premise
207	hospitalization	_	_	I-Premise
208	or	_	_	I-Premise
209	intravenous	_	_	I-Premise
210	fluids	_	_	I-Premise
211	,	_	_	I-Premise
212	dehydration	_	_	I-Premise
213	or	_	_	I-Premise
214	malnutrition	_	_	I-Premise
215	requiring	_	_	I-Premise
216	hospitalization	_	_	I-Premise
217	,	_	_	I-Premise
218	and	_	_	I-Premise
219	mild	_	_	I-Premise
220	or	_	_	I-Premise
221	moderate	_	_	I-Premise
222	fever	_	_	I-Premise
223	.	_	_	I-Premise

224	Although	_	_	B-Premise
225	patients	_	_	I-Premise
226	receiving	_	_	I-Premise
227	the	_	_	I-Premise
228	current	_	_	I-Premise
229	intensity	_	_	I-Premise
230	-	_	_	I-Premise
231	modulated	_	_	I-Premise
232	radiation	_	_	I-Premise
233	therapy	_	_	I-Premise
234	(	_	_	I-Premise
235	IMRT	_	_	I-Premise
236	)	_	_	I-Premise
237	protocol	_	_	I-Premise
238	using	_	_	I-Premise
239	the	_	_	I-Premise
240	Pinnacle	_	_	I-Premise
241	(	_	_	I-Premise
242	3	_	_	I-Premise
243	)	_	_	I-Premise
244	planning	_	_	I-Premise
245	system	_	_	I-Premise
246	had	_	_	I-Premise
247	more	_	_	I-Premise
248	toxicity	_	_	I-Premise
249	-	_	_	I-Premise
250	related	_	_	I-Premise
251	treatment	_	_	I-Premise
252	delays	_	_	I-Premise
253	,	_	_	I-Premise
254	they	_	_	B-Premise
255	had	_	_	I-Premise
256	fewer	_	_	I-Premise
257	toxicities	_	_	I-Premise
258	and	_	_	I-Premise
259	better	_	_	I-Premise
260	functional	_	_	I-Premise
261	and	_	_	I-Premise
262	health	_	_	I-Premise
263	-	_	_	I-Premise
264	related	_	_	I-Premise
265	quality	_	_	I-Premise
266	of	_	_	I-Premise
267	life	_	_	I-Premise
268	outcomes	_	_	I-Premise
269	compared	_	_	I-Premise
270	with	_	_	I-Premise
271	those	_	_	I-Premise
272	receiving	_	_	I-Premise
273	conventional	_	_	I-Premise
274	lateral	_	_	I-Premise
275	opposing	_	_	I-Premise
276	-	_	_	I-Premise
277	field	_	_	I-Premise
278	radiation	_	_	I-Premise
279	or	_	_	I-Premise
280	the	_	_	I-Premise
281	initial	_	_	I-Premise
282	IMRT	_	_	I-Premise
283	protocol	_	_	I-Premise
284	using	_	_	I-Premise
285	the	_	_	I-Premise
286	Best	_	_	I-Premise
287	nomos	_	_	I-Premise
288	PEACOCK	_	_	I-Premise
289	planning	_	_	I-Premise
290	system	_	_	I-Premise
291	.	_	_	I-Premise

292	Patients	_	_	B-Claim
293	receiving	_	_	I-Claim
294	CRT	_	_	I-Claim
295	experience	_	_	I-Claim
296	a	_	_	I-Claim
297	substantial	_	_	I-Claim
298	number	_	_	I-Claim
299	of	_	_	I-Claim
300	treatment	_	_	I-Claim
301	-	_	_	I-Claim
302	related	_	_	I-Claim
303	adverse	_	_	I-Claim
304	events	_	_	I-Claim
305	,	_	_	I-Claim
306	primarily	_	_	I-Claim
307	affecting	_	_	I-Claim
308	oropharyngeal	_	_	I-Claim
309	and	_	_	I-Claim
310	laryngeal	_	_	I-Claim
311	function	_	_	I-Claim
312	,	_	_	I-Claim
313	with	_	_	I-Claim
314	improvement	_	_	I-Claim
315	noted	_	_	I-Claim
316	for	_	_	I-Claim
317	the	_	_	I-Claim
318	current	_	_	I-Claim
319	IMRT	_	_	I-Claim
320	protocol	_	_	I-Claim
321	.	_	_	I-Claim

322	Improving	_	_	O
323	dental	_	_	O
324	prosthetic	_	_	O
325	rehabilitation	_	_	O
326	and	_	_	O
327	including	_	_	O
328	evaluations	_	_	O
329	with	_	_	O
330	speech	_	_	O
331	and	_	_	O
332	swallowing	_	_	O
333	pathologists	_	_	O
334	before	_	_	O
335	and	_	_	O
336	during	_	_	O
337	treatment	_	_	O
338	may	_	_	O
339	enhance	_	_	O
340	patient	_	_	O
341	outcomes	_	_	O
342	.	_	_	O


0	A	_	_	O
1	significant	_	_	O
2	proportion	_	_	O
3	of	_	_	O
4	patients	_	_	O
5	develop	_	_	O
6	urinary	_	_	O
7	incontinence	_	_	O
8	early	_	_	O
9	after	_	_	O
10	radical	_	_	O
11	prostatectomy	_	_	O
12	.	_	_	O

13	Posterior	_	_	O
14	reconstruction	_	_	O
15	of	_	_	O
16	supporting	_	_	O
17	tissues	_	_	O
18	has	_	_	O
19	been	_	_	O
20	found	_	_	O
21	to	_	_	O
22	reduce	_	_	O
23	incontinence	_	_	O
24	in	_	_	O
25	open	_	_	O
26	and	_	_	O
27	conventional	_	_	O
28	laparoscopic	_	_	O
29	prostatectomy	_	_	O
30	series	_	_	O
31	.	_	_	O

32	To	_	_	O
33	investigate	_	_	O
34	whether	_	_	O
35	our	_	_	O
36	version	_	_	O
37	of	_	_	O
38	a	_	_	O
39	posterior	_	_	O
40	musculofascial	_	_	O
41	reconstruction	_	_	O
42	will	_	_	O
43	reduce	_	_	O
44	early	_	_	O
45	incontinence	_	_	O
46	and	_	_	O
47	have	_	_	O
48	a	_	_	O
49	beneficial	_	_	O
50	effect	_	_	O
51	on	_	_	O
52	patients	_	_	O
53	'	_	_	O
54	quality	_	_	O
55	of	_	_	O
56	life	_	_	O
57	(	_	_	O
58	QoL	_	_	O
59	)	_	_	O
60	.	_	_	O

61	One	_	_	O
62	hundred	_	_	O
63	seven	_	_	O
64	consecutive	_	_	O
65	patients	_	_	O
66	undergoing	_	_	O
67	primary	_	_	O
68	robot	_	_	O
69	-	_	_	O
70	assisted	_	_	O
71	radical	_	_	O
72	laparoscopic	_	_	O
73	prostatectomy	_	_	O
74	(	_	_	O
75	RALP	_	_	O
76	)	_	_	O
77	performed	_	_	O
78	by	_	_	O
79	a	_	_	O
80	single	_	_	O
81	surgeon	_	_	O
82	at	_	_	O
83	one	_	_	O
84	tertiary	_	_	O
85	referral	_	_	O
86	oncology	_	_	O
87	institution	_	_	O
88	were	_	_	O
89	alternately	_	_	O
90	assigned	_	_	O
91	(	_	_	O
92	not	_	_	O
93	randomised	_	_	O
94	)	_	_	O
95	to	_	_	O
96	intervention	_	_	O
97	(	_	_	O
98	n	_	_	O
99	=	_	_	O
100	53	_	_	O
101	)	_	_	O
102	or	_	_	O
103	control	_	_	O
104	groups	_	_	O
105	(	_	_	O
106	n	_	_	O
107	=	_	_	O
108	54	_	_	O
109	)	_	_	O
110	.	_	_	O

111	RALP	_	_	O
112	with	_	_	O
113	median	_	_	O
114	fibrous	_	_	O
115	raphe	_	_	O
116	reconstruction	_	_	O
117	(	_	_	O
118	MFRR	_	_	O
119	)	_	_	O
120	followed	_	_	O
121	by	_	_	O
122	formation	_	_	O
123	of	_	_	O
124	the	_	_	O
125	urethrovesical	_	_	O
126	anastomosis	_	_	O
127	(	_	_	O
128	intervention	_	_	O
129	group	_	_	O
130	)	_	_	O
131	versus	_	_	O
132	standard	_	_	O
133	anastomosis	_	_	O
134	without	_	_	O
135	posterior	_	_	O
136	reconstruction	_	_	O
137	(	_	_	O
138	control	_	_	O
139	group	_	_	O
140	)	_	_	O
141	.	_	_	O

142	Measurements	_	_	O
143	included	_	_	O
144	incontinence	_	_	O
145	at	_	_	O
146	baseline	_	_	O
147	and	_	_	O
148	3	_	_	O
149	-	_	_	O
150	mo	_	_	O
151	intervals	_	_	O
152	;	_	_	O
153	QoL	_	_	O
154	as	_	_	O
155	measured	_	_	O
156	by	_	_	O
157	a	_	_	O
158	simple	_	_	O
159	questionnaire	_	_	O
160	,	_	_	O
161	the	_	_	O
162	European	_	_	O
163	Organisation	_	_	O
164	for	_	_	O
165	Research	_	_	O
166	and	_	_	O
167	Treatment	_	_	O
168	of	_	_	O
169	Cancer	_	_	O
170	(	_	_	O
171	EORTC	_	_	O
172	)	_	_	O
173	Quality	_	_	O
174	of	_	_	O
175	Life	_	_	O
176	-	_	_	O
177	Core	_	_	O
178	30	_	_	O
179	(	_	_	O
180	QLQ	_	_	O
181	-	_	_	O
182	C30	_	_	O
183	)	_	_	O
184	,	_	_	O
185	and	_	_	O
186	Prostate	_	_	O
187	Cancer	_	_	O
188	Module	_	_	O
189	(	_	_	O
190	PR25	_	_	O
191	)	_	_	O
192	questionnaires	_	_	O
193	preoperatively	_	_	O
194	and	_	_	O
195	at	_	_	O
196	6	_	_	O
197	mo	_	_	O
198	postprocedure	_	_	O
199	;	_	_	O
200	tumour	_	_	O
201	characteristics	_	_	O
202	;	_	_	O
203	operative	_	_	O
204	time	_	_	O
205	;	_	_	O
206	fascial	_	_	O
207	preservation	_	_	O
208	score	_	_	O
209	;	_	_	O
210	duration	_	_	O
211	of	_	_	O
212	catheterisation	_	_	O
213	;	_	_	O
214	and	_	_	O
215	anastomotic	_	_	O
216	leakage	_	_	O
217	on	_	_	O
218	cystogram	_	_	O
219	.	_	_	O

220	For	_	_	B-Premise
221	intervention	_	_	I-Premise
222	and	_	_	I-Premise
223	control	_	_	I-Premise
224	groups	_	_	I-Premise
225	respectively	_	_	I-Premise
226	,	_	_	I-Premise
227	mean	_	_	I-Premise
228	catheter	_	_	I-Premise
229	duration	_	_	I-Premise
230	was	_	_	I-Premise
231	11	_	_	I-Premise
232	.	_	_	I-Premise

233	74	_	_	I-Premise
234	d	_	_	I-Premise
235	and	_	_	I-Premise
236	12	_	_	I-Premise
237	.	_	_	I-Premise

238	74	_	_	I-Premise
239	d	_	_	I-Premise
240	(	_	_	I-Premise
241	p	_	_	I-Premise
242	=	_	_	I-Premise
243	0	_	_	I-Premise
244	.	_	_	I-Premise

245	451	_	_	I-Premise
246	)	_	_	I-Premise
247	;	_	_	I-Premise
248	leakage	_	_	I-Premise
249	on	_	_	I-Premise
250	cystogram	_	_	I-Premise
251	was	_	_	I-Premise
252	present	_	_	I-Premise
253	in	_	_	I-Premise
254	six	_	_	I-Premise
255	and	_	_	I-Premise
256	eight	_	_	I-Premise
257	cases	_	_	I-Premise
258	(	_	_	I-Premise
259	p	_	_	I-Premise
260	=	_	_	I-Premise
261	0	_	_	I-Premise
262	.	_	_	I-Premise

263	28	_	_	I-Premise
264	)	_	_	I-Premise
265	;	_	_	I-Premise
266	and	_	_	I-Premise
267	incontinence	_	_	I-Premise
268	(	_	_	I-Premise
269	any	_	_	I-Premise
270	involuntary	_	_	I-Premise
271	urine	_	_	I-Premise
272	loss	_	_	I-Premise
273	)	_	_	I-Premise
274	at	_	_	I-Premise
275	3	_	_	I-Premise
276	mo	_	_	I-Premise
277	was	_	_	I-Premise
278	75	_	_	I-Premise
279	%	_	_	I-Premise
280	and	_	_	I-Premise
281	69	_	_	I-Premise
282	%	_	_	I-Premise
283	(	_	_	I-Premise
284	p	_	_	I-Premise
285	=	_	_	I-Premise
286	0	_	_	I-Premise
287	.	_	_	I-Premise

288	391	_	_	I-Premise
289	)	_	_	I-Premise
290	and	_	_	I-Premise
291	at	_	_	I-Premise
292	6	_	_	I-Premise
293	mo	_	_	I-Premise
294	was	_	_	I-Premise
295	51	_	_	I-Premise
296	%	_	_	I-Premise
297	and	_	_	I-Premise
298	43	_	_	I-Premise
299	%	_	_	I-Premise
300	(	_	_	I-Premise
301	p	_	_	I-Premise
302	=	_	_	I-Premise
303	0	_	_	I-Premise
304	.	_	_	I-Premise

305	686	_	_	I-Premise
306	)	_	_	I-Premise
307	.	_	_	I-Premise

308	Urinary	_	_	B-Premise
309	retention	_	_	I-Premise
310	occurred	_	_	I-Premise
311	only	_	_	I-Premise
312	in	_	_	I-Premise
313	one	_	_	I-Premise
314	case	_	_	I-Premise
315	(	_	_	I-Premise
316	control	_	_	I-Premise
317	group	_	_	I-Premise
318	)	_	_	I-Premise
319	.	_	_	I-Premise

320	The	_	_	B-Premise
321	percentage	_	_	I-Premise
322	of	_	_	I-Premise
323	cases	_	_	I-Premise
324	returning	_	_	I-Premise
325	to	_	_	I-Premise
326	baseline	_	_	I-Premise
327	in	_	_	I-Premise
328	all	_	_	I-Premise
329	QoL	_	_	I-Premise
330	domains	_	_	I-Premise
331	(	_	_	I-Premise
332	except	_	_	I-Premise
333	insomnia	_	_	I-Premise
334	)	_	_	I-Premise
335	was	_	_	I-Premise
336	similar	_	_	I-Premise
337	at	_	_	I-Premise
338	6	_	_	I-Premise
339	mo	_	_	I-Premise
340	between	_	_	I-Premise
341	the	_	_	I-Premise
342	two	_	_	I-Premise
343	groups	_	_	I-Premise
344	.	_	_	I-Premise

345	Short	_	_	B-Premise
346	follow	_	_	I-Premise
347	-	_	_	I-Premise
348	up	_	_	I-Premise
349	,	_	_	I-Premise
350	lack	_	_	I-Premise
351	of	_	_	I-Premise
352	blinding	_	_	I-Premise
353	,	_	_	I-Premise
354	and	_	_	I-Premise
355	probable	_	_	I-Premise
356	small	_	_	I-Premise
357	differences	_	_	I-Premise
358	in	_	_	I-Premise
359	our	_	_	I-Premise
360	method	_	_	I-Premise
361	of	_	_	I-Premise
362	MFRR	_	_	I-Premise
363	performed	_	_	I-Premise
364	compared	_	_	I-Premise
365	with	_	_	I-Premise
366	other	_	_	I-Premise
367	studies	_	_	I-Premise
368	were	_	_	I-Premise
369	identified	_	_	I-Premise
370	as	_	_	I-Premise
371	significant	_	_	I-Premise
372	limitations	_	_	I-Premise
373	.	_	_	I-Premise

374	No	_	_	B-Premise
375	significant	_	_	I-Premise
376	difference	_	_	I-Premise
377	in	_	_	I-Premise
378	any	_	_	I-Premise
379	of	_	_	I-Premise
380	the	_	_	I-Premise
381	analysed	_	_	I-Premise
382	outcome	_	_	I-Premise
383	measures	_	_	I-Premise
384	was	_	_	I-Premise
385	observed	_	_	I-Premise
386	.	_	_	I-Premise

387	Posterior	_	_	B-Claim
388	reconstruction	_	_	I-Claim
389	of	_	_	I-Claim
390	the	_	_	I-Claim
391	musculofascial	_	_	I-Claim
392	complex	_	_	I-Claim
393	does	_	_	I-Claim
394	not	_	_	I-Claim
395	appear	_	_	I-Claim
396	to	_	_	I-Claim
397	improve	_	_	I-Claim
398	early	_	_	I-Claim
399	urinary	_	_	I-Claim
400	incontinence	_	_	I-Claim
401	after	_	_	I-Claim
402	RALP	_	_	I-Claim
403	.	_	_	I-Claim


0	The	_	_	B-Claim
1	choice	_	_	I-Claim
2	of	_	_	I-Claim
3	reconstruction	_	_	I-Claim
4	after	_	_	I-Claim
5	gastrectomy	_	_	I-Claim
6	and	_	_	I-Claim
7	the	_	_	I-Claim
8	significance	_	_	I-Claim
9	of	_	_	I-Claim
10	remaining	_	_	I-Claim
11	reservoir	_	_	I-Claim
12	function	_	_	I-Claim
13	is	_	_	I-Claim
14	a	_	_	I-Claim
15	matter	_	_	I-Claim
16	of	_	_	I-Claim
17	controversy	_	_	I-Claim
18	.	_	_	I-Claim

19	To	_	_	O
20	broaden	_	_	O
21	the	_	_	O
22	criteria	_	_	O
23	for	_	_	O
24	choice	_	_	O
25	of	_	_	O
26	treatment	_	_	O
27	,	_	_	O
28	we	_	_	O
29	conducted	_	_	O
30	a	_	_	O
31	prospective	_	_	O
32	randomized	_	_	O
33	clinical	_	_	O
34	trial	_	_	O
35	to	_	_	O
36	determine	_	_	O
37	the	_	_	O
38	impact	_	_	O
39	of	_	_	O
40	various	_	_	O
41	gastrectomy	_	_	O
42	procedures	_	_	O
43	on	_	_	O
44	quality	_	_	O
45	of	_	_	O
46	life	_	_	O
47	.	_	_	O

48	Consecutive	_	_	O
49	patients	_	_	O
50	(	_	_	O
51	n	_	_	O
52	=	_	_	O
53	64	_	_	O
54	)	_	_	O
55	eligible	_	_	O
56	for	_	_	O
57	curative	_	_	O
58	gastric	_	_	O
59	cancer	_	_	O
60	surgery	_	_	O
61	were	_	_	O
62	randomized	_	_	O
63	to	_	_	O
64	have	_	_	O
65	either	_	_	O
66	a	_	_	O
67	total	_	_	O
68	(	_	_	O
69	n	_	_	O
70	=	_	_	O
71	31	_	_	O
72	)	_	_	O
73	or	_	_	O
74	subtotal	_	_	O
75	(	_	_	O
76	n	_	_	O
77	=	_	_	O
78	13	_	_	O
79	)	_	_	O
80	gastrectomy	_	_	O
81	or	_	_	O
82	a	_	_	O
83	jejunal	_	_	O
84	S	_	_	O
85	-	_	_	O
86	shaped	_	_	O
87	pouch	_	_	O
88	(	_	_	O
89	n	_	_	O
90	=	_	_	O
91	20	_	_	O
92	)	_	_	O
93	implanted	_	_	O
94	as	_	_	O
95	a	_	_	O
96	gastric	_	_	O
97	substitute	_	_	O
98	.	_	_	O

99	The	_	_	O
100	quality	_	_	O
101	-	_	_	O
102	of	_	_	O
103	-	_	_	O
104	life	_	_	O
105	evaluation	_	_	O
106	was	_	_	O
107	based	_	_	O
108	on	_	_	O
109	a	_	_	O
110	battery	_	_	O
111	of	_	_	O
112	questionnaires	_	_	O
113	covering	_	_	O
114	both	_	_	O
115	general	_	_	O
116	and	_	_	O
117	specific	_	_	O
118	aspects	_	_	O
119	of	_	_	O
120	life	_	_	O
121	.	_	_	O

122	The	_	_	O
123	patients	_	_	O
124	were	_	_	O
125	rated	_	_	O
126	by	_	_	O
127	one	_	_	O
128	of	_	_	O
129	two	_	_	O
130	psychiatrists	_	_	O
131	who	_	_	O
132	were	_	_	O
133	blinded	_	_	O
134	to	_	_	O
135	the	_	_	O
136	patients	_	_	O
137	'	_	_	O
138	group	_	_	O
139	affiliation	_	_	O
140	.	_	_	O

141	Assessments	_	_	O
142	were	_	_	O
143	made	_	_	O
144	on	_	_	O
145	three	_	_	O
146	occasions	_	_	O
147	:	_	_	O
148	during	_	_	O
149	the	_	_	O
150	week	_	_	O
151	prior	_	_	O
152	to	_	_	O
153	surgery	_	_	O
154	and	_	_	O
155	3	_	_	O
156	and	_	_	O
157	12	_	_	O
158	months	_	_	O
159	after	_	_	O
160	the	_	_	O
161	surgical	_	_	O
162	intervention	_	_	O
163	.	_	_	O

164	The	_	_	B-Premise
165	postoperative	_	_	I-Premise
166	complication	_	_	I-Premise
167	and	_	_	I-Premise
168	mortality	_	_	I-Premise
169	rates	_	_	I-Premise
170	were	_	_	I-Premise
171	similar	_	_	I-Premise
172	in	_	_	I-Premise
173	all	_	_	I-Premise
174	treatment	_	_	I-Premise
175	groups	_	_	I-Premise
176	,	_	_	I-Premise
177	with	_	_	I-Premise
178	few	_	_	I-Premise
179	serious	_	_	I-Premise
180	complications	_	_	I-Premise
181	recorded	_	_	I-Premise
182	.	_	_	I-Premise

183	Irrespective	_	_	B-Premise
184	of	_	_	I-Premise
185	type	_	_	I-Premise
186	of	_	_	I-Premise
187	treatment	_	_	I-Premise
188	,	_	_	I-Premise
189	the	_	_	I-Premise
190	patients	_	_	I-Premise
191	suffered	_	_	I-Premise
192	from	_	_	I-Premise
193	alimentary	_	_	I-Premise
194	symptoms	_	_	I-Premise
195	and	_	_	I-Premise
196	functional	_	_	I-Premise
197	limitations	_	_	I-Premise
198	in	_	_	I-Premise
199	everyday	_	_	I-Premise
200	life	_	_	I-Premise
201	,	_	_	I-Premise
202	whereas	_	_	B-Premise
203	their	_	_	I-Premise
204	mental	_	_	I-Premise
205	well	_	_	I-Premise
206	-	_	_	I-Premise
207	being	_	_	I-Premise
208	improved	_	_	I-Premise
209	after	_	_	I-Premise
210	surgery	_	_	I-Premise
211	.	_	_	I-Premise

212	Patients	_	_	B-Premise
213	who	_	_	I-Premise
214	underwent	_	_	I-Premise
215	subtotal	_	_	I-Premise
216	gastrectomy	_	_	I-Premise
217	had	_	_	I-Premise
218	the	_	_	I-Premise
219	best	_	_	I-Premise
220	outcome	_	_	I-Premise
221	,	_	_	I-Premise
222	especially	_	_	I-Premise
223	with	_	_	I-Premise
224	respect	_	_	I-Premise
225	to	_	_	I-Premise
226	complaints	_	_	I-Premise
227	of	_	_	I-Premise
228	diarrhea	_	_	I-Premise
229	.	_	_	I-Premise

230	Patients	_	_	B-Premise
231	given	_	_	I-Premise
232	a	_	_	I-Premise
233	gastric	_	_	I-Premise
234	substitute	_	_	I-Premise
235	after	_	_	I-Premise
236	gastrectomy	_	_	I-Premise
237	showed	_	_	I-Premise
238	no	_	_	I-Premise
239	difference	_	_	I-Premise
240	from	_	_	I-Premise
241	those	_	_	I-Premise
242	who	_	_	I-Premise
243	had	_	_	I-Premise
244	only	_	_	I-Premise
245	a	_	_	I-Premise
246	total	_	_	I-Premise
247	gastrectomy	_	_	I-Premise
248	.	_	_	I-Premise

249	We	_	_	B-Claim
250	conclude	_	_	I-Claim
251	that	_	_	I-Claim
252	despite	_	_	I-Claim
253	significant	_	_	I-Claim
254	unfavorable	_	_	I-Claim
255	consequences	_	_	I-Claim
256	that	_	_	I-Claim
257	follow	_	_	I-Claim
258	gastrectomy	_	_	I-Claim
259	,	_	_	I-Claim
260	patients	_	_	I-Claim
261	recover	_	_	I-Claim
262	with	_	_	I-Claim
263	an	_	_	I-Claim
264	improved	_	_	I-Claim
265	mental	_	_	I-Claim
266	status	_	_	I-Claim
267	.	_	_	I-Claim

268	A	_	_	B-Claim
269	pouch	_	_	I-Claim
270	reconstruction	_	_	I-Claim
271	after	_	_	I-Claim
272	total	_	_	I-Claim
273	gastrectomy	_	_	I-Claim
274	does	_	_	I-Claim
275	not	_	_	I-Claim
276	improve	_	_	I-Claim
277	quality	_	_	I-Claim
278	of	_	_	I-Claim
279	life	_	_	I-Claim
280	,	_	_	I-Claim
281	but	_	_	O
282	a	_	_	B-Claim
283	subtotal	_	_	I-Claim
284	gastrectomy	_	_	I-Claim
285	has	_	_	I-Claim
286	advantages	_	_	I-Claim
287	that	_	_	I-Claim
288	must	_	_	I-Claim
289	be	_	_	I-Claim
290	considered	_	_	I-Claim
291	when	_	_	I-Claim
292	the	_	_	I-Claim
293	procedure	_	_	I-Claim
294	is	_	_	I-Claim
295	clinically	_	_	I-Claim
296	feasible	_	_	I-Claim
297	.	_	_	I-Claim


0	Mediating	_	_	O
1	mechanisms	_	_	O
2	of	_	_	O
3	a	_	_	O
4	12	_	_	O
5	-	_	_	O
6	week	_	_	O
7	group	_	_	O
8	-	_	_	O
9	based	_	_	O
10	exercise	_	_	O
11	intervention	_	_	O
12	on	_	_	O
13	cancer	_	_	O
14	survivors	_	_	O
15	'	_	_	O
16	quality	_	_	O
17	of	_	_	O
18	life	_	_	O
19	(	_	_	O
20	QoL	_	_	O
21	)	_	_	O
22	were	_	_	O
23	examined	_	_	O
24	to	_	_	O
25	inform	_	_	O
26	future	_	_	O
27	exercise	_	_	O
28	intervention	_	_	O
29	development	_	_	O
30	.	_	_	O

31	Two	_	_	O
32	hundred	_	_	O
33	nine	_	_	O
34	cancer	_	_	O
35	survivors	_	_	O
36	≥	_	_	O
37	3	_	_	O
38	months	_	_	O
39	posttreatment	_	_	O
40	(	_	_	O
41	57	_	_	O
42	%	_	_	O
43	breast	_	_	O
44	cancer	_	_	O
45	)	_	_	O
46	aged	_	_	O
47	49	_	_	O
48	.	_	_	O

49	5	_	_	O
50	(	_	_	O
51	±	_	_	O
52	10	_	_	O
53	.	_	_	O

54	4	_	_	O
55	)	_	_	O
56	years	_	_	O
57	were	_	_	O
58	assigned	_	_	O
59	to	_	_	O
60	physical	_	_	O
61	exercise	_	_	O
62	(	_	_	O
63	n	_	_	O
64	=	_	_	O
65	147	_	_	O
66	)	_	_	O
67	or	_	_	O
68	wait	_	_	O
69	-	_	_	O
70	list	_	_	O
71	control	_	_	O
72	(	_	_	O
73	n	_	_	O
74	=	_	_	O
75	62	_	_	O
76	)	_	_	O
77	.	_	_	O

78	QoL	_	_	O
79	,	_	_	O
80	fatigue	_	_	O
81	,	_	_	O
82	emotional	_	_	O
83	distress	_	_	O
84	,	_	_	O
85	physical	_	_	O
86	activity	_	_	O
87	,	_	_	O
88	general	_	_	O
89	self	_	_	O
90	-	_	_	O
91	efficacy	_	_	O
92	and	_	_	O
93	mastery	_	_	O
94	were	_	_	O
95	assessed	_	_	O
96	at	_	_	O
97	baseline	_	_	O
98	and	_	_	O
99	post	_	_	O
100	-	_	_	O
101	intervention	_	_	O
102	using	_	_	O
103	questionnaires	_	_	O
104	.	_	_	O

105	Path	_	_	O
106	analysis	_	_	O
107	was	_	_	O
108	conducted	_	_	O
109	using	_	_	O
110	Mplus	_	_	O
111	to	_	_	O
112	explore	_	_	O
113	whether	_	_	O
114	improved	_	_	O
115	physical	_	_	O
116	activity	_	_	O
117	,	_	_	O
118	general	_	_	O
119	self	_	_	O
120	-	_	_	O
121	efficacy	_	_	O
122	and	_	_	O
123	mastery	_	_	O
124	mediated	_	_	O
125	the	_	_	O
126	effects	_	_	O
127	of	_	_	O
128	exercise	_	_	O
129	on	_	_	O
130	fatigue	_	_	O
131	and	_	_	O
132	distress	_	_	O
133	and	_	_	O
134	consequently	_	_	O
135	QoL	_	_	O
136	.	_	_	O

137	The	_	_	B-Premise
138	intervention	_	_	I-Premise
139	was	_	_	I-Premise
140	associated	_	_	I-Premise
141	with	_	_	I-Premise
142	increased	_	_	I-Premise
143	physical	_	_	I-Premise
144	activity	_	_	I-Premise
145	(	_	_	I-Premise
146	β	_	_	I-Premise
147	=	_	_	I-Premise
148	0	_	_	I-Premise
149	.	_	_	I-Premise

150	46	_	_	I-Premise
151	,	_	_	I-Premise
152	95	_	_	I-Premise
153	%	_	_	I-Premise
154	confidence	_	_	I-Premise
155	interval	_	_	I-Premise
156	(	_	_	I-Premise
157	CI	_	_	I-Premise
158	)	_	_	I-Premise
159	=	_	_	I-Premise
160	0	_	_	I-Premise
161	.	_	_	I-Premise

162	14	_	_	I-Premise
163	;	_	_	I-Premise
164	0	_	_	I-Premise
165	.	_	_	I-Premise

166	59	_	_	I-Premise
167	)	_	_	I-Premise
168	,	_	_	I-Premise
169	general	_	_	I-Premise
170	self	_	_	I-Premise
171	-	_	_	I-Premise
172	efficacy	_	_	I-Premise
173	(	_	_	I-Premise
174	β	_	_	I-Premise
175	=	_	_	I-Premise
176	2	_	_	I-Premise
177	.	_	_	I-Premise

178	41	_	_	I-Premise
179	,	_	_	I-Premise
180	95	_	_	I-Premise
181	%	_	_	I-Premise
182	CI	_	_	I-Premise
183	=	_	_	I-Premise
184	0	_	_	I-Premise
185	.	_	_	I-Premise

186	35	_	_	I-Premise
187	;	_	_	I-Premise
188	4	_	_	I-Premise
189	.	_	_	I-Premise

190	73	_	_	I-Premise
191	)	_	_	I-Premise
192	,	_	_	I-Premise
193	and	_	_	I-Premise
194	mastery	_	_	I-Premise
195	(	_	_	I-Premise
196	β	_	_	I-Premise
197	=	_	_	I-Premise
198	1	_	_	I-Premise
199	.	_	_	I-Premise

200	75	_	_	I-Premise
201	,	_	_	I-Premise
202	95	_	_	I-Premise
203	%	_	_	I-Premise
204	CI	_	_	I-Premise
205	=	_	_	I-Premise
206	0	_	_	I-Premise
207	.	_	_	I-Premise

208	36	_	_	I-Premise
209	;	_	_	I-Premise
210	2	_	_	I-Premise
211	.	_	_	I-Premise

212	78	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	Further	_	_	O
216	,	_	_	O
217	the	_	_	B-Premise
218	intervention	_	_	I-Premise
219	had	_	_	I-Premise
220	both	_	_	I-Premise
221	a	_	_	I-Premise
222	direct	_	_	I-Premise
223	effect	_	_	I-Premise
224	on	_	_	I-Premise
225	fatigue	_	_	I-Premise
226	(	_	_	I-Premise
227	β	_	_	I-Premise
228	=	_	_	I-Premise
229	-	_	_	I-Premise
230	1	_	_	I-Premise
231	.	_	_	I-Premise

232	09	_	_	I-Premise
233	,	_	_	I-Premise
234	95	_	_	I-Premise
235	%	_	_	I-Premise
236	CI	_	_	I-Premise
237	=	_	_	I-Premise
238	-	_	_	I-Premise
239	2	_	_	I-Premise
240	.	_	_	I-Premise

241	12	_	_	I-Premise
242	;	_	_	I-Premise
243	0	_	_	I-Premise
244	.	_	_	I-Premise

245	01	_	_	I-Premise
246	)	_	_	I-Premise
247	,	_	_	I-Premise
248	and	_	_	I-Premise
249	an	_	_	I-Premise
250	indirect	_	_	I-Premise
251	effect	_	_	I-Premise
252	(	_	_	I-Premise
253	β	_	_	I-Premise
254	=	_	_	I-Premise
255	-	_	_	I-Premise
256	0	_	_	I-Premise
257	.	_	_	I-Premise

258	54	_	_	I-Premise
259	,	_	_	I-Premise
260	95	_	_	I-Premise
261	%	_	_	I-Premise
262	CI	_	_	I-Premise
263	=	_	_	I-Premise
264	-	_	_	I-Premise
265	1	_	_	I-Premise
266	.	_	_	I-Premise

267	00	_	_	I-Premise
268	;	_	_	I-Premise
269	-	_	_	I-Premise
270	0	_	_	I-Premise
271	.	_	_	I-Premise

272	21	_	_	I-Premise
273	)	_	_	I-Premise
274	via	_	_	I-Premise
275	physical	_	_	I-Premise
276	activity	_	_	I-Premise
277	(	_	_	I-Premise
278	β	_	_	I-Premise
279	=	_	_	I-Premise
280	-	_	_	I-Premise
281	0	_	_	I-Premise
282	.	_	_	I-Premise

283	29	_	_	I-Premise
284	,	_	_	I-Premise
285	95	_	_	I-Premise
286	%	_	_	I-Premise
287	CI	_	_	I-Premise
288	=	_	_	I-Premise
289	-	_	_	I-Premise
290	0	_	_	I-Premise
291	.	_	_	I-Premise

292	64	_	_	I-Premise
293	;	_	_	I-Premise
294	-	_	_	I-Premise
295	0	_	_	I-Premise
296	.	_	_	I-Premise

297	07	_	_	I-Premise
298	)	_	_	I-Premise
299	and	_	_	I-Premise
300	general	_	_	I-Premise
301	self	_	_	I-Premise
302	-	_	_	I-Premise
303	efficacy	_	_	I-Premise
304	(	_	_	I-Premise
305	β	_	_	I-Premise
306	=	_	_	I-Premise
307	-	_	_	I-Premise
308	0	_	_	I-Premise
309	.	_	_	I-Premise

310	25	_	_	I-Premise
311	,	_	_	I-Premise
312	95	_	_	I-Premise
313	%	_	_	I-Premise
314	CI	_	_	I-Premise
315	=	_	_	I-Premise
316	-	_	_	I-Premise
317	0	_	_	I-Premise
318	.	_	_	I-Premise

319	61	_	_	I-Premise
320	;	_	_	I-Premise
321	-	_	_	I-Premise
322	0	_	_	I-Premise
323	.	_	_	I-Premise

324	05	_	_	I-Premise
325	)	_	_	I-Premise
326	.	_	_	I-Premise

327	The	_	_	B-Premise
328	intervention	_	_	I-Premise
329	had	_	_	I-Premise
330	a	_	_	I-Premise
331	borderline	_	_	I-Premise
332	significant	_	_	I-Premise
333	direct	_	_	I-Premise
334	effect	_	_	I-Premise
335	on	_	_	I-Premise
336	reduced	_	_	I-Premise
337	distress	_	_	I-Premise
338	(	_	_	I-Premise
339	β	_	_	I-Premise
340	=	_	_	I-Premise
341	-	_	_	I-Premise
342	1	_	_	I-Premise
343	.	_	_	I-Premise

344	32	_	_	I-Premise
345	,	_	_	I-Premise
346	95	_	_	I-Premise
347	%	_	_	I-Premise
348	CI	_	_	I-Premise
349	=	_	_	I-Premise
350	-	_	_	I-Premise
351	2	_	_	I-Premise
352	.	_	_	I-Premise

353	68	_	_	I-Premise
354	;	_	_	I-Premise
355	0	_	_	I-Premise
356	.	_	_	I-Premise

357	11	_	_	I-Premise
358	)	_	_	I-Premise
359	,	_	_	I-Premise
360	and	_	_	I-Premise
361	a	_	_	I-Premise
362	significant	_	_	I-Premise
363	indirect	_	_	I-Premise
364	effect	_	_	I-Premise
365	via	_	_	I-Premise
366	increased	_	_	I-Premise
367	general	_	_	I-Premise
368	self	_	_	I-Premise
369	-	_	_	I-Premise
370	efficacy	_	_	I-Premise
371	and	_	_	I-Premise
372	mastery	_	_	I-Premise
373	(	_	_	I-Premise
374	β	_	_	I-Premise
375	=	_	_	I-Premise
376	-	_	_	I-Premise
377	1	_	_	I-Premise
378	.	_	_	I-Premise

379	06	_	_	I-Premise
380	,	_	_	I-Premise
381	95	_	_	I-Premise
382	%	_	_	I-Premise
383	CI	_	_	I-Premise
384	=	_	_	I-Premise
385	-	_	_	I-Premise
386	1	_	_	I-Premise
387	.	_	_	I-Premise

388	89	_	_	I-Premise
389	;	_	_	I-Premise
390	-	_	_	I-Premise
391	0	_	_	I-Premise
392	.	_	_	I-Premise

393	38	_	_	I-Premise
394	)	_	_	I-Premise
395	.	_	_	I-Premise

396	Reductions	_	_	B-Premise
397	in	_	_	I-Premise
398	fatigue	_	_	I-Premise
399	(	_	_	I-Premise
400	β	_	_	I-Premise
401	=	_	_	I-Premise
402	-	_	_	I-Premise
403	1	_	_	I-Premise
404	.	_	_	I-Premise

405	33	_	_	I-Premise
406	,	_	_	I-Premise
407	95	_	_	I-Premise
408	%	_	_	I-Premise
409	CI	_	_	I-Premise
410	=	_	_	I-Premise
411	-	_	_	I-Premise
412	1	_	_	I-Premise
413	.	_	_	I-Premise

414	85	_	_	I-Premise
415	;	_	_	I-Premise
416	-	_	_	I-Premise
417	0	_	_	I-Premise
418	.	_	_	I-Premise

419	83	_	_	I-Premise
420	)	_	_	I-Premise
421	and	_	_	I-Premise
422	distress	_	_	I-Premise
423	(	_	_	I-Premise
424	β	_	_	I-Premise
425	=	_	_	I-Premise
426	-	_	_	I-Premise
427	0	_	_	I-Premise
428	.	_	_	I-Premise

429	86	_	_	I-Premise
430	,	_	_	I-Premise
431	95	_	_	I-Premise
432	%	_	_	I-Premise
433	CI	_	_	I-Premise
434	=	_	_	I-Premise
435	-	_	_	I-Premise
436	1	_	_	I-Premise
437	.	_	_	I-Premise

438	25	_	_	I-Premise
439	;	_	_	I-Premise
440	-	_	_	I-Premise
441	0	_	_	I-Premise
442	.	_	_	I-Premise

443	52	_	_	I-Premise
444	)	_	_	I-Premise
445	were	_	_	I-Premise
446	associated	_	_	I-Premise
447	with	_	_	I-Premise
448	improved	_	_	I-Premise
449	QoL	_	_	I-Premise
450	.	_	_	I-Premise

451	Further	_	_	O
452	,	_	_	O
453	increased	_	_	B-Premise
454	physical	_	_	I-Premise
455	activity	_	_	I-Premise
456	was	_	_	I-Premise
457	directly	_	_	I-Premise
458	associated	_	_	I-Premise
459	with	_	_	I-Premise
460	improved	_	_	I-Premise
461	QoL	_	_	I-Premise
462	(	_	_	I-Premise
463	β	_	_	I-Premise
464	=	_	_	I-Premise
465	3	_	_	I-Premise
466	.	_	_	I-Premise

467	37	_	_	I-Premise
468	,	_	_	I-Premise
469	95	_	_	I-Premise
470	%	_	_	I-Premise
471	CI	_	_	I-Premise
472	=	_	_	I-Premise
473	1	_	_	I-Premise
474	.	_	_	I-Premise

475	01	_	_	I-Premise
476	;	_	_	I-Premise
477	5	_	_	I-Premise
478	.	_	_	I-Premise

479	54	_	_	I-Premise
480	)	_	_	I-Premise
481	.	_	_	I-Premise

482	The	_	_	B-Claim
483	beneficial	_	_	I-Claim
484	effect	_	_	I-Claim
485	of	_	_	I-Claim
486	group	_	_	I-Claim
487	-	_	_	I-Claim
488	based	_	_	I-Claim
489	physical	_	_	I-Claim
490	exercise	_	_	I-Claim
491	on	_	_	I-Claim
492	QoL	_	_	I-Claim
493	was	_	_	I-Claim
494	mediated	_	_	I-Claim
495	by	_	_	I-Claim
496	increased	_	_	I-Claim
497	physical	_	_	I-Claim
498	activity	_	_	I-Claim
499	,	_	_	I-Claim
500	general	_	_	I-Claim
501	self	_	_	I-Claim
502	-	_	_	I-Claim
503	efficacy	_	_	I-Claim
504	and	_	_	I-Claim
505	mastery	_	_	I-Claim
506	,	_	_	I-Claim
507	and	_	_	I-Claim
508	subsequent	_	_	I-Claim
509	reductions	_	_	I-Claim
510	in	_	_	I-Claim
511	fatigue	_	_	I-Claim
512	and	_	_	I-Claim
513	distress	_	_	I-Claim
514	.	_	_	I-Claim

515	In	_	_	B-Claim
516	addition	_	_	I-Claim
517	to	_	_	I-Claim
518	physical	_	_	I-Claim
519	activity	_	_	I-Claim
520	,	_	_	I-Claim
521	future	_	_	I-Claim
522	interventions	_	_	I-Claim
523	should	_	_	I-Claim
524	target	_	_	I-Claim
525	self	_	_	I-Claim
526	-	_	_	I-Claim
527	efficacy	_	_	I-Claim
528	and	_	_	I-Claim
529	mastery	_	_	I-Claim
530	.	_	_	I-Claim

531	This	_	_	B-Claim
532	may	_	_	I-Claim
533	lead	_	_	I-Claim
534	to	_	_	I-Claim
535	reduced	_	_	I-Claim
536	distress	_	_	I-Claim
537	and	_	_	I-Claim
538	fatigue	_	_	I-Claim
539	,	_	_	I-Claim
540	and	_	_	I-Claim
541	consequently	_	_	I-Claim
542	improved	_	_	I-Claim
543	QoL	_	_	I-Claim
544	of	_	_	I-Claim
545	cancer	_	_	I-Claim
546	survivors	_	_	I-Claim
547	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	whether	_	_	O
3	omission	_	_	O
4	of	_	_	O
5	post	_	_	O
6	-	_	_	O
7	operative	_	_	O
8	radiotherapy	_	_	O
9	(	_	_	O
10	RT	_	_	O
11	)	_	_	O
12	in	_	_	O
13	women	_	_	O
14	with	_	_	O
15	'	_	_	O
16	low	_	_	O
17	-	_	_	O
18	risk	_	_	O
19	'	_	_	O
20	axillary	_	_	O
21	node	_	_	O
22	-	_	_	O
23	negative	_	_	O
24	breast	_	_	O
25	cancer	_	_	O
26	[	_	_	O
27	tumour	_	_	O
28	size	_	_	O
29	of	_	_	O
30	less	_	_	O
31	than	_	_	O
32	5	_	_	O
33	cm	_	_	O
34	(	_	_	O
35	T0	_	_	O
36	-	_	_	O
37	2	_	_	O
38	)	_	_	O
39	although	_	_	O
40	the	_	_	O
41	eligibility	_	_	O
42	criteria	_	_	O
43	further	_	_	O
44	reduce	_	_	O
45	the	_	_	O
46	eligible	_	_	O
47	size	_	_	O
48	to	_	_	O
49	a	_	_	O
50	maximum	_	_	O
51	of	_	_	O
52	3	_	_	O
53	cm	_	_	O
54	]	_	_	O
55	treated	_	_	O
56	by	_	_	O
57	breast	_	_	O
58	-	_	_	O
59	conserving	_	_	O
60	surgery	_	_	O
61	and	_	_	O
62	endocrine	_	_	O
63	therapy	_	_	O
64	improves	_	_	O
65	quality	_	_	O
66	of	_	_	O
67	life	_	_	O
68	and	_	_	O
69	is	_	_	O
70	more	_	_	O
71	cost	_	_	O
72	-	_	_	O
73	effective	_	_	O
74	.	_	_	O

75	A	_	_	O
76	randomised	_	_	O
77	controlled	_	_	O
78	clinical	_	_	O
79	trial	_	_	O
80	,	_	_	O
81	using	_	_	O
82	a	_	_	O
83	method	_	_	O
84	of	_	_	O
85	minimisation	_	_	O
86	balanced	_	_	O
87	by	_	_	O
88	centre	_	_	O
89	,	_	_	O
90	grade	_	_	O
91	of	_	_	O
92	cancer	_	_	O
93	,	_	_	O
94	age	_	_	O
95	,	_	_	O
96	lymphovascular	_	_	O
97	invasion	_	_	O
98	and	_	_	O
99	preoperative	_	_	O
100	endocrine	_	_	O
101	therapy	_	_	O
102	was	_	_	O
103	performed	_	_	O
104	.	_	_	O

105	Breast	_	_	O
106	cancer	_	_	O
107	clinics	_	_	O
108	in	_	_	O
109	cancer	_	_	O
110	centres	_	_	O
111	in	_	_	O
112	the	_	_	O
113	UK	_	_	O
114	.	_	_	O

115	Patients	_	_	O
116	aged	_	_	O
117	≥	_	_	O
118	65	_	_	O
119	years	_	_	O
120	were	_	_	O
121	eligible	_	_	O
122	provided	_	_	O
123	that	_	_	O
124	their	_	_	O
125	breast	_	_	O
126	cancers	_	_	O
127	were	_	_	O
128	considered	_	_	O
129	to	_	_	O
130	be	_	_	O
131	at	_	_	O
132	low	_	_	O
133	risk	_	_	O
134	of	_	_	O
135	local	_	_	O
136	recurrence	_	_	O
137	,	_	_	O
138	they	_	_	O
139	were	_	_	O
140	suitable	_	_	O
141	for	_	_	O
142	breast	_	_	O
143	conservation	_	_	O
144	surgery	_	_	O
145	,	_	_	O
146	they	_	_	O
147	were	_	_	O
148	receiving	_	_	O
149	endocrine	_	_	O
150	therapy	_	_	O
151	and	_	_	O
152	they	_	_	O
153	were	_	_	O
154	willing	_	_	O
155	and	_	_	O
156	able	_	_	O
157	to	_	_	O
158	give	_	_	O
159	informed	_	_	O
160	consent	_	_	O
161	.	_	_	O

162	The	_	_	O
163	standard	_	_	O
164	treatment	_	_	O
165	of	_	_	O
166	post	_	_	O
167	-	_	_	O
168	operative	_	_	O
169	whole	_	_	O
170	breast	_	_	O
171	irradiation	_	_	O
172	or	_	_	O
173	the	_	_	O
174	omission	_	_	O
175	of	_	_	O
176	RT	_	_	O
177	.	_	_	O

178	Quality	_	_	O
179	of	_	_	O
180	life	_	_	O
181	was	_	_	O
182	the	_	_	O
183	primary	_	_	O
184	outcome	_	_	O
185	measure	_	_	O
186	,	_	_	O
187	together	_	_	O
188	with	_	_	O
189	anxiety	_	_	O
190	and	_	_	O
191	depression	_	_	O
192	and	_	_	O
193	cost	_	_	O
194	-	_	_	O
195	effectiveness	_	_	O
196	.	_	_	O

197	Secondary	_	_	O
198	outcome	_	_	O
199	measures	_	_	O
200	were	_	_	O
201	recurrence	_	_	O
202	rates	_	_	O
203	and	_	_	O
204	survival	_	_	O
205	,	_	_	O
206	and	_	_	O
207	treatment	_	_	O
208	-	_	_	O
209	related	_	_	O
210	morbidity	_	_	O
211	.	_	_	O

212	The	_	_	O
213	principal	_	_	O
214	method	_	_	O
215	of	_	_	O
216	data	_	_	O
217	collection	_	_	O
218	was	_	_	O
219	by	_	_	O
220	questionnaire	_	_	O
221	,	_	_	O
222	completed	_	_	O
223	at	_	_	O
224	home	_	_	O
225	with	_	_	O
226	a	_	_	O
227	research	_	_	O
228	nurse	_	_	O
229	on	_	_	O
230	four	_	_	O
231	occasions	_	_	O
232	over	_	_	O
233	15	_	_	O
234	months	_	_	O
235	,	_	_	O
236	then	_	_	O
237	by	_	_	O
238	postal	_	_	O
239	questionnaire	_	_	O
240	at	_	_	O
241	3	_	_	O
242	and	_	_	O
243	5	_	_	O
244	years	_	_	O
245	after	_	_	O
246	surgery	_	_	O
247	.	_	_	O

248	The	_	_	O
249	hypothesised	_	_	O
250	improvement	_	_	O
251	in	_	_	O
252	overall	_	_	O
253	quality	_	_	O
254	of	_	_	O
255	life	_	_	O
256	with	_	_	O
257	the	_	_	O
258	omission	_	_	O
259	of	_	_	O
260	RT	_	_	O
261	was	_	_	O
262	not	_	_	O
263	seen	_	_	O
264	in	_	_	O
265	the	_	_	O
266	summary	_	_	O
267	domains	_	_	O
268	of	_	_	O
269	the	_	_	O
270	European	_	_	O
271	Organisation	_	_	O
272	for	_	_	O
273	Research	_	_	O
274	in	_	_	O
275	the	_	_	O
276	Treatment	_	_	O
277	of	_	_	O
278	Cancer	_	_	O
279	(	_	_	O
280	EORTC	_	_	O
281	)	_	_	O
282	scales	_	_	O
283	.	_	_	O

284	Some	_	_	O
285	differences	_	_	O
286	were	_	_	O
287	apparent	_	_	O
288	within	_	_	O
289	subscales	_	_	O
290	of	_	_	O
291	the	_	_	O
292	EORTC	_	_	O
293	questionnaires	_	_	O
294	,	_	_	O
295	and	_	_	O
296	insights	_	_	O
297	into	_	_	O
298	the	_	_	O
299	impact	_	_	O
300	of	_	_	O
301	treatment	_	_	O
302	were	_	_	O
303	also	_	_	O
304	provided	_	_	O
305	by	_	_	O
306	the	_	_	O
307	qualitative	_	_	O
308	data	_	_	O
309	obtained	_	_	O
310	by	_	_	O
311	open	_	_	O
312	-	_	_	O
313	ended	_	_	O
314	questions	_	_	O
315	added	_	_	O
316	by	_	_	O
317	the	_	_	O
318	trial	_	_	O
319	team	_	_	O
320	.	_	_	O

321	Differences	_	_	O
322	were	_	_	O
323	most	_	_	O
324	apparent	_	_	O
325	shortly	_	_	O
326	after	_	_	O
327	the	_	_	O
328	time	_	_	O
329	of	_	_	O
330	completion	_	_	O
331	of	_	_	O
332	RT	_	_	O
333	.	_	_	O

334	RT	_	_	B-Premise
335	was	_	_	I-Premise
336	then	_	_	I-Premise
337	associated	_	_	I-Premise
338	with	_	_	I-Premise
339	increased	_	_	I-Premise
340	breast	_	_	I-Premise
341	symptoms	_	_	I-Premise
342	and	_	_	I-Premise
343	with	_	_	I-Premise
344	greater	_	_	I-Premise
345	(	_	_	I-Premise
346	self	_	_	I-Premise
347	-	_	_	I-Premise
348	reported	_	_	I-Premise
349	)	_	_	I-Premise
350	fatigue	_	_	I-Premise
351	,	_	_	I-Premise
352	but	_	_	I-Premise
353	with	_	_	I-Premise
354	lower	_	_	I-Premise
355	levels	_	_	I-Premise
356	of	_	_	I-Premise
357	insomnia	_	_	I-Premise
358	and	_	_	I-Premise
359	endocrine	_	_	I-Premise
360	side	_	_	I-Premise
361	effects	_	_	I-Premise
362	.	_	_	I-Premise

363	These	_	_	B-Premise
364	statistically	_	_	I-Premise
365	significant	_	_	I-Premise
366	differences	_	_	I-Premise
367	in	_	_	I-Premise
368	breast	_	_	I-Premise
369	symptoms	_	_	I-Premise
370	persisted	_	_	I-Premise
371	for	_	_	I-Premise
372	up	_	_	I-Premise
373	to	_	_	I-Premise
374	5	_	_	I-Premise
375	years	_	_	I-Premise
376	after	_	_	I-Premise
377	RT	_	_	I-Premise
378	[	_	_	I-Premise
379	mean	_	_	I-Premise
380	difference	_	_	I-Premise
381	,	_	_	I-Premise
382	RT	_	_	I-Premise
383	was	_	_	I-Premise
384	5	_	_	I-Premise
385	.	_	_	I-Premise

386	27	_	_	I-Premise
387	units	_	_	I-Premise
388	greater	_	_	I-Premise
389	than	_	_	I-Premise
390	no	_	_	I-Premise
391	RT	_	_	I-Premise
392	,	_	_	I-Premise
393	95	_	_	I-Premise
394	%	_	_	I-Premise
395	confidence	_	_	I-Premise
396	interval	_	_	I-Premise
397	(	_	_	I-Premise
398	CI	_	_	I-Premise
399	)	_	_	I-Premise
400	of	_	_	I-Premise
401	1	_	_	I-Premise
402	.	_	_	I-Premise

403	46	_	_	I-Premise
404	to	_	_	I-Premise
405	9	_	_	I-Premise
406	.	_	_	I-Premise

407	07	_	_	I-Premise
408	]	_	_	I-Premise
409	,	_	_	I-Premise
410	with	_	_	I-Premise
411	similar	_	_	I-Premise
412	,	_	_	I-Premise
413	though	_	_	I-Premise
414	non	_	_	I-Premise
415	-	_	_	I-Premise
416	significant	_	_	I-Premise
417	,	_	_	I-Premise
418	trends	_	_	I-Premise
419	in	_	_	I-Premise
420	insomnia	_	_	I-Premise
421	.	_	_	I-Premise

422	No	_	_	B-Premise
423	significant	_	_	I-Premise
424	difference	_	_	I-Premise
425	was	_	_	I-Premise
426	found	_	_	I-Premise
427	in	_	_	I-Premise
428	the	_	_	I-Premise
429	overall	_	_	I-Premise
430	quality	_	_	I-Premise
431	of	_	_	I-Premise
432	life	_	_	I-Premise
433	measure	_	_	I-Premise
434	,	_	_	I-Premise
435	with	_	_	I-Premise
436	the	_	_	I-Premise
437	no	_	_	I-Premise
438	RT	_	_	I-Premise
439	group	_	_	I-Premise
440	having	_	_	I-Premise
441	0	_	_	I-Premise
442	.	_	_	I-Premise

443	36	_	_	I-Premise
444	units	_	_	I-Premise
445	greater	_	_	I-Premise
446	quality	_	_	I-Premise
447	of	_	_	I-Premise
448	life	_	_	I-Premise
449	than	_	_	I-Premise
450	the	_	_	I-Premise
451	RT	_	_	I-Premise
452	group	_	_	I-Premise
453	(	_	_	I-Premise
454	95	_	_	I-Premise
455	%	_	_	I-Premise
456	CI	_	_	I-Premise
457	-	_	_	I-Premise
458	5	_	_	I-Premise
459	.	_	_	I-Premise

460	09	_	_	I-Premise
461	to	_	_	I-Premise
462	5	_	_	I-Premise
463	.	_	_	I-Premise

464	81	_	_	I-Premise
465	)	_	_	I-Premise
466	.	_	_	I-Premise

467	Breast	_	_	B-Claim
468	RT	_	_	I-Claim
469	is	_	_	I-Claim
470	tolerated	_	_	I-Claim
471	well	_	_	I-Claim
472	by	_	_	I-Claim
473	most	_	_	I-Claim
474	older	_	_	I-Claim
475	breast	_	_	I-Claim
476	cancer	_	_	I-Claim
477	patients	_	_	I-Claim
478	without	_	_	I-Claim
479	impairing	_	_	I-Claim
480	their	_	_	I-Claim
481	overall	_	_	I-Claim
482	health	_	_	I-Claim
483	-	_	_	I-Claim
484	related	_	_	I-Claim
485	quality	_	_	I-Claim
486	of	_	_	I-Claim
487	life	_	_	I-Claim
488	(	_	_	I-Claim
489	HRQoL	_	_	I-Claim
490	)	_	_	I-Claim
491	.	_	_	I-Claim

492	Although	_	_	O
493	HRQoL	_	_	O
494	should	_	_	O
495	always	_	_	O
496	be	_	_	O
497	taken	_	_	O
498	into	_	_	O
499	account	_	_	O
500	when	_	_	O
501	determining	_	_	O
502	treatment	_	_	O
503	,	_	_	O
504	our	_	_	B-Claim
505	results	_	_	I-Claim
506	show	_	_	I-Claim
507	that	_	_	I-Claim
508	the	_	_	I-Claim
509	addition	_	_	I-Claim
510	of	_	_	I-Claim
511	RT	_	_	I-Claim
512	does	_	_	I-Claim
513	not	_	_	I-Claim
514	impair	_	_	I-Claim
515	overall	_	_	I-Claim
516	quality	_	_	I-Claim
517	of	_	_	I-Claim
518	life	_	_	I-Claim
519	.	_	_	I-Claim

520	Further	_	_	B-Claim
521	economic	_	_	I-Claim
522	modelling	_	_	I-Claim
523	on	_	_	I-Claim
524	the	_	_	I-Claim
525	longer	_	_	I-Claim
526	-	_	_	I-Claim
527	term	_	_	I-Claim
528	costs	_	_	I-Claim
529	and	_	_	I-Claim
530	consequences	_	_	I-Claim
531	of	_	_	I-Claim
532	omitting	_	_	I-Claim
533	RT	_	_	I-Claim
534	is	_	_	I-Claim
535	required	_	_	I-Claim
536	.	_	_	I-Claim


0	Restorative	_	_	O
1	proctocolectomy	_	_	O
2	with	_	_	O
3	ileal	_	_	O
4	pouch	_	_	O
5	-	_	_	O
6	anal	_	_	O
7	anastomosis	_	_	O
8	(	_	_	O
9	IPAA	_	_	O
10	)	_	_	O
11	is	_	_	O
12	the	_	_	O
13	standard	_	_	O
14	surgical	_	_	O
15	procedure	_	_	O
16	for	_	_	O
17	ulcerative	_	_	O
18	colitis	_	_	O
19	(	_	_	O
20	UC	_	_	O
21	)	_	_	O
22	and	_	_	O
23	familial	_	_	O
24	adenomatous	_	_	O
25	polyposis	_	_	O
26	(	_	_	O
27	FAP	_	_	O
28	)	_	_	O
29	.	_	_	O

30	While	_	_	O
31	minimal	_	_	O
32	invasive	_	_	O
33	techniques	_	_	O
34	have	_	_	O
35	been	_	_	O
36	applied	_	_	O
37	increasingly	_	_	O
38	,	_	_	O
39	clear	_	_	O
40	evidence	_	_	O
41	of	_	_	O
42	superiority	_	_	O
43	for	_	_	O
44	laparoscopic	_	_	O
45	pouch	_	_	O
46	procedures	_	_	O
47	is	_	_	O
48	not	_	_	O
49	yet	_	_	O
50	available	_	_	O
51	.	_	_	O

52	The	_	_	O
53	aim	_	_	O
54	of	_	_	O
55	the	_	_	O
56	LapConPouch	_	_	O
57	Trial	_	_	O
58	was	_	_	O
59	to	_	_	O
60	compare	_	_	O
61	the	_	_	O
62	effectiveness	_	_	O
63	of	_	_	O
64	laparoscopic	_	_	O
65	(	_	_	O
66	LAP	_	_	O
67	)	_	_	O
68	versus	_	_	O
69	conventional	_	_	O
70	(	_	_	O
71	CON	_	_	O
72	)	_	_	O
73	ileoanal	_	_	O
74	pouch	_	_	O
75	procedure	_	_	O
76	in	_	_	O
77	patients	_	_	O
78	undergoing	_	_	O
79	elective	_	_	O
80	restorative	_	_	O
81	proctocolectomy	_	_	O
82	.	_	_	O

83	The	_	_	O
84	trial	_	_	O
85	was	_	_	O
86	designed	_	_	O
87	as	_	_	O
88	a	_	_	O
89	single	_	_	O
90	-	_	_	O
91	centre	_	_	O
92	,	_	_	O
93	pre	_	_	O
94	-	_	_	O
95	operatively	_	_	O
96	randomized	_	_	O
97	,	_	_	O
98	controlled	_	_	O
99	trial	_	_	O
100	using	_	_	O
101	a	_	_	O
102	two	_	_	O
103	-	_	_	O
104	group	_	_	O
105	parallel	_	_	O
106	superiority	_	_	O
107	design	_	_	O
108	.	_	_	O

109	Eligible	_	_	O
110	for	_	_	O
111	participation	_	_	O
112	were	_	_	O
113	patients	_	_	O
114	scheduled	_	_	O
115	for	_	_	O
116	restorative	_	_	O
117	proctocolectomy	_	_	O
118	either	_	_	O
119	for	_	_	O
120	FAP	_	_	O
121	or	_	_	O
122	for	_	_	O
123	UC	_	_	O
124	.	_	_	O

125	Patients	_	_	O
126	and	_	_	O
127	outcome	_	_	O
128	assessors	_	_	O
129	were	_	_	O
130	blinded	_	_	O
131	to	_	_	O
132	group	_	_	O
133	assignment	_	_	O
134	.	_	_	O

135	The	_	_	O
136	primary	_	_	O
137	endpoint	_	_	O
138	was	_	_	O
139	defined	_	_	O
140	as	_	_	O
141	the	_	_	O
142	amount	_	_	O
143	of	_	_	O
144	blood	_	_	O
145	loss	_	_	O
146	.	_	_	O

147	Statistical	_	_	O
148	analyses	_	_	O
149	were	_	_	O
150	explorative	_	_	O
151	since	_	_	O
152	the	_	_	O
153	trial	_	_	O
154	had	_	_	O
155	to	_	_	O
156	be	_	_	O
157	stopped	_	_	O
158	prematurely	_	_	O
159	.	_	_	O

160	A	_	_	O
161	total	_	_	O
162	of	_	_	O
163	42	_	_	O
164	patients	_	_	O
165	(	_	_	O
166	21	_	_	O
167	LAP	_	_	O
168	(	_	_	O
169	50	_	_	O
170	.	_	_	O

171	0	_	_	O
172	%	_	_	O
173	)	_	_	O
174	;	_	_	O
175	21	_	_	O
176	CON	_	_	O
177	(	_	_	O
178	50	_	_	O
179	.	_	_	O

180	0	_	_	O
181	%	_	_	O
182	)	_	_	O
183	)	_	_	O
184	were	_	_	O
185	randomized	_	_	O
186	.	_	_	O

187	The	_	_	B-Premise
188	trial	_	_	I-Premise
189	had	_	_	I-Premise
190	to	_	_	I-Premise
191	be	_	_	I-Premise
192	stopped	_	_	I-Premise
193	prematurely	_	_	I-Premise
194	due	_	_	I-Premise
195	to	_	_	I-Premise
196	insufficient	_	_	I-Premise
197	patient	_	_	I-Premise
198	recruitment	_	_	I-Premise
199	.	_	_	I-Premise

200	There	_	_	B-Premise
201	was	_	_	I-Premise
202	no	_	_	I-Premise
203	difference	_	_	I-Premise
204	in	_	_	I-Premise
205	the	_	_	I-Premise
206	amount	_	_	I-Premise
207	of	_	_	I-Premise
208	blood	_	_	I-Premise
209	loss	_	_	I-Premise
210	between	_	_	I-Premise
211	both	_	_	I-Premise
212	groups	_	_	I-Premise
213	:	_	_	I-Premise
214	LAP	_	_	I-Premise
215	261	_	_	I-Premise
216	.	_	_	I-Premise

217	5	_	_	I-Premise
218	±	_	_	I-Premise
219	195	_	_	I-Premise
220	.	_	_	I-Premise

221	4	_	_	I-Premise
222	ml	_	_	I-Premise
223	,	_	_	I-Premise
224	CON	_	_	I-Premise
225	228	_	_	I-Premise
226	.	_	_	I-Premise

227	1	_	_	I-Premise
228	±	_	_	I-Premise
229	119	_	_	I-Premise
230	.	_	_	I-Premise

231	5	_	_	I-Premise
232	ml	_	_	I-Premise
233	.	_	_	I-Premise

234	Secondary	_	_	O
235	endpoints	_	_	O
236	differ	_	_	O
237	in	_	_	O
238	both	_	_	O
239	groups	_	_	O
240	.	_	_	O

241	Laparoscopic	_	_	B-Claim
242	surgery	_	_	I-Claim
243	was	_	_	I-Claim
244	superior	_	_	I-Claim
245	regarding	_	_	I-Claim
246	the	_	_	I-Claim
247	length	_	_	I-Claim
248	of	_	_	I-Claim
249	skin	_	_	I-Claim
250	incision	_	_	I-Claim
251	;	_	_	I-Claim
252	in	_	_	O
253	contrast	_	_	O
254	,	_	_	O
255	the	_	_	B-Claim
256	conventional	_	_	I-Claim
257	approach	_	_	I-Claim
258	was	_	_	I-Claim
259	superior	_	_	I-Claim
260	in	_	_	I-Claim
261	duration	_	_	I-Claim
262	of	_	_	I-Claim
263	operation	_	_	I-Claim
264	.	_	_	I-Claim

265	There	_	_	B-Premise
266	were	_	_	I-Premise
267	no	_	_	I-Premise
268	discrepancies	_	_	I-Premise
269	in	_	_	I-Premise
270	length	_	_	I-Premise
271	of	_	_	I-Premise
272	hospital	_	_	I-Premise
273	stay	_	_	I-Premise
274	,	_	_	I-Premise
275	postoperative	_	_	I-Premise
276	pain	_	_	I-Premise
277	,	_	_	I-Premise
278	bowel	_	_	I-Premise
279	function	_	_	I-Premise
280	,	_	_	I-Premise
281	and	_	_	I-Premise
282	quality	_	_	I-Premise
283	of	_	_	I-Premise
284	life	_	_	I-Premise
285	between	_	_	I-Premise
286	both	_	_	I-Premise
287	approaches	_	_	I-Premise
288	.	_	_	I-Premise

289	The	_	_	O
290	conversion	_	_	O
291	rate	_	_	O
292	from	_	_	O
293	LAP	_	_	O
294	to	_	_	O
295	CON	_	_	O
296	approach	_	_	O
297	was	_	_	O
298	23	_	_	O
299	.	_	_	O

300	8	_	_	O
301	%	_	_	O
302	.	_	_	O

303	There	_	_	B-Claim
304	was	_	_	I-Claim
305	no	_	_	I-Claim
306	difference	_	_	I-Claim
307	with	_	_	I-Claim
308	respect	_	_	I-Claim
309	to	_	_	I-Claim
310	blood	_	_	I-Claim
311	loss	_	_	I-Claim
312	between	_	_	I-Claim
313	the	_	_	I-Claim
314	LAP	_	_	I-Claim
315	and	_	_	I-Claim
316	the	_	_	I-Claim
317	CON	_	_	I-Claim
318	group	_	_	I-Claim
319	.	_	_	I-Claim

320	The	_	_	B-Claim
321	LAP	_	_	I-Claim
322	approach	_	_	I-Claim
323	is	_	_	I-Claim
324	feasible	_	_	I-Claim
325	for	_	_	I-Claim
326	restorative	_	_	I-Claim
327	proctocolectomy	_	_	I-Claim
328	,	_	_	I-Claim
329	and	_	_	I-Claim
330	IPAA	_	_	I-Claim
331	seems	_	_	I-Claim
332	at	_	_	I-Claim
333	least	_	_	I-Claim
334	as	_	_	I-Claim
335	safe	_	_	I-Claim
336	as	_	_	I-Claim
337	CON	_	_	I-Claim
338	surgery	_	_	I-Claim
339	.	_	_	I-Claim

340	The	_	_	O
341	most	_	_	O
342	obvious	_	_	O
343	advantage	_	_	O
344	of	_	_	O
345	the	_	_	O
346	minimal	_	_	O
347	invasive	_	_	O
348	technique	_	_	O
349	is	_	_	O
350	the	_	_	O
351	improved	_	_	O
352	cosmesis	_	_	O
353	.	_	_	O


0	Older	_	_	B-Claim
1	patients	_	_	I-Claim
2	,	_	_	I-Claim
3	even	_	_	I-Claim
4	if	_	_	I-Claim
5	fit	_	_	I-Claim
6	,	_	_	I-Claim
7	are	_	_	I-Claim
8	often	_	_	I-Claim
9	considered	_	_	I-Claim
10	incapable	_	_	I-Claim
11	of	_	_	I-Claim
12	tolerating	_	_	I-Claim
13	platinum	_	_	I-Claim
14	-	_	_	I-Claim
15	based	_	_	I-Claim
16	systemic	_	_	I-Claim
17	therapy	_	_	I-Claim
18	.	_	_	I-Claim

19	We	_	_	O
20	performed	_	_	O
21	a	_	_	O
22	retrospective	_	_	O
23	analysis	_	_	O
24	of	_	_	O
25	Eastern	_	_	O
26	Cooperative	_	_	O
27	Oncology	_	_	O
28	Group	_	_	O
29	(	_	_	O
30	ECOG	_	_	O
31	)	_	_	O
32	5592	_	_	O
33	,	_	_	O
34	a	_	_	O
35	phase	_	_	O
36	III	_	_	O
37	randomized	_	_	O
38	trial	_	_	O
39	of	_	_	O
40	platinum	_	_	O
41	-	_	_	O
42	based	_	_	O
43	chemotherapy	_	_	O
44	regimens	_	_	O
45	for	_	_	O
46	non	_	_	O
47	-	_	_	O
48	small	_	_	O
49	-	_	_	O
50	cell	_	_	O
51	lung	_	_	O
52	cancer	_	_	O
53	(	_	_	O
54	NSCLC	_	_	O
55	)	_	_	O
56	,	_	_	O
57	and	_	_	O
58	compared	_	_	O
59	outcomes	_	_	O
60	in	_	_	O
61	enrollees	_	_	O
62	70	_	_	O
63	years	_	_	O
64	of	_	_	O
65	age	_	_	O
66	and	_	_	O
67	older	_	_	O
68	with	_	_	O
69	those	_	_	O
70	in	_	_	O
71	younger	_	_	O
72	patients	_	_	O
73	.	_	_	O

74	ECOG	_	_	O
75	carried	_	_	O
76	out	_	_	O
77	a	_	_	O
78	randomized	_	_	O
79	phase	_	_	O
80	III	_	_	O
81	trial	_	_	O
82	of	_	_	O
83	cisplatin	_	_	O
84	plus	_	_	O
85	either	_	_	O
86	etoposide	_	_	O
87	or	_	_	O
88	paclitaxel	_	_	O
89	in	_	_	O
90	chemotherapy	_	_	O
91	-	_	_	O
92	naïve	_	_	O
93	NSCLC	_	_	O
94	patients	_	_	O
95	with	_	_	O
96	stages	_	_	O
97	III	_	_	O
98	(	_	_	O
99	B	_	_	O
100	)	_	_	O
101	or	_	_	O
102	IV	_	_	O
103	disease	_	_	O
104	.	_	_	O

105	Toxic	_	_	O
106	effects	_	_	O
107	,	_	_	O
108	response	_	_	O
109	rates	_	_	O
110	,	_	_	O
111	and	_	_	O
112	survival	_	_	O
113	rates	_	_	O
114	were	_	_	O
115	compared	_	_	O
116	between	_	_	O
117	age	_	_	O
118	groups	_	_	O
119	.	_	_	O

120	All	_	_	O
121	P	_	_	O
122	values	_	_	O
123	were	_	_	O
124	two	_	_	O
125	-	_	_	O
126	sided	_	_	O
127	.	_	_	O

128	A	_	_	O
129	total	_	_	O
130	of	_	_	O
131	574	_	_	O
132	patients	_	_	O
133	enrolled	_	_	O
134	from	_	_	O
135	August	_	_	O
136	1993	_	_	O
137	through	_	_	O
138	December	_	_	O
139	1994	_	_	O
140	were	_	_	O
141	evaluable	_	_	O
142	.	_	_	O

143	Eighty	_	_	O
144	-	_	_	O
145	six	_	_	O
146	(	_	_	O
147	15	_	_	O
148	%	_	_	O
149	)	_	_	O
150	were	_	_	O
151	70	_	_	O
152	years	_	_	O
153	old	_	_	O
154	or	_	_	O
155	older	_	_	O
156	.	_	_	O

157	Older	_	_	B-Premise
158	patients	_	_	I-Premise
159	had	_	_	I-Premise
160	a	_	_	I-Premise
161	higher	_	_	I-Premise
162	incidence	_	_	I-Premise
163	of	_	_	I-Premise
164	cardiovascular	_	_	I-Premise
165	(	_	_	I-Premise
166	P	_	_	I-Premise
167	=	_	_	I-Premise
168	.	_	_	I-Premise

169	009	_	_	I-Premise
170	)	_	_	I-Premise
171	and	_	_	I-Premise
172	respiratory	_	_	I-Premise
173	(	_	_	I-Premise
174	P	_	_	I-Premise
175	=	_	_	I-Premise
176	.	_	_	I-Premise

177	04	_	_	I-Premise
178	)	_	_	I-Premise
179	comorbidities	_	_	I-Premise
180	and	_	_	I-Premise
181	nonanalgesic	_	_	I-Premise
182	medication	_	_	I-Premise
183	use	_	_	I-Premise
184	(	_	_	I-Premise
185	P	_	_	I-Premise
186	=	_	_	I-Premise
187	.	_	_	I-Premise

188	02	_	_	I-Premise
189	)	_	_	I-Premise
190	.	_	_	I-Premise

191	Leukopenia	_	_	B-Premise
192	(	_	_	I-Premise
193	P	_	_	I-Premise
194	<	_	_	I-Premise
195	.	_	_	I-Premise

196	001	_	_	I-Premise
197	)	_	_	I-Premise
198	and	_	_	I-Premise
199	neuropsychiatric	_	_	I-Premise
200	toxicity	_	_	I-Premise
201	(	_	_	I-Premise
202	P	_	_	I-Premise
203	=	_	_	I-Premise
204	.	_	_	I-Premise

205	002	_	_	I-Premise
206	)	_	_	I-Premise
207	were	_	_	I-Premise
208	more	_	_	I-Premise
209	common	_	_	I-Premise
210	in	_	_	I-Premise
211	elderly	_	_	I-Premise
212	men	_	_	I-Premise
213	than	_	_	I-Premise
214	in	_	_	I-Premise
215	younger	_	_	I-Premise
216	men	_	_	I-Premise
217	.	_	_	I-Premise

218	Elderly	_	_	B-Premise
219	women	_	_	I-Premise
220	lost	_	_	I-Premise
221	more	_	_	I-Premise
222	weight	_	_	I-Premise
223	than	_	_	I-Premise
224	younger	_	_	I-Premise
225	women	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	.	_	_	I-Premise

230	006	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	Other	_	_	B-Premise
234	toxic	_	_	I-Premise
235	effects	_	_	I-Premise
236	were	_	_	I-Premise
237	similar	_	_	I-Premise
238	in	_	_	I-Premise
239	older	_	_	I-Premise
240	and	_	_	I-Premise
241	younger	_	_	I-Premise
242	patients	_	_	I-Premise
243	.	_	_	I-Premise

244	The	_	_	B-Premise
245	proportions	_	_	I-Premise
246	with	_	_	I-Premise
247	clinical	_	_	I-Premise
248	partial	_	_	I-Premise
249	or	_	_	I-Premise
250	complete	_	_	I-Premise
251	response	_	_	I-Premise
252	(	_	_	I-Premise
253	21	_	_	I-Premise
254	.	_	_	I-Premise

255	5	_	_	I-Premise
256	%	_	_	I-Premise
257	versus	_	_	I-Premise
258	23	_	_	I-Premise
259	.	_	_	I-Premise

260	3	_	_	I-Premise
261	%	_	_	I-Premise
262	;	_	_	I-Premise
263	Fisher	_	_	I-Premise
264	'	_	_	I-Premise
265	s	_	_	I-Premise
266	exact	_	_	I-Premise
267	test	_	_	I-Premise
268	,	_	_	I-Premise
269	P	_	_	I-Premise
270	=	_	_	I-Premise
271	.	_	_	I-Premise

272	66	_	_	I-Premise
273	)	_	_	I-Premise
274	,	_	_	I-Premise
275	median	_	_	I-Premise
276	time	_	_	I-Premise
277	to	_	_	I-Premise
278	progression	_	_	I-Premise
279	(	_	_	I-Premise
280	4	_	_	I-Premise
281	.	_	_	I-Premise

282	37	_	_	I-Premise
283	versus	_	_	I-Premise
284	4	_	_	I-Premise
285	.	_	_	I-Premise

286	30	_	_	I-Premise
287	months	_	_	I-Premise
288	;	_	_	I-Premise
289	log	_	_	I-Premise
290	-	_	_	I-Premise
291	rank	_	_	I-Premise
292	test	_	_	I-Premise
293	,	_	_	I-Premise
294	P	_	_	I-Premise
295	=	_	_	I-Premise
296	.	_	_	I-Premise

297	29	_	_	I-Premise
298	)	_	_	I-Premise
299	,	_	_	I-Premise
300	and	_	_	I-Premise
301	survival	_	_	I-Premise
302	distribution	_	_	I-Premise
303	(	_	_	I-Premise
304	log	_	_	I-Premise
305	-	_	_	I-Premise
306	rank	_	_	I-Premise
307	test	_	_	I-Premise
308	,	_	_	I-Premise
309	P	_	_	I-Premise
310	=	_	_	I-Premise
311	.	_	_	I-Premise

312	29	_	_	I-Premise
313	;	_	_	I-Premise
314	median	_	_	I-Premise
315	survival	_	_	I-Premise
316	,	_	_	I-Premise
317	9	_	_	I-Premise
318	.	_	_	I-Premise

319	05	_	_	I-Premise
320	versus	_	_	I-Premise
321	8	_	_	I-Premise
322	.	_	_	I-Premise

323	53	_	_	I-Premise
324	months	_	_	I-Premise
325	;	_	_	I-Premise
326	1	_	_	I-Premise
327	-	_	_	I-Premise
328	year	_	_	I-Premise
329	survival	_	_	I-Premise
330	,	_	_	I-Premise
331	38	_	_	I-Premise
332	%	_	_	I-Premise
333	versus	_	_	I-Premise
334	29	_	_	I-Premise
335	%	_	_	I-Premise
336	;	_	_	I-Premise
337	and	_	_	I-Premise
338	2	_	_	I-Premise
339	-	_	_	I-Premise
340	year	_	_	I-Premise
341	survival	_	_	I-Premise
342	,	_	_	I-Premise
343	14	_	_	I-Premise
344	%	_	_	I-Premise
345	versus	_	_	I-Premise
346	12	_	_	I-Premise
347	%	_	_	I-Premise
348	)	_	_	I-Premise
349	were	_	_	I-Premise
350	similar	_	_	I-Premise
351	in	_	_	I-Premise
352	patients	_	_	I-Premise
353	younger	_	_	I-Premise
354	than	_	_	I-Premise
355	70	_	_	I-Premise
356	years	_	_	I-Premise
357	and	_	_	I-Premise
358	70	_	_	I-Premise
359	years	_	_	I-Premise
360	old	_	_	I-Premise
361	or	_	_	I-Premise
362	older	_	_	I-Premise
363	.	_	_	I-Premise

364	Baseline	_	_	B-Premise
365	quality	_	_	I-Premise
366	-	_	_	I-Premise
367	of	_	_	I-Premise
368	-	_	_	I-Premise
369	life	_	_	I-Premise
370	and	_	_	I-Premise
371	treatment	_	_	I-Premise
372	-	_	_	I-Premise
373	outcome	_	_	I-Premise
374	indices	_	_	I-Premise
375	were	_	_	I-Premise
376	similar	_	_	I-Premise
377	.	_	_	I-Premise

378	Equivalent	_	_	B-Premise
379	declines	_	_	I-Premise
380	over	_	_	I-Premise
381	time	_	_	I-Premise
382	in	_	_	I-Premise
383	functional	_	_	I-Premise
384	well	_	_	I-Premise
385	-	_	_	I-Premise
386	being	_	_	I-Premise
387	occurred	_	_	I-Premise
388	in	_	_	I-Premise
389	both	_	_	I-Premise
390	groups	_	_	I-Premise
391	.	_	_	I-Premise

392	Response	_	_	B-Claim
393	rate	_	_	I-Claim
394	,	_	_	I-Claim
395	toxicity	_	_	I-Claim
396	,	_	_	I-Claim
397	and	_	_	I-Claim
398	survival	_	_	I-Claim
399	in	_	_	I-Claim
400	fit	_	_	I-Claim
401	,	_	_	I-Claim
402	elderly	_	_	I-Claim
403	NSCLC	_	_	I-Claim
404	patients	_	_	I-Claim
405	receiving	_	_	I-Claim
406	platinum	_	_	I-Claim
407	-	_	_	I-Claim
408	based	_	_	I-Claim
409	treatment	_	_	I-Claim
410	appear	_	_	I-Claim
411	to	_	_	I-Claim
412	be	_	_	I-Claim
413	similar	_	_	I-Claim
414	to	_	_	I-Claim
415	those	_	_	I-Claim
416	in	_	_	I-Claim
417	younger	_	_	I-Claim
418	patients	_	_	I-Claim
419	,	_	_	I-Claim
420	although	_	_	B-Claim
421	patients	_	_	I-Claim
422	70	_	_	I-Claim
423	years	_	_	I-Claim
424	old	_	_	I-Claim
425	or	_	_	I-Claim
426	older	_	_	I-Claim
427	have	_	_	I-Claim
428	more	_	_	I-Claim
429	comorbidities	_	_	I-Claim
430	and	_	_	I-Claim
431	can	_	_	I-Claim
432	expect	_	_	I-Claim
433	more	_	_	I-Claim
434	leukopenia	_	_	I-Claim
435	and	_	_	I-Claim
436	neuropsychiatric	_	_	I-Claim
437	toxicity	_	_	I-Claim
438	.	_	_	I-Claim

439	Advanced	_	_	B-Claim
440	age	_	_	I-Claim
441	alone	_	_	I-Claim
442	should	_	_	I-Claim
443	not	_	_	I-Claim
444	preclude	_	_	I-Claim
445	appropriate	_	_	I-Claim
446	NSCLC	_	_	I-Claim
447	treatment	_	_	I-Claim
448	.	_	_	I-Claim


0	In	_	_	O
1	anorectal	_	_	O
2	cancer	_	_	O
3	patients	_	_	O
4	,	_	_	O
5	an	_	_	O
6	acute	_	_	O
7	side	_	_	O
8	effect	_	_	O
9	of	_	_	O
10	chemoradiotherapy	_	_	O
11	is	_	_	O
12	gastrointestinal	_	_	O
13	toxicity	_	_	O
14	,	_	_	O
15	which	_	_	O
16	often	_	_	O
17	impedes	_	_	O
18	treatment	_	_	O
19	delivery	_	_	O
20	.	_	_	O

21	Based	_	_	O
22	on	_	_	O
23	previous	_	_	O
24	trials	_	_	O
25	,	_	_	O
26	octreotide	_	_	O
27	acetate	_	_	O
28	is	_	_	O
29	widely	_	_	O
30	recommended	_	_	O
31	for	_	_	O
32	the	_	_	O
33	control	_	_	O
34	of	_	_	O
35	chemotherapy	_	_	O
36	-	_	_	O
37	induced	_	_	O
38	diarrhea	_	_	O
39	.	_	_	O

40	However	_	_	O
41	,	_	_	O
42	the	_	_	O
43	effectiveness	_	_	O
44	of	_	_	O
45	octreotide	_	_	O
46	in	_	_	O
47	preventing	_	_	O
48	or	_	_	O
49	controlling	_	_	O
50	radiation	_	_	O
51	-	_	_	O
52	and	_	_	O
53	chemoradiation	_	_	O
54	-	_	_	O
55	induced	_	_	O
56	diarrhea	_	_	O
57	is	_	_	O
58	not	_	_	O
59	known	_	_	O
60	.	_	_	O

61	A	_	_	O
62	randomized	_	_	O
63	,	_	_	O
64	double	_	_	O
65	-	_	_	O
66	blinded	_	_	O
67	,	_	_	O
68	placebo	_	_	O
69	-	_	_	O
70	controlled	_	_	O
71	trial	_	_	O
72	was	_	_	O
73	designed	_	_	O
74	to	_	_	O
75	determine	_	_	O
76	the	_	_	O
77	efficacy	_	_	O
78	of	_	_	O
79	long	_	_	O
80	-	_	_	O
81	acting	_	_	O
82	octreotide	_	_	O
83	acetate	_	_	O
84	(	_	_	O
85	LAO	_	_	O
86	)	_	_	O
87	in	_	_	O
88	preventing	_	_	O
89	the	_	_	O
90	onset	_	_	O
91	of	_	_	O
92	acute	_	_	O
93	diarrhea	_	_	O
94	in	_	_	O
95	patients	_	_	O
96	undergoing	_	_	O
97	chemoradiation	_	_	O
98	therapy	_	_	O
99	for	_	_	O
100	rectal	_	_	O
101	or	_	_	O
102	anal	_	_	O
103	cancer	_	_	O
104	.	_	_	O

105	Between	_	_	O
106	4	_	_	O
107	and	_	_	O
108	7	_	_	O
109	days	_	_	O
110	before	_	_	O
111	the	_	_	O
112	start	_	_	O
113	of	_	_	O
114	radiation	_	_	O
115	therapy	_	_	O
116	,	_	_	O
117	patients	_	_	O
118	received	_	_	O
119	a	_	_	O
120	30	_	_	O
121	-	_	_	O
122	mg	_	_	O
123	dose	_	_	O
124	of	_	_	O
125	LAO	_	_	O
126	(	_	_	O
127	109	_	_	O
128	patients	_	_	O
129	)	_	_	O
130	or	_	_	O
131	placebo	_	_	O
132	(	_	_	O
133	106	_	_	O
134	patients	_	_	O
135	)	_	_	O
136	via	_	_	O
137	intramuscular	_	_	O
138	injection	_	_	O
139	.	_	_	O

140	A	_	_	O
141	second	_	_	O
142	dose	_	_	O
143	was	_	_	O
144	given	_	_	O
145	on	_	_	O
146	day	_	_	O
147	22	_	_	O
148	(	_	_	O
149	+	_	_	O
150	/	_	_	O
151	-	_	_	O
152	3	_	_	O
153	days	_	_	O
154	)	_	_	O
155	of	_	_	O
156	radiation	_	_	O
157	treatment	_	_	O
158	.	_	_	O

159	A	_	_	O
160	total	_	_	O
161	of	_	_	O
162	215	_	_	O
163	patients	_	_	O
164	were	_	_	O
165	included	_	_	O
166	in	_	_	O
167	the	_	_	O
168	final	_	_	O
169	analysis	_	_	O
170	.	_	_	O

171	The	_	_	O
172	primary	_	_	O
173	endpoint	_	_	O
174	was	_	_	O
175	the	_	_	O
176	incidence	_	_	O
177	of	_	_	O
178	grade	_	_	O
179	2	_	_	O
180	-	_	_	O
181	4	_	_	O
182	acute	_	_	O
183	diarrhea	_	_	O
184	;	_	_	O
185	secondary	_	_	O
186	endpoints	_	_	O
187	included	_	_	O
188	treatment	_	_	O
189	compliance	_	_	O
190	,	_	_	O
191	medical	_	_	O
192	resource	_	_	O
193	utilization	_	_	O
194	,	_	_	O
195	patient	_	_	O
196	-	_	_	O
197	reported	_	_	O
198	bowel	_	_	O
199	function	_	_	O
200	,	_	_	O
201	and	_	_	O
202	quality	_	_	O
203	of	_	_	O
204	life	_	_	O
205	(	_	_	O
206	QoL	_	_	O
207	)	_	_	O
208	.	_	_	O

209	Statistical	_	_	O
210	tests	_	_	O
211	were	_	_	O
212	one	_	_	O
213	-	_	_	O
214	or	_	_	O
215	two	_	_	O
216	-	_	_	O
217	sided	_	_	O
218	,	_	_	O
219	as	_	_	O
220	specified	_	_	O
221	.	_	_	O

222	After	_	_	B-Premise
223	a	_	_	I-Premise
224	median	_	_	I-Premise
225	follow	_	_	I-Premise
226	-	_	_	I-Premise
227	up	_	_	I-Premise
228	time	_	_	I-Premise
229	of	_	_	I-Premise
230	9	_	_	I-Premise
231	.	_	_	I-Premise

232	64	_	_	I-Premise
233	months	_	_	I-Premise
234	,	_	_	I-Premise
235	incidence	_	_	I-Premise
236	rates	_	_	I-Premise
237	of	_	_	I-Premise
238	grades	_	_	I-Premise
239	2	_	_	I-Premise
240	-	_	_	I-Premise
241	4	_	_	I-Premise
242	acute	_	_	I-Premise
243	diarrhea	_	_	I-Premise
244	were	_	_	I-Premise
245	similar	_	_	I-Premise
246	in	_	_	I-Premise
247	both	_	_	I-Premise
248	groups	_	_	I-Premise
249	(	_	_	I-Premise
250	49	_	_	I-Premise
251	%	_	_	I-Premise
252	placebo	_	_	I-Premise
253	vs	_	_	I-Premise
254	44	_	_	I-Premise
255	%	_	_	I-Premise
256	LAO	_	_	I-Premise
257	;	_	_	I-Premise
258	P	_	_	I-Premise
259	=	_	_	I-Premise
260	.	_	_	I-Premise

261	21	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	No	_	_	B-Premise
265	statistically	_	_	I-Premise
266	significant	_	_	I-Premise
267	treatment	_	_	I-Premise
268	differences	_	_	I-Premise
269	in	_	_	I-Premise
270	chemotherapy	_	_	I-Premise
271	or	_	_	I-Premise
272	radiation	_	_	I-Premise
273	delivery	_	_	I-Premise
274	,	_	_	I-Premise
275	medical	_	_	I-Premise
276	resource	_	_	I-Premise
277	utilization	_	_	I-Premise
278	,	_	_	I-Premise
279	patient	_	_	I-Premise
280	-	_	_	I-Premise
281	reported	_	_	I-Premise
282	bowel	_	_	I-Premise
283	function	_	_	I-Premise
284	,	_	_	I-Premise
285	or	_	_	I-Premise
286	QoL	_	_	I-Premise
287	were	_	_	I-Premise
288	observed	_	_	I-Premise
289	.	_	_	I-Premise

290	In	_	_	B-Claim
291	this	_	_	I-Claim
292	study	_	_	I-Claim
293	,	_	_	I-Claim
294	the	_	_	I-Claim
295	prophylactic	_	_	I-Claim
296	use	_	_	I-Claim
297	of	_	_	I-Claim
298	LAO	_	_	I-Claim
299	did	_	_	I-Claim
300	not	_	_	I-Claim
301	prevent	_	_	I-Claim
302	the	_	_	I-Claim
303	incidence	_	_	I-Claim
304	or	_	_	I-Claim
305	reduce	_	_	I-Claim
306	the	_	_	I-Claim
307	severity	_	_	I-Claim
308	of	_	_	I-Claim
309	diarrhea	_	_	I-Claim
310	and	_	_	I-Claim
311	had	_	_	I-Claim
312	no	_	_	I-Claim
313	notable	_	_	I-Claim
314	impact	_	_	I-Claim
315	on	_	_	I-Claim
316	patient	_	_	I-Claim
317	-	_	_	I-Claim
318	reported	_	_	I-Claim
319	bowel	_	_	I-Claim
320	function	_	_	I-Claim
321	or	_	_	I-Claim
322	QoL	_	_	I-Claim
323	.	_	_	I-Claim


0	The	_	_	O
1	role	_	_	O
2	of	_	_	O
3	chemotherapy	_	_	O
4	for	_	_	O
5	advanced	_	_	O
6	NSCLC	_	_	O
7	patients	_	_	O
8	and	_	_	O
9	ECOG	_	_	O
10	PS2	_	_	O
11	remains	_	_	O
12	controversial	_	_	O
13	.	_	_	O

14	We	_	_	O
15	evaluated	_	_	O
16	4	_	_	O
17	doses	_	_	O
18	of	_	_	O
19	3	_	_	O
20	-	_	_	O
21	weekly	_	_	O
22	docetaxel	_	_	O
23	to	_	_	O
24	identify	_	_	O
25	a	_	_	O
26	less	_	_	O
27	toxic	_	_	O
28	,	_	_	O
29	clinically	_	_	O
30	effective	_	_	O
31	dose	_	_	O
32	.	_	_	O

33	Seventy	_	_	O
34	-	_	_	O
35	three	_	_	O
36	patients	_	_	O
37	with	_	_	O
38	stage	_	_	O
39	III	_	_	O
40	(	_	_	O
41	22	_	_	O
42	%	_	_	O
43	)	_	_	O
44	(	_	_	O
45	unsuitable	_	_	O
46	for	_	_	O
47	radical	_	_	O
48	surgery	_	_	O
49	/	_	_	O
50	radiotherapy	_	_	O
51	)	_	_	O
52	and	_	_	O
53	IV	_	_	O
54	(	_	_	O
55	78	_	_	O
56	%	_	_	O
57	)	_	_	O
58	NSCLC	_	_	O
59	were	_	_	O
60	randomized	_	_	O
61	to	_	_	O
62	receive	_	_	O
63	4	_	_	O
64	doses	_	_	O
65	of	_	_	O
66	3	_	_	O
67	-	_	_	O
68	weekly	_	_	O
69	docetaxel	_	_	O
70	,	_	_	O
71	for	_	_	O
72	4	_	_	O
73	cycles	_	_	O
74	:	_	_	O
75	arm	_	_	O
76	(	_	_	O
77	A	_	_	O
78	)	_	_	O
79	40	_	_	O
80	mg	_	_	O
81	/	_	_	O
82	m	_	_	O
83	(	_	_	O
84	2	_	_	O
85	)	_	_	O
86	(	_	_	O
87	n	_	_	O
88	=	_	_	O
89	17	_	_	O
90	)	_	_	O
91	,	_	_	O
92	arm	_	_	O
93	(	_	_	O
94	B	_	_	O
95	)	_	_	O
96	50	_	_	O
97	mg	_	_	O
98	/	_	_	O
99	m	_	_	O
100	(	_	_	O
101	2	_	_	O
102	)	_	_	O
103	(	_	_	O
104	n	_	_	O
105	=	_	_	O
106	17	_	_	O
107	)	_	_	O
108	,	_	_	O
109	arm	_	_	O
110	(	_	_	O
111	C	_	_	O
112	)	_	_	O
113	60	_	_	O
114	mg	_	_	O
115	/	_	_	O
116	m	_	_	O
117	(	_	_	O
118	2	_	_	O
119	)	_	_	O
120	(	_	_	O
121	n	_	_	O
122	=	_	_	O
123	19	_	_	O
124	)	_	_	O
125	,	_	_	O
126	arm	_	_	O
127	(	_	_	O
128	D	_	_	O
129	)	_	_	O
130	50	_	_	O
131	mg	_	_	O
132	/	_	_	O
133	m	_	_	O
134	(	_	_	O
135	2	_	_	O
136	)	_	_	O
137	escalated	_	_	O
138	by	_	_	O
139	10	_	_	O
140	mg	_	_	O
141	/	_	_	O
142	m	_	_	O
143	(	_	_	O
144	2	_	_	O
145	)	_	_	O
146	to	_	_	O
147	a	_	_	O
148	maximum	_	_	O
149	of	_	_	O
150	70	_	_	O
151	mg	_	_	O
152	/	_	_	O
153	m	_	_	O
154	(	_	_	O
155	2	_	_	O
156	)	_	_	O
157	(	_	_	O
158	n	_	_	O
159	=	_	_	O
160	19	_	_	O
161	)	_	_	O
162	.	_	_	O

163	Primary	_	_	O
164	endpoints	_	_	O
165	:	_	_	O
166	maximum	_	_	O
167	tolerated	_	_	O
168	dose	_	_	O
169	,	_	_	O
170	RR	_	_	O
171	,	_	_	O
172	duration	_	_	O
173	of	_	_	O
174	response	_	_	O
175	,	_	_	O
176	symptom	_	_	O
177	improvement	_	_	O
178	,	_	_	O
179	toxicity	_	_	O
180	and	_	_	O
181	QoL	_	_	O
182	.	_	_	O

183	Secondary	_	_	O
184	endpoint	_	_	O
185	:	_	_	O
186	overall	_	_	O
187	survival	_	_	O
188	(	_	_	O
189	OS	_	_	O
190	)	_	_	O
191	.	_	_	O

192	Patients	_	_	O
193	and	_	_	O
194	disease	_	_	O
195	characteristics	_	_	O
196	were	_	_	O
197	well	_	_	O
198	balanced	_	_	O
199	.	_	_	O

200	Median	_	_	O
201	age	_	_	O
202	was	_	_	O
203	67	_	_	O
204	(	_	_	O
205	range	_	_	O
206	45	_	_	O
207	-	_	_	O
208	81	_	_	O
209	)	_	_	O
210	,	_	_	O
211	there	_	_	O
212	were	_	_	O
213	32	_	_	O
214	male	_	_	O
215	and	_	_	O
216	41	_	_	O
217	female	_	_	O
218	,	_	_	O
219	histology	_	_	O
220	subtype	_	_	O
221	:	_	_	O
222	squamous	_	_	O
223	/	_	_	O
224	adenocarcinoma	_	_	O
225	/	_	_	O
226	mixed	_	_	O
227	/	_	_	O
228	NOS	_	_	O
229	=	_	_	O
230	42	_	_	O
231	%	_	_	O
232	/	_	_	O
233	49	_	_	O
234	%	_	_	O
235	/	_	_	O
236	4	_	_	O
237	%	_	_	O
238	/	_	_	O
239	5	_	_	O
240	%	_	_	O
241	.	_	_	O

242	Seven	_	_	O
243	patients	_	_	O
244	did	_	_	O
245	not	_	_	O
246	receive	_	_	O
247	any	_	_	O
248	treatment	_	_	O
249	because	_	_	O
250	of	_	_	O
251	deterioration	_	_	O
252	in	_	_	O
253	PS	_	_	O
254	or	_	_	O
255	death	_	_	O
256	.	_	_	O

257	50	_	_	O
258	%	_	_	O
259	of	_	_	O
260	patients	_	_	O
261	in	_	_	O
262	arm	_	_	O
263	D	_	_	O
264	,	_	_	O
265	who	_	_	O
266	received	_	_	O
267	more	_	_	O
268	than	_	_	O
269	one	_	_	O
270	cycle	_	_	O
271	,	_	_	O
272	received	_	_	O
273	dose	_	_	O
274	escalation	_	_	O
275	.	_	_	O

276	There	_	_	B-Premise
277	was	_	_	I-Premise
278	no	_	_	I-Premise
279	statistical	_	_	I-Premise
280	difference	_	_	I-Premise
281	in	_	_	I-Premise
282	the	_	_	I-Premise
283	number	_	_	I-Premise
284	of	_	_	I-Premise
285	cycles	_	_	I-Premise
286	administered	_	_	I-Premise
287	(	_	_	I-Premise
288	arms	_	_	I-Premise
289	A	_	_	I-Premise
290	,	_	_	I-Premise
291	B	_	_	I-Premise
292	and	_	_	I-Premise
293	D	_	_	I-Premise
294	:	_	_	I-Premise
295	median	_	_	I-Premise
296	2	_	_	I-Premise
297	cycles	_	_	I-Premise
298	and	_	_	I-Premise
299	arm	_	_	I-Premise
300	C	_	_	I-Premise
301	:	_	_	I-Premise
302	median	_	_	I-Premise
303	3	_	_	I-Premise
304	cycles	_	_	I-Premise
305	)	_	_	I-Premise
306	and	_	_	I-Premise
307	no	_	_	I-Premise
308	difference	_	_	I-Premise
309	in	_	_	I-Premise
310	RR	_	_	I-Premise
311	:	_	_	I-Premise
312	arm	_	_	I-Premise
313	A	_	_	I-Premise
314	=	_	_	I-Premise
315	6	_	_	I-Premise
316	%	_	_	I-Premise
317	,	_	_	I-Premise
318	arm	_	_	I-Premise
319	B	_	_	I-Premise
320	=	_	_	I-Premise
321	6	_	_	I-Premise
322	%	_	_	I-Premise
323	,	_	_	I-Premise
324	arm	_	_	I-Premise
325	C	_	_	I-Premise
326	=	_	_	I-Premise
327	10	_	_	I-Premise
328	%	_	_	I-Premise
329	,	_	_	I-Premise
330	and	_	_	I-Premise
331	arm	_	_	I-Premise
332	D	_	_	I-Premise
333	=	_	_	I-Premise
334	0	_	_	I-Premise
335	%	_	_	I-Premise
336	.	_	_	I-Premise

337	There	_	_	B-Premise
338	was	_	_	I-Premise
339	no	_	_	I-Premise
340	statistically	_	_	I-Premise
341	significant	_	_	I-Premise
342	difference	_	_	I-Premise
343	in	_	_	I-Premise
344	grade	_	_	I-Premise
345	3	_	_	I-Premise
346	/	_	_	I-Premise
347	4	_	_	I-Premise
348	neutropenia	_	_	I-Premise
349	and	_	_	I-Premise
350	thrombocytopenia	_	_	I-Premise
351	between	_	_	I-Premise
352	the	_	_	I-Premise
353	four	_	_	I-Premise
354	arms	_	_	I-Premise
355	.	_	_	I-Premise

356	No	_	_	B-Premise
357	difference	_	_	I-Premise
358	was	_	_	I-Premise
359	observed	_	_	I-Premise
360	in	_	_	I-Premise
361	hospitalization	_	_	I-Premise
362	rate	_	_	I-Premise
363	,	_	_	I-Premise
364	blood	_	_	I-Premise
365	transfusions	_	_	I-Premise
366	,	_	_	I-Premise
367	antibiotics	_	_	I-Premise
368	administration	_	_	I-Premise
369	and	_	_	I-Premise
370	non	_	_	I-Premise
371	-	_	_	I-Premise
372	haematological	_	_	I-Premise
373	toxicity	_	_	I-Premise
374	.	_	_	I-Premise

375	QoL	_	_	O
376	:	_	_	O
377	no	_	_	O
378	difference	_	_	O
379	in	_	_	O
380	total	_	_	O
381	scores	_	_	O
382	between	_	_	O
383	baseline	_	_	O
384	and	_	_	O
385	cycles	_	_	O
386	1	_	_	O
387	-	_	_	O
388	4	_	_	O
389	.	_	_	O

390	There	_	_	B-Premise
391	was	_	_	I-Premise
392	a	_	_	I-Premise
393	significant	_	_	I-Premise
394	decrease	_	_	I-Premise
395	in	_	_	I-Premise
396	pain	_	_	I-Premise
397	scores	_	_	I-Premise
398	from	_	_	I-Premise
399	baseline	_	_	I-Premise
400	to	_	_	I-Premise
401	post	_	_	I-Premise
402	cycles	_	_	I-Premise
403	2	_	_	I-Premise
404	and	_	_	I-Premise
405	3	_	_	I-Premise
406	(	_	_	I-Premise
407	p	_	_	I-Premise
408	=	_	_	I-Premise
409	0	_	_	I-Premise
410	.	_	_	I-Premise

411	025	_	_	I-Premise
412	and	_	_	I-Premise
413	p	_	_	I-Premise
414	=	_	_	I-Premise
415	0	_	_	I-Premise
416	.	_	_	I-Premise

417	002	_	_	I-Premise
418	,	_	_	I-Premise
419	respectively	_	_	I-Premise
420	)	_	_	I-Premise
421	.	_	_	I-Premise

422	There	_	_	B-Premise
423	was	_	_	I-Premise
424	no	_	_	I-Premise
425	difference	_	_	I-Premise
426	in	_	_	I-Premise
427	OS	_	_	I-Premise
428	(	_	_	I-Premise
429	p	_	_	I-Premise
430	=	_	_	I-Premise
431	0	_	_	I-Premise
432	.	_	_	I-Premise

433	992	_	_	I-Premise
434	)	_	_	I-Premise
435	.	_	_	I-Premise

436	Median	_	_	B-Premise
437	survival	_	_	I-Premise
438	and	_	_	I-Premise
439	6	_	_	I-Premise
440	-	_	_	I-Premise
441	month	_	_	I-Premise
442	survival	_	_	I-Premise
443	were	_	_	I-Premise
444	61	_	_	I-Premise
445	,	_	_	I-Premise
446	86	_	_	I-Premise
447	,	_	_	I-Premise
448	88	_	_	I-Premise
449	and	_	_	I-Premise
450	97	_	_	I-Premise
451	days	_	_	I-Premise
452	and	_	_	I-Premise
453	29	_	_	I-Premise
454	%	_	_	I-Premise
455	,	_	_	I-Premise
456	33	_	_	I-Premise
457	%	_	_	I-Premise
458	,	_	_	I-Premise
459	21	_	_	I-Premise
460	%	_	_	I-Premise
461	and	_	_	I-Premise
462	26	_	_	I-Premise
463	%	_	_	I-Premise
464	for	_	_	I-Premise
465	arms	_	_	I-Premise
466	A	_	_	I-Premise
467	,	_	_	I-Premise
468	B	_	_	I-Premise
469	,	_	_	I-Premise
470	C	_	_	I-Premise
471	,	_	_	I-Premise
472	and	_	_	I-Premise
473	D	_	_	I-Premise
474	,	_	_	I-Premise
475	respectively	_	_	I-Premise
476	.	_	_	I-Premise

477	Clinical	_	_	B-Claim
478	efficacy	_	_	I-Claim
479	of	_	_	I-Claim
480	docetaxel	_	_	I-Claim
481	was	_	_	I-Claim
482	observed	_	_	I-Claim
483	at	_	_	I-Claim
484	all	_	_	I-Claim
485	dose	_	_	I-Claim
486	levels	_	_	I-Claim
487	.	_	_	I-Claim

488	Higher	_	_	B-Claim
489	dose	_	_	I-Claim
490	levels	_	_	I-Claim
491	were	_	_	I-Claim
492	not	_	_	I-Claim
493	associated	_	_	I-Claim
494	with	_	_	I-Claim
495	increased	_	_	I-Claim
496	toxicities	_	_	I-Claim
497	,	_	_	I-Claim
498	use	_	_	I-Claim
499	of	_	_	I-Claim
500	IV	_	_	I-Claim
501	antibiotics	_	_	I-Claim
502	or	_	_	I-Claim
503	hospitalization	_	_	I-Claim
504	rates	_	_	I-Claim
505	.	_	_	I-Claim

506	However	_	_	O
507	,	_	_	O
508	the	_	_	B-Premise
509	median	_	_	I-Premise
510	survival	_	_	I-Premise
511	observed	_	_	I-Premise
512	is	_	_	I-Premise
513	shorter	_	_	I-Premise
514	than	_	_	I-Premise
515	historical	_	_	I-Premise
516	data	_	_	I-Premise
517	and	_	_	I-Premise
518	do	_	_	I-Premise
519	not	_	_	I-Premise
520	support	_	_	I-Premise
521	further	_	_	I-Premise
522	evaluation	_	_	I-Premise
523	of	_	_	I-Premise
524	these	_	_	I-Premise
525	doses	_	_	I-Premise
526	of	_	_	I-Premise
527	single	_	_	I-Premise
528	agent	_	_	I-Premise
529	docetaxel	_	_	I-Premise
530	in	_	_	I-Premise
531	this	_	_	I-Premise
532	population	_	_	I-Premise
533	.	_	_	I-Premise


0	Somatostatin	_	_	O
1	analogs	_	_	O
2	are	_	_	O
3	indicated	_	_	O
4	for	_	_	O
5	symptom	_	_	O
6	control	_	_	O
7	in	_	_	O
8	patients	_	_	O
9	with	_	_	O
10	gastroenteropancreatic	_	_	O
11	neuroendocrine	_	_	O
12	tumors	_	_	O
13	(	_	_	O
14	NETs	_	_	O
15	)	_	_	O
16	.	_	_	O

17	The	_	_	O
18	ability	_	_	O
19	of	_	_	O
20	somatostatin	_	_	O
21	analogs	_	_	O
22	to	_	_	O
23	control	_	_	O
24	the	_	_	O
25	growth	_	_	O
26	of	_	_	O
27	well	_	_	O
28	-	_	_	O
29	differentiated	_	_	O
30	metastatic	_	_	O
31	NETs	_	_	O
32	is	_	_	O
33	a	_	_	O
34	matter	_	_	O
35	of	_	_	O
36	debate	_	_	O
37	.	_	_	O

38	We	_	_	O
39	performed	_	_	O
40	a	_	_	O
41	placebo	_	_	O
42	-	_	_	O
43	controlled	_	_	O
44	,	_	_	O
45	double	_	_	O
46	-	_	_	O
47	blind	_	_	O
48	,	_	_	O
49	phase	_	_	O
50	IIIB	_	_	O
51	study	_	_	O
52	in	_	_	O
53	patients	_	_	O
54	with	_	_	O
55	well	_	_	O
56	-	_	_	O
57	differentiated	_	_	O
58	metastatic	_	_	O
59	midgut	_	_	O
60	NETs	_	_	O
61	.	_	_	O

62	The	_	_	O
63	hypothesis	_	_	O
64	was	_	_	O
65	that	_	_	O
66	octreotide	_	_	O
67	LAR	_	_	O
68	prolongs	_	_	O
69	time	_	_	O
70	to	_	_	O
71	tumor	_	_	O
72	progression	_	_	O
73	and	_	_	O
74	survival	_	_	O
75	.	_	_	O

76	Treatment	_	_	O
77	-	_	_	O
78	naive	_	_	O
79	patients	_	_	O
80	were	_	_	O
81	randomly	_	_	O
82	assigned	_	_	O
83	to	_	_	O
84	either	_	_	O
85	placebo	_	_	O
86	or	_	_	O
87	octreotide	_	_	O
88	LAR	_	_	O
89	30	_	_	O
90	mg	_	_	O
91	intramuscularly	_	_	O
92	in	_	_	O
93	monthly	_	_	O
94	intervals	_	_	O
95	until	_	_	O
96	tumor	_	_	O
97	progression	_	_	O
98	or	_	_	O
99	death	_	_	O
100	.	_	_	O

101	The	_	_	O
102	primary	_	_	O
103	efficacy	_	_	O
104	end	_	_	O
105	point	_	_	O
106	was	_	_	O
107	time	_	_	O
108	to	_	_	O
109	tumor	_	_	O
110	progression	_	_	O
111	.	_	_	O

112	Secondary	_	_	O
113	end	_	_	O
114	points	_	_	O
115	were	_	_	O
116	survival	_	_	O
117	time	_	_	O
118	and	_	_	O
119	tumor	_	_	O
120	response	_	_	O
121	.	_	_	O

122	This	_	_	O
123	report	_	_	O
124	is	_	_	O
125	based	_	_	O
126	on	_	_	O
127	67	_	_	O
128	tumor	_	_	O
129	progressions	_	_	O
130	and	_	_	O
131	16	_	_	O
132	observed	_	_	O
133	deaths	_	_	O
134	in	_	_	O
135	85	_	_	O
136	patients	_	_	O
137	at	_	_	O
138	the	_	_	O
139	time	_	_	O
140	of	_	_	O
141	the	_	_	O
142	planned	_	_	O
143	interim	_	_	O
144	analysis	_	_	O
145	.	_	_	O

146	Median	_	_	B-Premise
147	time	_	_	I-Premise
148	to	_	_	I-Premise
149	tumor	_	_	I-Premise
150	progression	_	_	I-Premise
151	in	_	_	I-Premise
152	the	_	_	I-Premise
153	octreotide	_	_	I-Premise
154	LAR	_	_	I-Premise
155	and	_	_	I-Premise
156	placebo	_	_	I-Premise
157	groups	_	_	I-Premise
158	was	_	_	I-Premise
159	14	_	_	I-Premise
160	.	_	_	I-Premise

161	3	_	_	I-Premise
162	and	_	_	I-Premise
163	6	_	_	I-Premise
164	months	_	_	I-Premise
165	,	_	_	I-Premise
166	respectively	_	_	I-Premise
167	(	_	_	I-Premise
168	hazard	_	_	I-Premise
169	ratio	_	_	I-Premise
170	[	_	_	I-Premise
171	HR	_	_	I-Premise
172	]	_	_	I-Premise
173	=	_	_	I-Premise
174	0	_	_	I-Premise
175	.	_	_	I-Premise

176	34	_	_	I-Premise
177	;	_	_	I-Premise
178	95	_	_	I-Premise
179	%	_	_	I-Premise
180	CI	_	_	I-Premise
181	,	_	_	I-Premise
182	0	_	_	I-Premise
183	.	_	_	I-Premise

184	20	_	_	I-Premise
185	to	_	_	I-Premise
186	0	_	_	I-Premise
187	.	_	_	I-Premise

188	59	_	_	I-Premise
189	;	_	_	I-Premise
190	P	_	_	I-Premise
191	=	_	_	I-Premise
192	.	_	_	I-Premise

193	000072	_	_	I-Premise
194	)	_	_	I-Premise
195	.	_	_	I-Premise

196	After	_	_	B-Premise
197	6	_	_	I-Premise
198	months	_	_	I-Premise
199	of	_	_	I-Premise
200	treatment	_	_	I-Premise
201	,	_	_	I-Premise
202	stable	_	_	I-Premise
203	disease	_	_	I-Premise
204	was	_	_	I-Premise
205	observed	_	_	I-Premise
206	in	_	_	I-Premise
207	66	_	_	I-Premise
208	.	_	_	I-Premise

209	7	_	_	I-Premise
210	%	_	_	I-Premise
211	of	_	_	I-Premise
212	patients	_	_	I-Premise
213	in	_	_	I-Premise
214	the	_	_	I-Premise
215	octreotide	_	_	I-Premise
216	LAR	_	_	I-Premise
217	group	_	_	I-Premise
218	and	_	_	I-Premise
219	37	_	_	I-Premise
220	.	_	_	I-Premise

221	2	_	_	I-Premise
222	%	_	_	I-Premise
223	of	_	_	I-Premise
224	patients	_	_	I-Premise
225	in	_	_	I-Premise
226	the	_	_	I-Premise
227	placebo	_	_	I-Premise
228	group	_	_	I-Premise
229	.	_	_	I-Premise

230	Functionally	_	_	O
231	active	_	_	O
232	and	_	_	O
233	inactive	_	_	O
234	tumors	_	_	O
235	responded	_	_	O
236	similarly	_	_	O
237	.	_	_	O

238	The	_	_	B-Premise
239	most	_	_	I-Premise
240	favorable	_	_	I-Premise
241	effect	_	_	I-Premise
242	was	_	_	I-Premise
243	observed	_	_	I-Premise
244	in	_	_	I-Premise
245	patients	_	_	I-Premise
246	with	_	_	I-Premise
247	low	_	_	I-Premise
248	hepatic	_	_	I-Premise
249	tumor	_	_	I-Premise
250	load	_	_	I-Premise
251	and	_	_	I-Premise
252	resected	_	_	I-Premise
253	primary	_	_	I-Premise
254	tumor	_	_	I-Premise
255	.	_	_	I-Premise

256	Seven	_	_	B-Premise
257	and	_	_	I-Premise
258	nine	_	_	I-Premise
259	deaths	_	_	I-Premise
260	were	_	_	I-Premise
261	observed	_	_	I-Premise
262	in	_	_	I-Premise
263	the	_	_	I-Premise
264	octreotide	_	_	I-Premise
265	LAR	_	_	I-Premise
266	and	_	_	I-Premise
267	placebo	_	_	I-Premise
268	groups	_	_	I-Premise
269	,	_	_	I-Premise
270	respectively	_	_	I-Premise
271	.	_	_	I-Premise

272	The	_	_	B-Premise
273	HR	_	_	I-Premise
274	for	_	_	I-Premise
275	overall	_	_	I-Premise
276	survival	_	_	I-Premise
277	was	_	_	I-Premise
278	0	_	_	I-Premise
279	.	_	_	I-Premise

280	81	_	_	I-Premise
281	(	_	_	I-Premise
282	95	_	_	I-Premise
283	%	_	_	I-Premise
284	CI	_	_	I-Premise
285	,	_	_	I-Premise
286	0	_	_	I-Premise
287	.	_	_	I-Premise

288	30	_	_	I-Premise
289	to	_	_	I-Premise
290	2	_	_	I-Premise
291	.	_	_	I-Premise

292	18	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	Octreotide	_	_	B-Claim
296	LAR	_	_	I-Claim
297	significantly	_	_	I-Claim
298	lengthens	_	_	I-Claim
299	time	_	_	I-Claim
300	to	_	_	I-Claim
301	tumor	_	_	I-Claim
302	progression	_	_	I-Claim
303	compared	_	_	I-Claim
304	with	_	_	I-Claim
305	placebo	_	_	I-Claim
306	in	_	_	I-Claim
307	patients	_	_	I-Claim
308	with	_	_	I-Claim
309	functionally	_	_	I-Claim
310	active	_	_	I-Claim
311	and	_	_	I-Claim
312	inactive	_	_	I-Claim
313	metastatic	_	_	I-Claim
314	midgut	_	_	I-Claim
315	NETs	_	_	I-Claim
316	.	_	_	I-Claim

317	Because	_	_	B-Premise
318	of	_	_	I-Premise
319	the	_	_	I-Premise
320	low	_	_	I-Premise
321	number	_	_	I-Premise
322	of	_	_	I-Premise
323	observed	_	_	I-Premise
324	deaths	_	_	I-Premise
325	,	_	_	I-Premise
326	survival	_	_	I-Premise
327	analysis	_	_	I-Premise
328	was	_	_	I-Premise
329	not	_	_	I-Premise
330	confirmatory	_	_	I-Premise
331	.	_	_	I-Premise


0	Oral	_	_	O
1	etoposide	_	_	O
2	is	_	_	O
3	an	_	_	O
4	active	_	_	O
5	single	_	_	O
6	agent	_	_	O
7	in	_	_	O
8	small	_	_	O
9	-	_	_	O
10	cell	_	_	O
11	lung	_	_	O
12	cancer	_	_	O
13	(	_	_	O
14	SCLC	_	_	O
15	)	_	_	O
16	and	_	_	O
17	is	_	_	O
18	widely	_	_	O
19	prescribed	_	_	O
20	as	_	_	O
21	first	_	_	O
22	-	_	_	O
23	line	_	_	O
24	treatment	_	_	O
25	as	_	_	O
26	an	_	_	O
27	alternative	_	_	O
28	to	_	_	O
29	intravenous	_	_	O
30	combination	_	_	O
31	chemotherapy	_	_	O
32	in	_	_	O
33	patients	_	_	O
34	with	_	_	O
35	extensive	_	_	O
36	disease	_	_	O
37	.	_	_	O

38	The	_	_	O
39	intention	_	_	O
40	of	_	_	O
41	this	_	_	O
42	study	_	_	O
43	was	_	_	O
44	to	_	_	O
45	determine	_	_	O
46	if	_	_	O
47	the	_	_	O
48	effects	_	_	O
49	of	_	_	O
50	oral	_	_	O
51	etoposide	_	_	O
52	therapy	_	_	O
53	on	_	_	O
54	survival	_	_	O
55	and	_	_	O
56	quality	_	_	O
57	of	_	_	O
58	life	_	_	O
59	are	_	_	O
60	equivalent	_	_	O
61	to	_	_	O
62	those	_	_	O
63	of	_	_	O
64	intravenous	_	_	O
65	chemotherapy	_	_	O
66	.	_	_	O

67	In	_	_	O
68	a	_	_	O
69	randomized	_	_	O
70	trial	_	_	O
71	of	_	_	O
72	palliative	_	_	O
73	treatment	_	_	O
74	in	_	_	O
75	advanced	_	_	O
76	SCLC	_	_	O
77	,	_	_	O
78	oral	_	_	O
79	etoposide	_	_	O
80	(	_	_	O
81	100	_	_	O
82	mg	_	_	O
83	given	_	_	O
84	twice	_	_	O
85	daily	_	_	O
86	for	_	_	O
87	5	_	_	O
88	days	_	_	O
89	)	_	_	O
90	was	_	_	O
91	compared	_	_	O
92	with	_	_	O
93	intravenous	_	_	O
94	chemotherapy	_	_	O
95	consisting	_	_	O
96	of	_	_	O
97	alternating	_	_	O
98	cycles	_	_	O
99	of	_	_	O
100	cisplatin	_	_	O
101	and	_	_	O
102	etoposide	_	_	O
103	(	_	_	O
104	PE	_	_	O
105	)	_	_	O
106	and	_	_	O
107	cyclophosphamide	_	_	O
108	,	_	_	O
109	doxorubicin	_	_	O
110	,	_	_	O
111	and	_	_	O
112	vincristine	_	_	O
113	(	_	_	O
114	CAV	_	_	O
115	)	_	_	O
116	.	_	_	O

117	Six	_	_	O
118	cycles	_	_	O
119	of	_	_	O
120	chemotherapy	_	_	O
121	were	_	_	O
122	administered	_	_	O
123	every	_	_	O
124	21	_	_	O
125	days	_	_	O
126	in	_	_	O
127	both	_	_	O
128	regimens	_	_	O
129	.	_	_	O

130	Symptom	_	_	O
131	control	_	_	O
132	and	_	_	O
133	quality	_	_	O
134	of	_	_	O
135	life	_	_	O
136	were	_	_	O
137	measured	_	_	O
138	with	_	_	O
139	the	_	_	O
140	Rotterdam	_	_	O
141	Symptom	_	_	O
142	Checklist	_	_	O
143	and	_	_	O
144	a	_	_	O
145	daily	_	_	O
146	diary	_	_	O
147	card	_	_	O
148	.	_	_	O

149	In	_	_	O
150	January	_	_	O
151	1996	_	_	O
152	,	_	_	O
153	after	_	_	O
154	155	_	_	O
155	patients	_	_	O
156	had	_	_	O
157	been	_	_	O
158	randomly	_	_	O
159	assigned	_	_	O
160	from	_	_	O
161	a	_	_	O
162	projected	_	_	O
163	intake	_	_	O
164	of	_	_	O
165	365	_	_	O
166	patients	_	_	O
167	,	_	_	O
168	an	_	_	O
169	independent	_	_	O
170	Data	_	_	O
171	Monitoring	_	_	O
172	Committee	_	_	O
173	examined	_	_	O
174	the	_	_	O
175	interim	_	_	O
176	results	_	_	O
177	.	_	_	O

178	Survival	_	_	O
179	was	_	_	O
180	determined	_	_	O
181	by	_	_	O
182	the	_	_	O
183	Kaplan	_	_	O
184	-	_	_	O
185	Meier	_	_	O
186	method	_	_	O
187	,	_	_	O
188	and	_	_	O
189	the	_	_	O
190	logrank	_	_	O
191	test	_	_	O
192	was	_	_	O
193	used	_	_	O
194	to	_	_	O
195	compare	_	_	O
196	treatments	_	_	O
197	.	_	_	O

198	For	_	_	O
199	quality	_	_	O
200	-	_	_	O
201	of	_	_	O
202	-	_	_	O
203	life	_	_	O
204	comparisons	_	_	O
205	,	_	_	O
206	average	_	_	O
207	scores	_	_	O
208	were	_	_	O
209	calculated	_	_	O
210	for	_	_	O
211	each	_	_	O
212	time	_	_	O
213	point	_	_	O
214	.	_	_	O

215	The	_	_	O
216	Mann	_	_	O
217	-	_	_	O
218	Whitney	_	_	O
219	U	_	_	O
220	test	_	_	O
221	was	_	_	O
222	used	_	_	O
223	to	_	_	O
224	determine	_	_	O
225	any	_	_	O
226	significant	_	_	O
227	overall	_	_	O
228	differences	_	_	O
229	between	_	_	O
230	treatments	_	_	O
231	.	_	_	O

232	For	_	_	O
233	the	_	_	O
234	Rotterdam	_	_	O
235	Symptom	_	_	O
236	Checklist	_	_	O
237	,	_	_	O
238	separate	_	_	O
239	analyses	_	_	O
240	were	_	_	O
241	done	_	_	O
242	for	_	_	O
243	each	_	_	O
244	subset	_	_	O
245	(	_	_	O
246	psychological	_	_	O
247	well	_	_	O
248	-	_	_	O
249	being	_	_	O
250	,	_	_	O
251	physical	_	_	O
252	symptoms	_	_	O
253	,	_	_	O
254	lung	_	_	O
255	cancer	_	_	O
256	symptoms	_	_	O
257	,	_	_	O
258	treatment	_	_	O
259	symptoms	_	_	O
260	,	_	_	O
261	activity	_	_	O
262	,	_	_	O
263	and	_	_	O
264	quality	_	_	O
265	of	_	_	O
266	life	_	_	O
267	)	_	_	O
268	.	_	_	O

269	Response	_	_	O
270	rates	_	_	O
271	and	_	_	O
272	toxicity	_	_	O
273	scores	_	_	O
274	were	_	_	O
275	compared	_	_	O
276	by	_	_	O
277	using	_	_	O
278	chi2	_	_	O
279	.	_	_	O

280	All	_	_	O
281	statistical	_	_	O
282	tests	_	_	O
283	were	_	_	O
284	two	_	_	O
285	-	_	_	O
286	sided	_	_	O
287	.	_	_	O

288	Survival	_	_	B-Premise
289	was	_	_	I-Premise
290	inferior	_	_	I-Premise
291	at	_	_	I-Premise
292	1	_	_	I-Premise
293	year	_	_	I-Premise
294	in	_	_	I-Premise
295	the	_	_	I-Premise
296	oral	_	_	I-Premise
297	etoposide	_	_	I-Premise
298	group	_	_	I-Premise
299	compared	_	_	I-Premise
300	with	_	_	I-Premise
301	intravenous	_	_	I-Premise
302	therapy	_	_	I-Premise
303	(	_	_	I-Premise
304	9	_	_	I-Premise
305	.	_	_	I-Premise

306	8	_	_	I-Premise
307	%	_	_	I-Premise
308	for	_	_	I-Premise
309	oral	_	_	I-Premise
310	versus	_	_	I-Premise
311	19	_	_	I-Premise
312	.	_	_	I-Premise

313	3	_	_	I-Premise
314	%	_	_	I-Premise
315	for	_	_	I-Premise
316	intravenous	_	_	I-Premise
317	;	_	_	I-Premise
318	difference	_	_	I-Premise
319	=	_	_	I-Premise
320	9	_	_	I-Premise
321	.	_	_	I-Premise

322	5	_	_	I-Premise
323	%	_	_	I-Premise
324	;	_	_	I-Premise
325	95	_	_	I-Premise
326	%	_	_	I-Premise
327	confidence	_	_	I-Premise
328	interval	_	_	I-Premise
329	of	_	_	I-Premise
330	difference	_	_	I-Premise
331	=	_	_	I-Premise
332	0	_	_	I-Premise
333	.	_	_	I-Premise

334	3	_	_	I-Premise
335	%	_	_	I-Premise
336	-	_	_	I-Premise
337	18	_	_	I-Premise
338	.	_	_	I-Premise

339	7	_	_	I-Premise
340	%	_	_	I-Premise
341	;	_	_	I-Premise
342	P	_	_	I-Premise
343	<	_	_	I-Premise
344	.	_	_	I-Premise

345	05	_	_	I-Premise
346	)	_	_	I-Premise
347	,	_	_	I-Premise
348	and	_	_	I-Premise
349	there	_	_	I-Premise
350	was	_	_	I-Premise
351	a	_	_	I-Premise
352	trend	_	_	I-Premise
353	toward	_	_	I-Premise
354	inferior	_	_	I-Premise
355	overall	_	_	I-Premise
356	survival	_	_	I-Premise
357	.	_	_	I-Premise

358	Median	_	_	B-Premise
359	survival	_	_	I-Premise
360	was	_	_	I-Premise
361	4	_	_	I-Premise
362	.	_	_	I-Premise

363	8	_	_	I-Premise
364	months	_	_	I-Premise
365	for	_	_	I-Premise
366	oral	_	_	I-Premise
367	treatment	_	_	I-Premise
368	and	_	_	I-Premise
369	5	_	_	I-Premise
370	.	_	_	I-Premise

371	9	_	_	I-Premise
372	months	_	_	I-Premise
373	for	_	_	I-Premise
374	intravenous	_	_	I-Premise
375	therapy	_	_	I-Premise
376	.	_	_	I-Premise

377	Progression	_	_	B-Premise
378	-	_	_	I-Premise
379	free	_	_	I-Premise
380	survival	_	_	I-Premise
381	was	_	_	I-Premise
382	worse	_	_	I-Premise
383	in	_	_	I-Premise
384	the	_	_	I-Premise
385	oral	_	_	I-Premise
386	etoposide	_	_	I-Premise
387	arm	_	_	I-Premise
388	(	_	_	I-Premise
389	median	_	_	I-Premise
390	=	_	_	I-Premise
391	3	_	_	I-Premise
392	.	_	_	I-Premise

393	6	_	_	I-Premise
394	months	_	_	I-Premise
395	versus	_	_	I-Premise
396	5	_	_	I-Premise
397	.	_	_	I-Premise

398	6	_	_	I-Premise
399	months	_	_	I-Premise
400	;	_	_	I-Premise
401	P	_	_	I-Premise
402	<	_	_	I-Premise
403	.	_	_	I-Premise

404	001	_	_	I-Premise
405	)	_	_	I-Premise
406	,	_	_	I-Premise
407	as	_	_	I-Premise
408	well	_	_	I-Premise
409	as	_	_	I-Premise
410	overall	_	_	I-Premise
411	response	_	_	I-Premise
412	rate	_	_	I-Premise
413	(	_	_	I-Premise
414	32	_	_	I-Premise
415	.	_	_	I-Premise

416	9	_	_	I-Premise
417	%	_	_	I-Premise
418	versus	_	_	I-Premise
419	46	_	_	I-Premise
420	.	_	_	I-Premise

421	3	_	_	I-Premise
422	%	_	_	I-Premise
423	;	_	_	I-Premise
424	P	_	_	I-Premise
425	<	_	_	I-Premise
426	.	_	_	I-Premise

427	01	_	_	I-Premise
428	)	_	_	I-Premise
429	.	_	_	I-Premise

430	With	_	_	B-Premise
431	the	_	_	I-Premise
432	exception	_	_	I-Premise
433	of	_	_	I-Premise
434	acute	_	_	I-Premise
435	nausea	_	_	I-Premise
436	and	_	_	I-Premise
437	vomiting	_	_	I-Premise
438	associated	_	_	I-Premise
439	with	_	_	I-Premise
440	intravenous	_	_	I-Premise
441	chemotherapy	_	_	I-Premise
442	,	_	_	I-Premise
443	all	_	_	B-Premise
444	aspects	_	_	I-Premise
445	of	_	_	I-Premise
446	symptom	_	_	I-Premise
447	control	_	_	I-Premise
448	and	_	_	I-Premise
449	quality	_	_	I-Premise
450	of	_	_	I-Premise
451	life	_	_	I-Premise
452	were	_	_	I-Premise
453	either	_	_	I-Premise
454	the	_	_	I-Premise
455	same	_	_	I-Premise
456	or	_	_	I-Premise
457	worse	_	_	I-Premise
458	in	_	_	I-Premise
459	the	_	_	I-Premise
460	oral	_	_	I-Premise
461	etoposide	_	_	I-Premise
462	group	_	_	I-Premise
463	.	_	_	I-Premise

464	Study	_	_	O
465	closure	_	_	O
466	was	_	_	O
467	recommended	_	_	O
468	.	_	_	O

469	These	_	_	B-Claim
470	interim	_	_	I-Claim
471	results	_	_	I-Claim
472	show	_	_	I-Claim
473	that	_	_	I-Claim
474	this	_	_	I-Claim
475	schedule	_	_	I-Claim
476	of	_	_	I-Claim
477	oral	_	_	I-Claim
478	etoposide	_	_	I-Claim
479	is	_	_	I-Claim
480	inferior	_	_	I-Claim
481	to	_	_	I-Claim
482	intravenous	_	_	I-Claim
483	chemotherapy	_	_	I-Claim
484	in	_	_	I-Claim
485	the	_	_	I-Claim
486	treatment	_	_	I-Claim
487	of	_	_	I-Claim
488	advanced	_	_	I-Claim
489	SCLC	_	_	I-Claim
490	and	_	_	I-Claim
491	should	_	_	I-Claim
492	not	_	_	I-Claim
493	be	_	_	I-Claim
494	used	_	_	I-Claim
495	as	_	_	I-Claim
496	first	_	_	I-Claim
497	-	_	_	I-Claim
498	line	_	_	I-Claim
499	treatment	_	_	I-Claim
500	of	_	_	I-Claim
501	this	_	_	I-Claim
502	disease	_	_	I-Claim
503	.	_	_	I-Claim


0	Patients	_	_	O
1	who	_	_	O
2	develop	_	_	O
3	castration	_	_	O
4	-	_	_	O
5	resistant	_	_	O
6	prostate	_	_	O
7	cancer	_	_	O
8	(	_	_	O
9	CRPCa	_	_	O
10	)	_	_	O
11	typically	_	_	O
12	continue	_	_	O
13	on	_	_	O
14	androgen	_	_	O
15	deprivation	_	_	O
16	therapy	_	_	O
17	(	_	_	O
18	ADT	_	_	O
19	)	_	_	O
20	.	_	_	O

21	Whether	_	_	O
22	these	_	_	O
23	patients	_	_	O
24	need	_	_	O
25	to	_	_	O
26	remain	_	_	O
27	on	_	_	O
28	ADT	_	_	O
29	has	_	_	O
30	not	_	_	O
31	been	_	_	O
32	well	_	_	O
33	studied	_	_	O
34	.	_	_	O

35	We	_	_	O
36	conducted	_	_	O
37	a	_	_	O
38	multicenter	_	_	O
39	randomized	_	_	O
40	trial	_	_	O
41	to	_	_	O
42	compare	_	_	O
43	an	_	_	O
44	intermittent	_	_	O
45	versus	_	_	O
46	continuous	_	_	O
47	approach	_	_	O
48	to	_	_	O
49	ADT	_	_	O
50	in	_	_	O
51	CRPCa	_	_	O
52	patients	_	_	O
53	.	_	_	O

54	Overall	_	_	O
55	survival	_	_	O
56	,	_	_	O
57	health	_	_	O
58	-	_	_	O
59	related	_	_	O
60	quality	_	_	O
61	of	_	_	O
62	life	_	_	O
63	(	_	_	O
64	QOL	_	_	O
65	)	_	_	O
66	,	_	_	O
67	and	_	_	O
68	cost	_	_	O
69	were	_	_	O
70	the	_	_	O
71	main	_	_	O
72	endpoints	_	_	O
73	.	_	_	O

74	CRPCa	_	_	O
75	patients	_	_	O
76	were	_	_	O
77	randomized	_	_	O
78	2	_	_	O
79	:	_	_	O
80	1	_	_	O
81	to	_	_	O
82	intermittent	_	_	O
83	or	_	_	O
84	continuous	_	_	O
85	luteinizing	_	_	O
86	hormone	_	_	O
87	-	_	_	O
88	releasing	_	_	O
89	hormone	_	_	O
90	agonists	_	_	O
91	(	_	_	O
92	LHRHa	_	_	O
93	)	_	_	O
94	.	_	_	O

95	Patients	_	_	O
96	were	_	_	O
97	followed	_	_	O
98	with	_	_	O
99	clinical	_	_	O
100	assessments	_	_	O
101	,	_	_	O
102	laboratory	_	_	O
103	investigations	_	_	O
104	,	_	_	O
105	and	_	_	O
106	QOL	_	_	O
107	questionnaires	_	_	O
108	(	_	_	O
109	EORTC	_	_	O
110	QLQ	_	_	O
111	-	_	_	O
112	C30	_	_	O
113	or	_	_	O
114	PROSQOLI	_	_	O
115	)	_	_	O
116	every	_	_	O
117	2	_	_	O
118	months	_	_	O
119	.	_	_	O

120	If	_	_	O
121	the	_	_	O
122	serum	_	_	O
123	testosterone	_	_	O
124	rose	_	_	O
125	above	_	_	O
126	castrate	_	_	O
127	levels	_	_	O
128	(	_	_	O
129	1	_	_	O
130	.	_	_	O

131	75	_	_	O
132	nmol	_	_	O
133	/	_	_	O
134	L	_	_	O
135	)	_	_	O
136	,	_	_	O
137	LHRHa	_	_	O
138	were	_	_	O
139	reinitiated	_	_	O
140	.	_	_	O

141	The	_	_	O
142	study	_	_	O
143	was	_	_	O
144	designed	_	_	O
145	to	_	_	O
146	close	_	_	O
147	if	_	_	O
148	>	_	_	O
149	50	_	_	O
150	%	_	_	O
151	of	_	_	O
152	patients	_	_	O
153	needed	_	_	O
154	to	_	_	O
155	restart	_	_	O
156	ADT	_	_	O
157	in	_	_	O
158	the	_	_	O
159	intermittent	_	_	O
160	arm	_	_	O
161	.	_	_	O

162	Thirty	_	_	O
163	-	_	_	O
164	one	_	_	O
165	patients	_	_	O
166	were	_	_	O
167	followed	_	_	O
168	with	_	_	O
169	a	_	_	O
170	median	_	_	O
171	follow	_	_	O
172	-	_	_	O
173	up	_	_	O
174	of	_	_	O
175	26	_	_	O
176	.	_	_	O

177	8	_	_	O
178	months	_	_	O
179	-	_	_	O
180	18	_	_	O
181	in	_	_	O
182	the	_	_	O
183	intermittent	_	_	O
184	arm	_	_	O
185	and	_	_	O
186	13	_	_	O
187	in	_	_	O
188	the	_	_	O
189	continuous	_	_	O
190	.	_	_	O

191	Twelve	_	_	O
192	of	_	_	O
193	18	_	_	O
194	patients	_	_	O
195	on	_	_	O
196	the	_	_	O
197	intermittent	_	_	O
198	arm	_	_	O
199	were	_	_	O
200	reinitiated	_	_	O
201	on	_	_	O
202	LHRHa	_	_	O
203	at	_	_	O
204	a	_	_	O
205	median	_	_	O
206	time	_	_	O
207	of	_	_	O
208	17	_	_	O
209	.	_	_	O

210	9	_	_	O
211	months	_	_	O
212	.	_	_	O

213	There	_	_	B-Premise
214	was	_	_	I-Premise
215	no	_	_	I-Premise
216	difference	_	_	I-Premise
217	in	_	_	I-Premise
218	overall	_	_	I-Premise
219	or	_	_	I-Premise
220	cancer	_	_	I-Premise
221	-	_	_	I-Premise
222	specific	_	_	I-Premise
223	survival	_	_	I-Premise
224	between	_	_	I-Premise
225	the	_	_	I-Premise
226	2	_	_	I-Premise
227	arms	_	_	I-Premise
228	.	_	_	I-Premise

229	There	_	_	B-Premise
230	was	_	_	I-Premise
231	no	_	_	I-Premise
232	statistically	_	_	I-Premise
233	significant	_	_	I-Premise
234	difference	_	_	I-Premise
235	in	_	_	I-Premise
236	QOL	_	_	I-Premise
237	between	_	_	I-Premise
238	the	_	_	I-Premise
239	2	_	_	I-Premise
240	arms	_	_	I-Premise
241	at	_	_	I-Premise
242	0	_	_	I-Premise
243	and	_	_	I-Premise
244	12	_	_	I-Premise
245	months	_	_	I-Premise
246	.	_	_	I-Premise

247	The	_	_	B-Premise
248	total	_	_	I-Premise
249	mean	_	_	I-Premise
250	costs	_	_	I-Premise
251	at	_	_	I-Premise
252	24	_	_	I-Premise
253	months	_	_	I-Premise
254	were	_	_	I-Premise
255	significantly	_	_	I-Premise
256	lower	_	_	I-Premise
257	in	_	_	I-Premise
258	the	_	_	I-Premise
259	intermittent	_	_	I-Premise
260	arm	_	_	I-Premise
261	(	_	_	I-Premise
262	$	_	_	I-Premise
263	3135	_	_	I-Premise
264	vs	_	_	I-Premise
265	.	_	_	I-Premise

266	$	_	_	I-Premise
267	8253	_	_	I-Premise
268	Canadian	_	_	I-Premise
269	dollars	_	_	I-Premise
270	,	_	_	I-Premise
271	P	_	_	I-Premise
272	=	_	_	I-Premise
273	0	_	_	I-Premise
274	.	_	_	I-Premise

275	0167	_	_	I-Premise
276	)	_	_	I-Premise
277	compared	_	_	I-Premise
278	with	_	_	I-Premise
279	the	_	_	I-Premise
280	continuous	_	_	I-Premise
281	.	_	_	I-Premise

282	The	_	_	B-Premise
283	main	_	_	I-Premise
284	limitation	_	_	I-Premise
285	of	_	_	I-Premise
286	this	_	_	I-Premise
287	study	_	_	I-Premise
288	is	_	_	I-Premise
289	the	_	_	I-Premise
290	small	_	_	I-Premise
291	sample	_	_	I-Premise
292	size	_	_	I-Premise
293	.	_	_	I-Premise

294	We	_	_	B-Claim
295	have	_	_	I-Claim
296	observed	_	_	I-Claim
297	that	_	_	I-Claim
298	intermittent	_	_	I-Claim
299	ADT	_	_	I-Claim
300	in	_	_	I-Claim
301	patients	_	_	I-Claim
302	with	_	_	I-Claim
303	CRPCa	_	_	I-Claim
304	,	_	_	I-Claim
305	using	_	_	I-Claim
306	a	_	_	I-Claim
307	testosterone	_	_	I-Claim
308	of	_	_	I-Claim
309	>	_	_	I-Claim
310	1	_	_	I-Claim
311	.	_	_	I-Claim

312	75	_	_	I-Claim
313	ngmol	_	_	I-Claim
314	/	_	_	I-Claim
315	L	_	_	I-Claim
316	as	_	_	I-Claim
317	a	_	_	I-Claim
318	trigger	_	_	I-Claim
319	to	_	_	I-Claim
320	reinitiate	_	_	I-Claim
321	LHRHa	_	_	I-Claim
322	,	_	_	I-Claim
323	results	_	_	I-Claim
324	in	_	_	I-Claim
325	a	_	_	I-Claim
326	substantial	_	_	I-Claim
327	cost	_	_	I-Claim
328	savings	_	_	I-Claim
329	with	_	_	I-Claim
330	no	_	_	I-Claim
331	negative	_	_	I-Claim
332	impact	_	_	I-Claim
333	on	_	_	I-Claim
334	oncologic	_	_	I-Claim
335	and	_	_	I-Claim
336	QOL	_	_	I-Claim
337	outcomes	_	_	I-Claim
338	.	_	_	I-Claim


0	Restoring	_	_	O
1	sensory	_	_	O
2	innervation	_	_	O
3	may	_	_	O
4	be	_	_	O
5	a	_	_	O
6	useful	_	_	O
7	adjunct	_	_	O
8	in	_	_	O
9	free	_	_	O
10	flap	_	_	O
11	head	_	_	O
12	and	_	_	O
13	neck	_	_	O
14	reconstruction	_	_	O
15	but	_	_	O
16	,	_	_	O
17	as	_	_	O
18	yet	_	_	O
19	,	_	_	O
20	has	_	_	O
21	not	_	_	O
22	been	_	_	O
23	shown	_	_	O
24	to	_	_	O
25	improve	_	_	O
26	outcomes	_	_	O
27	of	_	_	O
28	breast	_	_	O
29	reconstruction	_	_	O
30	.	_	_	O

31	The	_	_	O
32	authors	_	_	O
33	'	_	_	O
34	previous	_	_	O
35	study	_	_	O
36	demonstrated	_	_	O
37	objectively	_	_	O
38	improved	_	_	O
39	sensation	_	_	O
40	in	_	_	O
41	a	_	_	O
42	group	_	_	O
43	of	_	_	O
44	innervated	_	_	O
45	transverse	_	_	O
46	rectus	_	_	O
47	abdominis	_	_	O
48	musculocutaneous	_	_	O
49	(	_	_	O
50	TRAM	_	_	O
51	)	_	_	O
52	flap	_	_	O
53	breast	_	_	O
54	reconstruction	_	_	O
55	patients	_	_	O
56	relative	_	_	O
57	to	_	_	O
58	noninnervated	_	_	O
59	flaps	_	_	O
60	.	_	_	O

61	This	_	_	O
62	study	_	_	O
63	compared	_	_	O
64	patient	_	_	O
65	-	_	_	O
66	rated	_	_	O
67	outcomes	_	_	O
68	of	_	_	O
69	free	_	_	O
70	TRAM	_	_	O
71	breast	_	_	O
72	reconstruction	_	_	O
73	in	_	_	O
74	innervated	_	_	O
75	versus	_	_	O
76	noninnervated	_	_	O
77	flaps	_	_	O
78	.	_	_	O

79	Twenty	_	_	O
80	-	_	_	O
81	seven	_	_	O
82	women	_	_	O
83	were	_	_	O
84	randomized	_	_	O
85	prospectively	_	_	O
86	to	_	_	O
87	undergo	_	_	O
88	either	_	_	O
89	innervated	_	_	O
90	or	_	_	O
91	noninnervated	_	_	O
92	free	_	_	O
93	TRAM	_	_	O
94	flap	_	_	O
95	breast	_	_	O
96	reconstruction	_	_	O
97	.	_	_	O

98	For	_	_	O
99	innervated	_	_	O
100	flaps	_	_	O
101	,	_	_	O
102	the	_	_	O
103	T10	_	_	O
104	intercostal	_	_	O
105	nerve	_	_	O
106	was	_	_	O
107	harvested	_	_	O
108	with	_	_	O
109	the	_	_	O
110	TRAM	_	_	O
111	flap	_	_	O
112	and	_	_	O
113	neurotized	_	_	O
114	to	_	_	O
115	the	_	_	O
116	T4	_	_	O
117	sensory	_	_	O
118	nerve	_	_	O
119	at	_	_	O
120	the	_	_	O
121	recipient	_	_	O
122	site	_	_	O
123	.	_	_	O

124	Three	_	_	O
125	validated	_	_	O
126	outcome	_	_	O
127	tools	_	_	O
128	were	_	_	O
129	administered	_	_	O
130	after	_	_	O
131	surgery	_	_	O
132	:	_	_	O
133	the	_	_	O
134	Medical	_	_	O
135	Outcomes	_	_	O
136	Study	_	_	O
137	36	_	_	O
138	-	_	_	O
139	Item	_	_	O
140	Short	_	_	O
141	Form	_	_	O
142	Health	_	_	O
143	Survey	_	_	O
144	,	_	_	O
145	the	_	_	O
146	Body	_	_	O
147	Image	_	_	O
148	after	_	_	O
149	Breast	_	_	O
150	Cancer	_	_	O
151	Questionnaire	_	_	O
152	,	_	_	O
153	and	_	_	O
154	the	_	_	O
155	Functional	_	_	O
156	Assessment	_	_	O
157	of	_	_	O
158	Cancer	_	_	O
159	Therapy	_	_	O
160	-	_	_	O
161	Breast	_	_	O
162	.	_	_	O

163	Results	_	_	B-Premise
164	were	_	_	I-Premise
165	correlated	_	_	I-Premise
166	with	_	_	I-Premise
167	previously	_	_	I-Premise
168	reported	_	_	I-Premise
169	objective	_	_	I-Premise
170	sensibility	_	_	I-Premise
171	outcomes	_	_	I-Premise
172	.	_	_	I-Premise

173	Eighteen	_	_	O
174	of	_	_	O
175	27	_	_	O
176	women	_	_	O
177	returned	_	_	O
178	their	_	_	O
179	questionnaires	_	_	O
180	a	_	_	O
181	mean	_	_	O
182	48	_	_	O
183	months	_	_	O
184	after	_	_	O
185	free	_	_	O
186	TRAM	_	_	O
187	flap	_	_	O
188	reconstruction	_	_	O
189	.	_	_	O

190	Demographic	_	_	O
191	analysis	_	_	O
192	revealed	_	_	O
193	no	_	_	O
194	significant	_	_	O
195	differences	_	_	O
196	in	_	_	O
197	patient	_	_	O
198	age	_	_	O
199	,	_	_	O
200	height	_	_	O
201	,	_	_	O
202	smoking	_	_	O
203	,	_	_	O
204	radiation	_	_	O
205	therapy	_	_	O
206	,	_	_	O
207	and	_	_	O
208	nipple	_	_	O
209	-	_	_	O
210	areola	_	_	O
211	complex	_	_	O
212	reconstruction	_	_	O
213	between	_	_	O
214	randomized	_	_	O
215	patient	_	_	O
216	groups	_	_	O
217	.	_	_	O

218	There	_	_	B-Premise
219	was	_	_	I-Premise
220	a	_	_	I-Premise
221	statistically	_	_	I-Premise
222	significant	_	_	I-Premise
223	improvement	_	_	I-Premise
224	in	_	_	I-Premise
225	all	_	_	I-Premise
226	three	_	_	I-Premise
227	measures	_	_	I-Premise
228	in	_	_	I-Premise
229	patients	_	_	I-Premise
230	who	_	_	I-Premise
231	were	_	_	I-Premise
232	randomized	_	_	I-Premise
233	to	_	_	I-Premise
234	receive	_	_	I-Premise
235	innervated	_	_	I-Premise
236	free	_	_	I-Premise
237	TRAM	_	_	I-Premise
238	flaps	_	_	I-Premise
239	compared	_	_	I-Premise
240	with	_	_	I-Premise
241	those	_	_	I-Premise
242	receiving	_	_	I-Premise
243	noninnervated	_	_	I-Premise
244	flaps	_	_	I-Premise
245	.	_	_	I-Premise

246	This	_	_	B-Claim
247	study	_	_	I-Claim
248	demonstrates	_	_	I-Claim
249	that	_	_	I-Claim
250	innervation	_	_	I-Claim
251	of	_	_	I-Claim
252	free	_	_	I-Claim
253	TRAM	_	_	I-Claim
254	flaps	_	_	I-Claim
255	used	_	_	I-Claim
256	for	_	_	I-Claim
257	breast	_	_	I-Claim
258	reconstruction	_	_	I-Claim
259	not	_	_	I-Claim
260	only	_	_	I-Claim
261	improves	_	_	I-Claim
262	sensibility	_	_	I-Claim
263	but	_	_	I-Claim
264	also	_	_	I-Claim
265	has	_	_	I-Claim
266	a	_	_	I-Claim
267	positive	_	_	I-Claim
268	effect	_	_	I-Claim
269	on	_	_	I-Claim
270	patient	_	_	I-Claim
271	-	_	_	I-Claim
272	rated	_	_	I-Claim
273	quality	_	_	I-Claim
274	of	_	_	I-Claim
275	life	_	_	I-Claim
276	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	difference	_	_	O
4	of	_	_	O
5	efficacy	_	_	O
6	,	_	_	O
7	side	_	_	O
8	-	_	_	O
9	effects	_	_	O
10	and	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	in	_	_	O
15	advanced	_	_	O
16	non	_	_	O
17	-	_	_	O
18	small	_	_	O
19	-	_	_	O
20	cell	_	_	O
21	lung	_	_	O
22	cancer	_	_	O
23	(	_	_	O
24	NSCLC	_	_	O
25	)	_	_	O
26	patients	_	_	O
27	treated	_	_	O
28	with	_	_	O
29	oxaliplatin	_	_	O
30	plus	_	_	O
31	vinorelbine	_	_	O
32	or	_	_	O
33	cisplatin	_	_	O
34	plus	_	_	O
35	vinorelbine	_	_	O
36	.	_	_	O

37	Eligible	_	_	O
38	patients	_	_	O
39	were	_	_	O
40	randomly	_	_	O
41	assigned	_	_	O
42	to	_	_	O
43	NL	_	_	O
44	(	_	_	O
45	oxaliplatin	_	_	O
46	+	_	_	O
47	vinorelbine	_	_	O
48	)	_	_	O
49	group	_	_	O
50	and	_	_	O
51	NP	_	_	O
52	(	_	_	O
53	cisplatin	_	_	O
54	+	_	_	O
55	vinorelbine	_	_	O
56	)	_	_	O
57	group	_	_	O
58	in	_	_	O
59	a	_	_	O
60	2	_	_	O
61	:	_	_	O
62	1	_	_	O
63	ratio	_	_	O
64	.	_	_	O

65	In	_	_	O
66	the	_	_	O
67	NL	_	_	O
68	group	_	_	O
69	,	_	_	O
70	70	_	_	O
71	evaluable	_	_	O
72	cases	_	_	O
73	were	_	_	O
74	treated	_	_	O
75	with	_	_	O
76	oxaliplatin	_	_	O
77	130	_	_	O
78	mg	_	_	O
79	/	_	_	O
80	m	_	_	O
81	(	_	_	O
82	2	_	_	O
83	)	_	_	O
84	i	_	_	O
85	.	_	_	O

86	v	_	_	O
87	.	_	_	O

88	on	_	_	O
89	day	_	_	O
90	2	_	_	O
91	,	_	_	O
92	and	_	_	O
93	vinorelbine	_	_	O
94	25	_	_	O
95	mg	_	_	O
96	/	_	_	O
97	m	_	_	O
98	(	_	_	O
99	2	_	_	O
100	)	_	_	O
101	i	_	_	O
102	.	_	_	O

103	v	_	_	O
104	.	_	_	O

105	on	_	_	O
106	days	_	_	O
107	1	_	_	O
108	and	_	_	O
109	8	_	_	O
110	in	_	_	O
111	21	_	_	O
112	days	_	_	O
113	per	_	_	O
114	cycle	_	_	O
115	.	_	_	O

116	In	_	_	O
117	the	_	_	O
118	NP	_	_	O
119	group	_	_	O
120	,	_	_	O
121	32	_	_	O
122	evaluable	_	_	O
123	cases	_	_	O
124	were	_	_	O
125	treated	_	_	O
126	with	_	_	O
127	cisplatin	_	_	O
128	80	_	_	O
129	mg	_	_	O
130	/	_	_	O
131	m	_	_	O
132	(	_	_	O
133	2	_	_	O
134	)	_	_	O
135	i	_	_	O
136	.	_	_	O

137	v	_	_	O
138	.	_	_	O

139	divided	_	_	O
140	to	_	_	O
141	2	_	_	O
142	-	_	_	O
143	3	_	_	O
144	days	_	_	O
145	dosing	_	_	O
146	,	_	_	O
147	21	_	_	O
148	days	_	_	O
149	per	_	_	O
150	cycle	_	_	O
151	,	_	_	O
152	and	_	_	O
153	vinorelbine	_	_	O
154	administered	_	_	O
155	by	_	_	O
156	the	_	_	O
157	same	_	_	O
158	way	_	_	O
159	as	_	_	O
160	in	_	_	O
161	the	_	_	O
162	NL	_	_	O
163	group	_	_	O
164	.	_	_	O

165	The	_	_	O
166	response	_	_	O
167	rate	_	_	O
168	,	_	_	O
169	time	_	_	O
170	to	_	_	O
171	progression	_	_	O
172	(	_	_	O
173	TTP	_	_	O
174	)	_	_	O
175	,	_	_	O
176	one	_	_	O
177	-	_	_	O
178	year	_	_	O
179	survival	_	_	O
180	,	_	_	O
181	side	_	_	O
182	-	_	_	O
183	effects	_	_	O
184	and	_	_	O
185	the	_	_	O
186	quality	_	_	O
187	of	_	_	O
188	life	_	_	O
189	were	_	_	O
190	observed	_	_	O
191	.	_	_	O

192	The	_	_	B-Premise
193	response	_	_	I-Premise
194	rate	_	_	I-Premise
195	was	_	_	I-Premise
196	35	_	_	I-Premise
197	.	_	_	I-Premise

198	7	_	_	I-Premise
199	%	_	_	I-Premise
200	vs	_	_	I-Premise
201	.	_	_	I-Premise

202	43	_	_	I-Premise
203	.	_	_	I-Premise

204	8	_	_	I-Premise
205	%	_	_	I-Premise
206	(	_	_	I-Premise
207	P	_	_	I-Premise
208	=	_	_	I-Premise
209	0	_	_	I-Premise
210	.	_	_	I-Premise

211	4	_	_	I-Premise
212	)	_	_	I-Premise
213	,	_	_	I-Premise
214	median	_	_	I-Premise
215	TTP	_	_	I-Premise
216	was	_	_	I-Premise
217	4	_	_	I-Premise
218	.	_	_	I-Premise

219	7	_	_	I-Premise
220	months	_	_	I-Premise
221	vs	_	_	I-Premise
222	.	_	_	I-Premise

223	5	_	_	I-Premise
224	.	_	_	I-Premise

225	5	_	_	I-Premise
226	months	_	_	I-Premise
227	(	_	_	I-Premise
228	P	_	_	I-Premise
229	=	_	_	I-Premise
230	0	_	_	I-Premise
231	.	_	_	I-Premise

232	6	_	_	I-Premise
233	)	_	_	I-Premise
234	,	_	_	I-Premise
235	one	_	_	I-Premise
236	-	_	_	I-Premise
237	year	_	_	I-Premise
238	survival	_	_	I-Premise
239	rate	_	_	I-Premise
240	was	_	_	I-Premise
241	38	_	_	I-Premise
242	.	_	_	I-Premise

243	5	_	_	I-Premise
244	%	_	_	I-Premise
245	vs	_	_	I-Premise
246	.	_	_	I-Premise

247	58	_	_	I-Premise
248	.	_	_	I-Premise

249	6	_	_	I-Premise
250	%	_	_	I-Premise
251	(	_	_	I-Premise
252	P	_	_	I-Premise
253	=	_	_	I-Premise
254	0	_	_	I-Premise
255	.	_	_	I-Premise

256	07	_	_	I-Premise
257	)	_	_	I-Premise
258	in	_	_	I-Premise
259	the	_	_	I-Premise
260	NL	_	_	I-Premise
261	and	_	_	I-Premise
262	NP	_	_	I-Premise
263	groups	_	_	I-Premise
264	,	_	_	I-Premise
265	respectively	_	_	I-Premise
266	.	_	_	I-Premise

267	Grade	_	_	B-Premise
268	I	_	_	I-Premise
269	-	_	_	I-Premise
270	II	_	_	I-Premise
271	neuro	_	_	I-Premise
272	-	_	_	I-Premise
273	sensory	_	_	I-Premise
274	toxicity	_	_	I-Premise
275	occurred	_	_	I-Premise
276	significantly	_	_	I-Premise
277	more	_	_	I-Premise
278	frequent	_	_	I-Premise
279	in	_	_	I-Premise
280	NL	_	_	I-Premise
281	group	_	_	I-Premise
282	than	_	_	I-Premise
283	in	_	_	I-Premise
284	NP	_	_	I-Premise
285	group	_	_	I-Premise
286	(	_	_	I-Premise
287	68	_	_	I-Premise
288	.	_	_	I-Premise

289	4	_	_	I-Premise
290	%	_	_	I-Premise
291	vs	_	_	I-Premise
292	.	_	_	I-Premise

293	36	_	_	I-Premise
294	.	_	_	I-Premise

295	4	_	_	I-Premise
296	%	_	_	I-Premise
297	,	_	_	I-Premise
298	P	_	_	I-Premise
299	=	_	_	I-Premise
300	0	_	_	I-Premise
301	.	_	_	I-Premise

302	0017	_	_	I-Premise
303	)	_	_	I-Premise
304	.	_	_	I-Premise

305	However	_	_	B-Premise
306	,	_	_	I-Premise
307	Grade	_	_	I-Premise
308	I	_	_	I-Premise
309	-	_	_	I-Premise
310	II	_	_	I-Premise
311	granulocytopenia	_	_	I-Premise
312	was	_	_	I-Premise
313	significantly	_	_	I-Premise
314	less	_	_	I-Premise
315	occurred	_	_	I-Premise
316	in	_	_	I-Premise
317	NL	_	_	I-Premise
318	group	_	_	I-Premise
319	than	_	_	I-Premise
320	in	_	_	I-Premise
321	NP	_	_	I-Premise
322	group	_	_	I-Premise
323	(	_	_	I-Premise
324	49	_	_	I-Premise
325	.	_	_	I-Premise

326	4	_	_	I-Premise
327	%	_	_	I-Premise
328	vs	_	_	I-Premise
329	.	_	_	I-Premise

330	70	_	_	I-Premise
331	.	_	_	I-Premise

332	6	_	_	I-Premise
333	%	_	_	I-Premise
334	,	_	_	I-Premise
335	P	_	_	I-Premise
336	=	_	_	I-Premise
337	0	_	_	I-Premise
338	.	_	_	I-Premise

339	037	_	_	I-Premise
340	)	_	_	I-Premise
341	.	_	_	I-Premise

342	There	_	_	B-Premise
343	was	_	_	I-Premise
344	no	_	_	I-Premise
345	statistically	_	_	I-Premise
346	difference	_	_	I-Premise
347	between	_	_	I-Premise
348	the	_	_	I-Premise
349	two	_	_	I-Premise
350	groups	_	_	I-Premise
351	regarding	_	_	I-Premise
352	quality	_	_	I-Premise
353	of	_	_	I-Premise
354	life	_	_	I-Premise
355	.	_	_	I-Premise

356	Due	_	_	B-Claim
357	to	_	_	I-Claim
358	good	_	_	I-Claim
359	efficacy	_	_	I-Claim
360	and	_	_	I-Claim
361	tolerability	_	_	I-Claim
362	,	_	_	I-Claim
363	the	_	_	I-Claim
364	NL	_	_	I-Claim
365	regimen	_	_	I-Claim
366	offered	_	_	I-Claim
367	a	_	_	I-Claim
368	new	_	_	I-Claim
369	candidate	_	_	I-Claim
370	for	_	_	I-Claim
371	treating	_	_	I-Claim
372	advanced	_	_	I-Claim
373	NSCLC	_	_	I-Claim
374	.	_	_	I-Claim


0	The	_	_	B-Claim
1	extent	_	_	I-Claim
2	to	_	_	I-Claim
3	which	_	_	I-Claim
4	chemotherapy	_	_	I-Claim
5	may	_	_	I-Claim
6	relieve	_	_	I-Claim
7	tumour	_	_	I-Claim
8	-	_	_	I-Claim
9	related	_	_	I-Claim
10	symptoms	_	_	I-Claim
11	,	_	_	I-Claim
12	improve	_	_	I-Claim
13	quality	_	_	I-Claim
14	of	_	_	I-Claim
15	life	_	_	I-Claim
16	and	_	_	I-Claim
17	prolong	_	_	I-Claim
18	survival	_	_	I-Claim
19	in	_	_	I-Claim
20	patients	_	_	I-Claim
21	with	_	_	I-Claim
22	gastric	_	_	I-Claim
23	cancer	_	_	I-Claim
24	is	_	_	I-Claim
25	not	_	_	I-Claim
26	known	_	_	I-Claim
27	in	_	_	I-Claim
28	spite	_	_	I-Claim
29	of	_	_	I-Claim
30	the	_	_	I-Claim
31	extensive	_	_	I-Claim
32	use	_	_	I-Claim
33	of	_	_	I-Claim
34	this	_	_	I-Claim
35	treatment	_	_	I-Claim
36	modality	_	_	I-Claim
37	.	_	_	I-Claim

38	The	_	_	O
39	aim	_	_	O
40	of	_	_	O
41	this	_	_	O
42	study	_	_	O
43	was	_	_	O
44	to	_	_	O
45	estimate	_	_	O
46	any	_	_	O
47	gain	_	_	O
48	in	_	_	O
49	the	_	_	O
50	quantity	_	_	O
51	and	_	_	O
52	quality	_	_	O
53	of	_	_	O
54	life	_	_	O
55	produced	_	_	O
56	by	_	_	O
57	chemotherapy	_	_	O
58	in	_	_	O
59	these	_	_	O
60	patients	_	_	O
61	.	_	_	O

62	Between	_	_	O
63	January	_	_	O
64	1991	_	_	O
65	and	_	_	O
66	February	_	_	O
67	1995	_	_	O
68	,	_	_	O
69	61	_	_	O
70	patients	_	_	O
71	with	_	_	O
72	gastric	_	_	O
73	cancer	_	_	O
74	were	_	_	O
75	randomized	_	_	O
76	to	_	_	O
77	either	_	_	O
78	chemotherapy	_	_	O
79	in	_	_	O
80	addition	_	_	O
81	to	_	_	O
82	best	_	_	O
83	supportive	_	_	O
84	care	_	_	O
85	or	_	_	O
86	to	_	_	O
87	best	_	_	O
88	supportive	_	_	O
89	care	_	_	O
90	.	_	_	O

91	Chemotherapy	_	_	O
92	was	_	_	O
93	allowed	_	_	O
94	in	_	_	O
95	the	_	_	O
96	latter	_	_	O
97	group	_	_	O
98	if	_	_	O
99	the	_	_	O
100	supportive	_	_	O
101	measures	_	_	O
102	did	_	_	O
103	not	_	_	O
104	lead	_	_	O
105	to	_	_	O
106	palliation	_	_	O
107	.	_	_	O

108	Chemotherapy	_	_	O
109	was	_	_	O
110	the	_	_	O
111	ELF	_	_	O
112	-	_	_	O
113	regimen	_	_	O
114	consisting	_	_	O
115	of	_	_	O
116	5	_	_	O
117	-	_	_	O
118	fluorouracil	_	_	O
119	,	_	_	O
120	leucovorin	_	_	O
121	and	_	_	O
122	etoposide	_	_	O
123	,	_	_	O
124	or	_	_	O
125	,	_	_	O
126	in	_	_	O
127	elderly	_	_	O
128	patients	_	_	O
129	with	_	_	O
130	poor	_	_	O
131	performance	_	_	O
132	,	_	_	O
133	a	_	_	O
134	5	_	_	O
135	-	_	_	O
136	fluorouracil	_	_	O
137	/	_	_	O
138	leucovorin	_	_	O
139	regimen	_	_	O
140	(	_	_	O
141	FLv	_	_	O
142	)	_	_	O
143	.	_	_	O

144	Quality	_	_	O
145	of	_	_	O
146	life	_	_	O
147	was	_	_	O
148	evaluated	_	_	O
149	with	_	_	O
150	the	_	_	O
151	EORTC	_	_	O
152	-	_	_	O
153	QLQ	_	_	O
154	-	_	_	O
155	C30	_	_	O
156	instrument	_	_	O
157	.	_	_	O

158	More	_	_	B-Premise
159	patients	_	_	I-Premise
160	in	_	_	I-Premise
161	the	_	_	I-Premise
162	chemotherapy	_	_	I-Premise
163	group	_	_	I-Premise
164	(	_	_	I-Premise
165	45	_	_	I-Premise
166	%	_	_	I-Premise
167	,	_	_	I-Premise
168	14	_	_	I-Premise
169	/	_	_	I-Premise
170	31	_	_	I-Premise
171	)	_	_	I-Premise
172	had	_	_	I-Premise
173	an	_	_	I-Premise
174	improved	_	_	I-Premise
175	or	_	_	I-Premise
176	prolonged	_	_	I-Premise
177	high	_	_	I-Premise
178	quality	_	_	I-Premise
179	of	_	_	I-Premise
180	life	_	_	I-Premise
181	for	_	_	I-Premise
182	a	_	_	I-Premise
183	minimum	_	_	I-Premise
184	period	_	_	I-Premise
185	of	_	_	I-Premise
186	4	_	_	I-Premise
187	months	_	_	I-Premise
188	compared	_	_	I-Premise
189	to	_	_	I-Premise
190	those	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	best	_	_	I-Premise
194	supportive	_	_	I-Premise
195	care	_	_	I-Premise
196	group	_	_	I-Premise
197	(	_	_	I-Premise
198	20	_	_	I-Premise
199	%	_	_	I-Premise
200	,	_	_	I-Premise
201	6	_	_	I-Premise
202	/	_	_	I-Premise
203	30	_	_	I-Premise
204	,	_	_	I-Premise
205	P	_	_	I-Premise
206	<	_	_	I-Premise
207	0	_	_	I-Premise
208	.	_	_	I-Premise

209	05	_	_	I-Premise
210	)	_	_	I-Premise
211	.	_	_	I-Premise

212	A	_	_	B-Premise
213	similar	_	_	I-Premise
214	difference	_	_	I-Premise
215	was	_	_	I-Premise
216	seen	_	_	I-Premise
217	in	_	_	I-Premise
218	the	_	_	I-Premise
219	treating	_	_	I-Premise
220	physician	_	_	I-Premise
221	'	_	_	I-Premise
222	s	_	_	I-Premise
223	evaluation	_	_	I-Premise
224	of	_	_	I-Premise
225	whether	_	_	I-Premise
226	the	_	_	I-Premise
227	patient	_	_	I-Premise
228	was	_	_	I-Premise
229	subjectively	_	_	I-Premise
230	improved	_	_	I-Premise
231	or	_	_	I-Premise
232	continued	_	_	I-Premise
233	to	_	_	I-Premise
234	do	_	_	I-Premise
235	well	_	_	I-Premise
236	for	_	_	I-Premise
237	at	_	_	I-Premise
238	least	_	_	I-Premise
239	4	_	_	I-Premise
240	months	_	_	I-Premise
241	(	_	_	I-Premise
242	17	_	_	I-Premise
243	/	_	_	I-Premise
244	31	_	_	I-Premise
245	,	_	_	I-Premise
246	55	_	_	I-Premise
247	%	_	_	I-Premise
248	versus	_	_	I-Premise
249	6	_	_	I-Premise
250	/	_	_	I-Premise
251	30	_	_	I-Premise
252	,	_	_	I-Premise
253	20	_	_	I-Premise
254	%	_	_	I-Premise
255	,	_	_	I-Premise
256	P	_	_	I-Premise
257	<	_	_	I-Premise
258	0	_	_	I-Premise
259	.	_	_	I-Premise

260	01	_	_	I-Premise
261	)	_	_	I-Premise
262	.	_	_	I-Premise

263	Overall	_	_	B-Premise
264	survival	_	_	I-Premise
265	was	_	_	I-Premise
266	longer	_	_	I-Premise
267	in	_	_	I-Premise
268	the	_	_	I-Premise
269	chemotherapy	_	_	I-Premise
270	group	_	_	I-Premise
271	(	_	_	I-Premise
272	median	_	_	I-Premise
273	8	_	_	I-Premise
274	vs	_	_	I-Premise
275	.	_	_	I-Premise

276	5	_	_	I-Premise
277	months	_	_	I-Premise
278	)	_	_	I-Premise
279	although	_	_	B-Premise
280	the	_	_	I-Premise
281	difference	_	_	I-Premise
282	was	_	_	I-Premise
283	not	_	_	I-Premise
284	statistically	_	_	I-Premise
285	significant	_	_	I-Premise
286	(	_	_	I-Premise
287	P	_	_	I-Premise
288	=	_	_	I-Premise
289	0	_	_	I-Premise
290	.	_	_	I-Premise

291	12	_	_	I-Premise
292	)	_	_	I-Premise
293	.	_	_	I-Premise

294	After	_	_	B-Premise
295	corrections	_	_	I-Premise
296	for	_	_	I-Premise
297	imbalances	_	_	I-Premise
298	in	_	_	I-Premise
299	pretreatment	_	_	I-Premise
300	characteristics	_	_	I-Premise
301	,	_	_	I-Premise
302	chemotherapy	_	_	I-Premise
303	treatment	_	_	I-Premise
304	was	_	_	I-Premise
305	,	_	_	I-Premise
306	however	_	_	I-Premise
307	,	_	_	I-Premise
308	associated	_	_	I-Premise
309	with	_	_	I-Premise
310	a	_	_	I-Premise
311	survival	_	_	I-Premise
312	benefit	_	_	I-Premise
313	(	_	_	I-Premise
314	P	_	_	I-Premise
315	=	_	_	I-Premise
316	0	_	_	I-Premise
317	.	_	_	I-Premise

318	003	_	_	I-Premise
319	)	_	_	I-Premise
320	.	_	_	I-Premise

321	Also	_	_	B-Premise
322	,	_	_	I-Premise
323	the	_	_	I-Premise
324	quality	_	_	I-Premise
325	-	_	_	I-Premise
326	adjusted	_	_	I-Premise
327	survival	_	_	I-Premise
328	time	_	_	I-Premise
329	and	_	_	I-Premise
330	time	_	_	I-Premise
331	to	_	_	I-Premise
332	disease	_	_	I-Premise
333	progression	_	_	I-Premise
334	were	_	_	I-Premise
335	longer	_	_	I-Premise
336	for	_	_	I-Premise
337	patients	_	_	I-Premise
338	randomized	_	_	I-Premise
339	to	_	_	I-Premise
340	chemotherapy	_	_	I-Premise
341	(	_	_	I-Premise
342	median	_	_	I-Premise
343	5	_	_	I-Premise
344	vs	_	_	I-Premise
345	.	_	_	I-Premise

346	2	_	_	I-Premise
347	months	_	_	I-Premise
348	,	_	_	I-Premise
349	P	_	_	I-Premise
350	=	_	_	I-Premise
351	0	_	_	I-Premise
352	.	_	_	I-Premise

353	03	_	_	I-Premise
354	)	_	_	I-Premise
355	.	_	_	I-Premise

356	The	_	_	B-Claim
357	results	_	_	I-Claim
358	show	_	_	I-Claim
359	that	_	_	I-Claim
360	chemotherapy	_	_	I-Claim
361	can	_	_	I-Claim
362	add	_	_	I-Claim
363	to	_	_	I-Claim
364	both	_	_	I-Claim
365	quantity	_	_	I-Claim
366	and	_	_	I-Claim
367	quality	_	_	I-Claim
368	of	_	_	I-Claim
369	life	_	_	I-Claim
370	in	_	_	I-Claim
371	advanced	_	_	I-Claim
372	gastric	_	_	I-Claim
373	cancer	_	_	I-Claim
374	.	_	_	I-Claim

375	The	_	_	B-Claim
376	number	_	_	I-Claim
377	of	_	_	I-Claim
378	patients	_	_	I-Claim
379	who	_	_	I-Claim
380	benefit	_	_	I-Claim
381	from	_	_	I-Claim
382	treatment	_	_	I-Claim
383	is	_	_	I-Claim
384	,	_	_	I-Claim
385	however	_	_	I-Claim
386	,	_	_	I-Claim
387	still	_	_	I-Claim
388	rather	_	_	I-Claim
389	limited	_	_	I-Claim
390	.	_	_	I-Claim


0	Docetaxel	_	_	O
1	administered	_	_	O
2	every	_	_	O
3	3	_	_	O
4	weeks	_	_	O
5	is	_	_	O
6	a	_	_	O
7	standard	_	_	O
8	treatment	_	_	O
9	for	_	_	O
10	castration	_	_	O
11	-	_	_	O
12	resistant	_	_	O
13	advanced	_	_	O
14	prostate	_	_	O
15	cancer	_	_	O
16	.	_	_	O

17	We	_	_	O
18	hypothesised	_	_	O
19	that	_	_	O
20	2	_	_	O
21	-	_	_	O
22	weekly	_	_	O
23	administration	_	_	O
24	of	_	_	O
25	docetaxel	_	_	O
26	would	_	_	O
27	be	_	_	O
28	better	_	_	O
29	tolerated	_	_	O
30	than	_	_	O
31	3	_	_	O
32	-	_	_	O
33	weekly	_	_	O
34	docetaxel	_	_	O
35	in	_	_	O
36	patients	_	_	O
37	with	_	_	O
38	castration	_	_	O
39	-	_	_	O
40	resistant	_	_	O
41	advanced	_	_	O
42	prostate	_	_	O
43	cancer	_	_	O
44	,	_	_	O
45	and	_	_	O
46	did	_	_	O
47	a	_	_	O
48	prospective	_	_	O
49	,	_	_	O
50	multicentre	_	_	O
51	,	_	_	O
52	randomised	_	_	O
53	,	_	_	O
54	phase	_	_	O
55	3	_	_	O
56	study	_	_	O
57	to	_	_	O
58	compare	_	_	O
59	efficacy	_	_	O
60	and	_	_	O
61	safety	_	_	O
62	.	_	_	O

63	Eligible	_	_	O
64	patients	_	_	O
65	had	_	_	O
66	advanced	_	_	O
67	prostate	_	_	O
68	cancer	_	_	O
69	(	_	_	O
70	metastasis	_	_	O
71	,	_	_	O
72	a	_	_	O
73	prostate	_	_	O
74	-	_	_	O
75	specific	_	_	O
76	-	_	_	O
77	antigen	_	_	O
78	test	_	_	O
79	result	_	_	O
80	of	_	_	O
81	more	_	_	O
82	than	_	_	O
83	10	_	_	O
84	·	_	_	O
85	0	_	_	O
86	ng	_	_	O
87	/	_	_	O
88	mL	_	_	O
89	,	_	_	O
90	and	_	_	O
91	WHO	_	_	O
92	performance	_	_	O
93	status	_	_	O
94	score	_	_	O
95	of	_	_	O
96	0	_	_	O
97	-	_	_	O
98	2	_	_	O
99	)	_	_	O
100	,	_	_	O
101	had	_	_	O
102	received	_	_	O
103	no	_	_	O
104	chemotherapy	_	_	O
105	(	_	_	O
106	except	_	_	O
107	with	_	_	O
108	estramustine	_	_	O
109	)	_	_	O
110	,	_	_	O
111	had	_	_	O
112	undergone	_	_	O
113	surgical	_	_	O
114	or	_	_	O
115	chemical	_	_	O
116	castration	_	_	O
117	,	_	_	O
118	and	_	_	O
119	had	_	_	O
120	been	_	_	O
121	referred	_	_	O
122	to	_	_	O
123	a	_	_	O
124	treatment	_	_	O
125	centre	_	_	O
126	in	_	_	O
127	Finland	_	_	O
128	,	_	_	O
129	Ireland	_	_	O
130	,	_	_	O
131	or	_	_	O
132	Sweden	_	_	O
133	.	_	_	O

134	Enrolment	_	_	O
135	and	_	_	O
136	treatment	_	_	O
137	were	_	_	O
138	done	_	_	O
139	between	_	_	O
140	March	_	_	O
141	1	_	_	O
142	,	_	_	O
143	2004	_	_	O
144	,	_	_	O
145	and	_	_	O
146	May	_	_	O
147	31	_	_	O
148	,	_	_	O
149	2009	_	_	O
150	.	_	_	O

151	Randomisation	_	_	O
152	was	_	_	O
153	done	_	_	O
154	centrally	_	_	O
155	and	_	_	O
156	stratified	_	_	O
157	by	_	_	O
158	centre	_	_	O
159	and	_	_	O
160	WHO	_	_	O
161	performance	_	_	O
162	status	_	_	O
163	score	_	_	O
164	of	_	_	O
165	0	_	_	O
166	-	_	_	O
167	1	_	_	O
168	vs	_	_	O
169	2	_	_	O
170	.	_	_	O

171	Patients	_	_	O
172	were	_	_	O
173	assigned	_	_	O
174	75	_	_	O
175	mg	_	_	O
176	/	_	_	O
177	m	_	_	O
178	(	_	_	O
179	2	_	_	O
180	)	_	_	O
181	docetaxel	_	_	O
182	intravenously	_	_	O
183	on	_	_	O
184	day	_	_	O
185	1	_	_	O
186	of	_	_	O
187	a	_	_	O
188	3	_	_	O
189	-	_	_	O
190	week	_	_	O
191	cycle	_	_	O
192	,	_	_	O
193	or	_	_	O
194	50	_	_	O
195	mg	_	_	O
196	/	_	_	O
197	m	_	_	O
198	(	_	_	O
199	2	_	_	O
200	)	_	_	O
201	docetaxel	_	_	O
202	intravenously	_	_	O
203	on	_	_	O
204	days	_	_	O
205	1	_	_	O
206	and	_	_	O
207	15	_	_	O
208	of	_	_	O
209	a	_	_	O
210	4	_	_	O
211	-	_	_	O
212	week	_	_	O
213	cycle	_	_	O
214	.	_	_	O

215	10	_	_	O
216	mg	_	_	O
217	oral	_	_	O
218	prednisolone	_	_	O
219	was	_	_	O
220	administered	_	_	O
221	daily	_	_	O
222	to	_	_	O
223	all	_	_	O
224	patients	_	_	O
225	.	_	_	O

226	The	_	_	O
227	primary	_	_	O
228	endpoint	_	_	O
229	was	_	_	O
230	time	_	_	O
231	to	_	_	O
232	treatment	_	_	O
233	failure	_	_	O
234	(	_	_	O
235	TTTF	_	_	O
236	)	_	_	O
237	.	_	_	O

238	We	_	_	O
239	assessed	_	_	O
240	data	_	_	O
241	in	_	_	O
242	the	_	_	O
243	per	_	_	O
244	-	_	_	O
245	protocol	_	_	O
246	population	_	_	O
247	.	_	_	O

248	177	_	_	O
249	patients	_	_	O
250	were	_	_	O
251	randomly	_	_	O
252	assigned	_	_	O
253	to	_	_	O
254	the	_	_	O
255	2	_	_	O
256	-	_	_	O
257	weekly	_	_	O
258	docetaxel	_	_	O
259	group	_	_	O
260	and	_	_	O
261	184	_	_	O
262	to	_	_	O
263	the	_	_	O
264	3	_	_	O
265	-	_	_	O
266	weekly	_	_	O
267	group	_	_	O
268	.	_	_	O

269	170	_	_	O
270	patients	_	_	O
271	in	_	_	O
272	the	_	_	O
273	2	_	_	O
274	-	_	_	O
275	weekly	_	_	O
276	group	_	_	O
277	and	_	_	O
278	176	_	_	O
279	in	_	_	O
280	the	_	_	O
281	3	_	_	O
282	-	_	_	O
283	weekly	_	_	O
284	group	_	_	O
285	were	_	_	O
286	included	_	_	O
287	in	_	_	O
288	the	_	_	O
289	analysis	_	_	O
290	.	_	_	O

291	The	_	_	B-Premise
292	2	_	_	I-Premise
293	-	_	_	I-Premise
294	weekly	_	_	I-Premise
295	administration	_	_	I-Premise
296	was	_	_	I-Premise
297	associated	_	_	I-Premise
298	with	_	_	I-Premise
299	significantly	_	_	I-Premise
300	longer	_	_	I-Premise
301	TTTF	_	_	I-Premise
302	than	_	_	I-Premise
303	was	_	_	I-Premise
304	3	_	_	I-Premise
305	-	_	_	I-Premise
306	weekly	_	_	I-Premise
307	administration	_	_	I-Premise
308	(	_	_	I-Premise
309	5	_	_	I-Premise
310	·	_	_	I-Premise
311	6	_	_	I-Premise
312	months	_	_	I-Premise
313	,	_	_	I-Premise
314	95	_	_	I-Premise
315	%	_	_	I-Premise
316	CI	_	_	I-Premise
317	5	_	_	I-Premise
318	·	_	_	I-Premise
319	0	_	_	I-Premise
320	-	_	_	I-Premise
321	6	_	_	I-Premise
322	·	_	_	I-Premise
323	2	_	_	I-Premise
324	vs	_	_	I-Premise
325	4	_	_	I-Premise
326	·	_	_	I-Premise
327	9	_	_	I-Premise
328	months	_	_	I-Premise
329	,	_	_	I-Premise
330	4	_	_	I-Premise
331	·	_	_	I-Premise
332	5	_	_	I-Premise
333	-	_	_	I-Premise
334	5	_	_	I-Premise
335	·	_	_	I-Premise
336	4	_	_	I-Premise
337	;	_	_	I-Premise
338	hazard	_	_	I-Premise
339	ratio	_	_	I-Premise
340	1	_	_	I-Premise
341	·	_	_	I-Premise
342	3	_	_	I-Premise
343	,	_	_	I-Premise
344	95	_	_	I-Premise
345	%	_	_	I-Premise
346	CI	_	_	I-Premise
347	1	_	_	I-Premise
348	·	_	_	I-Premise
349	1	_	_	I-Premise
350	-	_	_	I-Premise
351	1	_	_	I-Premise
352	·	_	_	I-Premise
353	6	_	_	I-Premise
354	,	_	_	I-Premise
355	p	_	_	I-Premise
356	=	_	_	I-Premise
357	0	_	_	I-Premise
358	·	_	_	I-Premise
359	014	_	_	I-Premise
360	)	_	_	I-Premise
361	.	_	_	I-Premise

362	Grade	_	_	B-Premise
363	3	_	_	I-Premise
364	-	_	_	I-Premise
365	4	_	_	I-Premise
366	adverse	_	_	I-Premise
367	events	_	_	I-Premise
368	occurred	_	_	I-Premise
369	more	_	_	I-Premise
370	frequently	_	_	I-Premise
371	in	_	_	I-Premise
372	the	_	_	I-Premise
373	3	_	_	I-Premise
374	-	_	_	I-Premise
375	weekly	_	_	I-Premise
376	than	_	_	I-Premise
377	in	_	_	I-Premise
378	the	_	_	I-Premise
379	2	_	_	I-Premise
380	-	_	_	I-Premise
381	weekly	_	_	I-Premise
382	administration	_	_	I-Premise
383	group	_	_	I-Premise
384	,	_	_	I-Premise
385	including	_	_	I-Premise
386	neutropenia	_	_	I-Premise
387	(	_	_	I-Premise
388	93	_	_	I-Premise
389	[	_	_	I-Premise
390	53	_	_	I-Premise
391	%	_	_	I-Premise
392	]	_	_	I-Premise
393	vs	_	_	I-Premise
394	61	_	_	I-Premise
395	[	_	_	I-Premise
396	36	_	_	I-Premise
397	%	_	_	I-Premise
398	]	_	_	I-Premise
399	)	_	_	I-Premise
400	,	_	_	I-Premise
401	leucopenia	_	_	I-Premise
402	(	_	_	I-Premise
403	51	_	_	I-Premise
404	[	_	_	I-Premise
405	29	_	_	I-Premise
406	%	_	_	I-Premise
407	]	_	_	I-Premise
408	vs	_	_	I-Premise
409	22	_	_	I-Premise
410	[	_	_	I-Premise
411	13	_	_	I-Premise
412	%	_	_	I-Premise
413	]	_	_	I-Premise
414	)	_	_	I-Premise
415	,	_	_	I-Premise
416	and	_	_	I-Premise
417	febrile	_	_	I-Premise
418	neutropenia	_	_	I-Premise
419	(	_	_	I-Premise
420	25	_	_	I-Premise
421	[	_	_	I-Premise
422	14	_	_	I-Premise
423	%	_	_	I-Premise
424	]	_	_	I-Premise
425	vs	_	_	I-Premise
426	six	_	_	I-Premise
427	[	_	_	I-Premise
428	4	_	_	I-Premise
429	%	_	_	I-Premise
430	]	_	_	I-Premise
431	)	_	_	I-Premise
432	.	_	_	I-Premise

433	Neutropenic	_	_	B-Premise
434	infections	_	_	I-Premise
435	were	_	_	I-Premise
436	reported	_	_	I-Premise
437	more	_	_	I-Premise
438	frequently	_	_	I-Premise
439	in	_	_	I-Premise
440	patients	_	_	I-Premise
441	who	_	_	I-Premise
442	received	_	_	I-Premise
443	docetaxel	_	_	I-Premise
444	every	_	_	I-Premise
445	3	_	_	I-Premise
446	weeks	_	_	I-Premise
447	(	_	_	I-Premise
448	43	_	_	I-Premise
449	[	_	_	I-Premise
450	24	_	_	I-Premise
451	%	_	_	I-Premise
452	]	_	_	I-Premise
453	vs	_	_	I-Premise
454	11	_	_	I-Premise
455	[	_	_	I-Premise
456	6	_	_	I-Premise
457	%	_	_	I-Premise
458	]	_	_	I-Premise
459	,	_	_	I-Premise
460	p	_	_	I-Premise
461	=	_	_	I-Premise
462	0	_	_	I-Premise
463	·	_	_	I-Premise
464	002	_	_	I-Premise
465	)	_	_	I-Premise
466	.	_	_	I-Premise

467	Administration	_	_	B-Claim
468	of	_	_	I-Claim
469	docetaxel	_	_	I-Claim
470	every	_	_	I-Claim
471	2	_	_	I-Claim
472	weeks	_	_	I-Claim
473	seems	_	_	I-Claim
474	to	_	_	I-Claim
475	be	_	_	I-Claim
476	well	_	_	I-Claim
477	tolerated	_	_	I-Claim
478	in	_	_	I-Claim
479	patients	_	_	I-Claim
480	with	_	_	I-Claim
481	castration	_	_	I-Claim
482	-	_	_	I-Claim
483	resistant	_	_	I-Claim
484	advanced	_	_	I-Claim
485	prostate	_	_	I-Claim
486	cancer	_	_	I-Claim
487	and	_	_	I-Claim
488	could	_	_	I-Claim
489	be	_	_	I-Claim
490	a	_	_	I-Claim
491	useful	_	_	I-Claim
492	option	_	_	I-Claim
493	when	_	_	I-Claim
494	3	_	_	I-Claim
495	-	_	_	I-Claim
496	weekly	_	_	I-Claim
497	single	_	_	I-Claim
498	-	_	_	I-Claim
499	dose	_	_	I-Claim
500	administration	_	_	I-Claim
501	is	_	_	I-Claim
502	unlikely	_	_	I-Claim
503	to	_	_	I-Claim
504	be	_	_	I-Claim
505	tolerated	_	_	I-Claim
506	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	the	_	_	O
6	Chinese	_	_	O
7	medicine	_	_	O
8	(	_	_	O
9	CM	_	_	O
10	)	_	_	O
11	five	_	_	O
12	-	_	_	O
13	element	_	_	O
14	music	_	_	O
15	on	_	_	O
16	quality	_	_	O
17	of	_	_	O
18	life	_	_	O
19	for	_	_	O
20	senior	_	_	O
21	and	_	_	O
22	non	_	_	O
23	-	_	_	O
24	senior	_	_	O
25	advanced	_	_	O
26	cancer	_	_	O
27	patients	_	_	O
28	.	_	_	O

29	With	_	_	O
30	a	_	_	O
31	randomized	_	_	O
32	controlled	_	_	O
33	trial	_	_	O
34	,	_	_	O
35	170	_	_	O
36	advanced	_	_	O
37	cancer	_	_	O
38	patients	_	_	O
39	were	_	_	O
40	randomly	_	_	O
41	assigned	_	_	O
42	to	_	_	O
43	three	_	_	O
44	groups	_	_	O
45	:	_	_	O
46	the	_	_	O
47	CM	_	_	O
48	five	_	_	O
49	-	_	_	O
50	element	_	_	O
51	music	_	_	O
52	group	_	_	O
53	(	_	_	O
54	68	_	_	O
55	patients	_	_	O
56	)	_	_	O
57	,	_	_	O
58	the	_	_	O
59	Western	_	_	O
60	music	_	_	O
61	therapy	_	_	O
62	group	_	_	O
63	(	_	_	O
64	68	_	_	O
65	cases	_	_	O
66	)	_	_	O
67	,	_	_	O
68	and	_	_	O
69	the	_	_	O
70	no	_	_	O
71	music	_	_	O
72	therapy	_	_	O
73	group	_	_	O
74	(	_	_	O
75	34	_	_	O
76	cases	_	_	O
77	)	_	_	O
78	.	_	_	O

79	All	_	_	O
80	patients	_	_	O
81	of	_	_	O
82	70	_	_	O
83	years	_	_	O
84	old	_	_	O
85	or	_	_	O
86	older	_	_	O
87	were	_	_	O
88	considered	_	_	O
89	seniors	_	_	O
90	and	_	_	O
91	the	_	_	O
92	remaining	_	_	O
93	patients	_	_	O
94	younger	_	_	O
95	than	_	_	O
96	70	_	_	O
97	years	_	_	O
98	were	_	_	O
99	considered	_	_	O
100	nonseniors	_	_	O
101	.	_	_	O

102	Patients	_	_	O
103	in	_	_	O
104	the	_	_	O
105	CM	_	_	O
106	five	_	_	O
107	-	_	_	O
108	element	_	_	O
109	music	_	_	O
110	group	_	_	O
111	listened	_	_	O
112	to	_	_	O
113	CM	_	_	O
114	five	_	_	O
115	-	_	_	O
116	element	_	_	O
117	music	_	_	O
118	,	_	_	O
119	the	_	_	O
120	patients	_	_	O
121	in	_	_	O
122	the	_	_	O
123	Western	_	_	O
124	music	_	_	O
125	group	_	_	O
126	listened	_	_	O
127	to	_	_	O
128	Western	_	_	O
129	music	_	_	O
130	,	_	_	O
131	and	_	_	O
132	the	_	_	O
133	patients	_	_	O
134	in	_	_	O
135	the	_	_	O
136	no	_	_	O
137	music	_	_	O
138	group	_	_	O
139	did	_	_	O
140	not	_	_	O
141	listen	_	_	O
142	to	_	_	O
143	music	_	_	O
144	.	_	_	O

145	A	_	_	O
146	course	_	_	O
147	of	_	_	O
148	treatment	_	_	O
149	was	_	_	O
150	3	_	_	O
151	weeks	_	_	O
152	,	_	_	O
153	with	_	_	O
154	30	_	_	O
155	min	_	_	O
156	each	_	_	O
157	day	_	_	O
158	,	_	_	O
159	5	_	_	O
160	days	_	_	O
161	a	_	_	O
162	week	_	_	O
163	.	_	_	O

164	The	_	_	O
165	Hospice	_	_	O
166	Quality	_	_	O
167	of	_	_	O
168	Life	_	_	O
169	Index	_	_	O
170	-	_	_	O
171	Revised	_	_	O
172	(	_	_	O
173	HQOLI	_	_	O
174	-	_	_	O
175	R	_	_	O
176	)	_	_	O
177	and	_	_	O
178	Karnofsky	_	_	O
179	performance	_	_	O
180	score	_	_	O
181	(	_	_	O
182	KPS	_	_	O
183	)	_	_	O
184	were	_	_	O
185	measured	_	_	O
186	in	_	_	O
187	the	_	_	O
188	three	_	_	O
189	groups	_	_	O
190	before	_	_	O
191	and	_	_	O
192	after	_	_	O
193	treatment	_	_	O
194	.	_	_	O

195	The	_	_	O
196	symptom	_	_	O
197	diary	_	_	O
198	score	_	_	O
199	was	_	_	O
200	measured	_	_	O
201	in	_	_	O
202	the	_	_	O
203	three	_	_	O
204	groups	_	_	O
205	every	_	_	O
206	3	_	_	O
207	days	_	_	O
208	,	_	_	O
209	7	_	_	O
210	times	_	_	O
211	in	_	_	O
212	total	_	_	O
213	.	_	_	O

214	CM	_	_	B-Premise
215	five	_	_	I-Premise
216	-	_	_	I-Premise
217	element	_	_	I-Premise
218	music	_	_	I-Premise
219	group	_	_	I-Premise
220	showed	_	_	I-Premise
221	a	_	_	I-Premise
222	significant	_	_	I-Premise
223	difference	_	_	I-Premise
224	of	_	_	I-Premise
225	HQOLI	_	_	I-Premise
226	-	_	_	I-Premise
227	R	_	_	I-Premise
228	,	_	_	I-Premise
229	KPS	_	_	I-Premise
230	and	_	_	I-Premise
231	symptom	_	_	I-Premise
232	diary	_	_	I-Premise
233	score	_	_	I-Premise
234	with	_	_	I-Premise
235	other	_	_	I-Premise
236	groups	_	_	I-Premise
237	(	_	_	I-Premise
238	all	_	_	I-Premise
239	P	_	_	I-Premise
240	<	_	_	I-Premise
241	0	_	_	I-Premise
242	.	_	_	I-Premise

243	01	_	_	I-Premise
244	)	_	_	I-Premise
245	.	_	_	I-Premise

246	There	_	_	B-Premise
247	were	_	_	I-Premise
248	significant	_	_	I-Premise
249	differences	_	_	I-Premise
250	of	_	_	I-Premise
251	HQOLI	_	_	I-Premise
252	-	_	_	I-Premise
253	R	_	_	I-Premise
254	,	_	_	I-Premise
255	symptom	_	_	I-Premise
256	diary	_	_	I-Premise
257	score	_	_	I-Premise
258	,	_	_	I-Premise
259	and	_	_	I-Premise
260	KPS	_	_	I-Premise
261	after	_	_	I-Premise
262	treatment	_	_	I-Premise
263	in	_	_	I-Premise
264	CM	_	_	I-Premise
265	five	_	_	I-Premise
266	-	_	_	I-Premise
267	element	_	_	I-Premise
268	music	_	_	I-Premise
269	group	_	_	I-Premise
270	and	_	_	I-Premise
271	other	_	_	I-Premise
272	groups	_	_	I-Premise
273	in	_	_	I-Premise
274	the	_	_	I-Premise
275	non	_	_	I-Premise
276	-	_	_	I-Premise
277	senior	_	_	I-Premise
278	subgroup	_	_	I-Premise
279	(	_	_	I-Premise
280	P	_	_	I-Premise
281	<	_	_	I-Premise
282	0	_	_	I-Premise
283	.	_	_	I-Premise

284	05	_	_	I-Premise
285	)	_	_	I-Premise
286	.	_	_	I-Premise

287	Additionally	_	_	O
288	,	_	_	O
289	there	_	_	B-Premise
290	were	_	_	I-Premise
291	significant	_	_	I-Premise
292	differences	_	_	I-Premise
293	in	_	_	I-Premise
294	HQOLI	_	_	I-Premise
295	-	_	_	I-Premise
296	R	_	_	I-Premise
297	and	_	_	I-Premise
298	KPS	_	_	I-Premise
299	after	_	_	I-Premise
300	treatment	_	_	I-Premise
301	among	_	_	I-Premise
302	the	_	_	I-Premise
303	three	_	_	I-Premise
304	groups	_	_	I-Premise
305	in	_	_	I-Premise
306	the	_	_	I-Premise
307	senior	_	_	I-Premise
308	subgroup	_	_	I-Premise
309	(	_	_	I-Premise
310	P	_	_	I-Premise
311	<	_	_	I-Premise
312	0	_	_	I-Premise
313	.	_	_	I-Premise

314	05	_	_	I-Premise
315	)	_	_	I-Premise
316	.	_	_	I-Premise

317	CM	_	_	B-Claim
318	five	_	_	I-Claim
319	-	_	_	I-Claim
320	element	_	_	I-Claim
321	music	_	_	I-Claim
322	therapy	_	_	I-Claim
323	could	_	_	I-Claim
324	improve	_	_	I-Claim
325	the	_	_	I-Claim
326	quality	_	_	I-Claim
327	of	_	_	I-Claim
328	life	_	_	I-Claim
329	and	_	_	I-Claim
330	KPS	_	_	I-Claim
331	for	_	_	I-Claim
332	senior	_	_	I-Claim
333	and	_	_	I-Claim
334	non	_	_	I-Claim
335	senior	_	_	I-Claim
336	advanced	_	_	I-Claim
337	cancer	_	_	I-Claim
338	patients	_	_	I-Claim
339	,	_	_	I-Claim
340	and	_	_	I-Claim
341	it	_	_	I-Claim
342	could	_	_	I-Claim
343	improve	_	_	I-Claim
344	subjective	_	_	I-Claim
345	symptoms	_	_	I-Claim
346	for	_	_	I-Claim
347	non	_	_	I-Claim
348	-	_	_	I-Claim
349	senior	_	_	I-Claim
350	advanced	_	_	I-Claim
351	cancer	_	_	I-Claim
352	patients	_	_	I-Claim
353	.	_	_	I-Claim


0	Bacillus	_	_	B-Claim
1	Calmette	_	_	I-Claim
2	-	_	_	I-Claim
3	Guérin	_	_	I-Claim
4	and	_	_	I-Claim
5	intravesical	_	_	I-Claim
6	chemotherapy	_	_	I-Claim
7	represent	_	_	I-Claim
8	viable	_	_	I-Claim
9	adjuvant	_	_	I-Claim
10	options	_	_	I-Claim
11	for	_	_	I-Claim
12	intermediate	_	_	I-Claim
13	risk	_	_	I-Claim
14	nonmuscle	_	_	I-Claim
15	invasive	_	_	I-Claim
16	bladder	_	_	I-Claim
17	cancer	_	_	I-Claim
18	.	_	_	I-Claim

19	Although	_	_	O
20	bacillus	_	_	O
21	Calmette	_	_	O
22	-	_	_	O
23	Guérin	_	_	O
24	is	_	_	O
25	perceived	_	_	O
26	as	_	_	O
27	less	_	_	O
28	tolerable	_	_	O
29	than	_	_	O
30	intravesical	_	_	O
31	chemotherapy	_	_	O
32	,	_	_	O
33	to	_	_	O
34	our	_	_	O
35	knowledge	_	_	O
36	no	_	_	O
37	comparative	_	_	O
38	studies	_	_	O
39	have	_	_	O
40	addressed	_	_	O
41	quality	_	_	O
42	of	_	_	O
43	life	_	_	O
44	issues	_	_	O
45	.	_	_	O

46	We	_	_	O
47	compared	_	_	O
48	the	_	_	O
49	quality	_	_	O
50	of	_	_	O
51	life	_	_	O
52	of	_	_	O
53	patients	_	_	O
54	with	_	_	O
55	nonmuscle	_	_	O
56	invasive	_	_	O
57	bladder	_	_	O
58	cancer	_	_	O
59	who	_	_	O
60	received	_	_	O
61	adjuvant	_	_	O
62	intravesical	_	_	O
63	gemcitabine	_	_	O
64	or	_	_	O
65	1	_	_	O
66	/	_	_	O
67	3	_	_	O
68	dose	_	_	O
69	bacillus	_	_	O
70	Calmette	_	_	O
71	-	_	_	O
72	Guérin	_	_	O
73	.	_	_	O

74	Our	_	_	O
75	multicenter	_	_	O
76	,	_	_	O
77	prospective	_	_	O
78	,	_	_	O
79	randomized	_	_	O
80	,	_	_	O
81	phase	_	_	O
82	II	_	_	O
83	study	_	_	O
84	included	_	_	O
85	120	_	_	O
86	patients	_	_	O
87	with	_	_	O
88	intermediate	_	_	O
89	risk	_	_	O
90	nonmuscle	_	_	O
91	invasive	_	_	O
92	bladder	_	_	O
93	cancer	_	_	O
94	.	_	_	O

95	Of	_	_	O
96	these	_	_	O
97	patients	_	_	O
98	88	_	_	O
99	remained	_	_	O
100	assessable	_	_	O
101	at	_	_	O
102	1	_	_	O
103	-	_	_	O
104	year	_	_	O
105	followup	_	_	O
106	.	_	_	O

107	Only	_	_	O
108	1	_	_	O
109	patient	_	_	O
110	was	_	_	O
111	withdrawn	_	_	O
112	because	_	_	O
113	of	_	_	O
114	adverse	_	_	O
115	events	_	_	O
116	.	_	_	O

117	Overall	_	_	O
118	61	_	_	O
119	patients	_	_	O
120	received	_	_	O
121	2	_	_	O
122	,	_	_	O
123	000	_	_	O
124	mg	_	_	O
125	/	_	_	O
126	50	_	_	O
127	cc	_	_	O
128	gemcitabine	_	_	O
129	weekly	_	_	O
130	for	_	_	O
131	6	_	_	O
132	weeks	_	_	O
133	(	_	_	O
134	maintenance	_	_	O
135	monthly	_	_	O
136	for	_	_	O
137	1	_	_	O
138	year	_	_	O
139	)	_	_	O
140	while	_	_	O
141	59	_	_	O
142	received	_	_	O
143	1	_	_	O
144	/	_	_	O
145	3	_	_	O
146	dose	_	_	O
147	bacillus	_	_	O
148	Calmette	_	_	O
149	-	_	_	O
150	Guérin	_	_	O
151	Connaught	_	_	O
152	weekly	_	_	O
153	for	_	_	O
154	6	_	_	O
155	weeks	_	_	O
156	(	_	_	O
157	maintenance	_	_	O
158	3	_	_	O
159	weekly	_	_	O
160	instillations	_	_	O
161	at	_	_	O
162	3	_	_	O
163	,	_	_	O
164	6	_	_	O
165	and	_	_	O
166	12	_	_	O
167	months	_	_	O
168	)	_	_	O
169	.	_	_	O

170	Quality	_	_	O
171	of	_	_	O
172	life	_	_	O
173	was	_	_	O
174	measured	_	_	O
175	by	_	_	O
176	the	_	_	O
177	EORTC	_	_	O
178	QLQ	_	_	O
179	-	_	_	O
180	C30	_	_	O
181	(	_	_	O
182	European	_	_	O
183	Organization	_	_	O
184	for	_	_	O
185	the	_	_	O
186	Research	_	_	O
187	and	_	_	O
188	Treatment	_	_	O
189	of	_	_	O
190	Cancer	_	_	O
191	Quality	_	_	O
192	of	_	_	O
193	Life	_	_	O
194	Questionnaire	_	_	O
195	Core	_	_	O
196	30	_	_	O
197	version	_	_	O
198	3	_	_	O
199	.	_	_	O

200	0	_	_	O
201	)	_	_	O
202	and	_	_	O
203	QLQ	_	_	O
204	-	_	_	O
205	BLS24	_	_	O
206	(	_	_	O
207	Quality	_	_	O
208	of	_	_	O
209	Life	_	_	O
210	Superficial	_	_	O
211	Bladder	_	_	O
212	Cancer	_	_	O
213	-	_	_	O
214	Specific	_	_	O
215	24	_	_	O
216	)	_	_	O
217	questionnaires	_	_	O
218	.	_	_	O

219	Group	_	_	O
220	differences	_	_	O
221	were	_	_	O
222	calculated	_	_	O
223	using	_	_	O
224	ANOVA	_	_	O
225	(	_	_	O
226	ANOVA	_	_	O
227	/	_	_	O
228	MANOVA	_	_	O
229	)	_	_	O
230	.	_	_	O

231	Treatment	_	_	B-Premise
232	was	_	_	I-Premise
233	well	_	_	I-Premise
234	tolerated	_	_	I-Premise
235	in	_	_	I-Premise
236	both	_	_	I-Premise
237	groups	_	_	I-Premise
238	,	_	_	I-Premise
239	although	_	_	B-Premise
240	local	_	_	I-Premise
241	and	_	_	I-Premise
242	systemic	_	_	I-Premise
243	side	_	_	I-Premise
244	effects	_	_	I-Premise
245	were	_	_	I-Premise
246	more	_	_	I-Premise
247	frequently	_	_	I-Premise
248	reported	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	bacillus	_	_	I-Premise
252	Calmette	_	_	I-Premise
253	-	_	_	I-Premise
254	Guérin	_	_	I-Premise
255	arm	_	_	I-Premise
256	.	_	_	I-Premise

257	Multivariate	_	_	B-Premise
258	analyses	_	_	I-Premise
259	showed	_	_	I-Premise
260	no	_	_	I-Premise
261	significant	_	_	I-Premise
262	differences	_	_	I-Premise
263	between	_	_	I-Premise
264	the	_	_	I-Premise
265	2	_	_	I-Premise
266	groups	_	_	I-Premise
267	in	_	_	I-Premise
268	all	_	_	I-Premise
269	quality	_	_	I-Premise
270	of	_	_	I-Premise
271	life	_	_	I-Premise
272	dimensions	_	_	I-Premise
273	.	_	_	I-Premise

274	No	_	_	B-Premise
275	significant	_	_	I-Premise
276	changes	_	_	I-Premise
277	over	_	_	I-Premise
278	time	_	_	I-Premise
279	in	_	_	I-Premise
280	quality	_	_	I-Premise
281	of	_	_	I-Premise
282	life	_	_	I-Premise
283	domains	_	_	I-Premise
284	were	_	_	I-Premise
285	detected	_	_	I-Premise
286	for	_	_	I-Premise
287	patients	_	_	I-Premise
288	on	_	_	I-Premise
289	bacillus	_	_	I-Premise
290	Calmette	_	_	I-Premise
291	-	_	_	I-Premise
292	Guérin	_	_	I-Premise
293	and	_	_	I-Premise
294	gemcitabine	_	_	I-Premise
295	except	_	_	I-Premise
296	for	_	_	I-Premise
297	physical	_	_	I-Premise
298	functioning	_	_	I-Premise
299	,	_	_	I-Premise
300	which	_	_	I-Premise
301	decreased	_	_	I-Premise
302	significantly	_	_	I-Premise
303	in	_	_	I-Premise
304	both	_	_	I-Premise
305	groups	_	_	I-Premise
306	(	_	_	I-Premise
307	p	_	_	I-Premise
308	=	_	_	I-Premise
309	0	_	_	I-Premise
310	.	_	_	I-Premise

311	002	_	_	I-Premise
312	)	_	_	I-Premise
313	.	_	_	I-Premise

314	No	_	_	B-Premise
315	significant	_	_	I-Premise
316	differences	_	_	I-Premise
317	were	_	_	I-Premise
318	detected	_	_	I-Premise
319	in	_	_	I-Premise
320	terms	_	_	I-Premise
321	of	_	_	I-Premise
322	recurrence	_	_	I-Premise
323	and	_	_	I-Premise
324	progression	_	_	I-Premise
325	between	_	_	I-Premise
326	the	_	_	I-Premise
327	2	_	_	I-Premise
328	groups	_	_	I-Premise
329	at	_	_	I-Premise
330	1	_	_	I-Premise
331	-	_	_	I-Premise
332	year	_	_	I-Premise
333	followup	_	_	I-Premise
334	.	_	_	I-Premise

335	While	_	_	O
336	a	_	_	B-Claim
337	higher	_	_	I-Claim
338	rate	_	_	I-Claim
339	of	_	_	I-Claim
340	side	_	_	I-Claim
341	effects	_	_	I-Claim
342	,	_	_	I-Claim
343	albeit	_	_	I-Claim
344	mild	_	_	I-Claim
345	to	_	_	I-Claim
346	moderate	_	_	I-Claim
347	,	_	_	I-Claim
348	was	_	_	I-Claim
349	detected	_	_	I-Claim
350	with	_	_	I-Claim
351	1	_	_	I-Claim
352	/	_	_	I-Claim
353	3	_	_	I-Claim
354	dose	_	_	I-Claim
355	bacillus	_	_	I-Claim
356	Calmette	_	_	I-Claim
357	-	_	_	I-Claim
358	Guérin	_	_	I-Claim
359	compared	_	_	I-Claim
360	to	_	_	I-Claim
361	gemcitabine	_	_	I-Claim
362	,	_	_	I-Claim
363	our	_	_	B-Claim
364	study	_	_	I-Claim
365	failed	_	_	I-Claim
366	to	_	_	I-Claim
367	show	_	_	I-Claim
368	significant	_	_	I-Claim
369	differences	_	_	I-Claim
370	between	_	_	I-Claim
371	the	_	_	I-Claim
372	2	_	_	I-Claim
373	drugs	_	_	I-Claim
374	in	_	_	I-Claim
375	terms	_	_	I-Claim
376	of	_	_	I-Claim
377	quality	_	_	I-Claim
378	of	_	_	I-Claim
379	life	_	_	I-Claim
380	.	_	_	I-Claim


0	In	_	_	B-Claim
1	the	_	_	I-Claim
2	context	_	_	I-Claim
3	of	_	_	I-Claim
4	chronic	_	_	I-Claim
5	physical	_	_	I-Claim
6	illness	_	_	I-Claim
7	,	_	_	I-Claim
8	such	_	_	I-Claim
9	as	_	_	I-Claim
10	breast	_	_	I-Claim
11	cancer	_	_	I-Claim
12	,	_	_	I-Claim
13	depression	_	_	I-Claim
14	is	_	_	I-Claim
15	associated	_	_	I-Claim
16	with	_	_	I-Claim
17	increased	_	_	I-Claim
18	morbidity	_	_	I-Claim
19	,	_	_	I-Claim
20	longer	_	_	I-Claim
21	periods	_	_	I-Claim
22	of	_	_	I-Claim
23	hospitalization	_	_	I-Claim
24	,	_	_	I-Claim
25	and	_	_	I-Claim
26	greater	_	_	I-Claim
27	overall	_	_	I-Claim
28	disability	_	_	I-Claim
29	.	_	_	I-Claim

30	Prompt	_	_	B-Claim
31	diagnosis	_	_	I-Claim
32	and	_	_	I-Claim
33	effective	_	_	I-Claim
34	treatment	_	_	I-Claim
35	is	_	_	I-Claim
36	,	_	_	I-Claim
37	therefore	_	_	I-Claim
38	,	_	_	I-Claim
39	essential	_	_	I-Claim
40	.	_	_	I-Claim

41	Several	_	_	O
42	small	_	_	O
43	studies	_	_	O
44	have	_	_	O
45	established	_	_	O
46	the	_	_	O
47	efficacy	_	_	O
48	of	_	_	O
49	tricyclic	_	_	O
50	antidepressants	_	_	O
51	(	_	_	O
52	TCAs	_	_	O
53	)	_	_	O
54	in	_	_	O
55	this	_	_	O
56	setting	_	_	O
57	,	_	_	O
58	and	_	_	O
59	the	_	_	O
60	selective	_	_	O
61	serotonin	_	_	O
62	reuptake	_	_	O
63	inhibitors	_	_	O
64	(	_	_	O
65	SSRIs	_	_	O
66	)	_	_	O
67	would	_	_	O
68	appear	_	_	O
69	to	_	_	O
70	be	_	_	O
71	an	_	_	O
72	alternative	_	_	O
73	therapeutic	_	_	O
74	option	_	_	O
75	because	_	_	O
76	of	_	_	O
77	their	_	_	O
78	established	_	_	O
79	efficacy	_	_	O
80	and	_	_	O
81	better	_	_	O
82	tolerability	_	_	O
83	profile	_	_	O
84	.	_	_	O

85	This	_	_	O
86	was	_	_	O
87	a	_	_	O
88	multicenter	_	_	O
89	.	_	_	O

90	double	_	_	O
91	-	_	_	O
92	blind	_	_	O
93	,	_	_	O
94	parallel	_	_	O
95	-	_	_	O
96	group	_	_	O
97	study	_	_	O
98	in	_	_	O
99	which	_	_	O
100	179	_	_	O
101	women	_	_	O
102	with	_	_	O
103	breast	_	_	O
104	cancer	_	_	O
105	were	_	_	O
106	randomized	_	_	O
107	to	_	_	O
108	treatment	_	_	O
109	with	_	_	O
110	either	_	_	O
111	the	_	_	O
112	SSRI	_	_	O
113	paroxetine	_	_	O
114	(	_	_	O
115	20	_	_	O
116	-	_	_	O
117	40	_	_	O
118	mg	_	_	O
119	/	_	_	O
120	day	_	_	O
121	)	_	_	O
122	,	_	_	O
123	or	_	_	O
124	the	_	_	O
125	TCA	_	_	O
126	,	_	_	O
127	amitriptyline	_	_	O
128	(	_	_	O
129	75	_	_	O
130	-	_	_	O
131	150	_	_	O
132	mg	_	_	O
133	/	_	_	O
134	day	_	_	O
135	)	_	_	O
136	.	_	_	O

137	After	_	_	B-Premise
138	8	_	_	I-Premise
139	-	_	_	I-Premise
140	weeks	_	_	I-Premise
141	treatment	_	_	I-Premise
142	,	_	_	I-Premise
143	depressive	_	_	I-Premise
144	symptomatology	_	_	I-Premise
145	had	_	_	I-Premise
146	improved	_	_	I-Premise
147	markedly	_	_	I-Premise
148	and	_	_	I-Premise
149	to	_	_	I-Premise
150	a	_	_	I-Premise
151	similar	_	_	I-Premise
152	extent	_	_	I-Premise
153	in	_	_	I-Premise
154	both	_	_	I-Premise
155	groups	_	_	I-Premise
156	on	_	_	I-Premise
157	the	_	_	I-Premise
158	Montgomery	_	_	I-Premise
159	Asberg	_	_	I-Premise
160	Depression	_	_	I-Premise
161	Rating	_	_	I-Premise
162	Scale	_	_	I-Premise
163	.	_	_	I-Premise

164	Clinical	_	_	B-Premise
165	global	_	_	I-Premise
166	impression	_	_	I-Premise
167	(	_	_	I-Premise
168	CGI	_	_	I-Premise
169	)	_	_	I-Premise
170	Global	_	_	I-Premise
171	improvement	_	_	I-Premise
172	and	_	_	I-Premise
173	Patient	_	_	I-Premise
174	global	_	_	I-Premise
175	evaluation	_	_	I-Premise
176	scales	_	_	I-Premise
177	indicated	_	_	I-Premise
178	that	_	_	I-Premise
179	patients	_	_	I-Premise
180	were	_	_	I-Premise
181	minimally	_	_	I-Premise
182	to	_	_	I-Premise
183	much	_	_	I-Premise
184	improved	_	_	I-Premise
185	at	_	_	I-Premise
186	study	_	_	I-Premise
187	endpoint	_	_	I-Premise
188	:	_	_	I-Premise
189	a	_	_	I-Premise
190	change	_	_	I-Premise
191	from	_	_	I-Premise
192	moderately	_	_	I-Premise
193	/	_	_	I-Premise
194	mildly	_	_	I-Premise
195	ill	_	_	I-Premise
196	to	_	_	I-Premise
197	borderline	_	_	I-Premise
198	ill	_	_	I-Premise
199	on	_	_	I-Premise
200	the	_	_	I-Premise
201	CGI	_	_	I-Premise
202	severity	_	_	I-Premise
203	of	_	_	I-Premise
204	Illness	_	_	I-Premise
205	scale	_	_	I-Premise
206	.	_	_	I-Premise

207	A	_	_	B-Claim
208	steady	_	_	I-Claim
209	improvement	_	_	I-Claim
210	in	_	_	I-Claim
211	quality	_	_	I-Claim
212	of	_	_	I-Claim
213	life	_	_	I-Claim
214	was	_	_	I-Claim
215	also	_	_	I-Claim
216	observed	_	_	I-Claim
217	in	_	_	I-Claim
218	both	_	_	I-Claim
219	groups	_	_	I-Claim
220	.	_	_	I-Claim

221	There	_	_	B-Premise
222	were	_	_	I-Premise
223	no	_	_	I-Premise
224	clinically	_	_	I-Premise
225	significant	_	_	I-Premise
226	differences	_	_	I-Premise
227	between	_	_	I-Premise
228	the	_	_	I-Premise
229	groups	_	_	I-Premise
230	.	_	_	I-Premise

231	In	_	_	B-Premise
232	total	_	_	I-Premise
233	,	_	_	I-Premise
234	47	_	_	I-Premise
235	(	_	_	I-Premise
236	53	_	_	I-Premise
237	.	_	_	I-Premise

238	4	_	_	I-Premise
239	%	_	_	I-Premise
240	)	_	_	I-Premise
241	patients	_	_	I-Premise
242	in	_	_	I-Premise
243	the	_	_	I-Premise
244	paroxetine	_	_	I-Premise
245	group	_	_	I-Premise
246	and	_	_	I-Premise
247	53	_	_	I-Premise
248	(	_	_	I-Premise
249	59	_	_	I-Premise
250	.	_	_	I-Premise

251	6	_	_	I-Premise
252	%	_	_	I-Premise
253	)	_	_	I-Premise
254	patients	_	_	I-Premise
255	in	_	_	I-Premise
256	the	_	_	I-Premise
257	amitriptyline	_	_	I-Premise
258	group	_	_	I-Premise
259	had	_	_	I-Premise
260	adverse	_	_	I-Premise
261	experiences	_	_	I-Premise
262	,	_	_	I-Premise
263	the	_	_	I-Premise
264	most	_	_	I-Premise
265	common	_	_	I-Premise
266	of	_	_	I-Premise
267	which	_	_	I-Premise
268	were	_	_	I-Premise
269	the	_	_	I-Premise
270	well	_	_	I-Premise
271	-	_	_	I-Premise
272	recognized	_	_	I-Premise
273	side	_	_	I-Premise
274	-	_	_	I-Premise
275	effects	_	_	I-Premise
276	of	_	_	I-Premise
277	the	_	_	I-Premise
278	antidepressant	_	_	I-Premise
279	medications	_	_	I-Premise
280	or	_	_	I-Premise
281	chemotherapy	_	_	I-Premise
282	.	_	_	I-Premise

283	Anticholinergic	_	_	B-Premise
284	effects	_	_	I-Premise
285	were	_	_	I-Premise
286	almost	_	_	I-Premise
287	twice	_	_	I-Premise
288	as	_	_	I-Premise
289	frequent	_	_	I-Premise
290	in	_	_	I-Premise
291	the	_	_	I-Premise
292	amitriptyline	_	_	I-Premise
293	group	_	_	I-Premise
294	(	_	_	I-Premise
295	19	_	_	I-Premise
296	.	_	_	I-Premise

297	1	_	_	I-Premise
298	%	_	_	I-Premise
299	)	_	_	I-Premise
300	compared	_	_	I-Premise
301	with	_	_	I-Premise
302	paroxetine	_	_	I-Premise
303	(	_	_	I-Premise
304	11	_	_	I-Premise
305	.	_	_	I-Premise

306	4	_	_	I-Premise
307	%	_	_	I-Premise
308	)	_	_	I-Premise
309	.	_	_	I-Premise

310	This	_	_	O
311	study	_	_	O
312	has	_	_	O
313	demonstrated	_	_	O
314	that	_	_	O
315	paroxetine	_	_	B-Claim
316	is	_	_	I-Claim
317	a	_	_	I-Claim
318	suitable	_	_	I-Claim
319	alternative	_	_	I-Claim
320	to	_	_	I-Claim
321	amitriptyline	_	_	I-Claim
322	for	_	_	I-Claim
323	the	_	_	I-Claim
324	treatment	_	_	I-Claim
325	of	_	_	I-Claim
326	depression	_	_	I-Claim
327	in	_	_	I-Claim
328	patients	_	_	I-Claim
329	with	_	_	I-Claim
330	breast	_	_	I-Claim
331	cancer	_	_	I-Claim
332	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	vinflunine	_	_	O
3	(	_	_	O
4	VFL	_	_	O
5	)	_	_	O
6	to	_	_	O
7	docetaxel	_	_	O
8	in	_	_	O
9	patients	_	_	O
10	with	_	_	O
11	stage	_	_	O
12	IIIB	_	_	O
13	/	_	_	O
14	IV	_	_	O
15	non	_	_	O
16	-	_	_	O
17	small	_	_	O
18	-	_	_	O
19	cell	_	_	O
20	lung	_	_	O
21	cancer	_	_	O
22	(	_	_	O
23	NSCLC	_	_	O
24	)	_	_	O
25	who	_	_	O
26	have	_	_	O
27	experienced	_	_	O
28	treatment	_	_	O
29	failure	_	_	O
30	with	_	_	O
31	first	_	_	O
32	-	_	_	O
33	line	_	_	O
34	platinum	_	_	O
35	-	_	_	O
36	based	_	_	O
37	chemotherapy	_	_	O
38	.	_	_	O

39	Randomized	_	_	O
40	,	_	_	O
41	multicenter	_	_	O
42	,	_	_	O
43	phase	_	_	O
44	III	_	_	O
45	study	_	_	O
46	,	_	_	O
47	551	_	_	O
48	patients	_	_	O
49	received	_	_	O
50	either	_	_	O
51	vinflunine	_	_	O
52	320	_	_	O
53	mg	_	_	O
54	/	_	_	O
55	m	_	_	O
56	(	_	_	O
57	2	_	_	O
58	)	_	_	O
59	or	_	_	O
60	docetaxel	_	_	O
61	75	_	_	O
62	mg	_	_	O
63	/	_	_	O
64	m	_	_	O
65	(	_	_	O
66	2	_	_	O
67	)	_	_	O
68	every	_	_	O
69	21	_	_	O
70	days	_	_	O
71	until	_	_	O
72	disease	_	_	O
73	progression	_	_	O
74	or	_	_	O
75	serious	_	_	O
76	toxicity	_	_	O
77	.	_	_	O

78	The	_	_	O
79	primary	_	_	O
80	end	_	_	O
81	point	_	_	O
82	was	_	_	O
83	progression	_	_	O
84	-	_	_	O
85	free	_	_	O
86	survival	_	_	O
87	(	_	_	O
88	PFS	_	_	O
89	)	_	_	O
90	.	_	_	O

91	The	_	_	O
92	noninferiority	_	_	O
93	analysis	_	_	O
94	was	_	_	O
95	based	_	_	O
96	on	_	_	O
97	a	_	_	O
98	10	_	_	O
99	%	_	_	O
100	difference	_	_	O
101	(	_	_	O
102	types	_	_	O
103	I	_	_	O
104	/	_	_	O
105	II	_	_	O
106	error	_	_	O
107	rates	_	_	O
108	:	_	_	O
109	5	_	_	O
110	%	_	_	O
111	/	_	_	O
112	20	_	_	O
113	%	_	_	O
114	)	_	_	O
115	.	_	_	O

116	Secondary	_	_	O
117	end	_	_	O
118	points	_	_	O
119	included	_	_	O
120	response	_	_	O
121	rate	_	_	O
122	(	_	_	O
123	ORR	_	_	O
124	)	_	_	O
125	,	_	_	O
126	response	_	_	O
127	duration	_	_	O
128	,	_	_	O
129	overall	_	_	O
130	survival	_	_	O
131	(	_	_	O
132	OS	_	_	O
133	)	_	_	O
134	,	_	_	O
135	clinical	_	_	O
136	benefit	_	_	O
137	,	_	_	O
138	quality	_	_	O
139	of	_	_	O
140	life	_	_	O
141	(	_	_	O
142	QOL	_	_	O
143	)	_	_	O
144	,	_	_	O
145	and	_	_	O
146	safety	_	_	O
147	.	_	_	O

148	Median	_	_	B-Premise
149	PFS	_	_	I-Premise
150	was	_	_	I-Premise
151	2	_	_	I-Premise
152	.	_	_	I-Premise

153	3	_	_	I-Premise
154	months	_	_	I-Premise
155	for	_	_	I-Premise
156	each	_	_	I-Premise
157	arm	_	_	I-Premise
158	(	_	_	I-Premise
159	HR	_	_	I-Premise
160	,	_	_	I-Premise
161	1	_	_	I-Premise
162	.	_	_	I-Premise

163	004	_	_	I-Premise
164	;	_	_	I-Premise
165	95	_	_	I-Premise
166	%	_	_	I-Premise
167	CI	_	_	I-Premise
168	,	_	_	I-Premise
169	0	_	_	I-Premise
170	.	_	_	I-Premise

171	841	_	_	I-Premise
172	to	_	_	I-Premise
173	1	_	_	I-Premise
174	.	_	_	I-Premise

175	199	_	_	I-Premise
176	)	_	_	I-Premise
177	.	_	_	I-Premise

178	ORR	_	_	B-Premise
179	,	_	_	I-Premise
180	stable	_	_	I-Premise
181	disease	_	_	I-Premise
182	,	_	_	I-Premise
183	median	_	_	I-Premise
184	OS	_	_	I-Premise
185	,	_	_	I-Premise
186	were	_	_	I-Premise
187	4	_	_	I-Premise
188	.	_	_	I-Premise

189	4	_	_	I-Premise
190	%	_	_	I-Premise
191	versus	_	_	I-Premise
192	5	_	_	I-Premise
193	.	_	_	I-Premise

194	5	_	_	I-Premise
195	%	_	_	I-Premise
196	,	_	_	I-Premise
197	36	_	_	I-Premise
198	.	_	_	I-Premise

199	0	_	_	I-Premise
200	%	_	_	I-Premise
201	versus	_	_	I-Premise
202	39	_	_	I-Premise
203	.	_	_	I-Premise

204	6	_	_	I-Premise
205	%	_	_	I-Premise
206	,	_	_	I-Premise
207	6	_	_	I-Premise
208	.	_	_	I-Premise

209	7	_	_	I-Premise
210	versus	_	_	I-Premise
211	7	_	_	I-Premise
212	.	_	_	I-Premise

213	2	_	_	I-Premise
214	months	_	_	I-Premise
215	(	_	_	I-Premise
216	HR	_	_	I-Premise
217	,	_	_	I-Premise
218	0	_	_	I-Premise
219	.	_	_	I-Premise

220	973	_	_	I-Premise
221	;	_	_	I-Premise
222	95	_	_	I-Premise
223	%	_	_	I-Premise
224	CI	_	_	I-Premise
225	,	_	_	I-Premise
226	0	_	_	I-Premise
227	.	_	_	I-Premise

228	805	_	_	I-Premise
229	to	_	_	I-Premise
230	1	_	_	I-Premise
231	.	_	_	I-Premise

232	176	_	_	I-Premise
233	)	_	_	I-Premise
234	,	_	_	I-Premise
235	respectively	_	_	I-Premise
236	.	_	_	I-Premise

237	No	_	_	B-Premise
238	significant	_	_	I-Premise
239	difference	_	_	I-Premise
240	in	_	_	I-Premise
241	patient	_	_	I-Premise
242	benefit	_	_	I-Premise
243	and	_	_	I-Premise
244	QOL	_	_	I-Premise
245	(	_	_	I-Premise
246	Functional	_	_	I-Premise
247	Assessment	_	_	I-Premise
248	of	_	_	I-Premise
249	Cancer	_	_	I-Premise
250	Therapy	_	_	I-Premise
251	-	_	_	I-Premise
252	Lung	_	_	I-Premise
253	)	_	_	I-Premise
254	.	_	_	I-Premise

255	No	_	_	B-Premise
256	unexpected	_	_	I-Premise
257	adverse	_	_	I-Premise
258	events	_	_	I-Premise
259	were	_	_	I-Premise
260	observed	_	_	I-Premise
261	.	_	_	I-Premise

262	Grade	_	_	B-Premise
263	higher	_	_	I-Premise
264	than	_	_	I-Premise
265	0	_	_	I-Premise
266	(	_	_	I-Premise
267	vinflunine	_	_	I-Premise
268	v	_	_	I-Premise
269	docetaxel	_	_	I-Premise
270	)	_	_	I-Premise
271	anemia	_	_	I-Premise
272	(	_	_	I-Premise
273	82	_	_	I-Premise
274	.	_	_	I-Premise

275	1	_	_	I-Premise
276	%	_	_	I-Premise
277	v	_	_	I-Premise
278	79	_	_	I-Premise
279	.	_	_	I-Premise

280	8	_	_	I-Premise
281	%	_	_	I-Premise
282	)	_	_	I-Premise
283	,	_	_	I-Premise
284	neutropenia	_	_	I-Premise
285	(	_	_	I-Premise
286	49	_	_	I-Premise
287	.	_	_	I-Premise

288	3	_	_	I-Premise
289	v	_	_	I-Premise
290	39	_	_	I-Premise
291	.	_	_	I-Premise

292	02	_	_	I-Premise
293	%	_	_	I-Premise
294	)	_	_	I-Premise
295	,	_	_	I-Premise
296	thrombocytopenia	_	_	I-Premise
297	(	_	_	I-Premise
298	30	_	_	I-Premise
299	.	_	_	I-Premise

300	6	_	_	I-Premise
301	%	_	_	I-Premise
302	v	_	_	I-Premise
303	14	_	_	I-Premise
304	.	_	_	I-Premise

305	3	_	_	I-Premise
306	%	_	_	I-Premise
307	)	_	_	I-Premise
308	,	_	_	I-Premise
309	febrile	_	_	I-Premise
310	neutropenia	_	_	I-Premise
311	(	_	_	I-Premise
312	3	_	_	I-Premise
313	.	_	_	I-Premise

314	3	_	_	I-Premise
315	%	_	_	I-Premise
316	v	_	_	I-Premise
317	4	_	_	I-Premise
318	.	_	_	I-Premise

319	7	_	_	I-Premise
320	%	_	_	I-Premise
321	)	_	_	I-Premise
322	,	_	_	I-Premise
323	constipation	_	_	I-Premise
324	(	_	_	I-Premise
325	39	_	_	I-Premise
326	.	_	_	I-Premise

327	2	_	_	I-Premise
328	%	_	_	I-Premise
329	v	_	_	I-Premise
330	11	_	_	I-Premise
331	.	_	_	I-Premise

332	7	_	_	I-Premise
333	%	_	_	I-Premise
334	)	_	_	I-Premise
335	,	_	_	I-Premise
336	fatigue	_	_	I-Premise
337	(	_	_	I-Premise
338	36	_	_	I-Premise
339	.	_	_	I-Premise

340	6	_	_	I-Premise
341	%	_	_	I-Premise
342	v	_	_	I-Premise
343	33	_	_	I-Premise
344	.	_	_	I-Premise

345	9	_	_	I-Premise
346	%	_	_	I-Premise
347	)	_	_	I-Premise
348	,	_	_	I-Premise
349	injection	_	_	I-Premise
350	site	_	_	I-Premise
351	reaction	_	_	I-Premise
352	(	_	_	I-Premise
353	31	_	_	I-Premise
354	.	_	_	I-Premise

355	9	_	_	I-Premise
356	%	_	_	I-Premise
357	v	_	_	I-Premise
358	0	_	_	I-Premise
359	.	_	_	I-Premise

360	7	_	_	I-Premise
361	%	_	_	I-Premise
362	)	_	_	I-Premise
363	,	_	_	I-Premise
364	nausea	_	_	I-Premise
365	(	_	_	I-Premise
366	26	_	_	I-Premise
367	.	_	_	I-Premise

368	7	_	_	I-Premise
369	%	_	_	I-Premise
370	v	_	_	I-Premise
371	23	_	_	I-Premise
372	.	_	_	I-Premise

373	7	_	_	I-Premise
374	%	_	_	I-Premise
375	)	_	_	I-Premise
376	,	_	_	I-Premise
377	vomiting	_	_	I-Premise
378	(	_	_	I-Premise
379	23	_	_	I-Premise
380	.	_	_	I-Premise

381	8	_	_	I-Premise
382	%	_	_	I-Premise
383	v	_	_	I-Premise
384	14	_	_	I-Premise
385	.	_	_	I-Premise

386	2	_	_	I-Premise
387	%	_	_	I-Premise
388	)	_	_	I-Premise
389	,	_	_	I-Premise
390	alopecia	_	_	I-Premise
391	(	_	_	I-Premise
392	19	_	_	I-Premise
393	.	_	_	I-Premise

394	8	_	_	I-Premise
395	%	_	_	I-Premise
396	v	_	_	I-Premise
397	35	_	_	I-Premise
398	.	_	_	I-Premise

399	4	_	_	I-Premise
400	%	_	_	I-Premise
401	)	_	_	I-Premise
402	,	_	_	I-Premise
403	stomatis	_	_	I-Premise
404	(	_	_	I-Premise
405	19	_	_	I-Premise
406	.	_	_	I-Premise

407	4	_	_	I-Premise
408	%	_	_	I-Premise
409	v	_	_	I-Premise
410	12	_	_	I-Premise
411	.	_	_	I-Premise

412	4	_	_	I-Premise
413	%	_	_	I-Premise
414	)	_	_	I-Premise
415	,	_	_	I-Premise
416	abdominal	_	_	I-Premise
417	pain	_	_	I-Premise
418	(	_	_	I-Premise
419	20	_	_	I-Premise
420	.	_	_	I-Premise

421	1	_	_	I-Premise
422	%	_	_	I-Premise
423	v	_	_	I-Premise
424	3	_	_	I-Premise
425	.	_	_	I-Premise

426	6	_	_	I-Premise
427	%	_	_	I-Premise
428	)	_	_	I-Premise
429	,	_	_	I-Premise
430	myalgia	_	_	I-Premise
431	(	_	_	I-Premise
432	14	_	_	I-Premise
433	.	_	_	I-Premise

434	7	_	_	I-Premise
435	%	_	_	I-Premise
436	v	_	_	I-Premise
437	6	_	_	I-Premise
438	.	_	_	I-Premise

439	6	_	_	I-Premise
440	%	_	_	I-Premise
441	)	_	_	I-Premise
442	,	_	_	I-Premise
443	peripheral	_	_	I-Premise
444	neuropathy	_	_	I-Premise
445	(	_	_	I-Premise
446	10	_	_	I-Premise
447	.	_	_	I-Premise

448	7	_	_	I-Premise
449	%	_	_	I-Premise
450	v	_	_	I-Premise
451	15	_	_	I-Premise
452	.	_	_	I-Premise

453	0	_	_	I-Premise
454	%	_	_	I-Premise
455	)	_	_	I-Premise
456	,	_	_	I-Premise
457	arthralgia	_	_	I-Premise
458	(	_	_	I-Premise
459	7	_	_	I-Premise
460	.	_	_	I-Premise

461	0	_	_	I-Premise
462	%	_	_	I-Premise
463	v	_	_	I-Premise
464	7	_	_	I-Premise
465	.	_	_	I-Premise

466	7	_	_	I-Premise
467	%	_	_	I-Premise
468	)	_	_	I-Premise
469	,	_	_	I-Premise
470	diarrhea	_	_	I-Premise
471	(	_	_	I-Premise
472	6	_	_	I-Premise
473	.	_	_	I-Premise

474	2	_	_	I-Premise
475	%	_	_	I-Premise
476	v	_	_	I-Premise
477	12	_	_	I-Premise
478	.	_	_	I-Premise

479	4	_	_	I-Premise
480	%	_	_	I-Premise
481	)	_	_	I-Premise
482	,	_	_	I-Premise
483	edema	_	_	I-Premise
484	(	_	_	I-Premise
485	1	_	_	I-Premise
486	.	_	_	I-Premise

487	5	_	_	I-Premise
488	%	_	_	I-Premise
489	v	_	_	I-Premise
490	5	_	_	I-Premise
491	.	_	_	I-Premise

492	4	_	_	I-Premise
493	%	_	_	I-Premise
494	)	_	_	I-Premise
495	,	_	_	I-Premise
496	and	_	_	I-Premise
497	nail	_	_	I-Premise
498	disorders	_	_	I-Premise
499	(	_	_	I-Premise
500	1	_	_	I-Premise
501	.	_	_	I-Premise

502	1	_	_	I-Premise
503	%	_	_	I-Premise
504	v	_	_	I-Premise
505	5	_	_	I-Premise
506	;	_	_	I-Premise
507	1	_	_	I-Premise
508	%	_	_	I-Premise
509	)	_	_	I-Premise
510	were	_	_	I-Premise
511	observed	_	_	I-Premise
512	.	_	_	I-Premise

513	This	_	_	B-Claim
514	noninferiority	_	_	I-Claim
515	phase	_	_	I-Claim
516	III	_	_	I-Claim
517	study	_	_	I-Claim
518	showed	_	_	I-Claim
519	similar	_	_	I-Claim
520	efficacy	_	_	I-Claim
521	end	_	_	I-Claim
522	points	_	_	I-Claim
523	for	_	_	I-Claim
524	vinflunine	_	_	I-Claim
525	and	_	_	I-Claim
526	docetaxel	_	_	I-Claim
527	.	_	_	I-Claim

528	Despite	_	_	B-Claim
529	higher	_	_	I-Claim
530	rates	_	_	I-Claim
531	of	_	_	I-Claim
532	some	_	_	I-Claim
533	adverse	_	_	I-Claim
534	effects	_	_	I-Claim
535	(	_	_	I-Claim
536	anemia	_	_	I-Claim
537	,	_	_	I-Claim
538	abdominal	_	_	I-Claim
539	pain	_	_	I-Claim
540	,	_	_	I-Claim
541	constipation	_	_	I-Claim
542	,	_	_	I-Claim
543	fatigue	_	_	I-Claim
544	)	_	_	I-Claim
545	the	_	_	B-Claim
546	overall	_	_	I-Claim
547	toxicity	_	_	I-Claim
548	profile	_	_	I-Claim
549	of	_	_	I-Claim
550	vinflunine	_	_	I-Claim
551	was	_	_	I-Claim
552	manageable	_	_	I-Claim
553	.	_	_	I-Claim

554	Therefore	_	_	O
555	,	_	_	O
556	VFL	_	_	B-Claim
557	may	_	_	I-Claim
558	be	_	_	I-Claim
559	another	_	_	I-Claim
560	option	_	_	I-Claim
561	in	_	_	I-Claim
562	the	_	_	I-Claim
563	second	_	_	I-Claim
564	-	_	_	I-Claim
565	line	_	_	I-Claim
566	treatment	_	_	I-Claim
567	of	_	_	I-Claim
568	patients	_	_	I-Claim
569	with	_	_	I-Claim
570	advanced	_	_	I-Claim
571	NSCLC	_	_	I-Claim
572	.	_	_	I-Claim


0	Laparoscopic	_	_	B-Claim
1	-	_	_	I-Claim
2	assisted	_	_	I-Claim
3	colectomy	_	_	I-Claim
4	(	_	_	I-Claim
5	LAC	_	_	I-Claim
6	)	_	_	I-Claim
7	has	_	_	I-Claim
8	emerged	_	_	I-Claim
9	as	_	_	I-Claim
10	the	_	_	I-Claim
11	preferred	_	_	I-Claim
12	minimally	_	_	I-Claim
13	invasive	_	_	I-Claim
14	surgical	_	_	I-Claim
15	strategy	_	_	I-Claim
16	for	_	_	I-Claim
17	diseases	_	_	I-Claim
18	of	_	_	I-Claim
19	the	_	_	I-Claim
20	colon	_	_	I-Claim
21	.	_	_	I-Claim

22	The	_	_	B-Claim
23	safety	_	_	I-Claim
24	and	_	_	I-Claim
25	efficacy	_	_	I-Claim
26	of	_	_	I-Claim
27	LAC	_	_	I-Claim
28	for	_	_	I-Claim
29	colon	_	_	I-Claim
30	cancer	_	_	I-Claim
31	are	_	_	I-Claim
32	unknown	_	_	I-Claim
33	,	_	_	I-Claim
34	and	_	_	O
35	the	_	_	B-Claim
36	nature	_	_	I-Claim
37	and	_	_	I-Claim
38	magnitude	_	_	I-Claim
39	of	_	_	I-Claim
40	any	_	_	I-Claim
41	quality	_	_	I-Claim
42	-	_	_	I-Claim
43	of	_	_	I-Claim
44	-	_	_	I-Claim
45	life	_	_	I-Claim
46	(	_	_	I-Claim
47	QOL	_	_	I-Claim
48	)	_	_	I-Claim
49	benefit	_	_	I-Claim
50	resulting	_	_	I-Claim
51	from	_	_	I-Claim
52	LAC	_	_	I-Claim
53	for	_	_	I-Claim
54	colon	_	_	I-Claim
55	cancer	_	_	I-Claim
56	is	_	_	I-Claim
57	also	_	_	I-Claim
58	unknown	_	_	I-Claim
59	.	_	_	I-Claim

60	To	_	_	O
61	compare	_	_	O
62	short	_	_	O
63	-	_	_	O
64	term	_	_	O
65	QOL	_	_	O
66	outcomes	_	_	O
67	after	_	_	O
68	LAC	_	_	O
69	vs	_	_	O
70	open	_	_	O
71	colectomy	_	_	O
72	for	_	_	O
73	colon	_	_	O
74	cancer	_	_	O
75	.	_	_	O

76	Multicenter	_	_	O
77	,	_	_	O
78	randomized	_	_	O
79	controlled	_	_	O
80	trial	_	_	O
81	(	_	_	O
82	Clinical	_	_	O
83	Outcomes	_	_	O
84	of	_	_	O
85	Surgical	_	_	O
86	Therapy	_	_	O
87	[	_	_	O
88	COST	_	_	O
89	]	_	_	O
90	)	_	_	O
91	.	_	_	O

92	Between	_	_	O
93	September	_	_	O
94	1994	_	_	O
95	and	_	_	O
96	February	_	_	O
97	1999	_	_	O
98	,	_	_	O
99	37	_	_	O
100	of	_	_	O
101	48	_	_	O
102	centers	_	_	O
103	provided	_	_	O
104	data	_	_	O
105	for	_	_	O
106	the	_	_	O
107	QOL	_	_	O
108	component	_	_	O
109	of	_	_	O
110	the	_	_	O
111	trial	_	_	O
112	for	_	_	O
113	449	_	_	O
114	consecutive	_	_	O
115	patients	_	_	O
116	with	_	_	O
117	clinically	_	_	O
118	resectable	_	_	O
119	colon	_	_	O
120	cancer	_	_	O
121	.	_	_	O

122	Scores	_	_	O
123	on	_	_	O
124	the	_	_	O
125	Symptoms	_	_	O
126	Distress	_	_	O
127	Scale	_	_	O
128	(	_	_	O
129	SDS	_	_	O
130	)	_	_	O
131	,	_	_	O
132	Quality	_	_	O
133	of	_	_	O
134	Life	_	_	O
135	Index	_	_	O
136	,	_	_	O
137	and	_	_	O
138	a	_	_	O
139	single	_	_	O
140	-	_	_	O
141	item	_	_	O
142	global	_	_	O
143	rating	_	_	O
144	scale	_	_	O
145	at	_	_	O
146	2	_	_	O
147	days	_	_	O
148	,	_	_	O
149	2	_	_	O
150	weeks	_	_	O
151	,	_	_	O
152	and	_	_	O
153	2	_	_	O
154	months	_	_	O
155	postoperative	_	_	O
156	;	_	_	O
157	duration	_	_	O
158	of	_	_	O
159	postoperative	_	_	O
160	in	_	_	O
161	-	_	_	O
162	hospital	_	_	O
163	analgesic	_	_	O
164	use	_	_	O
165	;	_	_	O
166	and	_	_	O
167	length	_	_	O
168	of	_	_	O
169	stay	_	_	O
170	.	_	_	O

171	Of	_	_	O
172	449	_	_	O
173	patients	_	_	O
174	,	_	_	O
175	428	_	_	O
176	provided	_	_	O
177	QOL	_	_	O
178	data	_	_	O
179	.	_	_	O

180	In	_	_	B-Premise
181	an	_	_	I-Premise
182	intention	_	_	I-Premise
183	-	_	_	I-Premise
184	to	_	_	I-Premise
185	-	_	_	I-Premise
186	treat	_	_	I-Premise
187	analysis	_	_	I-Premise
188	comparing	_	_	I-Premise
189	SDS	_	_	I-Premise
190	pain	_	_	I-Premise
191	intensity	_	_	I-Premise
192	,	_	_	I-Premise
193	SDS	_	_	I-Premise
194	summary	_	_	I-Premise
195	,	_	_	I-Premise
196	QOL	_	_	I-Premise
197	Index	_	_	I-Premise
198	summary	_	_	I-Premise
199	,	_	_	I-Premise
200	and	_	_	I-Premise
201	global	_	_	I-Premise
202	rating	_	_	I-Premise
203	scale	_	_	I-Premise
204	scores	_	_	I-Premise
205	at	_	_	I-Premise
206	each	_	_	I-Premise
207	time	_	_	I-Premise
208	point	_	_	I-Premise
209	,	_	_	I-Premise
210	the	_	_	I-Premise
211	only	_	_	I-Premise
212	statistically	_	_	I-Premise
213	significant	_	_	I-Premise
214	difference	_	_	I-Premise
215	observed	_	_	I-Premise
216	between	_	_	I-Premise
217	groups	_	_	I-Premise
218	was	_	_	I-Premise
219	the	_	_	I-Premise
220	global	_	_	I-Premise
221	rating	_	_	I-Premise
222	scale	_	_	I-Premise
223	score	_	_	I-Premise
224	for	_	_	I-Premise
225	2	_	_	I-Premise
226	weeks	_	_	I-Premise
227	postsurgery	_	_	I-Premise
228	.	_	_	I-Premise

229	The	_	_	B-Premise
230	mean	_	_	I-Premise
231	(	_	_	I-Premise
232	median	_	_	I-Premise
233	)	_	_	I-Premise
234	global	_	_	I-Premise
235	rating	_	_	I-Premise
236	scale	_	_	I-Premise
237	scores	_	_	I-Premise
238	for	_	_	I-Premise
239	2	_	_	I-Premise
240	weeks	_	_	I-Premise
241	postsurgery	_	_	I-Premise
242	were	_	_	I-Premise
243	76	_	_	I-Premise
244	.	_	_	I-Premise

245	9	_	_	I-Premise
246	(	_	_	I-Premise
247	80	_	_	I-Premise
248	)	_	_	I-Premise
249	for	_	_	I-Premise
250	LAC	_	_	I-Premise
251	vs	_	_	I-Premise
252	74	_	_	I-Premise
253	.	_	_	I-Premise

254	4	_	_	I-Premise
255	(	_	_	I-Premise
256	75	_	_	I-Premise
257	)	_	_	I-Premise
258	for	_	_	I-Premise
259	open	_	_	I-Premise
260	colectomy	_	_	I-Premise
261	(	_	_	I-Premise
262	P	_	_	I-Premise
263	=	_	_	I-Premise
264	.	_	_	I-Premise

265	009	_	_	I-Premise
266	)	_	_	I-Premise
267	.	_	_	I-Premise

268	While	_	_	B-Premise
269	in	_	_	I-Premise
270	the	_	_	I-Premise
271	hospital	_	_	I-Premise
272	,	_	_	I-Premise
273	patients	_	_	I-Premise
274	assigned	_	_	I-Premise
275	to	_	_	I-Premise
276	LAC	_	_	I-Premise
277	required	_	_	I-Premise
278	fewer	_	_	I-Premise
279	days	_	_	I-Premise
280	of	_	_	I-Premise
281	both	_	_	I-Premise
282	parenteral	_	_	I-Premise
283	analgesics	_	_	I-Premise
284	compared	_	_	I-Premise
285	with	_	_	I-Premise
286	patients	_	_	I-Premise
287	assigned	_	_	I-Premise
288	to	_	_	I-Premise
289	open	_	_	I-Premise
290	colectomy	_	_	I-Premise
291	(	_	_	I-Premise
292	mean	_	_	I-Premise
293	[	_	_	I-Premise
294	median	_	_	I-Premise
295	]	_	_	I-Premise
296	,	_	_	I-Premise
297	3	_	_	I-Premise
298	.	_	_	I-Premise

299	2	_	_	I-Premise
300	[	_	_	I-Premise
301	3	_	_	I-Premise
302	]	_	_	I-Premise
303	vs	_	_	I-Premise
304	4	_	_	I-Premise
305	.	_	_	I-Premise

306	0	_	_	I-Premise
307	[	_	_	I-Premise
308	4	_	_	I-Premise
309	]	_	_	I-Premise
310	days	_	_	I-Premise
311	;	_	_	I-Premise
312	P	_	_	I-Premise
313	<	_	_	I-Premise
314	.	_	_	I-Premise

315	001	_	_	I-Premise
316	)	_	_	I-Premise
317	and	_	_	I-Premise
318	oral	_	_	I-Premise
319	analgesics	_	_	I-Premise
320	(	_	_	I-Premise
321	mean	_	_	I-Premise
322	[	_	_	I-Premise
323	median	_	_	I-Premise
324	]	_	_	I-Premise
325	,	_	_	I-Premise
326	1	_	_	I-Premise
327	.	_	_	I-Premise

328	9	_	_	I-Premise
329	[	_	_	I-Premise
330	1	_	_	I-Premise
331	]	_	_	I-Premise
332	vs	_	_	I-Premise
333	2	_	_	I-Premise
334	.	_	_	I-Premise

335	2	_	_	I-Premise
336	[	_	_	I-Premise
337	2	_	_	I-Premise
338	]	_	_	I-Premise
339	days	_	_	I-Premise
340	;	_	_	I-Premise
341	P	_	_	I-Premise
342	=	_	_	I-Premise
343	.	_	_	I-Premise

344	03	_	_	I-Premise
345	)	_	_	I-Premise
346	.	_	_	I-Premise

347	Only	_	_	B-Claim
348	minimal	_	_	I-Claim
349	short	_	_	I-Claim
350	-	_	_	I-Claim
351	term	_	_	I-Claim
352	QOL	_	_	I-Claim
353	benefits	_	_	I-Claim
354	were	_	_	I-Claim
355	found	_	_	I-Claim
356	with	_	_	I-Claim
357	LAC	_	_	I-Claim
358	for	_	_	I-Claim
359	colon	_	_	I-Claim
360	cancer	_	_	I-Claim
361	compared	_	_	I-Claim
362	with	_	_	I-Claim
363	standard	_	_	I-Claim
364	open	_	_	I-Claim
365	colectomy	_	_	I-Claim
366	.	_	_	I-Claim

367	Until	_	_	B-Claim
368	ongoing	_	_	I-Claim
369	trials	_	_	I-Claim
370	establish	_	_	I-Claim
371	that	_	_	I-Claim
372	LAC	_	_	I-Claim
373	is	_	_	I-Claim
374	as	_	_	I-Claim
375	effective	_	_	I-Claim
376	as	_	_	I-Claim
377	open	_	_	I-Claim
378	colectomy	_	_	I-Claim
379	in	_	_	I-Claim
380	preventing	_	_	I-Claim
381	recurrence	_	_	I-Claim
382	and	_	_	I-Claim
383	death	_	_	I-Claim
384	from	_	_	I-Claim
385	colon	_	_	I-Claim
386	cancer	_	_	I-Claim
387	,	_	_	I-Claim
388	this	_	_	I-Claim
389	procedure	_	_	I-Claim
390	should	_	_	I-Claim
391	not	_	_	I-Claim
392	be	_	_	I-Claim
393	offered	_	_	I-Claim
394	to	_	_	I-Claim
395	patients	_	_	I-Claim
396	with	_	_	I-Claim
397	colon	_	_	I-Claim
398	cancer	_	_	I-Claim
399	.	_	_	I-Claim


0	For	_	_	B-Claim
1	patients	_	_	I-Claim
2	with	_	_	I-Claim
3	advanced	_	_	I-Claim
4	gastric	_	_	I-Claim
5	or	_	_	I-Claim
6	gastroesophageal	_	_	I-Claim
7	cancer	_	_	I-Claim
8	(	_	_	I-Claim
9	AGGEC	_	_	I-Claim
10	)	_	_	I-Claim
11	providing	_	_	I-Claim
12	clinical	_	_	I-Claim
13	benefit	_	_	I-Claim
14	with	_	_	I-Claim
15	improved	_	_	I-Claim
16	palliation	_	_	I-Claim
17	is	_	_	I-Claim
18	highly	_	_	I-Claim
19	desirable	_	_	I-Claim
20	.	_	_	I-Claim

21	However	_	_	O
22	,	_	_	O
23	a	_	_	O
24	prospective	_	_	O
25	evaluation	_	_	O
26	of	_	_	O
27	clinical	_	_	O
28	benefit	_	_	O
29	in	_	_	O
30	AGGEC	_	_	O
31	patients	_	_	O
32	has	_	_	O
33	never	_	_	O
34	before	_	_	O
35	been	_	_	O
36	reported	_	_	O
37	in	_	_	O
38	a	_	_	O
39	phase	_	_	O
40	III	_	_	O
41	setting	_	_	O
42	.	_	_	O

43	In	_	_	O
44	a	_	_	O
45	multinational	_	_	O
46	trial	_	_	O
47	(	_	_	O
48	V325	_	_	O
49	)	_	_	O
50	,	_	_	O
51	445	_	_	O
52	patients	_	_	O
53	were	_	_	O
54	randomly	_	_	O
55	assigned	_	_	O
56	and	_	_	O
57	treated	_	_	O
58	with	_	_	O
59	either	_	_	O
60	docetaxel	_	_	O
61	plus	_	_	O
62	cisplatin	_	_	O
63	and	_	_	O
64	fluorouracil	_	_	O
65	(	_	_	O
66	DCF	_	_	O
67	)	_	_	O
68	or	_	_	O
69	cisplatin	_	_	O
70	and	_	_	O
71	fluorouracil	_	_	O
72	(	_	_	O
73	CF	_	_	O
74	)	_	_	O
75	.	_	_	O

76	Clinical	_	_	O
77	benefit	_	_	O
78	was	_	_	O
79	prospectively	_	_	O
80	evaluated	_	_	O
81	in	_	_	O
82	this	_	_	O
83	trial	_	_	O
84	as	_	_	O
85	a	_	_	O
86	secondary	_	_	O
87	end	_	_	O
88	point	_	_	O
89	.	_	_	O

90	The	_	_	O
91	primary	_	_	O
92	measure	_	_	O
93	for	_	_	O
94	clinical	_	_	O
95	benefit	_	_	O
96	analysis	_	_	O
97	was	_	_	O
98	time	_	_	O
99	to	_	_	O
100	definitive	_	_	O
101	worsening	_	_	O
102	by	_	_	O
103	one	_	_	O
104	or	_	_	O
105	more	_	_	O
106	categories	_	_	O
107	of	_	_	O
108	Karnofsky	_	_	O
109	performance	_	_	O
110	status	_	_	O
111	(	_	_	O
112	KPS	_	_	O
113	)	_	_	O
114	.	_	_	O

115	Secondary	_	_	O
116	clinical	_	_	O
117	benefit	_	_	O
118	end	_	_	O
119	points	_	_	O
120	included	_	_	O
121	time	_	_	O
122	to	_	_	O
123	5	_	_	O
124	%	_	_	O
125	definitive	_	_	O
126	weight	_	_	O
127	loss	_	_	O
128	,	_	_	O
129	time	_	_	O
130	to	_	_	O
131	definitive	_	_	O
132	worsening	_	_	O
133	of	_	_	O
134	appetite	_	_	O
135	by	_	_	O
136	one	_	_	O
137	grade	_	_	O
138	,	_	_	O
139	pain	_	_	O
140	-	_	_	O
141	free	_	_	O
142	survival	_	_	O
143	(	_	_	O
144	defined	_	_	O
145	as	_	_	O
146	time	_	_	O
147	to	_	_	O
148	first	_	_	O
149	appearance	_	_	O
150	of	_	_	O
151	pain	_	_	O
152	)	_	_	O
153	,	_	_	O
154	and	_	_	O
155	time	_	_	O
156	to	_	_	O
157	first	_	_	O
158	cancer	_	_	O
159	pain	_	_	O
160	-	_	_	O
161	related	_	_	O
162	opioid	_	_	O
163	intake	_	_	O
164	.	_	_	O

165	Clinical	_	_	O
166	benefit	_	_	O
167	assessments	_	_	O
168	were	_	_	O
169	recorded	_	_	O
170	at	_	_	O
171	each	_	_	O
172	clinic	_	_	O
173	visit	_	_	O
174	.	_	_	O

175	Clinical	_	_	O
176	benefit	_	_	O
177	assessments	_	_	O
178	were	_	_	O
179	performed	_	_	O
180	in	_	_	O
181	more	_	_	O
182	than	_	_	O
183	75	_	_	O
184	%	_	_	O
185	of	_	_	O
186	patients	_	_	O
187	throughout	_	_	O
188	V325	_	_	O
189	.	_	_	O

190	DCF	_	_	B-Premise
191	significantly	_	_	I-Premise
192	prolonged	_	_	I-Premise
193	time	_	_	I-Premise
194	to	_	_	I-Premise
195	definitive	_	_	I-Premise
196	worsening	_	_	I-Premise
197	of	_	_	I-Premise
198	KPS	_	_	I-Premise
199	compared	_	_	I-Premise
200	with	_	_	I-Premise
201	CF	_	_	I-Premise
202	(	_	_	I-Premise
203	median	_	_	I-Premise
204	,	_	_	I-Premise
205	6	_	_	I-Premise
206	.	_	_	I-Premise

207	1	_	_	I-Premise
208	v	_	_	I-Premise
209	4	_	_	I-Premise
210	.	_	_	I-Premise

211	8	_	_	I-Premise
212	months	_	_	I-Premise
213	;	_	_	I-Premise
214	hazard	_	_	I-Premise
215	ratio	_	_	I-Premise
216	,	_	_	I-Premise
217	1	_	_	I-Premise
218	.	_	_	I-Premise

219	38	_	_	I-Premise
220	;	_	_	I-Premise
221	95	_	_	I-Premise
222	%	_	_	I-Premise
223	CI	_	_	I-Premise
224	,	_	_	I-Premise
225	1	_	_	I-Premise
226	.	_	_	I-Premise

227	08	_	_	I-Premise
228	to	_	_	I-Premise
229	1	_	_	I-Premise
230	.	_	_	I-Premise

231	76	_	_	I-Premise
232	;	_	_	I-Premise
233	log	_	_	I-Premise
234	-	_	_	I-Premise
235	rank	_	_	I-Premise
236	P	_	_	I-Premise
237	=	_	_	I-Premise
238	.	_	_	I-Premise

239	009	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	Although	_	_	B-Premise
243	time	_	_	I-Premise
244	to	_	_	I-Premise
245	definitive	_	_	I-Premise
246	weight	_	_	I-Premise
247	loss	_	_	I-Premise
248	and	_	_	I-Premise
249	time	_	_	I-Premise
250	to	_	_	I-Premise
251	definitive	_	_	I-Premise
252	worsening	_	_	I-Premise
253	of	_	_	I-Premise
254	appetite	_	_	I-Premise
255	favored	_	_	I-Premise
256	DCF	_	_	I-Premise
257	,	_	_	I-Premise
258	the	_	_	B-Premise
259	results	_	_	I-Premise
260	were	_	_	I-Premise
261	not	_	_	I-Premise
262	statistically	_	_	I-Premise
263	significant	_	_	I-Premise
264	.	_	_	I-Premise

265	Pain	_	_	B-Premise
266	-	_	_	I-Premise
267	free	_	_	I-Premise
268	survival	_	_	I-Premise
269	and	_	_	I-Premise
270	time	_	_	I-Premise
271	to	_	_	I-Premise
272	first	_	_	I-Premise
273	cancer	_	_	I-Premise
274	pain	_	_	I-Premise
275	-	_	_	I-Premise
276	related	_	_	I-Premise
277	opioid	_	_	I-Premise
278	intake	_	_	I-Premise
279	were	_	_	I-Premise
280	comparable	_	_	I-Premise
281	.	_	_	I-Premise

282	To	_	_	O
283	our	_	_	O
284	knowledge	_	_	O
285	,	_	_	O
286	V325	_	_	O
287	is	_	_	O
288	the	_	_	O
289	first	_	_	O
290	phase	_	_	O
291	III	_	_	O
292	trial	_	_	O
293	to	_	_	O
294	report	_	_	O
295	clinical	_	_	O
296	benefit	_	_	O
297	in	_	_	O
298	AGGEC	_	_	O
299	patients	_	_	O
300	.	_	_	O

301	Clinical	_	_	O
302	benefit	_	_	O
303	was	_	_	O
304	assessed	_	_	O
305	beyond	_	_	O
306	protocol	_	_	O
307	-	_	_	O
308	specific	_	_	O
309	chemotherapy	_	_	O
310	.	_	_	O

311	The	_	_	B-Claim
312	addition	_	_	I-Claim
313	of	_	_	I-Claim
314	D	_	_	I-Claim
315	to	_	_	I-Claim
316	CF	_	_	I-Claim
317	not	_	_	I-Claim
318	only	_	_	I-Claim
319	significantly	_	_	I-Claim
320	improved	_	_	I-Claim
321	clinical	_	_	I-Claim
322	benefit	_	_	I-Claim
323	but	_	_	I-Claim
324	also	_	_	I-Claim
325	improved	_	_	I-Claim
326	quality	_	_	I-Claim
327	of	_	_	I-Claim
328	life	_	_	I-Claim
329	,	_	_	I-Claim
330	time	_	_	I-Claim
331	to	_	_	I-Claim
332	progression	_	_	I-Claim
333	,	_	_	I-Claim
334	and	_	_	I-Claim
335	overall	_	_	I-Claim
336	survival	_	_	I-Claim
337	compared	_	_	I-Claim
338	with	_	_	I-Claim
339	CF	_	_	I-Claim
340	.	_	_	I-Claim


0	Evaluation	_	_	O
1	of	_	_	O
2	health	_	_	O
3	-	_	_	O
4	related	_	_	O
5	quality	_	_	O
6	-	_	_	O
7	of	_	_	O
8	-	_	_	O
9	life	_	_	O
10	(	_	_	O
11	HRQoL	_	_	O
12	)	_	_	O
13	and	_	_	O
14	symptom	_	_	O
15	improvement	_	_	O
16	were	_	_	O
17	preplanned	_	_	O
18	secondary	_	_	O
19	objectives	_	_	O
20	for	_	_	O
21	the	_	_	O
22	overall	_	_	O
23	population	_	_	O
24	and	_	_	O
25	posthoc	_	_	O
26	analyses	_	_	O
27	for	_	_	O
28	epidermal	_	_	O
29	growth	_	_	O
30	factor	_	_	O
31	receptor	_	_	O
32	(	_	_	O
33	EGFR	_	_	O
34	)	_	_	O
35	mutation	_	_	O
36	-	_	_	O
37	positive	_	_	O
38	/	_	_	O
39	negative	_	_	O
40	subgroups	_	_	O
41	in	_	_	O
42	IPASS	_	_	O
43	.	_	_	O

44	HRQoL	_	_	O
45	was	_	_	O
46	assessed	_	_	O
47	using	_	_	O
48	the	_	_	O
49	Functional	_	_	O
50	Assessment	_	_	O
51	of	_	_	O
52	Cancer	_	_	O
53	Therapy	_	_	O
54	-	_	_	O
55	Lung	_	_	O
56	(	_	_	O
57	FACT	_	_	O
58	-	_	_	O
59	L	_	_	O
60	)	_	_	O
61	and	_	_	O
62	Trial	_	_	O
63	Outcome	_	_	O
64	Index	_	_	O
65	(	_	_	O
66	TOI	_	_	O
67	)	_	_	O
68	;	_	_	O
69	symptom	_	_	O
70	improvement	_	_	O
71	by	_	_	O
72	the	_	_	O
73	Lung	_	_	O
74	Cancer	_	_	O
75	Subscale	_	_	O
76	(	_	_	O
77	LCS	_	_	O
78	)	_	_	O
79	.	_	_	O

80	Improvements	_	_	O
81	defined	_	_	O
82	as	_	_	O
83	:	_	_	O
84	6	_	_	O
85	or	_	_	O
86	more	_	_	O
87	(	_	_	O
88	FACT	_	_	O
89	-	_	_	O
90	L	_	_	O
91	;	_	_	O
92	TOI	_	_	O
93	)	_	_	O
94	,	_	_	O
95	2	_	_	O
96	or	_	_	O
97	more	_	_	O
98	(	_	_	O
99	LCS	_	_	O
100	)	_	_	O
101	points	_	_	O
102	increase	_	_	O
103	maintained	_	_	O
104	for	_	_	O
105	21	_	_	O
106	or	_	_	O
107	more	_	_	O
108	days	_	_	O
109	.	_	_	O

110	Overall	_	_	O
111	(	_	_	O
112	n	_	_	O
113	=	_	_	O
114	1151	_	_	O
115	/	_	_	O
116	1217	_	_	O
117	evaluable	_	_	O
118	)	_	_	O
119	,	_	_	O
120	HRQoL	_	_	O
121	improvement	_	_	O
122	rates	_	_	O
123	were	_	_	O
124	significantly	_	_	O
125	greater	_	_	O
126	with	_	_	O
127	gefitinib	_	_	O
128	versus	_	_	O
129	carboplatin	_	_	O
130	/	_	_	O
131	paclitaxel	_	_	O
132	;	_	_	O
133	symptom	_	_	O
134	improvement	_	_	O
135	rates	_	_	O
136	were	_	_	O
137	similar	_	_	O
138	for	_	_	O
139	both	_	_	O
140	treatments	_	_	O
141	.	_	_	O

142	Significantly	_	_	B-Premise
143	more	_	_	I-Premise
144	patients	_	_	I-Premise
145	recorded	_	_	I-Premise
146	improvements	_	_	I-Premise
147	in	_	_	I-Premise
148	HRQoL	_	_	I-Premise
149	and	_	_	I-Premise
150	symptoms	_	_	I-Premise
151	with	_	_	I-Premise
152	gefitinib	_	_	I-Premise
153	in	_	_	I-Premise
154	the	_	_	I-Premise
155	EGFR	_	_	I-Premise
156	mutation	_	_	I-Premise
157	-	_	_	I-Premise
158	positive	_	_	I-Premise
159	subgroup	_	_	I-Premise
160	(	_	_	I-Premise
161	n	_	_	I-Premise
162	=	_	_	I-Premise
163	259	_	_	I-Premise
164	;	_	_	I-Premise
165	FACT	_	_	I-Premise
166	-	_	_	I-Premise
167	L	_	_	I-Premise
168	70	_	_	I-Premise
169	.	_	_	I-Premise

170	2	_	_	I-Premise
171	%	_	_	I-Premise
172	versus	_	_	I-Premise
173	44	_	_	I-Premise
174	.	_	_	I-Premise

175	5	_	_	I-Premise
176	%	_	_	I-Premise
177	;	_	_	I-Premise
178	odds	_	_	I-Premise
179	ratio	_	_	I-Premise
180	,	_	_	I-Premise
181	3	_	_	I-Premise
182	.	_	_	I-Premise

183	01	_	_	I-Premise
184	[	_	_	I-Premise
185	95	_	_	I-Premise
186	%	_	_	I-Premise
187	confidence	_	_	I-Premise
188	interval	_	_	I-Premise
189	,	_	_	I-Premise
190	1	_	_	I-Premise
191	.	_	_	I-Premise

192	79	_	_	I-Premise
193	-	_	_	I-Premise
194	5	_	_	I-Premise
195	.	_	_	I-Premise

196	07	_	_	I-Premise
197	]	_	_	I-Premise
198	;	_	_	I-Premise
199	p	_	_	I-Premise
200	<	_	_	I-Premise
201	0	_	_	I-Premise
202	.	_	_	I-Premise

203	001	_	_	I-Premise
204	;	_	_	I-Premise
205	TOI	_	_	I-Premise
206	70	_	_	I-Premise
207	.	_	_	I-Premise

208	2	_	_	I-Premise
209	%	_	_	I-Premise
210	versus	_	_	I-Premise
211	38	_	_	I-Premise
212	.	_	_	I-Premise

213	3	_	_	I-Premise
214	%	_	_	I-Premise
215	;	_	_	I-Premise
216	3	_	_	I-Premise
217	.	_	_	I-Premise

218	96	_	_	I-Premise
219	[	_	_	I-Premise
220	2	_	_	I-Premise
221	.	_	_	I-Premise

222	33	_	_	I-Premise
223	-	_	_	I-Premise
224	6	_	_	I-Premise
225	.	_	_	I-Premise

226	71	_	_	I-Premise
227	]	_	_	I-Premise
228	;	_	_	I-Premise
229	p	_	_	I-Premise
230	<	_	_	I-Premise
231	0	_	_	I-Premise
232	.	_	_	I-Premise

233	001	_	_	I-Premise
234	;	_	_	I-Premise
235	LCS	_	_	I-Premise
236	75	_	_	I-Premise
237	.	_	_	I-Premise

238	6	_	_	I-Premise
239	%	_	_	I-Premise
240	versus	_	_	I-Premise
241	53	_	_	I-Premise
242	.	_	_	I-Premise

243	9	_	_	I-Premise
244	%	_	_	I-Premise
245	;	_	_	I-Premise
246	2	_	_	I-Premise
247	.	_	_	I-Premise

248	70	_	_	I-Premise
249	[	_	_	I-Premise
250	1	_	_	I-Premise
251	.	_	_	I-Premise

252	58	_	_	I-Premise
253	-	_	_	I-Premise
254	4	_	_	I-Premise
255	.	_	_	I-Premise

256	62	_	_	I-Premise
257	]	_	_	I-Premise
258	;	_	_	I-Premise
259	p	_	_	I-Premise
260	<	_	_	I-Premise
261	0	_	_	I-Premise
262	.	_	_	I-Premise

263	001	_	_	I-Premise
264	)	_	_	I-Premise
265	,	_	_	I-Premise
266	and	_	_	I-Premise
267	with	_	_	I-Premise
268	carboplatin	_	_	I-Premise
269	/	_	_	I-Premise
270	paclitaxel	_	_	I-Premise
271	in	_	_	I-Premise
272	the	_	_	I-Premise
273	EGFR	_	_	I-Premise
274	mutation	_	_	I-Premise
275	-	_	_	I-Premise
276	negative	_	_	I-Premise
277	subgroup	_	_	I-Premise
278	(	_	_	I-Premise
279	n	_	_	I-Premise
280	=	_	_	I-Premise
281	169	_	_	I-Premise
282	;	_	_	I-Premise
283	FACT	_	_	I-Premise
284	-	_	_	I-Premise
285	L	_	_	I-Premise
286	14	_	_	I-Premise
287	.	_	_	I-Premise

288	6	_	_	I-Premise
289	%	_	_	I-Premise
290	versus	_	_	I-Premise
291	36	_	_	I-Premise
292	.	_	_	I-Premise

293	3	_	_	I-Premise
294	%	_	_	I-Premise
295	;	_	_	I-Premise
296	odds	_	_	I-Premise
297	ratio	_	_	I-Premise
298	,	_	_	I-Premise
299	0	_	_	I-Premise
300	.	_	_	I-Premise

301	31	_	_	I-Premise
302	[	_	_	I-Premise
303	0	_	_	I-Premise
304	.	_	_	I-Premise

305	15	_	_	I-Premise
306	-	_	_	I-Premise
307	0	_	_	I-Premise
308	.	_	_	I-Premise

309	65	_	_	I-Premise
310	]	_	_	I-Premise
311	;	_	_	I-Premise
312	p	_	_	I-Premise
313	=	_	_	I-Premise
314	0	_	_	I-Premise
315	.	_	_	I-Premise

316	002	_	_	I-Premise
317	;	_	_	I-Premise
318	TOI	_	_	I-Premise
319	12	_	_	I-Premise
320	.	_	_	I-Premise

321	4	_	_	I-Premise
322	%	_	_	I-Premise
323	versus	_	_	I-Premise
324	28	_	_	I-Premise
325	.	_	_	I-Premise

326	8	_	_	I-Premise
327	%	_	_	I-Premise
328	;	_	_	I-Premise
329	0	_	_	I-Premise
330	.	_	_	I-Premise

331	35	_	_	I-Premise
332	[	_	_	I-Premise
333	0	_	_	I-Premise
334	.	_	_	I-Premise

335	16	_	_	I-Premise
336	-	_	_	I-Premise
337	0	_	_	I-Premise
338	.	_	_	I-Premise

339	79	_	_	I-Premise
340	]	_	_	I-Premise
341	;	_	_	I-Premise
342	p	_	_	I-Premise
343	=	_	_	I-Premise
344	0	_	_	I-Premise
345	.	_	_	I-Premise

346	011	_	_	I-Premise
347	;	_	_	I-Premise
348	LCS	_	_	I-Premise
349	20	_	_	I-Premise
350	.	_	_	I-Premise

351	2	_	_	I-Premise
352	%	_	_	I-Premise
353	versus	_	_	I-Premise
354	47	_	_	I-Premise
355	.	_	_	I-Premise

356	5	_	_	I-Premise
357	%	_	_	I-Premise
358	;	_	_	I-Premise
359	0	_	_	I-Premise
360	.	_	_	I-Premise

361	28	_	_	I-Premise
362	[	_	_	I-Premise
363	0	_	_	I-Premise
364	.	_	_	I-Premise

365	14	_	_	I-Premise
366	-	_	_	I-Premise
367	0	_	_	I-Premise
368	.	_	_	I-Premise

369	55	_	_	I-Premise
370	]	_	_	I-Premise
371	;	_	_	I-Premise
372	p	_	_	I-Premise
373	<	_	_	I-Premise
374	0	_	_	I-Premise
375	.	_	_	I-Premise

376	001	_	_	I-Premise
377	)	_	_	I-Premise
378	.	_	_	I-Premise

379	Median	_	_	B-Premise
380	time	_	_	I-Premise
381	-	_	_	I-Premise
382	to	_	_	I-Premise
383	-	_	_	I-Premise
384	worsening	_	_	I-Premise
385	(	_	_	I-Premise
386	months	_	_	I-Premise
387	)	_	_	I-Premise
388	FACT	_	_	I-Premise
389	-	_	_	I-Premise
390	L	_	_	I-Premise
391	score	_	_	I-Premise
392	was	_	_	I-Premise
393	longer	_	_	I-Premise
394	with	_	_	I-Premise
395	gefitinib	_	_	I-Premise
396	versus	_	_	I-Premise
397	carboplatin	_	_	I-Premise
398	/	_	_	I-Premise
399	paclitaxel	_	_	I-Premise
400	for	_	_	I-Premise
401	the	_	_	I-Premise
402	overall	_	_	I-Premise
403	population	_	_	I-Premise
404	(	_	_	I-Premise
405	8	_	_	I-Premise
406	.	_	_	I-Premise

407	3	_	_	I-Premise
408	versus	_	_	I-Premise
409	2	_	_	I-Premise
410	.	_	_	I-Premise

411	5	_	_	I-Premise
412	)	_	_	I-Premise
413	and	_	_	I-Premise
414	EGFR	_	_	I-Premise
415	mutation	_	_	I-Premise
416	-	_	_	I-Premise
417	positive	_	_	I-Premise
418	subgroup	_	_	I-Premise
419	(	_	_	I-Premise
420	15	_	_	I-Premise
421	.	_	_	I-Premise

422	6	_	_	I-Premise
423	versus	_	_	I-Premise
424	3	_	_	I-Premise
425	.	_	_	I-Premise

426	0	_	_	I-Premise
427	)	_	_	I-Premise
428	,	_	_	I-Premise
429	and	_	_	I-Premise
430	similar	_	_	I-Premise
431	for	_	_	I-Premise
432	both	_	_	I-Premise
433	treatments	_	_	I-Premise
434	in	_	_	I-Premise
435	the	_	_	I-Premise
436	EGFR	_	_	I-Premise
437	mutation	_	_	I-Premise
438	-	_	_	I-Premise
439	negative	_	_	I-Premise
440	subgroup	_	_	I-Premise
441	(	_	_	I-Premise
442	1	_	_	I-Premise
443	.	_	_	I-Premise

444	4	_	_	I-Premise
445	versus	_	_	I-Premise
446	1	_	_	I-Premise
447	.	_	_	I-Premise

448	4	_	_	I-Premise
449	)	_	_	I-Premise
450	.	_	_	I-Premise

451	Median	_	_	B-Premise
452	time	_	_	I-Premise
453	-	_	_	I-Premise
454	to	_	_	I-Premise
455	-	_	_	I-Premise
456	improvement	_	_	I-Premise
457	with	_	_	I-Premise
458	gefitinib	_	_	I-Premise
459	was	_	_	I-Premise
460	8	_	_	I-Premise
461	days	_	_	I-Premise
462	in	_	_	I-Premise
463	patients	_	_	I-Premise
464	with	_	_	I-Premise
465	EGFR	_	_	I-Premise
466	mutation	_	_	I-Premise
467	-	_	_	I-Premise
468	positive	_	_	I-Premise
469	tumors	_	_	I-Premise
470	who	_	_	I-Premise
471	improved	_	_	I-Premise
472	.	_	_	I-Premise

473	HRQoL	_	_	B-Claim
474	and	_	_	I-Claim
475	symptom	_	_	I-Claim
476	endpoints	_	_	I-Claim
477	were	_	_	I-Claim
478	consistent	_	_	I-Claim
479	with	_	_	I-Claim
480	efficacy	_	_	I-Claim
481	outcomes	_	_	I-Claim
482	in	_	_	I-Claim
483	IPASS	_	_	I-Claim
484	and	_	_	I-Claim
485	favored	_	_	I-Claim
486	gefitinib	_	_	I-Claim
487	in	_	_	I-Claim
488	patients	_	_	I-Claim
489	with	_	_	I-Claim
490	EGFR	_	_	I-Claim
491	mutation	_	_	I-Claim
492	-	_	_	I-Claim
493	positive	_	_	I-Claim
494	tumors	_	_	I-Claim
495	and	_	_	I-Claim
496	carboplatin	_	_	I-Claim
497	/	_	_	I-Claim
498	paclitaxel	_	_	I-Claim
499	in	_	_	I-Claim
500	patients	_	_	I-Claim
501	with	_	_	I-Claim
502	EGFR	_	_	I-Claim
503	mutation	_	_	I-Claim
504	-	_	_	I-Claim
505	negative	_	_	I-Claim
506	tumors	_	_	I-Claim
507	.	_	_	I-Claim


0	The	_	_	B-Claim
1	impact	_	_	I-Claim
2	of	_	_	I-Claim
3	prolonged	_	_	I-Claim
4	subclinical	_	_	I-Claim
5	hyperthyroidism	_	_	I-Claim
6	on	_	_	I-Claim
7	quality	_	_	I-Claim
8	of	_	_	I-Claim
9	life	_	_	I-Claim
10	is	_	_	I-Claim
11	unclear	_	_	I-Claim
12	.	_	_	I-Claim

13	Therefore	_	_	O
14	,	_	_	O
15	we	_	_	O
16	evaluated	_	_	O
17	quality	_	_	O
18	of	_	_	O
19	life	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	differentiated	_	_	O
24	thyroid	_	_	O
25	carcinoma	_	_	O
26	(	_	_	O
27	DTC	_	_	O
28	)	_	_	O
29	on	_	_	O
30	TSH	_	_	O
31	-	_	_	O
32	suppressive	_	_	O
33	thyroxine	_	_	O
34	therapy	_	_	O
35	as	_	_	O
36	a	_	_	O
37	model	_	_	O
38	for	_	_	O
39	subclinical	_	_	O
40	hyperthyroidism	_	_	O
41	and	_	_	O
42	we	_	_	O
43	investigated	_	_	O
44	whether	_	_	O
45	restoration	_	_	O
46	to	_	_	O
47	euthyroidism	_	_	O
48	affects	_	_	O
49	quality	_	_	O
50	of	_	_	O
51	life	_	_	O
52	.	_	_	O

53	We	_	_	O
54	performed	_	_	O
55	a	_	_	O
56	prospective	_	_	O
57	,	_	_	O
58	single	_	_	O
59	-	_	_	O
60	blinded	_	_	O
61	,	_	_	O
62	placebo	_	_	O
63	-	_	_	O
64	controlled	_	_	O
65	,	_	_	O
66	randomized	_	_	O
67	trial	_	_	O
68	of	_	_	O
69	6	_	_	O
70	months	_	_	O
71	'	_	_	O
72	duration	_	_	O
73	with	_	_	O
74	two	_	_	O
75	parallel	_	_	O
76	groups	_	_	O
77	.	_	_	O

78	Twenty	_	_	O
79	-	_	_	O
80	four	_	_	O
81	subjects	_	_	O
82	with	_	_	O
83	a	_	_	O
84	history	_	_	O
85	of	_	_	O
86	differentiated	_	_	O
87	thyroid	_	_	O
88	carcinoma	_	_	O
89	with	_	_	O
90	>	_	_	O
91	10	_	_	O
92	years	_	_	O
93	TSH	_	_	O
94	-	_	_	O
95	suppressive	_	_	O
96	therapy	_	_	O
97	with	_	_	O
98	L	_	_	O
99	-	_	_	O
100	thyroxine	_	_	O
101	completed	_	_	O
102	the	_	_	O
103	study	_	_	O
104	.	_	_	O

105	L	_	_	O
106	-	_	_	O
107	thyroxine	_	_	O
108	dose	_	_	O
109	was	_	_	O
110	replaced	_	_	O
111	by	_	_	O
112	study	_	_	O
113	medication	_	_	O
114	containing	_	_	O
115	L	_	_	O
116	-	_	_	O
117	thyroxine	_	_	O
118	or	_	_	O
119	L	_	_	O
120	-	_	_	O
121	thyroxine	_	_	O
122	plus	_	_	O
123	placebo	_	_	O
124	.	_	_	O

125	Medication	_	_	O
126	was	_	_	O
127	titrated	_	_	O
128	to	_	_	O
129	establish	_	_	O
130	continuation	_	_	O
131	of	_	_	O
132	TSH	_	_	O
133	suppression	_	_	O
134	(	_	_	O
135	low	_	_	O
136	-	_	_	O
137	TSH	_	_	O
138	group	_	_	O
139	)	_	_	O
140	and	_	_	O
141	euthyroidism	_	_	O
142	(	_	_	O
143	euthyroid	_	_	O
144	group	_	_	O
145	)	_	_	O
146	.	_	_	O

147	Both	_	_	O
148	groups	_	_	O
149	consisted	_	_	O
150	of	_	_	O
151	12	_	_	O
152	patients	_	_	O
153	.	_	_	O

154	We	_	_	O
155	evaluated	_	_	O
156	quality	_	_	O
157	of	_	_	O
158	life	_	_	O
159	using	_	_	O
160	five	_	_	O
161	validated	_	_	O
162	questionnaires	_	_	O
163	.	_	_	O

164	At	_	_	O
165	baseline	_	_	O
166	,	_	_	O
167	the	_	_	O
168	somatic	_	_	O
169	disorder	_	_	O
170	questionnaire	_	_	O
171	(	_	_	O
172	SDQ	_	_	O
173	)	_	_	O
174	indicated	_	_	O
175	more	_	_	O
176	somatic	_	_	O
177	dysfunction	_	_	O
178	in	_	_	O
179	patients	_	_	O
180	as	_	_	O
181	compared	_	_	O
182	with	_	_	O
183	reference	_	_	O
184	values	_	_	O
185	,	_	_	O
186	whereas	_	_	O
187	the	_	_	O
188	depression	_	_	O
189	score	_	_	O
190	(	_	_	O
191	HADS	_	_	O
192	)	_	_	O
193	revealed	_	_	O
194	a	_	_	O
195	better	_	_	O
196	score	_	_	O
197	than	_	_	O
198	the	_	_	O
199	reference	_	_	O
200	group	_	_	O
201	.	_	_	O

202	All	_	_	O
203	other	_	_	O
204	quality	_	_	O
205	of	_	_	O
206	life	_	_	O
207	parameters	_	_	O
208	were	_	_	O
209	normal	_	_	O
210	.	_	_	O

211	At	_	_	O
212	baseline	_	_	O
213	,	_	_	O
214	no	_	_	O
215	significant	_	_	O
216	differences	_	_	O
217	between	_	_	O
218	the	_	_	O
219	low	_	_	O
220	-	_	_	O
221	TSH	_	_	O
222	and	_	_	O
223	the	_	_	O
224	euthyroidism	_	_	O
225	groups	_	_	O
226	were	_	_	O
227	observed	_	_	O
228	.	_	_	O

229	After	_	_	B-Premise
230	6	_	_	I-Premise
231	months	_	_	I-Premise
232	,	_	_	I-Premise
233	none	_	_	I-Premise
234	of	_	_	I-Premise
235	the	_	_	I-Premise
236	quality	_	_	I-Premise
237	of	_	_	I-Premise
238	life	_	_	I-Premise
239	parameters	_	_	I-Premise
240	in	_	_	I-Premise
241	the	_	_	I-Premise
242	low	_	_	I-Premise
243	-	_	_	I-Premise
244	TSH	_	_	I-Premise
245	group	_	_	I-Premise
246	was	_	_	I-Premise
247	different	_	_	I-Premise
248	from	_	_	I-Premise
249	baseline	_	_	I-Premise
250	values	_	_	I-Premise
251	.	_	_	I-Premise

252	In	_	_	B-Premise
253	the	_	_	I-Premise
254	euthyroid	_	_	I-Premise
255	group	_	_	I-Premise
256	,	_	_	I-Premise
257	motivation	_	_	I-Premise
258	was	_	_	I-Premise
259	significantly	_	_	I-Premise
260	improved	_	_	I-Premise
261	(	_	_	I-Premise
262	Multidimensional	_	_	I-Premise
263	Fatigue	_	_	I-Premise
264	Index	_	_	I-Premise
265	-	_	_	I-Premise
266	20	_	_	I-Premise
267	,	_	_	I-Premise
268	P	_	_	I-Premise
269	=	_	_	I-Premise
270	0	_	_	I-Premise
271	.	_	_	I-Premise

272	003	_	_	I-Premise
273	)	_	_	I-Premise
274	,	_	_	I-Premise
275	although	_	_	B-Premise
276	this	_	_	I-Premise
277	parameter	_	_	I-Premise
278	did	_	_	I-Premise
279	not	_	_	I-Premise
280	differ	_	_	I-Premise
281	from	_	_	I-Premise
282	the	_	_	I-Premise
283	reference	_	_	I-Premise
284	group	_	_	I-Premise
285	at	_	_	I-Premise
286	baseline	_	_	I-Premise
287	.	_	_	I-Premise

288	A	_	_	B-Premise
289	probable	_	_	I-Premise
290	worsening	_	_	I-Premise
291	in	_	_	I-Premise
292	role	_	_	I-Premise
293	limitations	_	_	I-Premise
294	as	_	_	I-Premise
295	a	_	_	I-Premise
296	result	_	_	I-Premise
297	of	_	_	I-Premise
298	physical	_	_	I-Premise
299	problems	_	_	I-Premise
300	(	_	_	I-Premise
301	Short	_	_	I-Premise
302	Form	_	_	I-Premise
303	-	_	_	I-Premise
304	36	_	_	I-Premise
305	;	_	_	I-Premise
306	P	_	_	I-Premise
307	=	_	_	I-Premise
308	0	_	_	I-Premise
309	.	_	_	I-Premise

310	050	_	_	I-Premise
311	)	_	_	I-Premise
312	was	_	_	I-Premise
313	observed	_	_	I-Premise
314	.	_	_	I-Premise

315	No	_	_	B-Premise
316	improvement	_	_	I-Premise
317	in	_	_	I-Premise
318	the	_	_	I-Premise
319	SDQ	_	_	I-Premise
320	score	_	_	I-Premise
321	was	_	_	I-Premise
322	observed	_	_	I-Premise
323	.	_	_	I-Premise

324	In	_	_	B-Claim
325	summary	_	_	I-Claim
326	,	_	_	I-Claim
327	quality	_	_	I-Claim
328	of	_	_	I-Claim
329	life	_	_	I-Claim
330	in	_	_	I-Claim
331	patients	_	_	I-Claim
332	with	_	_	I-Claim
333	DTC	_	_	I-Claim
334	and	_	_	I-Claim
335	long	_	_	I-Claim
336	-	_	_	I-Claim
337	term	_	_	I-Claim
338	subclinical	_	_	I-Claim
339	hyperthyroidism	_	_	I-Claim
340	in	_	_	I-Claim
341	general	_	_	I-Claim
342	is	_	_	I-Claim
343	preserved	_	_	I-Claim
344	.	_	_	I-Claim

345	Restoration	_	_	B-Claim
346	of	_	_	I-Claim
347	euthyroidism	_	_	I-Claim
348	in	_	_	I-Claim
349	general	_	_	I-Claim
350	does	_	_	I-Claim
351	not	_	_	I-Claim
352	affect	_	_	I-Claim
353	quality	_	_	I-Claim
354	of	_	_	I-Claim
355	life	_	_	I-Claim
356	.	_	_	I-Claim


0	Colorectal	_	_	O
1	cancer	_	_	O
2	survivors	_	_	O
3	are	_	_	O
4	at	_	_	O
5	risk	_	_	O
6	for	_	_	O
7	poor	_	_	O
8	health	_	_	O
9	outcomes	_	_	O
10	because	_	_	O
11	of	_	_	O
12	unhealthy	_	_	O
13	lifestyles	_	_	O
14	,	_	_	O
15	but	_	_	O
16	few	_	_	O
17	studies	_	_	O
18	have	_	_	O
19	developed	_	_	O
20	translatable	_	_	O
21	health	_	_	O
22	behavior	_	_	O
23	change	_	_	O
24	interventions	_	_	O
25	.	_	_	O

26	This	_	_	O
27	study	_	_	O
28	aimed	_	_	O
29	to	_	_	O
30	determine	_	_	O
31	the	_	_	O
32	effects	_	_	O
33	of	_	_	O
34	a	_	_	O
35	telephone	_	_	O
36	-	_	_	O
37	delivered	_	_	O
38	multiple	_	_	O
39	health	_	_	O
40	behavior	_	_	O
41	change	_	_	O
42	intervention	_	_	O
43	(	_	_	O
44	CanChange	_	_	O
45	)	_	_	O
46	on	_	_	O
47	health	_	_	O
48	and	_	_	O
49	behavioral	_	_	O
50	outcomes	_	_	O
51	among	_	_	O
52	colorectal	_	_	O
53	cancer	_	_	O
54	survivors	_	_	O
55	.	_	_	O

56	In	_	_	O
57	this	_	_	O
58	two	_	_	O
59	-	_	_	O
60	group	_	_	O
61	randomized	_	_	O
62	controlled	_	_	O
63	trial	_	_	O
64	,	_	_	O
65	410	_	_	O
66	colorectal	_	_	O
67	cancer	_	_	O
68	survivors	_	_	O
69	were	_	_	O
70	randomly	_	_	O
71	assigned	_	_	O
72	to	_	_	O
73	the	_	_	O
74	health	_	_	O
75	coaching	_	_	O
76	intervention	_	_	O
77	(	_	_	O
78	11	_	_	O
79	theory	_	_	O
80	-	_	_	O
81	based	_	_	O
82	telephone	_	_	O
83	-	_	_	O
84	delivered	_	_	O
85	health	_	_	O
86	coaching	_	_	O
87	sessions	_	_	O
88	delivered	_	_	O
89	over	_	_	O
90	6	_	_	O
91	months	_	_	O
92	focusing	_	_	O
93	on	_	_	O
94	physical	_	_	O
95	activity	_	_	O
96	,	_	_	O
97	weight	_	_	O
98	management	_	_	O
99	,	_	_	O
100	dietary	_	_	O
101	habits	_	_	O
102	,	_	_	O
103	alcohol	_	_	O
104	,	_	_	O
105	and	_	_	O
106	smoking	_	_	O
107	)	_	_	O
108	or	_	_	O
109	usual	_	_	O
110	care	_	_	O
111	.	_	_	O

112	Assessment	_	_	O
113	of	_	_	O
114	primary	_	_	O
115	(	_	_	O
116	ie	_	_	O
117	,	_	_	O
118	physical	_	_	O
119	activity	_	_	O
120	[	_	_	O
121	Godin	_	_	O
122	Leisure	_	_	O
123	Time	_	_	O
124	Index	_	_	O
125	]	_	_	O
126	,	_	_	O
127	health	_	_	O
128	-	_	_	O
129	related	_	_	O
130	quality	_	_	O
131	of	_	_	O
132	life	_	_	O
133	[	_	_	O
134	HRQoL	_	_	O
135	;	_	_	O
136	Short	_	_	O
137	Form	_	_	O
138	-	_	_	O
139	36	_	_	O
140	]	_	_	O
141	,	_	_	O
142	and	_	_	O
143	cancer	_	_	O
144	-	_	_	O
145	related	_	_	O
146	fatigue	_	_	O
147	[	_	_	O
148	Functional	_	_	O
149	Assessment	_	_	O
150	of	_	_	O
151	Chronic	_	_	O
152	Illness	_	_	O
153	Therapy	_	_	O
154	Fatigue	_	_	O
155	Scale	_	_	O
156	]	_	_	O
157	)	_	_	O
158	and	_	_	O
159	secondary	_	_	O
160	outcomes	_	_	O
161	(	_	_	O
162	ie	_	_	O
163	,	_	_	O
164	body	_	_	O
165	mass	_	_	O
166	index	_	_	O
167	[	_	_	O
168	kg	_	_	O
169	/	_	_	O
170	m	_	_	O
171	(	_	_	O
172	2	_	_	O
173	)	_	_	O
174	]	_	_	O
175	,	_	_	O
176	diet	_	_	O
177	and	_	_	O
178	alcohol	_	_	O
179	intake	_	_	O
180	[	_	_	O
181	Food	_	_	O
182	Frequency	_	_	O
183	Questionnaire	_	_	O
184	]	_	_	O
185	,	_	_	O
186	and	_	_	O
187	smoking	_	_	O
188	)	_	_	O
189	were	_	_	O
190	conducted	_	_	O
191	at	_	_	O
192	baseline	_	_	O
193	and	_	_	O
194	6	_	_	O
195	and	_	_	O
196	12	_	_	O
197	months	_	_	O
198	.	_	_	O

199	At	_	_	B-Premise
200	12	_	_	I-Premise
201	months	_	_	I-Premise
202	,	_	_	I-Premise
203	significant	_	_	I-Premise
204	intervention	_	_	I-Premise
205	effects	_	_	I-Premise
206	were	_	_	I-Premise
207	observed	_	_	I-Premise
208	for	_	_	I-Premise
209	moderate	_	_	I-Premise
210	physical	_	_	I-Premise
211	activity	_	_	I-Premise
212	(	_	_	I-Premise
213	28	_	_	I-Premise
214	.	_	_	I-Premise

215	5	_	_	I-Premise
216	minutes	_	_	I-Premise
217	;	_	_	I-Premise
218	P	_	_	I-Premise
219	=	_	_	I-Premise
220	.	_	_	I-Premise

221	003	_	_	I-Premise
222	)	_	_	I-Premise
223	,	_	_	I-Premise
224	body	_	_	I-Premise
225	mass	_	_	I-Premise
226	index	_	_	I-Premise
227	(	_	_	I-Premise
228	-	_	_	I-Premise
229	0	_	_	I-Premise
230	.	_	_	I-Premise

231	9	_	_	I-Premise
232	kg	_	_	I-Premise
233	/	_	_	I-Premise
234	m	_	_	I-Premise
235	(	_	_	I-Premise
236	2	_	_	I-Premise
237	)	_	_	I-Premise
238	;	_	_	I-Premise
239	P	_	_	I-Premise
240	=	_	_	I-Premise
241	.	_	_	I-Premise

242	001	_	_	I-Premise
243	)	_	_	I-Premise
244	,	_	_	I-Premise
245	energy	_	_	I-Premise
246	from	_	_	I-Premise
247	total	_	_	I-Premise
248	fat	_	_	I-Premise
249	(	_	_	I-Premise
250	-	_	_	I-Premise
251	7	_	_	I-Premise
252	.	_	_	I-Premise

253	0	_	_	I-Premise
254	%	_	_	I-Premise
255	;	_	_	I-Premise
256	P	_	_	I-Premise
257	=	_	_	I-Premise
258	.	_	_	I-Premise

259	006	_	_	I-Premise
260	)	_	_	I-Premise
261	,	_	_	I-Premise
262	and	_	_	I-Premise
263	energy	_	_	I-Premise
264	from	_	_	I-Premise
265	saturated	_	_	I-Premise
266	fat	_	_	I-Premise
267	(	_	_	I-Premise
268	-	_	_	I-Premise
269	2	_	_	I-Premise
270	.	_	_	I-Premise

271	8	_	_	I-Premise
272	%	_	_	I-Premise
273	;	_	_	I-Premise
274	P	_	_	I-Premise
275	=	_	_	I-Premise
276	.	_	_	I-Premise

277	016	_	_	I-Premise
278	)	_	_	I-Premise
279	.	_	_	I-Premise

280	A	_	_	B-Premise
281	significant	_	_	I-Premise
282	intervention	_	_	I-Premise
283	effect	_	_	I-Premise
284	was	_	_	I-Premise
285	reported	_	_	I-Premise
286	for	_	_	I-Premise
287	vegetable	_	_	I-Premise
288	intake	_	_	I-Premise
289	(	_	_	I-Premise
290	0	_	_	I-Premise
291	.	_	_	I-Premise

292	4	_	_	I-Premise
293	servings	_	_	I-Premise
294	per	_	_	I-Premise
295	day	_	_	I-Premise
296	;	_	_	I-Premise
297	P	_	_	I-Premise
298	=	_	_	I-Premise
299	.	_	_	I-Premise

300	001	_	_	I-Premise
301	)	_	_	I-Premise
302	at	_	_	I-Premise
303	6	_	_	I-Premise
304	months	_	_	I-Premise
305	.	_	_	I-Premise

306	No	_	_	B-Premise
307	significant	_	_	I-Premise
308	group	_	_	I-Premise
309	differences	_	_	I-Premise
310	were	_	_	I-Premise
311	found	_	_	I-Premise
312	at	_	_	I-Premise
313	6	_	_	I-Premise
314	or	_	_	I-Premise
315	12	_	_	I-Premise
316	months	_	_	I-Premise
317	for	_	_	I-Premise
318	HRQoL	_	_	I-Premise
319	,	_	_	I-Premise
320	cancer	_	_	I-Premise
321	-	_	_	I-Premise
322	related	_	_	I-Premise
323	fatigue	_	_	I-Premise
324	,	_	_	I-Premise
325	fruit	_	_	I-Premise
326	,	_	_	I-Premise
327	fiber	_	_	I-Premise
328	,	_	_	I-Premise
329	or	_	_	I-Premise
330	alcohol	_	_	I-Premise
331	intake	_	_	I-Premise
332	,	_	_	I-Premise
333	or	_	_	I-Premise
334	smoking	_	_	I-Premise
335	.	_	_	I-Premise

336	The	_	_	B-Claim
337	CanChange	_	_	I-Claim
338	intervention	_	_	I-Claim
339	was	_	_	I-Claim
340	effective	_	_	I-Claim
341	for	_	_	I-Claim
342	improving	_	_	I-Claim
343	physical	_	_	I-Claim
344	activity	_	_	I-Claim
345	,	_	_	I-Claim
346	dietary	_	_	I-Claim
347	habits	_	_	I-Claim
348	,	_	_	I-Claim
349	and	_	_	I-Claim
350	body	_	_	I-Claim
351	mass	_	_	I-Claim
352	index	_	_	I-Claim
353	in	_	_	I-Claim
354	colorectal	_	_	I-Claim
355	cancer	_	_	I-Claim
356	survivors	_	_	I-Claim
357	.	_	_	I-Claim

358	The	_	_	O
359	intervention	_	_	O
360	is	_	_	O
361	translatable	_	_	O
362	through	_	_	O
363	existing	_	_	O
364	telephone	_	_	O
365	cancer	_	_	O
366	support	_	_	O
367	and	_	_	O
368	information	_	_	O
369	services	_	_	O
370	in	_	_	O
371	Australia	_	_	O
372	and	_	_	O
373	other	_	_	O
374	countries	_	_	O
375	.	_	_	O


0	Quality	_	_	O
1	of	_	_	O
2	life	_	_	O
3	(	_	_	O
4	QoL	_	_	O
5	)	_	_	O
6	after	_	_	O
7	breast	_	_	O
8	cancer	_	_	O
9	is	_	_	O
10	nowadays	_	_	O
11	a	_	_	O
12	major	_	_	O
13	challenge	_	_	O
14	.	_	_	O

15	Complementary	_	_	O
16	interventions	_	_	O
17	are	_	_	O
18	necessary	_	_	O
19	because	_	_	O
20	of	_	_	O
21	frequent	_	_	O
22	depression	_	_	O
23	symptoms	_	_	O
24	after	_	_	O
25	treatment	_	_	O
26	and	_	_	O
27	also	_	_	O
28	to	_	_	O
29	favour	_	_	O
30	return	_	_	O
31	to	_	_	O
32	activity	_	_	O
33	.	_	_	O

34	Besides	_	_	O
35	,	_	_	O
36	radio	_	_	O
37	-	_	_	O
38	chemotherapy	_	_	O
39	has	_	_	O
40	side	_	_	O
41	-	_	_	O
42	effects	_	_	O
43	like	_	_	O
44	weight	_	_	O
45	gain	_	_	O
46	and	_	_	O
47	fatigue	_	_	O
48	.	_	_	O

49	Several	_	_	O
50	strategies	_	_	O
51	including	_	_	O
52	group	_	_	O
53	behavioural	_	_	O
54	-	_	_	O
55	educational	_	_	O
56	interventions	_	_	O
57	,	_	_	O
58	physical	_	_	O
59	training	_	_	O
60	and	_	_	O
61	/	_	_	O
62	or	_	_	O
63	dietary	_	_	O
64	education	_	_	O
65	,	_	_	O
66	have	_	_	O
67	been	_	_	O
68	tested	_	_	O
69	to	_	_	O
70	answer	_	_	O
71	these	_	_	O
72	difficulties	_	_	O
73	with	_	_	O
74	moderate	_	_	O
75	success	_	_	O
76	in	_	_	O
77	the	_	_	O
78	long	_	_	O
79	run	_	_	O
80	.	_	_	O

81	Two	_	_	O
82	hundred	_	_	O
83	and	_	_	O
84	fifty	_	_	O
85	-	_	_	O
86	one	_	_	O
87	non	_	_	O
88	-	_	_	O
89	metastatic	_	_	O
90	patients	_	_	O
91	were	_	_	O
92	accrued	_	_	O
93	after	_	_	O
94	chemotherapy	_	_	O
95	in	_	_	O
96	a	_	_	O
97	prospective	_	_	O
98	randomised	_	_	O
99	multicenter	_	_	O
100	trial	_	_	O
101	between	_	_	O
102	2008	_	_	O
103	and	_	_	O
104	2010	_	_	O
105	,	_	_	O
106	testing	_	_	O
107	a	_	_	O
108	2	_	_	O
109	-	_	_	O
110	week	_	_	O
111	intervention	_	_	O
112	in	_	_	O
113	SPA	_	_	O
114	centres	_	_	O
115	.	_	_	O

116	Intervention	_	_	O
117	comprised	_	_	O
118	group	_	_	O
119	physical	_	_	O
120	training	_	_	O
121	,	_	_	O
122	dietary	_	_	O
123	education	_	_	O
124	and	_	_	O
125	physiotherapy	_	_	O
126	.	_	_	O

127	Selected	_	_	O
128	patients	_	_	O
129	were	_	_	O
130	in	_	_	O
131	complete	_	_	O
132	remission	_	_	O
133	.	_	_	O

134	QoL	_	_	O
135	was	_	_	O
136	evaluated	_	_	O
137	with	_	_	O
138	SF36	_	_	O
139	questionnaire	_	_	O
140	,	_	_	O
141	anxiety	_	_	O
142	and	_	_	O
143	depression	_	_	O
144	with	_	_	O
145	the	_	_	O
146	hospital	_	_	O
147	anxiety	_	_	O
148	and	_	_	O
149	depression	_	_	O
150	(	_	_	O
151	HAD	_	_	O
152	)	_	_	O
153	one	_	_	O
154	.	_	_	O

155	Anthropometric	_	_	O
156	measures	_	_	O
157	and	_	_	O
158	QoL	_	_	O
159	evaluations	_	_	O
160	were	_	_	O
161	obtained	_	_	O
162	before	_	_	O
163	randomisation	_	_	O
164	and	_	_	O
165	every	_	_	O
166	6	_	_	O
167	months	_	_	O
168	during	_	_	O
169	3	_	_	O
170	years	_	_	O
171	.	_	_	O

172	Two	_	_	O
173	hundred	_	_	O
174	and	_	_	O
175	twenty	_	_	O
176	patients	_	_	O
177	were	_	_	O
178	evaluable	_	_	O
179	at	_	_	O
180	1	_	_	O
181	year	_	_	O
182	.	_	_	O

183	Intervention	_	_	B-Premise
184	increased	_	_	I-Premise
185	SF36	_	_	I-Premise
186	score	_	_	I-Premise
187	by	_	_	I-Premise
188	9	_	_	I-Premise
189	.	_	_	I-Premise

190	5	_	_	I-Premise
191	points	_	_	I-Premise
192	(	_	_	I-Premise
193	p	_	_	I-Premise
194	=	_	_	I-Premise
195	0	_	_	I-Premise
196	.	_	_	I-Premise

197	000006	_	_	I-Premise
198	)	_	_	I-Premise
199	,	_	_	I-Premise
200	4	_	_	I-Premise
201	.	_	_	I-Premise

202	6	_	_	I-Premise
203	(	_	_	I-Premise
204	p	_	_	I-Premise
205	=	_	_	I-Premise
206	0	_	_	I-Premise
207	.	_	_	I-Premise

208	032	_	_	I-Premise
209	)	_	_	I-Premise
210	and	_	_	I-Premise
211	6	_	_	I-Premise
212	.	_	_	I-Premise

213	2	_	_	I-Premise
214	(	_	_	I-Premise
215	p	_	_	I-Premise
216	=	_	_	I-Premise
217	0	_	_	I-Premise
218	.	_	_	I-Premise

219	028	_	_	I-Premise
220	)	_	_	I-Premise
221	respectively	_	_	I-Premise
222	at	_	_	I-Premise
223	6	_	_	I-Premise
224	,	_	_	I-Premise
225	12	_	_	I-Premise
226	and	_	_	I-Premise
227	24	_	_	I-Premise
228	months	_	_	I-Premise
229	.	_	_	I-Premise

230	Effect	_	_	B-Premise
231	size	_	_	I-Premise
232	(	_	_	I-Premise
233	ES	_	_	I-Premise
234	)	_	_	I-Premise
235	was	_	_	I-Premise
236	0	_	_	I-Premise
237	.	_	_	I-Premise

238	63	_	_	I-Premise
239	[	_	_	I-Premise
240	0	_	_	I-Premise
241	.	_	_	I-Premise

242	37	_	_	I-Premise
243	;	_	_	I-Premise
244	0	_	_	I-Premise
245	.	_	_	I-Premise

246	90	_	_	I-Premise
247	]	_	_	I-Premise
248	,	_	_	I-Premise
249	0	_	_	I-Premise
250	.	_	_	I-Premise

251	29	_	_	I-Premise
252	[	_	_	I-Premise
253	0	_	_	I-Premise
254	.	_	_	I-Premise

255	03	_	_	I-Premise
256	;	_	_	I-Premise
257	0	_	_	I-Premise
258	.	_	_	I-Premise

259	55	_	_	I-Premise
260	]	_	_	I-Premise
261	and	_	_	I-Premise
262	0	_	_	I-Premise
263	.	_	_	I-Premise

264	41	_	_	I-Premise
265	[	_	_	I-Premise
266	0	_	_	I-Premise
267	.	_	_	I-Premise

268	04	_	_	I-Premise
269	;	_	_	I-Premise
270	0	_	_	I-Premise
271	.	_	_	I-Premise

272	78	_	_	I-Premise
273	]	_	_	I-Premise
274	.	_	_	I-Premise

275	Anxiety	_	_	B-Premise
276	score	_	_	I-Premise
277	was	_	_	I-Premise
278	shortly	_	_	I-Premise
279	minored	_	_	I-Premise
280	by	_	_	I-Premise
281	intervention	_	_	I-Premise
282	(	_	_	I-Premise
283	6	_	_	I-Premise
284	-	_	_	I-Premise
285	month	_	_	I-Premise
286	ES	_	_	I-Premise
287	=	_	_	I-Premise
288	-	_	_	I-Premise
289	0	_	_	I-Premise
290	.	_	_	I-Premise

291	24	_	_	I-Premise
292	[	_	_	I-Premise
293	-	_	_	I-Premise
294	0	_	_	I-Premise
295	.	_	_	I-Premise

296	42	_	_	I-Premise
297	;	_	_	I-Premise
298	-	_	_	I-Premise
299	0	_	_	I-Premise
300	.	_	_	I-Premise

301	05	_	_	I-Premise
302	]	_	_	I-Premise
303	)	_	_	I-Premise
304	and	_	_	I-Premise
305	depression	_	_	I-Premise
306	score	_	_	I-Premise
307	more	_	_	I-Premise
308	durably	_	_	I-Premise
309	:	_	_	I-Premise
310	ES	_	_	I-Premise
311	=	_	_	I-Premise
312	-	_	_	I-Premise
313	0	_	_	I-Premise
314	.	_	_	I-Premise

315	45	_	_	I-Premise
316	[	_	_	I-Premise
317	-	_	_	I-Premise
318	0	_	_	I-Premise
319	.	_	_	I-Premise

320	72	_	_	I-Premise
321	;	_	_	I-Premise
322	-	_	_	I-Premise
323	0	_	_	I-Premise
324	.	_	_	I-Premise

325	18	_	_	I-Premise
326	]	_	_	I-Premise
327	,	_	_	I-Premise
328	-	_	_	I-Premise
329	0	_	_	I-Premise
330	.	_	_	I-Premise

331	34	_	_	I-Premise
332	[	_	_	I-Premise
333	-	_	_	I-Premise
334	061	_	_	I-Premise
335	;	_	_	I-Premise
336	-	_	_	I-Premise
337	0	_	_	I-Premise
338	.	_	_	I-Premise

339	08	_	_	I-Premise
340	]	_	_	I-Premise
341	,	_	_	I-Premise
342	and	_	_	I-Premise
343	-	_	_	I-Premise
344	0	_	_	I-Premise
345	.	_	_	I-Premise

346	26	_	_	I-Premise
347	[	_	_	I-Premise
348	-	_	_	I-Premise
349	0	_	_	I-Premise
350	.	_	_	I-Premise

351	63	_	_	I-Premise
352	;	_	_	I-Premise
353	0	_	_	I-Premise
354	.	_	_	I-Premise

355	11	_	_	I-Premise
356	]	_	_	I-Premise
357	at	_	_	I-Premise
358	6	_	_	I-Premise
359	,	_	_	I-Premise
360	12	_	_	I-Premise
361	and	_	_	I-Premise
362	24	_	_	I-Premise
363	months	_	_	I-Premise
364	.	_	_	I-Premise

365	This	_	_	B-Claim
366	2	_	_	I-Claim
367	-	_	_	I-Claim
368	week	_	_	I-Claim
369	group	_	_	I-Claim
370	intervention	_	_	I-Claim
371	seemed	_	_	I-Claim
372	to	_	_	I-Claim
373	durably	_	_	I-Claim
374	influence	_	_	I-Claim
375	QoL	_	_	I-Claim
376	of	_	_	I-Claim
377	breast	_	_	I-Claim
378	cancer	_	_	I-Claim
379	patients	_	_	I-Claim
380	treated	_	_	I-Claim
381	by	_	_	I-Claim
382	chemotherapy	_	_	I-Claim
383	.	_	_	I-Claim

384	Differences	_	_	B-Claim
385	,	_	_	I-Claim
386	smaller	_	_	I-Claim
387	at	_	_	I-Claim
388	12	_	_	I-Claim
389	months	_	_	I-Claim
390	than	_	_	I-Claim
391	at	_	_	I-Claim
392	six	_	_	I-Claim
393	,	_	_	I-Claim
394	suggest	_	_	I-Claim
395	that	_	_	I-Claim
396	a	_	_	I-Claim
397	second	_	_	I-Claim
398	but	_	_	I-Claim
399	shorter	_	_	I-Claim
400	intervention	_	_	I-Claim
401	could	_	_	I-Claim
402	help	_	_	I-Claim
403	maintain	_	_	I-Claim
404	the	_	_	I-Claim
405	6	_	_	I-Claim
406	-	_	_	I-Claim
407	month	_	_	I-Claim
408	benefits	_	_	I-Claim
409	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	epoetin	_	_	O
6	alfa	_	_	O
7	on	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	(	_	_	O
12	QOL	_	_	O
13	)	_	_	O
14	in	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	solid	_	_	O
18	tumors	_	_	O
19	and	_	_	O
20	mild	_	_	O
21	-	_	_	O
22	to	_	_	O
23	-	_	_	O
24	moderate	_	_	O
25	anemia	_	_	O
26	receiving	_	_	O
27	platinum	_	_	O
28	-	_	_	O
29	based	_	_	O
30	chemotherapy	_	_	O
31	relative	_	_	O
32	to	_	_	O
33	population	_	_	O
34	norms	_	_	O
35	.	_	_	O

36	In	_	_	O
37	the	_	_	O
38	original	_	_	O
39	study	_	_	O
40	,	_	_	O
41	patients	_	_	O
42	(	_	_	O
43	n	_	_	O
44	=	_	_	O
45	316	_	_	O
46	)	_	_	O
47	with	_	_	O
48	hemoglobin	_	_	O
49	(	_	_	O
50	Hb	_	_	O
51	)	_	_	O
52	levels	_	_	O
53	<	_	_	O
54	or	_	_	O
55	=	_	_	O
56	12	_	_	O
57	.	_	_	O

58	1	_	_	O
59	g	_	_	O
60	/	_	_	O
61	dl	_	_	O
62	were	_	_	O
63	randomized	_	_	O
64	2	_	_	O
65	:	_	_	O
66	1	_	_	O
67	to	_	_	O
68	receive	_	_	O
69	either	_	_	O
70	epoetin	_	_	O
71	alfa	_	_	O
72	at	_	_	O
73	a	_	_	O
74	dose	_	_	O
75	of	_	_	O
76	10	_	_	O
77	,	_	_	O
78	000	_	_	O
79	U	_	_	O
80	thrice	_	_	O
81	weekly	_	_	O
82	s	_	_	O
83	.	_	_	O

84	c	_	_	O
85	.	_	_	O

86	or	_	_	O
87	best	_	_	O
88	supportive	_	_	O
89	care	_	_	O
90	(	_	_	O
91	BSC	_	_	O
92	)	_	_	O
93	to	_	_	O
94	compare	_	_	O
95	the	_	_	O
96	effects	_	_	O
97	on	_	_	O
98	transfusion	_	_	O
99	use	_	_	O
100	,	_	_	O
101	hematologic	_	_	O
102	response	_	_	O
103	,	_	_	O
104	and	_	_	O
105	QOL	_	_	O
106	(	_	_	O
107	measured	_	_	O
108	by	_	_	O
109	the	_	_	O
110	Functional	_	_	O
111	Assessment	_	_	O
112	of	_	_	O
113	Cancer	_	_	O
114	Therapy	_	_	O
115	-	_	_	O
116	Anemia	_	_	O
117	[	_	_	O
118	FACT	_	_	O
119	-	_	_	O
120	An	_	_	O
121	]	_	_	O
122	and	_	_	O
123	Cancer	_	_	O
124	Linear	_	_	O
125	Analogue	_	_	O
126	Scale	_	_	O
127	[	_	_	O
128	CLAS	_	_	O
129	]	_	_	O
130	)	_	_	O
131	.	_	_	O

132	The	_	_	O
133	QOL	_	_	O
134	data	_	_	O
135	from	_	_	O
136	this	_	_	O
137	previously	_	_	O
138	reported	_	_	O
139	trial	_	_	O
140	were	_	_	O
141	reanalyzed	_	_	O
142	here	_	_	O
143	relative	_	_	O
144	to	_	_	O
145	population	_	_	O
146	norms	_	_	O
147	.	_	_	O

148	Mean	_	_	O
149	baseline	_	_	O
150	QOL	_	_	O
151	scores	_	_	O
152	were	_	_	O
153	similar	_	_	O
154	between	_	_	O
155	groups	_	_	O
156	.	_	_	O

157	At	_	_	O
158	study	_	_	O
159	completion	_	_	O
160	,	_	_	O
161	mean	_	_	O
162	CLAS	_	_	O
163	,	_	_	O
164	FACT	_	_	O
165	-	_	_	O
166	An	_	_	O
167	,	_	_	O
168	FACT	_	_	O
169	-	_	_	O
170	An	_	_	O
171	Anemia	_	_	O
172	subscale	_	_	O
173	,	_	_	O
174	and	_	_	O
175	FACT	_	_	O
176	-	_	_	O
177	An	_	_	O
178	Fatigue	_	_	O
179	subscale	_	_	O
180	scores	_	_	O
181	were	_	_	O
182	significantly	_	_	O
183	higher	_	_	O
184	for	_	_	O
185	patients	_	_	O
186	given	_	_	O
187	epoetin	_	_	O
188	alfa	_	_	O
189	than	_	_	O
190	for	_	_	O
191	those	_	_	O
192	treated	_	_	O
193	with	_	_	O
194	BSC	_	_	O
195	.	_	_	O

196	Compared	_	_	O
197	with	_	_	O
198	population	_	_	O
199	norms	_	_	O
200	,	_	_	O
201	both	_	_	O
202	groups	_	_	O
203	had	_	_	O
204	impaired	_	_	O
205	QOL	_	_	O
206	at	_	_	O
207	baseline	_	_	O
208	.	_	_	O

209	Differences	_	_	B-Premise
210	in	_	_	I-Premise
211	mean	_	_	I-Premise
212	QOL	_	_	I-Premise
213	change	_	_	I-Premise
214	scores	_	_	I-Premise
215	from	_	_	I-Premise
216	baseline	_	_	I-Premise
217	to	_	_	I-Premise
218	study	_	_	I-Premise
219	end	_	_	I-Premise
220	for	_	_	I-Premise
221	epoetin	_	_	I-Premise
222	alfa	_	_	I-Premise
223	versus	_	_	I-Premise
224	BSC	_	_	I-Premise
225	were	_	_	I-Premise
226	3	_	_	I-Premise
227	.	_	_	I-Premise

228	17	_	_	I-Premise
229	points	_	_	I-Premise
230	for	_	_	I-Premise
231	the	_	_	I-Premise
232	FACT	_	_	I-Premise
233	-	_	_	I-Premise
234	General	_	_	I-Premise
235	Total	_	_	I-Premise
236	,	_	_	I-Premise
237	9	_	_	I-Premise
238	.	_	_	I-Premise

239	90	_	_	I-Premise
240	for	_	_	I-Premise
241	the	_	_	I-Premise
242	FACT	_	_	I-Premise
243	-	_	_	I-Premise
244	An	_	_	I-Premise
245	Fatigue	_	_	I-Premise
246	subscale	_	_	I-Premise
247	,	_	_	I-Premise
248	and	_	_	I-Premise
249	7	_	_	I-Premise
250	.	_	_	I-Premise

251	30	_	_	I-Premise
252	for	_	_	I-Premise
253	the	_	_	I-Premise
254	FACT	_	_	I-Premise
255	-	_	_	I-Premise
256	An	_	_	I-Premise
257	Anemia	_	_	I-Premise
258	subscale	_	_	I-Premise
259	.	_	_	I-Premise

260	This	_	_	B-Premise
261	was	_	_	I-Premise
262	equivalent	_	_	I-Premise
263	to	_	_	I-Premise
264	corrections	_	_	I-Premise
265	in	_	_	I-Premise
266	QOL	_	_	I-Premise
267	deficits	_	_	I-Premise
268	attributable	_	_	I-Premise
269	to	_	_	I-Premise
270	epoetin	_	_	I-Premise
271	alfa	_	_	I-Premise
272	of	_	_	I-Premise
273	97	_	_	I-Premise
274	.	_	_	I-Premise

275	3	_	_	I-Premise
276	%	_	_	I-Premise
277	,	_	_	I-Premise
278	40	_	_	I-Premise
279	.	_	_	I-Premise

280	7	_	_	I-Premise
281	%	_	_	I-Premise
282	,	_	_	I-Premise
283	and	_	_	I-Premise
284	38	_	_	I-Premise
285	.	_	_	I-Premise

286	0	_	_	I-Premise
287	%	_	_	I-Premise
288	for	_	_	I-Premise
289	the	_	_	I-Premise
290	FACT	_	_	I-Premise
291	-	_	_	I-Premise
292	General	_	_	I-Premise
293	Total	_	_	I-Premise
294	,	_	_	I-Premise
295	FACT	_	_	I-Premise
296	-	_	_	I-Premise
297	An	_	_	I-Premise
298	Fatigue	_	_	I-Premise
299	,	_	_	I-Premise
300	and	_	_	I-Premise
301	FACT	_	_	I-Premise
302	-	_	_	I-Premise
303	An	_	_	I-Premise
304	Anemia	_	_	I-Premise
305	subscale	_	_	I-Premise
306	scores	_	_	I-Premise
307	,	_	_	I-Premise
308	respectively	_	_	I-Premise
309	,	_	_	I-Premise
310	versus	_	_	I-Premise
311	BSC	_	_	I-Premise
312	.	_	_	I-Premise

313	A	_	_	B-Premise
314	somewhat	_	_	I-Premise
315	greater	_	_	I-Premise
316	QOL	_	_	I-Premise
317	benefit	_	_	I-Premise
318	was	_	_	I-Premise
319	observed	_	_	I-Premise
320	for	_	_	I-Premise
321	the	_	_	I-Premise
322	FACT	_	_	I-Premise
323	-	_	_	I-Premise
324	An	_	_	I-Premise
325	Fatigue	_	_	I-Premise
326	and	_	_	I-Premise
327	FACT	_	_	I-Premise
328	-	_	_	I-Premise
329	An	_	_	I-Premise
330	Anemia	_	_	I-Premise
331	subscales	_	_	I-Premise
332	in	_	_	I-Premise
333	the	_	_	I-Premise
334	subset	_	_	I-Premise
335	of	_	_	I-Premise
336	patients	_	_	I-Premise
337	with	_	_	I-Premise
338	baseline	_	_	I-Premise
339	Hb	_	_	I-Premise
340	levels	_	_	I-Premise
341	>	_	_	I-Premise
342	10	_	_	I-Premise
343	.	_	_	I-Premise

344	5	_	_	I-Premise
345	g	_	_	I-Premise
346	/	_	_	I-Premise
347	dl	_	_	I-Premise
348	.	_	_	I-Premise

349	Patients	_	_	B-Premise
350	in	_	_	I-Premise
351	this	_	_	I-Premise
352	study	_	_	I-Premise
353	had	_	_	I-Premise
354	impaired	_	_	I-Premise
355	QOL	_	_	I-Premise
356	compared	_	_	I-Premise
357	with	_	_	I-Premise
358	population	_	_	I-Premise
359	norms	_	_	I-Premise
360	.	_	_	I-Premise

361	Early	_	_	B-Claim
362	treatment	_	_	I-Claim
363	with	_	_	I-Claim
364	epoetin	_	_	I-Claim
365	alfa	_	_	I-Claim
366	to	_	_	I-Claim
367	correct	_	_	I-Claim
368	anemia	_	_	I-Claim
369	improved	_	_	I-Claim
370	QOL	_	_	I-Claim
371	in	_	_	I-Claim
372	a	_	_	I-Claim
373	statistically	_	_	I-Claim
374	significant	_	_	I-Claim
375	and	_	_	I-Claim
376	clinically	_	_	I-Claim
377	meaningful	_	_	I-Claim
378	way	_	_	I-Claim
379	,	_	_	I-Claim
380	and	_	_	I-Claim
381	improvements	_	_	I-Claim
382	were	_	_	I-Claim
383	greater	_	_	I-Claim
384	in	_	_	I-Claim
385	patients	_	_	I-Claim
386	with	_	_	I-Claim
387	baseline	_	_	I-Claim
388	Hb	_	_	I-Claim
389	levels	_	_	I-Claim
390	>	_	_	I-Claim
391	10	_	_	I-Claim
392	.	_	_	I-Claim

393	5	_	_	I-Claim
394	g	_	_	I-Claim
395	/	_	_	I-Claim
396	dl	_	_	I-Claim
397	.	_	_	I-Claim


0	Although	_	_	O
1	chemotherapy	_	_	O
2	-	_	_	O
3	induced	_	_	O
4	cognitive	_	_	O
5	impairment	_	_	O
6	is	_	_	O
7	common	_	_	O
8	among	_	_	O
9	breast	_	_	O
10	cancer	_	_	O
11	patients	_	_	O
12	,	_	_	O
13	evidence	_	_	O
14	for	_	_	O
15	effective	_	_	O
16	interventions	_	_	O
17	addressing	_	_	O
18	cognitive	_	_	O
19	deficits	_	_	O
20	is	_	_	O
21	limited	_	_	O
22	.	_	_	O

23	This	_	_	O
24	randomized	_	_	O
25	controlled	_	_	O
26	trial	_	_	O
27	examined	_	_	O
28	the	_	_	O
29	feasibility	_	_	O
30	and	_	_	O
31	preliminary	_	_	O
32	efficacy	_	_	O
33	of	_	_	O
34	a	_	_	O
35	Tibetan	_	_	O
36	Sound	_	_	O
37	Meditation	_	_	O
38	(	_	_	O
39	TSM	_	_	O
40	)	_	_	O
41	program	_	_	O
42	to	_	_	O
43	improve	_	_	O
44	cognitive	_	_	O
45	function	_	_	O
46	and	_	_	O
47	quality	_	_	O
48	of	_	_	O
49	life	_	_	O
50	in	_	_	O
51	breast	_	_	O
52	cancer	_	_	O
53	patients	_	_	O
54	.	_	_	O

55	Forty	_	_	O
56	-	_	_	O
57	seven	_	_	O
58	breast	_	_	O
59	cancer	_	_	O
60	patients	_	_	O
61	(	_	_	O
62	mean	_	_	O
63	age	_	_	O
64	56	_	_	O
65	.	_	_	O

66	3	_	_	O
67	years	_	_	O
68	)	_	_	O
69	,	_	_	O
70	who	_	_	O
71	were	_	_	O
72	staged	_	_	O
73	I	_	_	O
74	-	_	_	O
75	III	_	_	O
76	at	_	_	O
77	diagnosis	_	_	O
78	,	_	_	O
79	6	_	_	O
80	-	_	_	O
81	60	_	_	O
82	months	_	_	O
83	post	_	_	O
84	-	_	_	O
85	chemotherapy	_	_	O
86	,	_	_	O
87	and	_	_	O
88	reported	_	_	O
89	cognitive	_	_	O
90	impairment	_	_	O
91	at	_	_	O
92	study	_	_	O
93	entry	_	_	O
94	were	_	_	O
95	recruited	_	_	O
96	.	_	_	O

97	Participants	_	_	O
98	were	_	_	O
99	randomized	_	_	O
100	to	_	_	O
101	either	_	_	O
102	two	_	_	O
103	weekly	_	_	O
104	TSM	_	_	O
105	sessions	_	_	O
106	for	_	_	O
107	6	_	_	O
108	weeks	_	_	O
109	or	_	_	O
110	a	_	_	O
111	wait	_	_	O
112	list	_	_	O
113	control	_	_	O
114	group	_	_	O
115	.	_	_	O

116	Neuropsychological	_	_	O
117	assessments	_	_	O
118	were	_	_	O
119	completed	_	_	O
120	at	_	_	O
121	baseline	_	_	O
122	and	_	_	O
123	1	_	_	O
124	month	_	_	O
125	post	_	_	O
126	-	_	_	O
127	treatment	_	_	O
128	.	_	_	O

129	Self	_	_	O
130	-	_	_	O
131	report	_	_	O
132	measures	_	_	O
133	of	_	_	O
134	cognitive	_	_	O
135	function	_	_	O
136	(	_	_	O
137	Functional	_	_	O
138	Assessment	_	_	O
139	of	_	_	O
140	Cancer	_	_	O
141	Therapy	_	_	O
142	(	_	_	O
143	FACT	_	_	O
144	)	_	_	O
145	-	_	_	O
146	Cog	_	_	O
147	)	_	_	O
148	,	_	_	O
149	quality	_	_	O
150	of	_	_	O
151	life	_	_	O
152	(	_	_	O
153	SF	_	_	O
154	-	_	_	O
155	36	_	_	O
156	)	_	_	O
157	,	_	_	O
158	depressive	_	_	O
159	symptoms	_	_	O
160	(	_	_	O
161	Center	_	_	O
162	for	_	_	O
163	Epidemiologic	_	_	O
164	Studies	_	_	O
165	Depression	_	_	O
166	Scale	_	_	O
167	)	_	_	O
168	,	_	_	O
169	sleep	_	_	O
170	disturbance	_	_	O
171	(	_	_	O
172	Pittsburgh	_	_	O
173	Sleep	_	_	O
174	Quality	_	_	O
175	Index	_	_	O
176	)	_	_	O
177	,	_	_	O
178	fatigue	_	_	O
179	(	_	_	O
180	Brief	_	_	O
181	Fatigue	_	_	O
182	Inventory	_	_	O
183	)	_	_	O
184	,	_	_	O
185	and	_	_	O
186	spirituality	_	_	O
187	(	_	_	O
188	FACT	_	_	O
189	-	_	_	O
190	Sp	_	_	O
191	)	_	_	O
192	were	_	_	O
193	completed	_	_	O
194	at	_	_	O
195	baseline	_	_	O
196	,	_	_	O
197	the	_	_	O
198	end	_	_	O
199	of	_	_	O
200	treatment	_	_	O
201	,	_	_	O
202	and	_	_	O
203	1	_	_	O
204	month	_	_	O
205	later	_	_	O
206	.	_	_	O

207	Relative	_	_	B-Premise
208	to	_	_	I-Premise
209	the	_	_	I-Premise
210	control	_	_	I-Premise
211	group	_	_	I-Premise
212	,	_	_	I-Premise
213	women	_	_	I-Premise
214	in	_	_	I-Premise
215	the	_	_	I-Premise
216	TSM	_	_	I-Premise
217	group	_	_	I-Premise
218	performed	_	_	I-Premise
219	better	_	_	I-Premise
220	on	_	_	I-Premise
221	the	_	_	I-Premise
222	verbal	_	_	I-Premise
223	memory	_	_	I-Premise
224	test	_	_	I-Premise
225	(	_	_	I-Premise
226	Rey	_	_	I-Premise
227	Auditory	_	_	I-Premise
228	Verbal	_	_	I-Premise
229	Learning	_	_	I-Premise
230	Test	_	_	I-Premise
231	trial	_	_	I-Premise
232	1	_	_	I-Premise
233	)	_	_	I-Premise
234	(	_	_	I-Premise
235	p	_	_	I-Premise
236	=	_	_	I-Premise
237	0	_	_	I-Premise
238	.	_	_	I-Premise

239	06	_	_	I-Premise
240	)	_	_	I-Premise
241	and	_	_	I-Premise
242	the	_	_	I-Premise
243	short	_	_	I-Premise
244	-	_	_	I-Premise
245	term	_	_	I-Premise
246	memory	_	_	I-Premise
247	and	_	_	I-Premise
248	processing	_	_	I-Premise
249	speed	_	_	I-Premise
250	task	_	_	I-Premise
251	(	_	_	I-Premise
252	Digit	_	_	I-Premise
253	Symbol	_	_	I-Premise
254	)	_	_	I-Premise
255	(	_	_	I-Premise
256	p	_	_	I-Premise
257	=	_	_	I-Premise
258	0	_	_	I-Premise
259	.	_	_	I-Premise

260	09	_	_	I-Premise
261	)	_	_	I-Premise
262	and	_	_	I-Premise
263	reported	_	_	I-Premise
264	improved	_	_	I-Premise
265	cognitive	_	_	I-Premise
266	function	_	_	I-Premise
267	(	_	_	I-Premise
268	p	_	_	I-Premise
269	=	_	_	I-Premise
270	0	_	_	I-Premise
271	.	_	_	I-Premise

272	06	_	_	I-Premise
273	)	_	_	I-Premise
274	,	_	_	I-Premise
275	cognitive	_	_	I-Premise
276	abilities	_	_	I-Premise
277	(	_	_	I-Premise
278	p	_	_	I-Premise
279	=	_	_	I-Premise
280	0	_	_	I-Premise
281	.	_	_	I-Premise

282	08	_	_	I-Premise
283	)	_	_	I-Premise
284	,	_	_	I-Premise
285	mental	_	_	I-Premise
286	health	_	_	I-Premise
287	(	_	_	I-Premise
288	p	_	_	I-Premise
289	=	_	_	I-Premise
290	0	_	_	I-Premise
291	.	_	_	I-Premise

292	04	_	_	I-Premise
293	)	_	_	I-Premise
294	,	_	_	I-Premise
295	and	_	_	I-Premise
296	spirituality	_	_	I-Premise
297	(	_	_	I-Premise
298	p	_	_	I-Premise
299	=	_	_	I-Premise
300	0	_	_	I-Premise
301	.	_	_	I-Premise

302	05	_	_	I-Premise
303	)	_	_	I-Premise
304	at	_	_	I-Premise
305	the	_	_	I-Premise
306	end	_	_	I-Premise
307	of	_	_	I-Premise
308	treatment	_	_	I-Premise
309	but	_	_	I-Premise
310	not	_	_	I-Premise
311	1	_	_	I-Premise
312	month	_	_	I-Premise
313	later	_	_	I-Premise
314	.	_	_	I-Premise

315	This	_	_	B-Claim
316	randomized	_	_	I-Claim
317	controlled	_	_	I-Claim
318	trial	_	_	I-Claim
319	revealed	_	_	I-Claim
320	that	_	_	I-Claim
321	TSM	_	_	I-Claim
322	program	_	_	I-Claim
323	appears	_	_	I-Claim
324	to	_	_	I-Claim
325	be	_	_	I-Claim
326	a	_	_	I-Claim
327	feasible	_	_	I-Claim
328	and	_	_	I-Claim
329	acceptable	_	_	I-Claim
330	intervention	_	_	I-Claim
331	and	_	_	I-Claim
332	may	_	_	I-Claim
333	be	_	_	I-Claim
334	associated	_	_	I-Claim
335	with	_	_	I-Claim
336	short	_	_	I-Claim
337	-	_	_	I-Claim
338	term	_	_	I-Claim
339	improvements	_	_	I-Claim
340	in	_	_	I-Claim
341	objective	_	_	I-Claim
342	and	_	_	I-Claim
343	subjective	_	_	I-Claim
344	cognitive	_	_	I-Claim
345	function	_	_	I-Claim
346	as	_	_	I-Claim
347	well	_	_	I-Claim
348	as	_	_	I-Claim
349	mental	_	_	I-Claim
350	health	_	_	I-Claim
351	and	_	_	I-Claim
352	spirituality	_	_	I-Claim
353	in	_	_	I-Claim
354	breast	_	_	I-Claim
355	cancer	_	_	I-Claim
356	patients	_	_	I-Claim
357	.	_	_	I-Claim


0	We	_	_	O
1	investigated	_	_	O
2	the	_	_	O
3	influence	_	_	O
4	of	_	_	O
5	bladder	_	_	O
6	neck	_	_	O
7	preservation	_	_	O
8	on	_	_	O
9	urinary	_	_	O
10	continence	_	_	O
11	,	_	_	O
12	quality	_	_	O
13	of	_	_	O
14	life	_	_	O
15	and	_	_	O
16	surgical	_	_	O
17	margins	_	_	O
18	after	_	_	O
19	radical	_	_	O
20	prostatectomy	_	_	O
21	.	_	_	O

22	A	_	_	O
23	total	_	_	O
24	of	_	_	O
25	208	_	_	O
26	men	_	_	O
27	who	_	_	O
28	presented	_	_	O
29	for	_	_	O
30	radical	_	_	O
31	prostatectomy	_	_	O
32	were	_	_	O
33	randomized	_	_	O
34	to	_	_	O
35	complete	_	_	O
36	bladder	_	_	O
37	neck	_	_	O
38	preservation	_	_	O
39	with	_	_	O
40	subsequent	_	_	O
41	urethro	_	_	O
42	-	_	_	O
43	urethral	_	_	O
44	anastomosis	_	_	O
45	or	_	_	O
46	to	_	_	O
47	no	_	_	O
48	preservation	_	_	O
49	as	_	_	O
50	controls	_	_	O
51	.	_	_	O

52	Patients	_	_	O
53	with	_	_	O
54	failed	_	_	O
55	bladder	_	_	O
56	neck	_	_	O
57	preservation	_	_	O
58	were	_	_	O
59	not	_	_	O
60	included	_	_	O
61	in	_	_	O
62	study	_	_	O
63	.	_	_	O

64	We	_	_	O
65	documented	_	_	O
66	objective	_	_	O
67	continence	_	_	O
68	by	_	_	O
69	the	_	_	O
70	24	_	_	O
71	-	_	_	O
72	hour	_	_	O
73	pad	_	_	O
74	test	_	_	O
75	,	_	_	O
76	social	_	_	O
77	continence	_	_	O
78	by	_	_	O
79	the	_	_	O
80	number	_	_	O
81	of	_	_	O
82	pads	_	_	O
83	per	_	_	O
84	day	_	_	O
85	and	_	_	O
86	quality	_	_	O
87	of	_	_	O
88	life	_	_	O
89	outcomes	_	_	O
90	by	_	_	O
91	the	_	_	O
92	validated	_	_	O
93	Incontinence	_	_	O
94	Quality	_	_	O
95	of	_	_	O
96	Life	_	_	O
97	questionnaire	_	_	O
98	in	_	_	O
99	a	_	_	O
100	single	_	_	O
101	blind	_	_	O
102	setting	_	_	O
103	.	_	_	O

104	Cancer	_	_	O
105	resection	_	_	O
106	was	_	_	O
107	assessed	_	_	O
108	by	_	_	O
109	surgical	_	_	O
110	margin	_	_	O
111	status	_	_	O
112	.	_	_	O

113	At	_	_	B-Premise
114	0	_	_	I-Premise
115	,	_	_	I-Premise
116	3	_	_	I-Premise
117	,	_	_	I-Premise
118	6	_	_	I-Premise
119	and	_	_	I-Premise
120	12	_	_	I-Premise
121	months	_	_	I-Premise
122	mean	_	_	I-Premise
123	urine	_	_	I-Premise
124	loss	_	_	I-Premise
125	in	_	_	I-Premise
126	the	_	_	I-Premise
127	control	_	_	I-Premise
128	vs	_	_	I-Premise
129	the	_	_	I-Premise
130	bladder	_	_	I-Premise
131	neck	_	_	I-Premise
132	preservation	_	_	I-Premise
133	group	_	_	I-Premise
134	was	_	_	I-Premise
135	713	_	_	I-Premise
136	.	_	_	I-Premise

137	3	_	_	I-Premise
138	vs	_	_	I-Premise
139	237	_	_	I-Premise
140	.	_	_	I-Premise

141	0	_	_	I-Premise
142	,	_	_	I-Premise
143	49	_	_	I-Premise
144	.	_	_	I-Premise

145	6	_	_	I-Premise
146	vs	_	_	I-Premise
147	15	_	_	I-Premise
148	.	_	_	I-Premise

149	6	_	_	I-Premise
150	,	_	_	I-Premise
151	44	_	_	I-Premise
152	.	_	_	I-Premise

153	4	_	_	I-Premise
154	vs	_	_	I-Premise
155	5	_	_	I-Premise
156	.	_	_	I-Premise

157	5	_	_	I-Premise
158	and	_	_	I-Premise
159	25	_	_	I-Premise
160	.	_	_	I-Premise

161	4	_	_	I-Premise
162	vs	_	_	I-Premise
163	3	_	_	I-Premise
164	.	_	_	I-Premise

165	1	_	_	I-Premise
166	gm	_	_	I-Premise
167	,	_	_	I-Premise
168	respectively	_	_	I-Premise
169	(	_	_	I-Premise
170	each	_	_	I-Premise
171	p	_	_	I-Premise
172	<	_	_	I-Premise
173	0	_	_	I-Premise
174	.	_	_	I-Premise

175	001	_	_	I-Premise
176	)	_	_	I-Premise
177	.	_	_	I-Premise

178	At	_	_	B-Premise
179	3	_	_	I-Premise
180	,	_	_	I-Premise
181	6	_	_	I-Premise
182	and	_	_	I-Premise
183	12	_	_	I-Premise
184	months	_	_	I-Premise
185	in	_	_	I-Premise
186	the	_	_	I-Premise
187	control	_	_	I-Premise
188	vs	_	_	I-Premise
189	the	_	_	I-Premise
190	preservation	_	_	I-Premise
191	group	_	_	I-Premise
192	the	_	_	I-Premise
193	social	_	_	I-Premise
194	continence	_	_	I-Premise
195	rate	_	_	I-Premise
196	was	_	_	I-Premise
197	55	_	_	I-Premise
198	.	_	_	I-Premise

199	3	_	_	I-Premise
200	%	_	_	I-Premise
201	vs	_	_	I-Premise
202	84	_	_	I-Premise
203	.	_	_	I-Premise

204	2	_	_	I-Premise
205	%	_	_	I-Premise
206	(	_	_	I-Premise
207	p	_	_	I-Premise
208	<	_	_	I-Premise
209	0	_	_	I-Premise
210	.	_	_	I-Premise

211	001	_	_	I-Premise
212	)	_	_	I-Premise
213	,	_	_	I-Premise
214	74	_	_	I-Premise
215	.	_	_	I-Premise

216	8	_	_	I-Premise
217	%	_	_	I-Premise
218	vs	_	_	I-Premise
219	89	_	_	I-Premise
220	.	_	_	I-Premise

221	5	_	_	I-Premise
222	%	_	_	I-Premise
223	(	_	_	I-Premise
224	p	_	_	I-Premise
225	=	_	_	I-Premise
226	0	_	_	I-Premise
227	.	_	_	I-Premise

228	05	_	_	I-Premise
229	)	_	_	I-Premise
230	and	_	_	I-Premise
231	81	_	_	I-Premise
232	.	_	_	I-Premise

233	4	_	_	I-Premise
234	%	_	_	I-Premise
235	vs	_	_	I-Premise
236	94	_	_	I-Premise
237	.	_	_	I-Premise

238	7	_	_	I-Premise
239	%	_	_	I-Premise
240	(	_	_	I-Premise
241	p	_	_	I-Premise
242	=	_	_	I-Premise
243	0	_	_	I-Premise
244	.	_	_	I-Premise

245	027	_	_	I-Premise
246	)	_	_	I-Premise
247	,	_	_	I-Premise
248	and	_	_	I-Premise
249	the	_	_	I-Premise
250	quality	_	_	I-Premise
251	of	_	_	I-Premise
252	life	_	_	I-Premise
253	score	_	_	I-Premise
254	was	_	_	I-Premise
255	80	_	_	I-Premise
256	.	_	_	I-Premise

257	4	_	_	I-Premise
258	vs	_	_	I-Premise
259	90	_	_	I-Premise
260	.	_	_	I-Premise

261	3	_	_	I-Premise
262	(	_	_	I-Premise
263	p	_	_	I-Premise
264	<	_	_	I-Premise
265	0	_	_	I-Premise
266	.	_	_	I-Premise

267	001	_	_	I-Premise
268	)	_	_	I-Premise
269	,	_	_	I-Premise
270	85	_	_	I-Premise
271	.	_	_	I-Premise

272	4	_	_	I-Premise
273	vs	_	_	I-Premise
274	91	_	_	I-Premise
275	.	_	_	I-Premise

276	7	_	_	I-Premise
277	(	_	_	I-Premise
278	p	_	_	I-Premise
279	=	_	_	I-Premise
280	0	_	_	I-Premise
281	.	_	_	I-Premise

282	016	_	_	I-Premise
283	)	_	_	I-Premise
284	and	_	_	I-Premise
285	86	_	_	I-Premise
286	.	_	_	I-Premise

287	0	_	_	I-Premise
288	vs	_	_	I-Premise
289	93	_	_	I-Premise
290	.	_	_	I-Premise

291	8	_	_	I-Premise
292	(	_	_	I-Premise
293	p	_	_	I-Premise
294	=	_	_	I-Premise
295	0	_	_	I-Premise
296	.	_	_	I-Premise

297	001	_	_	I-Premise
298	)	_	_	I-Premise
299	,	_	_	I-Premise
300	respectively	_	_	I-Premise
301	.	_	_	I-Premise

302	We	_	_	B-Premise
303	noted	_	_	I-Premise
304	significantly	_	_	I-Premise
305	less	_	_	I-Premise
306	urine	_	_	I-Premise
307	loss	_	_	I-Premise
308	,	_	_	I-Premise
309	higher	_	_	I-Premise
310	objective	_	_	I-Premise
311	and	_	_	I-Premise
312	social	_	_	I-Premise
313	continence	_	_	I-Premise
314	rates	_	_	I-Premise
315	,	_	_	I-Premise
316	and	_	_	I-Premise
317	higher	_	_	I-Premise
318	quality	_	_	I-Premise
319	of	_	_	I-Premise
320	life	_	_	I-Premise
321	scores	_	_	I-Premise
322	after	_	_	I-Premise
323	complete	_	_	I-Premise
324	bladder	_	_	I-Premise
325	neck	_	_	I-Premise
326	preservation	_	_	I-Premise
327	at	_	_	I-Premise
328	all	_	_	I-Premise
329	followup	_	_	I-Premise
330	points	_	_	I-Premise
331	.	_	_	I-Premise

332	On	_	_	O
333	multiple	_	_	O
334	logistic	_	_	O
335	regression	_	_	O
336	analysis	_	_	O
337	complete	_	_	O
338	bladder	_	_	O
339	neck	_	_	O
340	preservation	_	_	O
341	was	_	_	O
342	an	_	_	O
343	independent	_	_	O
344	positive	_	_	O
345	predictor	_	_	O
346	of	_	_	O
347	continence	_	_	O
348	.	_	_	O

349	No	_	_	B-Premise
350	significant	_	_	I-Premise
351	difference	_	_	I-Premise
352	was	_	_	I-Premise
353	found	_	_	I-Premise
354	in	_	_	I-Premise
355	surgical	_	_	I-Premise
356	margin	_	_	I-Premise
357	status	_	_	I-Premise
358	between	_	_	I-Premise
359	the	_	_	I-Premise
360	control	_	_	I-Premise
361	and	_	_	I-Premise
362	bladder	_	_	I-Premise
363	neck	_	_	I-Premise
364	preservation	_	_	I-Premise
365	groups	_	_	I-Premise
366	(	_	_	I-Premise
367	12	_	_	I-Premise
368	.	_	_	I-Premise

369	5	_	_	I-Premise
370	%	_	_	I-Premise
371	vs	_	_	I-Premise
372	14	_	_	I-Premise
373	.	_	_	I-Premise

374	7	_	_	I-Premise
375	%	_	_	I-Premise
376	,	_	_	I-Premise
377	p	_	_	I-Premise
378	=	_	_	I-Premise
379	0	_	_	I-Premise
380	.	_	_	I-Premise

381	65	_	_	I-Premise
382	)	_	_	I-Premise
383	.	_	_	I-Premise

384	In	_	_	B-Claim
385	what	_	_	I-Claim
386	is	_	_	I-Claim
387	to	_	_	I-Claim
388	our	_	_	I-Claim
389	knowledge	_	_	I-Claim
390	the	_	_	I-Claim
391	first	_	_	I-Claim
392	prospective	_	_	I-Claim
393	,	_	_	I-Claim
394	randomized	_	_	I-Claim
395	,	_	_	I-Claim
396	controlled	_	_	I-Claim
397	,	_	_	I-Claim
398	single	_	_	I-Claim
399	blind	_	_	I-Claim
400	trial	_	_	I-Claim
401	complete	_	_	I-Claim
402	bladder	_	_	I-Claim
403	neck	_	_	I-Claim
404	preservation	_	_	I-Claim
405	during	_	_	I-Claim
406	radical	_	_	I-Claim
407	prostatectomy	_	_	I-Claim
408	was	_	_	I-Claim
409	associated	_	_	I-Claim
410	with	_	_	I-Claim
411	a	_	_	I-Claim
412	significantly	_	_	I-Claim
413	higher	_	_	I-Claim
414	urinary	_	_	I-Claim
415	continence	_	_	I-Claim
416	rate	_	_	I-Claim
417	and	_	_	I-Claim
418	increased	_	_	I-Claim
419	patient	_	_	I-Claim
420	satisfaction	_	_	I-Claim
421	without	_	_	I-Claim
422	compromising	_	_	I-Claim
423	resection	_	_	I-Claim
424	margins	_	_	I-Claim
425	.	_	_	I-Claim


0	Implant	_	_	O
1	-	_	_	O
2	based	_	_	O
3	reconstruction	_	_	O
4	is	_	_	O
5	performed	_	_	O
6	in	_	_	O
7	the	_	_	O
8	majority	_	_	O
9	of	_	_	O
10	women	_	_	O
11	offered	_	_	O
12	primary	_	_	O
13	reconstruction	_	_	O
14	for	_	_	O
15	breast	_	_	O
16	cancer	_	_	O
17	.	_	_	O

18	Two	_	_	O
19	different	_	_	O
20	expander	_	_	O
21	implants	_	_	O
22	were	_	_	O
23	compared	_	_	O
24	prospectively	_	_	O
25	.	_	_	O

26	The	_	_	O
27	primary	_	_	O
28	endpoint	_	_	O
29	was	_	_	O
30	the	_	_	O
31	number	_	_	O
32	of	_	_	O
33	operations	_	_	O
34	needed	_	_	O
35	in	_	_	O
36	each	_	_	O
37	group	_	_	O
38	to	_	_	O
39	obtain	_	_	O
40	patient	_	_	O
41	satisfaction	_	_	O
42	.	_	_	O

43	Secondary	_	_	O
44	endpoints	_	_	O
45	were	_	_	O
46	evaluation	_	_	O
47	of	_	_	O
48	breast	_	_	O
49	volume	_	_	O
50	and	_	_	O
51	shape	_	_	O
52	and	_	_	O
53	aspects	_	_	O
54	of	_	_	O
55	quality	_	_	O
56	of	_	_	O
57	life	_	_	O
58	.	_	_	O

59	Seventy	_	_	O
60	consecutive	_	_	O
61	breast	_	_	O
62	cancer	_	_	O
63	patients	_	_	O
64	were	_	_	O
65	randomized	_	_	O
66	to	_	_	O
67	either	_	_	O
68	a	_	_	O
69	one	_	_	O
70	-	_	_	O
71	stage	_	_	O
72	reconstruction	_	_	O
73	with	_	_	O
74	a	_	_	O
75	round	_	_	O
76	permanent	_	_	O
77	expander	_	_	O
78	implant	_	_	O
79	(	_	_	O
80	Becker	_	_	O
81	25	_	_	O
82	;	_	_	O
83	n	_	_	O
84	=	_	_	O
85	35	_	_	O
86	)	_	_	O
87	or	_	_	O
88	a	_	_	O
89	two	_	_	O
90	-	_	_	O
91	stage	_	_	O
92	reconstruction	_	_	O
93	with	_	_	O
94	a	_	_	O
95	crescent	_	_	O
96	-	_	_	O
97	shaped	_	_	O
98	expander	_	_	O
99	(	_	_	O
100	LV	_	_	O
101	133	_	_	O
102	;	_	_	O
103	n	_	_	O
104	=	_	_	O
105	35	_	_	O
106	)	_	_	O
107	,	_	_	O
108	later	_	_	O
109	replaced	_	_	O
110	by	_	_	O
111	a	_	_	O
112	form	_	_	O
113	-	_	_	O
114	stable	_	_	O
115	anatomical	_	_	O
116	implant	_	_	O
117	.	_	_	O

118	Thirty	_	_	O
119	patients	_	_	O
120	had	_	_	O
121	to	_	_	O
122	be	_	_	O
123	excluded	_	_	O
124	and	_	_	O
125	40	_	_	O
126	patients	_	_	O
127	,	_	_	O
128	20	_	_	O
129	in	_	_	O
130	each	_	_	O
131	group	_	_	O
132	,	_	_	O
133	were	_	_	O
134	evaluated	_	_	O
135	.	_	_	O

136	The	_	_	O
137	median	_	_	O
138	follow	_	_	O
139	-	_	_	O
140	up	_	_	O
141	for	_	_	O
142	both	_	_	O
143	groups	_	_	O
144	was	_	_	O
145	3	_	_	O
146	.	_	_	O

147	5	_	_	O
148	years	_	_	O
149	(	_	_	O
150	range	_	_	O
151	,	_	_	O
152	1	_	_	O
153	.	_	_	O

154	5	_	_	O
155	to	_	_	O
156	5	_	_	O
157	years	_	_	O
158	)	_	_	O
159	.	_	_	O

160	Plastic	_	_	O
161	cups	_	_	O
162	,	_	_	O
163	plastic	_	_	O
164	casts	_	_	O
165	,	_	_	O
166	and	_	_	O
167	two	_	_	O
168	-	_	_	O
169	and	_	_	O
170	three	_	_	O
171	-	_	_	O
172	dimensional	_	_	O
173	scanning	_	_	O
174	techniques	_	_	O
175	were	_	_	O
176	used	_	_	O
177	for	_	_	O
178	objective	_	_	O
179	assessment	_	_	O
180	of	_	_	O
181	breast	_	_	O
182	volume	_	_	O
183	and	_	_	O
184	shape	_	_	O
185	.	_	_	O

186	The	_	_	O
187	aesthetic	_	_	O
188	outcome	_	_	O
189	was	_	_	O
190	evaluated	_	_	O
191	by	_	_	O
192	a	_	_	O
193	panel	_	_	O
194	of	_	_	O
195	experts	_	_	O
196	and	_	_	O
197	lay	_	_	O
198	people	_	_	O
199	,	_	_	O
200	and	_	_	O
201	by	_	_	O
202	the	_	_	O
203	patients	_	_	O
204	.	_	_	O

205	Quality	_	_	O
206	of	_	_	O
207	life	_	_	O
208	was	_	_	O
209	evaluated	_	_	O
210	with	_	_	O
211	a	_	_	O
212	validated	_	_	O
213	questionnaire	_	_	O
214	(	_	_	O
215	36	_	_	O
216	-	_	_	O
217	Item	_	_	O
218	Short	_	_	O
219	Form	_	_	O
220	Health	_	_	O
221	Survey	_	_	O
222	)	_	_	O
223	.	_	_	O

224	Of	_	_	B-Premise
225	the	_	_	I-Premise
226	patients	_	_	I-Premise
227	in	_	_	I-Premise
228	the	_	_	I-Premise
229	one	_	_	I-Premise
230	-	_	_	I-Premise
231	stage	_	_	I-Premise
232	group	_	_	I-Premise
233	,	_	_	I-Premise
234	70	_	_	I-Premise
235	percent	_	_	I-Premise
236	had	_	_	I-Premise
237	revision	_	_	I-Premise
238	surgery	_	_	I-Premise
239	,	_	_	I-Premise
240	mostly	_	_	I-Premise
241	because	_	_	I-Premise
242	of	_	_	I-Premise
243	upper	_	_	I-Premise
244	pole	_	_	I-Premise
245	fullness	_	_	I-Premise
246	and	_	_	I-Premise
247	poor	_	_	I-Premise
248	ptosis	_	_	I-Premise
249	.	_	_	I-Premise

250	These	_	_	O
251	findings	_	_	O
252	agreed	_	_	O
253	with	_	_	O
254	the	_	_	O
255	data	_	_	O
256	from	_	_	O
257	the	_	_	O
258	two	_	_	O
259	-	_	_	O
260	dimensional	_	_	O
261	scanning	_	_	O
262	and	_	_	O
263	from	_	_	O
264	the	_	_	O
265	expert	_	_	O
266	panel	_	_	O
267	and	_	_	O
268	the	_	_	O
269	patients	_	_	O
270	'	_	_	O
271	subjective	_	_	O
272	judgment	_	_	O
273	.	_	_	O

274	Quality	_	_	B-Premise
275	of	_	_	I-Premise
276	life	_	_	I-Premise
277	was	_	_	I-Premise
278	similar	_	_	I-Premise
279	in	_	_	I-Premise
280	the	_	_	I-Premise
281	two	_	_	I-Premise
282	groups	_	_	I-Premise
283	.	_	_	I-Premise

284	The	_	_	B-Claim
285	permanent	_	_	I-Claim
286	expander	_	_	I-Claim
287	method	_	_	I-Claim
288	failed	_	_	I-Claim
289	significantly	_	_	I-Claim
290	as	_	_	I-Claim
291	a	_	_	I-Claim
292	one	_	_	I-Claim
293	-	_	_	I-Claim
294	stage	_	_	I-Claim
295	procedure	_	_	I-Claim
296	.	_	_	I-Claim

297	The	_	_	B-Claim
298	crescent	_	_	I-Claim
299	two	_	_	I-Claim
300	-	_	_	I-Claim
301	stage	_	_	I-Claim
302	method	_	_	I-Claim
303	gave	_	_	I-Claim
304	the	_	_	I-Claim
305	most	_	_	I-Claim
306	acceptable	_	_	I-Claim
307	results	_	_	I-Claim
308	both	_	_	I-Claim
309	objectively	_	_	I-Claim
310	and	_	_	I-Claim
311	subjectively	_	_	I-Claim
312	.	_	_	I-Claim


0	This	_	_	O
1	analysis	_	_	O
2	of	_	_	O
3	the	_	_	O
4	results	_	_	O
5	of	_	_	O
6	a	_	_	O
7	randomized	_	_	O
8	,	_	_	O
9	controlled	_	_	O
10	trial	_	_	O
11	evaluating	_	_	O
12	the	_	_	O
13	effects	_	_	O
14	of	_	_	O
15	epoetin	_	_	O
16	alfa	_	_	O
17	(	_	_	O
18	EPO	_	_	O
19	)	_	_	O
20	therapy	_	_	O
21	on	_	_	O
22	transfusion	_	_	O
23	requirements	_	_	O
24	,	_	_	O
25	hemoglobin	_	_	O
26	(	_	_	O
27	Hb	_	_	O
28	)	_	_	O
29	,	_	_	O
30	and	_	_	O
31	quality	_	_	O
32	of	_	_	O
33	life	_	_	O
34	(	_	_	O
35	QOL	_	_	O
36	)	_	_	O
37	in	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	cancer	_	_	O
41	receiving	_	_	O
42	platinum	_	_	O
43	-	_	_	O
44	based	_	_	O
45	chemotherapy	_	_	O
46	was	_	_	O
47	conducted	_	_	O
48	to	_	_	O
49	evaluate	_	_	O
50	the	_	_	O
51	effect	_	_	O
52	of	_	_	O
53	initial	_	_	O
54	Hb	_	_	O
55	level	_	_	O
56	on	_	_	O
57	study	_	_	O
58	outcomes	_	_	O
59	.	_	_	O

60	Patients	_	_	O
61	with	_	_	O
62	Hb	_	_	O
63	levels	_	_	O
64	<	_	_	O
65	or	_	_	O
66	=	_	_	O
67	12	_	_	O
68	.	_	_	O

69	1	_	_	O
70	g	_	_	O
71	/	_	_	O
72	dl	_	_	O
73	were	_	_	O
74	randomized	_	_	O
75	2	_	_	O
76	:	_	_	O
77	1	_	_	O
78	to	_	_	O
79	receive	_	_	O
80	EPO	_	_	O
81	,	_	_	O
82	10	_	_	O
83	,	_	_	O
84	000	_	_	O
85	U	_	_	O
86	three	_	_	O
87	times	_	_	O
88	weekly	_	_	O
89	s	_	_	O
90	.	_	_	O

91	c	_	_	O
92	.	_	_	O

93	or	_	_	O
94	best	_	_	O
95	supportive	_	_	O
96	care	_	_	O
97	(	_	_	O
98	BSC	_	_	O
99	)	_	_	O
100	until	_	_	O
101	4	_	_	O
102	weeks	_	_	O
103	after	_	_	O
104	their	_	_	O
105	last	_	_	O
106	chemotherapy	_	_	O
107	cycle	_	_	O
108	.	_	_	O

109	For	_	_	O
110	this	_	_	O
111	analysis	_	_	O
112	,	_	_	O
113	patients	_	_	O
114	were	_	_	O
115	stratified	_	_	O
116	by	_	_	O
117	baseline	_	_	O
118	Hb	_	_	O
119	level	_	_	O
120	(	_	_	O
121	<	_	_	O
122	or	_	_	O
123	=	_	_	O
124	9	_	_	O
125	.	_	_	O

126	7	_	_	O
127	g	_	_	O
128	/	_	_	O
129	dl	_	_	O
130	,	_	_	O
131	>	_	_	O
132	9	_	_	O
133	.	_	_	O

134	7	_	_	O
135	g	_	_	O
136	/	_	_	O
137	dl	_	_	O
138	to	_	_	O
139	<	_	_	O
140	or	_	_	O
141	=	_	_	O
142	10	_	_	O
143	.	_	_	O

144	5	_	_	O
145	g	_	_	O
146	/	_	_	O
147	dl	_	_	O
148	,	_	_	O
149	>	_	_	O
150	10	_	_	O
151	.	_	_	O

152	5	_	_	O
153	g	_	_	O
154	/	_	_	O
155	dl	_	_	O
156	to	_	_	O
157	<	_	_	O
158	or	_	_	O
159	=	_	_	O
160	11	_	_	O
161	.	_	_	O

162	3	_	_	O
163	g	_	_	O
164	/	_	_	O
165	dl	_	_	O
166	,	_	_	O
167	and	_	_	O
168	>	_	_	O
169	11	_	_	O
170	.	_	_	O

171	3	_	_	O
172	g	_	_	O
173	/	_	_	O
174	dl	_	_	O
175	to	_	_	O
176	<	_	_	O
177	or	_	_	O
178	=	_	_	O
179	12	_	_	O
180	.	_	_	O

181	1	_	_	O
182	g	_	_	O
183	/	_	_	O
184	dl	_	_	O
185	)	_	_	O
186	,	_	_	O
187	and	_	_	O
188	study	_	_	O
189	results	_	_	O
190	were	_	_	O
191	reanalyzed	_	_	O
192	.	_	_	O

193	Significantly	_	_	B-Premise
194	fewer	_	_	I-Premise
195	EPO	_	_	I-Premise
196	patients	_	_	I-Premise
197	than	_	_	I-Premise
198	BSC	_	_	I-Premise
199	patients	_	_	I-Premise
200	with	_	_	I-Premise
201	initial	_	_	I-Premise
202	Hb	_	_	I-Premise
203	levels	_	_	I-Premise
204	>	_	_	I-Premise
205	9	_	_	I-Premise
206	.	_	_	I-Premise

207	7	_	_	I-Premise
208	g	_	_	I-Premise
209	/	_	_	I-Premise
210	dl	_	_	I-Premise
211	to	_	_	I-Premise
212	<	_	_	I-Premise
213	or	_	_	I-Premise
214	=	_	_	I-Premise
215	12	_	_	I-Premise
216	.	_	_	I-Premise

217	1	_	_	I-Premise
218	g	_	_	I-Premise
219	/	_	_	I-Premise
220	dl	_	_	I-Premise
221	required	_	_	I-Premise
222	transfusions	_	_	I-Premise
223	.	_	_	I-Premise

224	EPO	_	_	B-Premise
225	maintained	_	_	I-Premise
226	Hb	_	_	I-Premise
227	levels	_	_	I-Premise
228	throughout	_	_	I-Premise
229	the	_	_	I-Premise
230	study	_	_	I-Premise
231	for	_	_	I-Premise
232	patients	_	_	I-Premise
233	with	_	_	I-Premise
234	Hb	_	_	I-Premise
235	levels	_	_	I-Premise
236	>	_	_	I-Premise
237	11	_	_	I-Premise
238	.	_	_	I-Premise

239	3	_	_	I-Premise
240	g	_	_	I-Premise
241	/	_	_	I-Premise
242	dl	_	_	I-Premise
243	to	_	_	I-Premise
244	<	_	_	I-Premise
245	or	_	_	I-Premise
246	=	_	_	I-Premise
247	12	_	_	I-Premise
248	.	_	_	I-Premise

249	1	_	_	I-Premise
250	g	_	_	I-Premise
251	/	_	_	I-Premise
252	dl	_	_	I-Premise
253	,	_	_	I-Premise
254	compared	_	_	I-Premise
255	with	_	_	I-Premise
256	a	_	_	I-Premise
257	decrease	_	_	I-Premise
258	with	_	_	I-Premise
259	BSC	_	_	I-Premise
260	.	_	_	I-Premise

261	For	_	_	B-Premise
262	patients	_	_	I-Premise
263	with	_	_	I-Premise
264	baseline	_	_	I-Premise
265	Hb	_	_	I-Premise
266	levels	_	_	I-Premise
267	>	_	_	I-Premise
268	10	_	_	I-Premise
269	.	_	_	I-Premise

270	5	_	_	I-Premise
271	g	_	_	I-Premise
272	/	_	_	I-Premise
273	dl	_	_	I-Premise
274	,	_	_	I-Premise
275	for	_	_	I-Premise
276	whom	_	_	I-Premise
277	the	_	_	I-Premise
278	mean	_	_	I-Premise
279	changes	_	_	I-Premise
280	from	_	_	I-Premise
281	baseline	_	_	I-Premise
282	to	_	_	I-Premise
283	last	_	_	I-Premise
284	assessment	_	_	I-Premise
285	were	_	_	I-Premise
286	measured	_	_	I-Premise
287	by	_	_	I-Premise
288	the	_	_	I-Premise
289	Cancer	_	_	I-Premise
290	Linear	_	_	I-Premise
291	Analogue	_	_	I-Premise
292	Scale	_	_	I-Premise
293	assessments	_	_	I-Premise
294	of	_	_	I-Premise
295	energy	_	_	I-Premise
296	and	_	_	I-Premise
297	overall	_	_	I-Premise
298	QOL	_	_	I-Premise
299	as	_	_	I-Premise
300	well	_	_	I-Premise
301	as	_	_	I-Premise
302	by	_	_	I-Premise
303	the	_	_	I-Premise
304	Functional	_	_	I-Premise
305	Assessment	_	_	I-Premise
306	of	_	_	I-Premise
307	Cancer	_	_	I-Premise
308	Therapy	_	_	I-Premise
309	(	_	_	I-Premise
310	FACT	_	_	I-Premise
311	)	_	_	I-Premise
312	-	_	_	I-Premise
313	Fatigue	_	_	I-Premise
314	and	_	_	I-Premise
315	FACT	_	_	I-Premise
316	-	_	_	I-Premise
317	An	_	_	I-Premise
318	Anemia	_	_	I-Premise
319	subscale	_	_	I-Premise
320	,	_	_	I-Premise
321	QOL	_	_	I-Premise
322	scores	_	_	I-Premise
323	were	_	_	I-Premise
324	significantly	_	_	I-Premise
325	greater	_	_	I-Premise
326	with	_	_	I-Premise
327	EPO	_	_	I-Premise
328	than	_	_	I-Premise
329	with	_	_	I-Premise
330	BSC	_	_	I-Premise
331	.	_	_	I-Premise

332	QOL	_	_	B-Premise
333	declined	_	_	I-Premise
334	in	_	_	I-Premise
335	patients	_	_	I-Premise
336	receiving	_	_	I-Premise
337	BSC	_	_	I-Premise
338	,	_	_	I-Premise
339	and	_	_	O
340	the	_	_	B-Premise
341	mean	_	_	I-Premise
342	decreases	_	_	I-Premise
343	in	_	_	I-Premise
344	QOL	_	_	I-Premise
345	scores	_	_	I-Premise
346	were	_	_	I-Premise
347	greater	_	_	I-Premise
348	for	_	_	I-Premise
349	BSC	_	_	I-Premise
350	patients	_	_	I-Premise
351	with	_	_	I-Premise
352	baseline	_	_	I-Premise
353	Hb	_	_	I-Premise
354	levels	_	_	I-Premise
355	>	_	_	I-Premise
356	10	_	_	I-Premise
357	.	_	_	I-Premise

358	5	_	_	I-Premise
359	g	_	_	I-Premise
360	/	_	_	I-Premise
361	dl	_	_	I-Premise
362	,	_	_	I-Premise
363	compared	_	_	I-Premise
364	with	_	_	I-Premise
365	the	_	_	I-Premise
366	overall	_	_	I-Premise
367	BSC	_	_	I-Premise
368	group	_	_	I-Premise
369	.	_	_	I-Premise

370	In	_	_	B-Claim
371	patients	_	_	I-Claim
372	with	_	_	I-Claim
373	cancer	_	_	I-Claim
374	receiving	_	_	I-Claim
375	platinum	_	_	I-Claim
376	-	_	_	I-Claim
377	based	_	_	I-Claim
378	chemotherapy	_	_	I-Claim
379	and	_	_	I-Claim
380	with	_	_	I-Claim
381	baseline	_	_	I-Claim
382	Hb	_	_	I-Claim
383	levels	_	_	I-Claim
384	>	_	_	I-Claim
385	10	_	_	I-Claim
386	.	_	_	I-Claim

387	5	_	_	I-Claim
388	g	_	_	I-Claim
389	/	_	_	I-Claim
390	dl	_	_	I-Claim
391	,	_	_	I-Claim
392	early	_	_	I-Claim
393	intervention	_	_	I-Claim
394	with	_	_	I-Claim
395	EPO	_	_	I-Claim
396	reduces	_	_	I-Claim
397	transfusions	_	_	I-Claim
398	,	_	_	I-Claim
399	maintains	_	_	I-Claim
400	Hb	_	_	I-Claim
401	level	_	_	I-Claim
402	,	_	_	I-Claim
403	and	_	_	I-Claim
404	maintains	_	_	I-Claim
405	or	_	_	I-Claim
406	improves	_	_	I-Claim
407	QOL	_	_	I-Claim
408	.	_	_	I-Claim

409	This	_	_	B-Claim
410	study	_	_	I-Claim
411	supports	_	_	I-Claim
412	the	_	_	I-Claim
413	positive	_	_	I-Claim
414	effects	_	_	I-Claim
415	of	_	_	I-Claim
416	early	_	_	I-Claim
417	intervention	_	_	I-Claim
418	when	_	_	I-Claim
419	analyzed	_	_	I-Claim
420	according	_	_	I-Claim
421	to	_	_	I-Claim
422	initial	_	_	I-Claim
423	Hb	_	_	I-Claim
424	value	_	_	I-Claim
425	.	_	_	I-Claim


0	To	_	_	O
1	observe	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	Chinese	_	_	O
6	medicine	_	_	O
7	(	_	_	O
8	CM	_	_	O
9	)	_	_	O
10	comprehensive	_	_	O
11	regimen	_	_	O
12	as	_	_	O
13	the	_	_	O
14	maintenance	_	_	O
15	therapy	_	_	O
16	(	_	_	O
17	MT	_	_	O
18	)	_	_	O
19	on	_	_	O
20	time	_	_	O
21	to	_	_	O
22	progression	_	_	O
23	(	_	_	O
24	TTP	_	_	O
25	)	_	_	O
26	and	_	_	O
27	quality	_	_	O
28	of	_	_	O
29	life	_	_	O
30	(	_	_	O
31	QOL	_	_	O
32	)	_	_	O
33	of	_	_	O
34	patients	_	_	O
35	with	_	_	O
36	advanced	_	_	O
37	non	_	_	O
38	-	_	_	O
39	small	_	_	O
40	-	_	_	O
41	cell	_	_	O
42	lung	_	_	O
43	cancer	_	_	O
44	(	_	_	O
45	NSCLC	_	_	O
46	)	_	_	O
47	.	_	_	O

48	The	_	_	O
49	study	_	_	O
50	was	_	_	O
51	a	_	_	O
52	prospective	_	_	O
53	,	_	_	O
54	randomized	_	_	O
55	and	_	_	O
56	controlled	_	_	O
57	clinical	_	_	O
58	trial	_	_	O
59	.	_	_	O

60	Fifty	_	_	O
61	non	_	_	O
62	-	_	_	O
63	progressive	_	_	O
64	patients	_	_	O
65	with	_	_	O
66	advanced	_	_	O
67	NSCLC	_	_	O
68	who	_	_	O
69	responded	_	_	O
70	to	_	_	O
71	first	_	_	O
72	-	_	_	O
73	line	_	_	O
74	therapy	_	_	O
75	were	_	_	O
76	randomized	_	_	O
77	into	_	_	O
78	the	_	_	O
79	test	_	_	O
80	group	_	_	O
81	(	_	_	O
82	25	_	_	O
83	cases	_	_	O
84	,	_	_	O
85	treated	_	_	O
86	with	_	_	O
87	CM	_	_	O
88	comprehensive	_	_	O
89	regimen	_	_	O
90	:	_	_	O
91	intravenous	_	_	O
92	dripping	_	_	O
93	of	_	_	O
94	Chinese	_	_	O
95	herbal	_	_	O
96	preparation	_	_	O
97	,	_	_	O
98	oral	_	_	O
99	administration	_	_	O
100	of	_	_	O
101	Chinese	_	_	O
102	herbal	_	_	O
103	decoction	_	_	O
104	,	_	_	O
105	and	_	_	O
106	point	_	_	O
107	application	_	_	O
108	)	_	_	O
109	and	_	_	O
110	the	_	_	O
111	control	_	_	O
112	group	_	_	O
113	[	_	_	O
114	25	_	_	O
115	cases	_	_	O
116	,	_	_	O
117	treated	_	_	O
118	with	_	_	O
119	one	_	_	O
120	of	_	_	O
121	three	_	_	O
122	single	_	_	O
123	-	_	_	O
124	agent	_	_	O
125	maintenance	_	_	O
126	chemotherapy	_	_	O
127	regimens	_	_	O
128	:	_	_	O
129	pemetrexed	_	_	O
130	(	_	_	O
131	500	_	_	O
132	mg	_	_	O
133	/	_	_	O
134	m2	_	_	O
135	,	_	_	O
136	day	_	_	O
137	1	_	_	O
138	)	_	_	O
139	,	_	_	O
140	docetaxel	_	_	O
141	(	_	_	O
142	75	_	_	O
143	mg	_	_	O
144	/	_	_	O
145	m2	_	_	O
146	,	_	_	O
147	day	_	_	O
148	1	_	_	O
149	)	_	_	O
150	,	_	_	O
151	and	_	_	O
152	gemcitabine	_	_	O
153	(	_	_	O
154	1000	_	_	O
155	mg	_	_	O
156	/	_	_	O
157	mi	_	_	O
158	,	_	_	O
159	day	_	_	O
160	1	_	_	O
161	and	_	_	O
162	day	_	_	O
163	8	_	_	O
164	)	_	_	O
165	in	_	_	O
166	the	_	_	O
167	ratio	_	_	O
168	of	_	_	O
169	1	_	_	O
170	:	_	_	O
171	1	_	_	O
172	]	_	_	O
173	.	_	_	O

174	Each	_	_	O
175	cycle	_	_	O
176	consisted	_	_	O
177	of	_	_	O
178	21	_	_	O
179	days	_	_	O
180	.	_	_	O

181	Cycles	_	_	O
182	were	_	_	O
183	repeated	_	_	O
184	until	_	_	O
185	the	_	_	O
186	disease	_	_	O
187	progressed	_	_	O
188	,	_	_	O
189	or	_	_	O
190	intolerable	_	_	O
191	toxic	_	_	O
192	or	_	_	O
193	adverse	_	_	O
194	reaction	_	_	O
195	occurred	_	_	O
196	,	_	_	O
197	or	_	_	O
198	patients	_	_	O
199	refused	_	_	O
200	to	_	_	O
201	continue	_	_	O
202	the	_	_	O
203	treatment	_	_	O
204	.	_	_	O

205	The	_	_	O
206	primary	_	_	O
207	end	_	_	O
208	point	_	_	O
209	was	_	_	O
210	TTP	_	_	O
211	and	_	_	O
212	the	_	_	O
213	secondary	_	_	O
214	end	_	_	O
215	point	_	_	O
216	was	_	_	O
217	QOL	_	_	O
218	.	_	_	O

219	QOL	_	_	O
220	was	_	_	O
221	evaluated	_	_	O
222	using	_	_	O
223	the	_	_	O
224	European	_	_	O
225	Organization	_	_	O
226	for	_	_	O
227	Research	_	_	O
228	and	_	_	O
229	Treatment	_	_	O
230	of	_	_	O
231	Cancer	_	_	O
232	quality	_	_	O
233	-	_	_	O
234	of	_	_	O
235	-	_	_	O
236	life	_	_	O
237	questionnaire	_	_	O
238	QLQ	_	_	O
239	-	_	_	O
240	LC43	_	_	O
241	(	_	_	O
242	EORTC	_	_	O
243	QLQ	_	_	O
244	-	_	_	O
245	LC43	_	_	O
246	)	_	_	O
247	.	_	_	O

248	TTP	_	_	O
249	of	_	_	O
250	fifty	_	_	O
251	patients	_	_	O
252	and	_	_	O
253	QOL	_	_	O
254	of	_	_	O
255	43	_	_	O
256	patients	_	_	O
257	had	_	_	O
258	been	_	_	O
259	statistically	_	_	O
260	analyzed	_	_	O
261	.	_	_	O

262	(	_	_	O
263	1	_	_	O
264	)	_	_	O
265	The	_	_	B-Premise
266	TTP	_	_	I-Premise
267	in	_	_	I-Premise
268	the	_	_	I-Premise
269	test	_	_	I-Premise
270	group	_	_	I-Premise
271	was	_	_	I-Premise
272	prolonged	_	_	I-Premise
273	for	_	_	I-Premise
274	23	_	_	I-Premise
275	days	_	_	I-Premise
276	when	_	_	I-Premise
277	compared	_	_	I-Premise
278	with	_	_	I-Premise
279	that	_	_	I-Premise
280	of	_	_	I-Premise
281	the	_	_	I-Premise
282	control	_	_	I-Premise
283	group	_	_	I-Premise
284	,	_	_	I-Premise
285	with	_	_	I-Premise
286	insignificant	_	_	I-Premise
287	difference	_	_	I-Premise
288	(	_	_	I-Premise
289	87	_	_	I-Premise
290	days	_	_	I-Premise
291	vs	_	_	I-Premise
292	64	_	_	I-Premise
293	days	_	_	I-Premise
294	,	_	_	I-Premise
295	P	_	_	I-Premise
296	=	_	_	I-Premise
297	0	_	_	I-Premise
298	.	_	_	I-Premise

299	063	_	_	I-Premise
300	)	_	_	I-Premise
301	.	_	_	I-Premise

302	(	_	_	O
303	2	_	_	O
304	)	_	_	O
305	The	_	_	B-Premise
306	scores	_	_	I-Premise
307	of	_	_	I-Premise
308	domains	_	_	I-Premise
309	in	_	_	I-Premise
310	EORTC	_	_	I-Premise
311	QLQ	_	_	I-Premise
312	-	_	_	I-Premise
313	LC43	_	_	I-Premise
314	were	_	_	I-Premise
315	statistically	_	_	I-Premise
316	significantly	_	_	I-Premise
317	better	_	_	I-Premise
318	in	_	_	I-Premise
319	the	_	_	I-Premise
320	test	_	_	I-Premise
321	group	_	_	I-Premise
322	than	_	_	I-Premise
323	in	_	_	I-Premise
324	the	_	_	I-Premise
325	control	_	_	I-Premise
326	group	_	_	I-Premise
327	(	_	_	I-Premise
328	P	_	_	I-Premise
329	<	_	_	I-Premise
330	0	_	_	I-Premise
331	.	_	_	I-Premise

332	05	_	_	I-Premise
333	)	_	_	I-Premise
334	except	_	_	B-Premise
335	cognitive	_	_	I-Premise
336	and	_	_	I-Premise
337	social	_	_	I-Premise
338	functions	_	_	I-Premise
339	,	_	_	I-Premise
340	the	_	_	I-Premise
341	symptoms	_	_	I-Premise
342	of	_	_	I-Premise
343	dysphagia	_	_	I-Premise
344	and	_	_	I-Premise
345	pain	_	_	I-Premise
346	in	_	_	I-Premise
347	other	_	_	I-Premise
348	parts	_	_	I-Premise
349	.	_	_	I-Premise

350	(	_	_	O
351	1	_	_	O
352	)	_	_	O
353	The	_	_	B-Claim
354	CM	_	_	I-Claim
355	comprehensive	_	_	I-Claim
356	regimen	_	_	I-Claim
357	as	_	_	I-Claim
358	MT	_	_	I-Claim
359	had	_	_	I-Claim
360	equivalent	_	_	I-Claim
361	efficacy	_	_	I-Claim
362	on	_	_	I-Claim
363	TTP	_	_	I-Claim
364	when	_	_	I-Claim
365	compared	_	_	I-Claim
366	with	_	_	I-Claim
367	single	_	_	I-Claim
368	-	_	_	I-Claim
369	agent	_	_	I-Claim
370	maintenance	_	_	I-Claim
371	chemotherapy	_	_	I-Claim
372	regimen	_	_	I-Claim
373	.	_	_	I-Claim

374	It	_	_	B-Claim
375	was	_	_	I-Claim
376	advantageous	_	_	I-Claim
377	over	_	_	I-Claim
378	improving	_	_	I-Claim
379	the	_	_	I-Claim
380	QOL	_	_	I-Claim
381	.	_	_	I-Claim

382	(	_	_	O
383	2	_	_	O
384	)	_	_	O
385	It	_	_	B-Claim
386	is	_	_	I-Claim
387	necessary	_	_	I-Claim
388	to	_	_	I-Claim
389	enlarge	_	_	I-Claim
390	the	_	_	I-Claim
391	sample	_	_	I-Claim
392	size	_	_	I-Claim
393	to	_	_	I-Claim
394	further	_	_	I-Claim
395	confirm	_	_	I-Claim
396	the	_	_	I-Claim
397	therapeutic	_	_	I-Claim
398	efficacy	_	_	I-Claim
399	of	_	_	I-Claim
400	CM	_	_	I-Claim
401	comprehensive	_	_	I-Claim
402	regimen	_	_	I-Claim
403	as	_	_	I-Claim
404	MT	_	_	I-Claim
405	in	_	_	I-Claim
406	treatment	_	_	I-Claim
407	of	_	_	I-Claim
408	patients	_	_	I-Claim
409	with	_	_	I-Claim
410	advanced	_	_	I-Claim
411	NSCLC	_	_	I-Claim
412	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	the	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	response	_	_	O
9	rate	_	_	O
10	,	_	_	O
11	clinical	_	_	O
12	outcome	_	_	O
13	,	_	_	O
14	organ	_	_	O
15	/	_	_	O
16	function	_	_	O
17	preservation	_	_	O
18	and	_	_	O
19	toxicity	_	_	O
20	in	_	_	O
21	head	_	_	O
22	and	_	_	O
23	neck	_	_	O
24	cancer	_	_	O
25	patients	_	_	O
26	treated	_	_	O
27	with	_	_	O
28	induction	_	_	O
29	chemotherapy	_	_	O
30	followed	_	_	O
31	by	_	_	O
32	concomitant	_	_	O
33	chemoradiotherapy	_	_	O
34	and	_	_	O
35	,	_	_	O
36	when	_	_	O
37	necessary	_	_	O
38	,	_	_	O
39	limited	_	_	O
40	surgery	_	_	O
41	.	_	_	O

42	The	_	_	O
43	study	_	_	O
44	design	_	_	O
45	was	_	_	O
46	a	_	_	O
47	phase	_	_	O
48	II	_	_	O
49	non	_	_	O
50	-	_	_	O
51	randomized	_	_	O
52	trial	_	_	O
53	in	_	_	O
54	hospitalized	_	_	O
55	patients	_	_	O
56	setting	_	_	O
57	.	_	_	O

58	The	_	_	O
59	treatment	_	_	O
60	plan	_	_	O
61	consisted	_	_	O
62	of	_	_	O
63	3	_	_	O
64	cycles	_	_	O
65	of	_	_	O
66	induction	_	_	O
67	chemotherapy	_	_	O
68	with	_	_	O
69	cisplatin	_	_	O
70	,	_	_	O
71	fluorouracil	_	_	O
72	(	_	_	O
73	5	_	_	O
74	-	_	_	O
75	FU	_	_	O
76	)	_	_	O
77	,	_	_	O
78	l	_	_	O
79	-	_	_	O
80	leucovorin	_	_	O
81	and	_	_	O
82	interferon	_	_	O
83	alpha2b	_	_	O
84	(	_	_	O
85	PFL	_	_	O
86	-	_	_	O
87	IFN	_	_	O
88	)	_	_	O
89	followed	_	_	O
90	by	_	_	O
91	7	_	_	O
92	cycles	_	_	O
93	of	_	_	O
94	5	_	_	O
95	-	_	_	O
96	FU	_	_	O
97	,	_	_	O
98	hydroxyurea	_	_	O
99	and	_	_	O
100	concomitant	_	_	O
101	radiation	_	_	O
102	for	_	_	O
103	5	_	_	O
104	days	_	_	O
105	(	_	_	O
106	FHX	_	_	O
107	)	_	_	O
108	for	_	_	O
109	a	_	_	O
110	total	_	_	O
111	radiation	_	_	O
112	dose	_	_	O
113	of	_	_	O
114	70	_	_	O
115	Gy	_	_	O
116	.	_	_	O

117	13	_	_	O
118	Cis	_	_	O
119	-	_	_	O
120	retinoic	_	_	O
121	acid	_	_	O
122	was	_	_	O
123	added	_	_	O
124	to	_	_	O
125	treatment	_	_	O
126	regimen	_	_	O
127	for	_	_	O
128	chemoprevention	_	_	O
129	and	_	_	O
130	a	_	_	O
131	systematic	_	_	O
132	prophylaxis	_	_	O
133	of	_	_	O
134	mucositis	_	_	O
135	was	_	_	O
136	administered	_	_	O
137	to	_	_	O
138	all	_	_	O
139	patients	_	_	O
140	during	_	_	O
141	FHX	_	_	O
142	.	_	_	O

143	Conservative	_	_	O
144	surgical	_	_	O
145	resection	_	_	O
146	was	_	_	O
147	reserved	_	_	O
148	to	_	_	O
149	patients	_	_	O
150	with	_	_	O
151	no	_	_	O
152	optimal	_	_	O
153	response	_	_	O
154	(	_	_	O
155	PR	_	_	O
156	>	_	_	O
157	or	_	_	O
158	=	_	_	O
159	70	_	_	O
160	%	_	_	O
161	)	_	_	O
162	,	_	_	O
163	whereas	_	_	O
164	radical	_	_	O
165	surgery	_	_	O
166	was	_	_	O
167	performed	_	_	O
168	as	_	_	O
169	salvage	_	_	O
170	treatment	_	_	O
171	.	_	_	O

172	Twenty	_	_	O
173	-	_	_	O
174	six	_	_	O
175	patients	_	_	O
176	were	_	_	O
177	treated	_	_	O
178	at	_	_	O
179	one	_	_	O
180	institution	_	_	O
181	:	_	_	O
182	more	_	_	O
183	than	_	_	O
184	90	_	_	O
185	%	_	_	O
186	had	_	_	O
187	stage	_	_	O
188	IV	_	_	O
189	disease	_	_	O
190	and	_	_	O
191	only	_	_	O
192	19	_	_	O
193	.	_	_	O

194	2	_	_	O
195	%	_	_	O
196	had	_	_	O
197	laryngeal	_	_	O
198	cancer	_	_	O
199	.	_	_	O

200	Eighty	_	_	O
201	-	_	_	O
202	one	_	_	O
203	percent	_	_	O
204	of	_	_	O
205	patients	_	_	O
206	had	_	_	O
207	performance	_	_	O
208	status	_	_	O
209	0	_	_	O
210	and	_	_	O
211	23	_	_	O
212	.	_	_	O

213	1	_	_	O
214	%	_	_	O
215	of	_	_	O
216	patients	_	_	O
217	had	_	_	O
218	>	_	_	O
219	5	_	_	O
220	%	_	_	O
221	weight	_	_	O
222	loss	_	_	O
223	at	_	_	O
224	the	_	_	O
225	start	_	_	O
226	of	_	_	O
227	treatment	_	_	O
228	.	_	_	O

229	Nineteen	_	_	O
230	patients	_	_	O
231	were	_	_	O
232	analyzed	_	_	O
233	for	_	_	O
234	response	_	_	O
235	to	_	_	O
236	PFL	_	_	O
237	-	_	_	O
238	IFN	_	_	O
239	:	_	_	O
240	3	_	_	O
241	/	_	_	O
242	19	_	_	O
243	(	_	_	O
244	15	_	_	O
245	.	_	_	O

246	8	_	_	O
247	%	_	_	O
248	)	_	_	O
249	patients	_	_	O
250	achieved	_	_	O
251	a	_	_	O
252	CR	_	_	O
253	and	_	_	O
254	7	_	_	O
255	/	_	_	O
256	19	_	_	O
257	(	_	_	O
258	36	_	_	O
259	.	_	_	O

260	8	_	_	O
261	%	_	_	O
262	)	_	_	O
263	achieved	_	_	O
264	a	_	_	O
265	PR	_	_	O
266	for	_	_	O
267	an	_	_	O
268	ORR	_	_	O
269	of	_	_	O
270	52	_	_	O
271	.	_	_	O

272	6	_	_	O
273	%	_	_	O
274	.	_	_	O

275	FHX	_	_	O
276	was	_	_	O
277	administered	_	_	O
278	on	_	_	O
279	protocol	_	_	O
280	to	_	_	O
281	12	_	_	O
282	patients	_	_	O
283	:	_	_	O
284	6	_	_	O
285	patients	_	_	O
286	(	_	_	O
287	50	_	_	O
288	%	_	_	O
289	)	_	_	O
290	had	_	_	O
291	CR	_	_	O
292	,	_	_	O
293	1	_	_	O
294	patient	_	_	O
295	(	_	_	O
296	8	_	_	O
297	.	_	_	O

298	3	_	_	O
299	%	_	_	O
300	)	_	_	O
301	had	_	_	O
302	PR	_	_	O
303	for	_	_	O
304	an	_	_	O
305	ORR	_	_	O
306	of	_	_	O
307	58	_	_	O
308	.	_	_	O

309	3	_	_	O
310	%	_	_	O
311	,	_	_	O
312	2	_	_	O
313	patients	_	_	O
314	(	_	_	O
315	16	_	_	O
316	.	_	_	O

317	7	_	_	O
318	%	_	_	O
319	)	_	_	O
320	had	_	_	O
321	SD	_	_	O
322	and	_	_	O
323	3	_	_	O
324	patients	_	_	O
325	(	_	_	O
326	25	_	_	O
327	%	_	_	O
328	)	_	_	O
329	had	_	_	O
330	PD	_	_	O
331	.	_	_	O

332	At	_	_	O
333	the	_	_	O
334	completion	_	_	O
335	of	_	_	O
336	FHX	_	_	O
337	,	_	_	O
338	no	_	_	O
339	patient	_	_	O
340	underwent	_	_	O
341	local	_	_	O
342	therapy	_	_	O
343	according	_	_	O
344	to	_	_	O
345	treatment	_	_	O
346	plan	_	_	O
347	.	_	_	O

348	At	_	_	B-Premise
349	a	_	_	I-Premise
350	median	_	_	I-Premise
351	follow	_	_	I-Premise
352	-	_	_	I-Premise
353	up	_	_	I-Premise
354	time	_	_	I-Premise
355	of	_	_	I-Premise
356	13	_	_	I-Premise
357	.	_	_	I-Premise

358	5	_	_	I-Premise
359	months	_	_	I-Premise
360	(	_	_	I-Premise
361	range	_	_	I-Premise
362	1	_	_	I-Premise
363	-	_	_	I-Premise
364	28	_	_	I-Premise
365	+	_	_	I-Premise
366	)	_	_	I-Premise
367	at	_	_	I-Premise
368	June	_	_	I-Premise
369	2001	_	_	I-Premise
370	,	_	_	I-Premise
371	among	_	_	I-Premise
372	26	_	_	I-Premise
373	patients	_	_	I-Premise
374	enrolled	_	_	I-Premise
375	12	_	_	I-Premise
376	(	_	_	I-Premise
377	46	_	_	I-Premise
378	.	_	_	I-Premise

379	1	_	_	I-Premise
380	%	_	_	I-Premise
381	)	_	_	I-Premise
382	were	_	_	I-Premise
383	still	_	_	I-Premise
384	alive	_	_	I-Premise
385	and	_	_	I-Premise
386	9	_	_	I-Premise
387	(	_	_	I-Premise
388	75	_	_	I-Premise
389	%	_	_	I-Premise
390	)	_	_	I-Premise
391	of	_	_	I-Premise
392	them	_	_	I-Premise
393	were	_	_	I-Premise
394	progression	_	_	I-Premise
395	-	_	_	I-Premise
396	free	_	_	I-Premise
397	.	_	_	I-Premise

398	The	_	_	B-Premise
399	median	_	_	I-Premise
400	duration	_	_	I-Premise
401	of	_	_	I-Premise
402	response	_	_	I-Premise
403	was	_	_	I-Premise
404	9	_	_	I-Premise
405	months	_	_	I-Premise
406	(	_	_	I-Premise
407	range	_	_	I-Premise
408	0	_	_	I-Premise
409	-	_	_	I-Premise
410	25	_	_	I-Premise
411	+	_	_	I-Premise
412	)	_	_	I-Premise
413	,	_	_	I-Premise
414	the	_	_	I-Premise
415	median	_	_	I-Premise
416	progression	_	_	I-Premise
417	-	_	_	I-Premise
418	free	_	_	I-Premise
419	survival	_	_	I-Premise
420	was	_	_	I-Premise
421	10	_	_	I-Premise
422	.	_	_	I-Premise

423	5	_	_	I-Premise
424	months	_	_	I-Premise
425	(	_	_	I-Premise
426	range	_	_	I-Premise
427	0	_	_	I-Premise
428	-	_	_	I-Premise
429	28	_	_	I-Premise
430	+	_	_	I-Premise
431	)	_	_	I-Premise
432	,	_	_	I-Premise
433	the	_	_	I-Premise
434	median	_	_	I-Premise
435	overall	_	_	I-Premise
436	survival	_	_	I-Premise
437	time	_	_	I-Premise
438	was	_	_	I-Premise
439	9	_	_	I-Premise
440	months	_	_	I-Premise
441	(	_	_	I-Premise
442	range	_	_	I-Premise
443	1	_	_	I-Premise
444	-	_	_	I-Premise
445	22	_	_	I-Premise
446	)	_	_	I-Premise
447	.	_	_	I-Premise

448	The	_	_	B-Premise
449	toxicity	_	_	I-Premise
450	was	_	_	I-Premise
451	significant	_	_	I-Premise
452	and	_	_	I-Premise
453	consisted	_	_	I-Premise
454	mainly	_	_	I-Premise
455	of	_	_	I-Premise
456	mucositis	_	_	I-Premise
457	and	_	_	I-Premise
458	,	_	_	I-Premise
459	to	_	_	I-Premise
460	a	_	_	I-Premise
461	lesser	_	_	I-Premise
462	extent	_	_	I-Premise
463	,	_	_	I-Premise
464	neutropenia	_	_	I-Premise
465	/	_	_	I-Premise
466	thrombocytopenia	_	_	I-Premise
467	.	_	_	I-Premise

468	In	_	_	O
469	the	_	_	O
470	present	_	_	O
471	study	_	_	O
472	,	_	_	O
473	the	_	_	B-Claim
474	low	_	_	I-Claim
475	serum	_	_	I-Claim
476	levels	_	_	I-Claim
477	of	_	_	I-Claim
478	leptin	_	_	I-Claim
479	and	_	_	I-Claim
480	the	_	_	I-Claim
481	high	_	_	I-Claim
482	serum	_	_	I-Claim
483	levels	_	_	I-Claim
484	of	_	_	I-Claim
485	proinflammatory	_	_	I-Claim
486	cytokines	_	_	I-Claim
487	in	_	_	I-Claim
488	advanced	_	_	I-Claim
489	stage	_	_	I-Claim
490	cancer	_	_	I-Claim
491	patients	_	_	I-Claim
492	were	_	_	I-Claim
493	confirmed	_	_	I-Claim
494	.	_	_	I-Claim

495	In	_	_	O
496	conclusion	_	_	O
497	,	_	_	O
498	this	_	_	B-Claim
499	sequential	_	_	I-Claim
500	induction	_	_	I-Claim
501	chemotherapy	_	_	I-Claim
502	and	_	_	I-Claim
503	chemoradiotherapy	_	_	I-Claim
504	program	_	_	I-Claim
505	has	_	_	I-Claim
506	been	_	_	I-Claim
507	found	_	_	I-Claim
508	moderately	_	_	I-Claim
509	active	_	_	I-Claim
510	and	_	_	I-Claim
511	significantly	_	_	I-Claim
512	toxic	_	_	I-Claim
513	;	_	_	I-Claim
514	moreover	_	_	O
515	,	_	_	O
516	the	_	_	O
517	long	_	_	O
518	overall	_	_	O
519	treatment	_	_	O
520	duration	_	_	O
521	must	_	_	O
522	be	_	_	O
523	taken	_	_	O
524	into	_	_	O
525	consideration	_	_	O
526	.	_	_	O

527	For	_	_	O
528	these	_	_	O
529	reasons	_	_	O
530	,	_	_	O
531	this	_	_	B-Claim
532	regimen	_	_	I-Claim
533	could	_	_	I-Claim
534	not	_	_	I-Claim
535	be	_	_	I-Claim
536	recommended	_	_	I-Claim
537	for	_	_	I-Claim
538	a	_	_	I-Claim
539	phase	_	_	I-Claim
540	III	_	_	I-Claim
541	randomized	_	_	I-Claim
542	study	_	_	I-Claim
543	.	_	_	I-Claim


0	Despite	_	_	O
1	improvements	_	_	O
2	in	_	_	O
3	surgical	_	_	O
4	techniques	_	_	O
5	,	_	_	O
6	urinary	_	_	O
7	incontinence	_	_	O
8	(	_	_	O
9	UI	_	_	O
10	)	_	_	O
11	is	_	_	O
12	not	_	_	O
13	uncommon	_	_	O
14	after	_	_	O
15	radical	_	_	O
16	prostatectomy	_	_	O
17	(	_	_	O
18	RP	_	_	O
19	)	_	_	O
20	,	_	_	O
21	and	_	_	O
22	it	_	_	O
23	may	_	_	O
24	dramatically	_	_	O
25	worsen	_	_	O
26	quality	_	_	O
27	of	_	_	O
28	life	_	_	O
29	(	_	_	O
30	QoL	_	_	O
31	)	_	_	O
32	.	_	_	O

33	To	_	_	O
34	determine	_	_	O
35	the	_	_	O
36	benefit	_	_	O
37	of	_	_	O
38	starting	_	_	O
39	pelvic	_	_	O
40	floor	_	_	O
41	muscle	_	_	O
42	exercise	_	_	O
43	(	_	_	O
44	PFME	_	_	O
45	)	_	_	O
46	30d	_	_	O
47	before	_	_	O
48	RP	_	_	O
49	and	_	_	O
50	of	_	_	O
51	continuing	_	_	O
52	PFME	_	_	O
53	postoperatively	_	_	O
54	for	_	_	O
55	early	_	_	O
56	recovery	_	_	O
57	of	_	_	O
58	continence	_	_	O
59	.	_	_	O

60	A	_	_	O
61	randomised	_	_	O
62	,	_	_	O
63	prospective	_	_	O
64	study	_	_	O
65	was	_	_	O
66	designed	_	_	O
67	.	_	_	O

68	Men	_	_	O
69	with	_	_	O
70	localised	_	_	O
71	prostate	_	_	O
72	cancer	_	_	O
73	(	_	_	O
74	PCa	_	_	O
75	)	_	_	O
76	who	_	_	O
77	underwent	_	_	O
78	an	_	_	O
79	open	_	_	O
80	radical	_	_	O
81	retropubic	_	_	O
82	prostatectomy	_	_	O
83	(	_	_	O
84	RRP	_	_	O
85	)	_	_	O
86	at	_	_	O
87	our	_	_	O
88	department	_	_	O
89	of	_	_	O
90	urology	_	_	O
91	were	_	_	O
92	included	_	_	O
93	.	_	_	O

94	Patients	_	_	O
95	were	_	_	O
96	randomised	_	_	O
97	to	_	_	O
98	start	_	_	O
99	PFME	_	_	O
100	preoperatively	_	_	O
101	and	_	_	O
102	continue	_	_	O
103	postoperatively	_	_	O
104	(	_	_	O
105	active	_	_	O
106	group	_	_	O
107	:	_	_	O
108	A	_	_	O
109	)	_	_	O
110	or	_	_	O
111	to	_	_	O
112	start	_	_	O
113	PFME	_	_	O
114	postoperatively	_	_	O
115	alone	_	_	O
116	(	_	_	O
117	control	_	_	O
118	group	_	_	O
119	:	_	_	O
120	B	_	_	O
121	)	_	_	O
122	.	_	_	O

123	The	_	_	O
124	primary	_	_	O
125	outcome	_	_	O
126	measure	_	_	O
127	was	_	_	O
128	self	_	_	O
129	-	_	_	O
130	reported	_	_	O
131	continence	_	_	O
132	after	_	_	O
133	surgery	_	_	O
134	.	_	_	O

135	Secondary	_	_	O
136	outcome	_	_	O
137	measures	_	_	O
138	were	_	_	O
139	assessed	_	_	O
140	by	_	_	O
141	degree	_	_	O
142	of	_	_	O
143	UI	_	_	O
144	based	_	_	O
145	on	_	_	O
146	a	_	_	O
147	24	_	_	O
148	-	_	_	O
149	h	_	_	O
150	pad	_	_	O
151	test	_	_	O
152	and	_	_	O
153	QoL	_	_	O
154	instruments	_	_	O
155	(	_	_	O
156	International	_	_	O
157	Continence	_	_	O
158	Society	_	_	O
159	[	_	_	O
160	ICS	_	_	O
161	]	_	_	O
162	male	_	_	O
163	short	_	_	O
164	form	_	_	O
165	[	_	_	O
166	SF	_	_	O
167	]	_	_	O
168	)	_	_	O
169	.	_	_	O

170	Of	_	_	O
171	143	_	_	O
172	men	_	_	O
173	evaluated	_	_	O
174	for	_	_	O
175	the	_	_	O
176	study	_	_	O
177	,	_	_	O
178	118	_	_	O
179	were	_	_	O
180	randomised	_	_	O
181	either	_	_	O
182	to	_	_	O
183	start	_	_	O
184	PFME	_	_	O
185	preoperatively	_	_	O
186	and	_	_	O
187	continue	_	_	O
188	postoperatively	_	_	O
189	(	_	_	O
190	group	_	_	O
191	A	_	_	O
192	;	_	_	O
193	n	_	_	O
194	=	_	_	O
195	59	_	_	O
196	)	_	_	O
197	or	_	_	O
198	to	_	_	O
199	start	_	_	O
200	postoperative	_	_	O
201	PFME	_	_	O
202	(	_	_	O
203	group	_	_	O
204	B	_	_	O
205	;	_	_	O
206	n	_	_	O
207	=	_	_	O
208	59	_	_	O
209	)	_	_	O
210	.	_	_	O

211	After	_	_	B-Premise
212	1	_	_	I-Premise
213	mo	_	_	I-Premise
214	,	_	_	I-Premise
215	44	_	_	I-Premise
216	.	_	_	I-Premise

217	1	_	_	I-Premise
218	%	_	_	I-Premise
219	(	_	_	I-Premise
220	26	_	_	I-Premise
221	of	_	_	I-Premise
222	59	_	_	I-Premise
223	)	_	_	I-Premise
224	of	_	_	I-Premise
225	patients	_	_	I-Premise
226	were	_	_	I-Premise
227	continent	_	_	I-Premise
228	in	_	_	I-Premise
229	group	_	_	I-Premise
230	A	_	_	I-Premise
231	,	_	_	I-Premise
232	while	_	_	I-Premise
233	20	_	_	I-Premise
234	.	_	_	I-Premise

235	3	_	_	I-Premise
236	%	_	_	I-Premise
237	(	_	_	I-Premise
238	12	_	_	I-Premise
239	of	_	_	I-Premise
240	59	_	_	I-Premise
241	)	_	_	I-Premise
242	were	_	_	I-Premise
243	continent	_	_	I-Premise
244	in	_	_	I-Premise
245	group	_	_	I-Premise
246	B	_	_	I-Premise
247	(	_	_	I-Premise
248	p	_	_	I-Premise
249	=	_	_	I-Premise
250	0	_	_	I-Premise
251	.	_	_	I-Premise

252	018	_	_	I-Premise
253	)	_	_	I-Premise
254	.	_	_	I-Premise

255	At	_	_	B-Premise
256	3	_	_	I-Premise
257	mo	_	_	I-Premise
258	,	_	_	I-Premise
259	59	_	_	I-Premise
260	.	_	_	I-Premise

261	3	_	_	I-Premise
262	%	_	_	I-Premise
263	(	_	_	I-Premise
264	35	_	_	I-Premise
265	of	_	_	I-Premise
266	59	_	_	I-Premise
267	)	_	_	I-Premise
268	and	_	_	I-Premise
269	37	_	_	I-Premise
270	.	_	_	I-Premise

271	3	_	_	I-Premise
272	%	_	_	I-Premise
273	(	_	_	I-Premise
274	22	_	_	I-Premise
275	of	_	_	I-Premise
276	59	_	_	I-Premise
277	)	_	_	I-Premise
278	patients	_	_	I-Premise
279	were	_	_	I-Premise
280	continent	_	_	I-Premise
281	in	_	_	I-Premise
282	group	_	_	I-Premise
283	A	_	_	I-Premise
284	and	_	_	I-Premise
285	group	_	_	I-Premise
286	B	_	_	I-Premise
287	,	_	_	I-Premise
288	respectively	_	_	I-Premise
289	(	_	_	I-Premise
290	p	_	_	I-Premise
291	=	_	_	I-Premise
292	0	_	_	I-Premise
293	.	_	_	I-Premise

294	028	_	_	I-Premise
295	)	_	_	I-Premise
296	.	_	_	I-Premise

297	The	_	_	B-Premise
298	ICS	_	_	I-Premise
299	male	_	_	I-Premise
300	SF	_	_	I-Premise
301	mean	_	_	I-Premise
302	score	_	_	I-Premise
303	showed	_	_	I-Premise
304	better	_	_	I-Premise
305	results	_	_	I-Premise
306	in	_	_	I-Premise
307	group	_	_	I-Premise
308	A	_	_	I-Premise
309	than	_	_	I-Premise
310	in	_	_	I-Premise
311	group	_	_	I-Premise
312	B	_	_	I-Premise
313	patients	_	_	I-Premise
314	at	_	_	I-Premise
315	both	_	_	I-Premise
316	1	_	_	I-Premise
317	mo	_	_	I-Premise
318	(	_	_	I-Premise
319	14	_	_	I-Premise
320	.	_	_	I-Premise

321	6	_	_	I-Premise
322	vs	_	_	I-Premise
323	18	_	_	I-Premise
324	.	_	_	I-Premise

325	3	_	_	I-Premise
326	)	_	_	I-Premise
327	and	_	_	I-Premise
328	3	_	_	I-Premise
329	mo	_	_	I-Premise
330	(	_	_	I-Premise
331	8	_	_	I-Premise
332	.	_	_	I-Premise

333	1	_	_	I-Premise
334	vs	_	_	I-Premise
335	12	_	_	I-Premise
336	.	_	_	I-Premise

337	2	_	_	I-Premise
338	)	_	_	I-Premise
339	after	_	_	I-Premise
340	RP	_	_	I-Premise
341	(	_	_	I-Premise
342	p	_	_	I-Premise
343	=	_	_	I-Premise
344	0	_	_	I-Premise
345	.	_	_	I-Premise

346	002	_	_	I-Premise
347	)	_	_	I-Premise
348	.	_	_	I-Premise

349	In	_	_	B-Premise
350	age	_	_	I-Premise
351	-	_	_	I-Premise
352	adjusted	_	_	I-Premise
353	logistic	_	_	I-Premise
354	regression	_	_	I-Premise
355	analyses	_	_	I-Premise
356	,	_	_	I-Premise
357	patients	_	_	I-Premise
358	who	_	_	I-Premise
359	performed	_	_	I-Premise
360	preoperative	_	_	I-Premise
361	PFME	_	_	I-Premise
362	had	_	_	I-Premise
363	a	_	_	I-Premise
364	0	_	_	I-Premise
365	.	_	_	I-Premise

366	41	_	_	I-Premise
367	-	_	_	I-Premise
368	fold	_	_	I-Premise
369	lower	_	_	I-Premise
370	risk	_	_	I-Premise
371	of	_	_	I-Premise
372	being	_	_	I-Premise
373	incontinent	_	_	I-Premise
374	1	_	_	I-Premise
375	mo	_	_	I-Premise
376	after	_	_	I-Premise
377	RP	_	_	I-Premise
378	and	_	_	I-Premise
379	a	_	_	I-Premise
380	0	_	_	I-Premise
381	.	_	_	I-Premise

382	38	_	_	I-Premise
383	-	_	_	I-Premise
384	fold	_	_	I-Premise
385	lower	_	_	I-Premise
386	risk	_	_	I-Premise
387	of	_	_	I-Premise
388	being	_	_	I-Premise
389	incontinent	_	_	I-Premise
390	3	_	_	I-Premise
391	mo	_	_	I-Premise
392	after	_	_	I-Premise
393	RP	_	_	I-Premise
394	(	_	_	I-Premise
395	p	_	_	I-Premise
396	≤	_	_	I-Premise
397	0	_	_	I-Premise
398	.	_	_	I-Premise

399	001	_	_	I-Premise
400	)	_	_	I-Premise
401	.	_	_	I-Premise

402	Preoperative	_	_	B-Claim
403	PFME	_	_	I-Claim
404	may	_	_	I-Claim
405	improve	_	_	I-Claim
406	early	_	_	I-Claim
407	continence	_	_	I-Claim
408	and	_	_	I-Claim
409	QoL	_	_	I-Claim
410	outcomes	_	_	I-Claim
411	after	_	_	I-Claim
412	RP	_	_	I-Claim
413	.	_	_	I-Claim

414	Further	_	_	B-Claim
415	studies	_	_	I-Claim
416	are	_	_	I-Claim
417	needed	_	_	I-Claim
418	to	_	_	I-Claim
419	corroborate	_	_	I-Claim
420	our	_	_	I-Claim
421	results	_	_	I-Claim
422	.	_	_	I-Claim


0	Enhanced	_	_	O
1	recovery	_	_	O
2	programmes	_	_	O
3	(	_	_	O
4	ERPs	_	_	O
5	)	_	_	O
6	have	_	_	O
7	been	_	_	O
8	shown	_	_	O
9	to	_	_	O
10	reduce	_	_	O
11	length	_	_	O
12	of	_	_	O
13	hospital	_	_	O
14	stay	_	_	O
15	(	_	_	O
16	LOS	_	_	O
17	)	_	_	O
18	and	_	_	O
19	complications	_	_	O
20	in	_	_	O
21	colorectal	_	_	O
22	surgery	_	_	O
23	.	_	_	O

24	Whether	_	_	O
25	ERPs	_	_	O
26	have	_	_	O
27	the	_	_	O
28	same	_	_	O
29	benefits	_	_	O
30	in	_	_	O
31	open	_	_	O
32	liver	_	_	O
33	resection	_	_	O
34	surgery	_	_	O
35	is	_	_	O
36	unclear	_	_	O
37	,	_	_	O
38	and	_	_	O
39	randomized	_	_	O
40	clinical	_	_	O
41	trials	_	_	O
42	are	_	_	O
43	lacking	_	_	O
44	.	_	_	O

45	Consecutive	_	_	O
46	patients	_	_	O
47	scheduled	_	_	O
48	for	_	_	O
49	open	_	_	O
50	liver	_	_	O
51	resection	_	_	O
52	were	_	_	O
53	randomized	_	_	O
54	to	_	_	O
55	an	_	_	O
56	ERP	_	_	O
57	group	_	_	O
58	or	_	_	O
59	standard	_	_	O
60	care	_	_	O
61	.	_	_	O

62	Primary	_	_	O
63	endpoints	_	_	O
64	were	_	_	O
65	time	_	_	O
66	until	_	_	O
67	medically	_	_	O
68	fit	_	_	O
69	for	_	_	O
70	discharge	_	_	O
71	(	_	_	O
72	MFD	_	_	O
73	)	_	_	O
74	and	_	_	O
75	LOS	_	_	O
76	.	_	_	O

77	Secondary	_	_	O
78	endpoints	_	_	O
79	were	_	_	O
80	postoperative	_	_	O
81	morbidity	_	_	O
82	,	_	_	O
83	pain	_	_	O
84	scores	_	_	O
85	,	_	_	O
86	readmission	_	_	O
87	rate	_	_	O
88	,	_	_	O
89	mortality	_	_	O
90	,	_	_	O
91	quality	_	_	O
92	of	_	_	O
93	life	_	_	O
94	(	_	_	O
95	QoL	_	_	O
96	)	_	_	O
97	and	_	_	O
98	patient	_	_	O
99	satisfaction	_	_	O
100	.	_	_	O

101	ERP	_	_	O
102	elements	_	_	O
103	included	_	_	O
104	greater	_	_	O
105	preoperative	_	_	O
106	education	_	_	O
107	,	_	_	O
108	preoperative	_	_	O
109	oral	_	_	O
110	carbohydrate	_	_	O
111	loading	_	_	O
112	,	_	_	O
113	postoperative	_	_	O
114	goal	_	_	O
115	-	_	_	O
116	directed	_	_	O
117	fluid	_	_	O
118	therapy	_	_	O
119	,	_	_	O
120	early	_	_	O
121	mobilization	_	_	O
122	and	_	_	O
123	physiotherapy	_	_	O
124	.	_	_	O

125	Both	_	_	O
126	groups	_	_	O
127	received	_	_	O
128	standardized	_	_	O
129	anaesthesia	_	_	O
130	with	_	_	O
131	epidural	_	_	O
132	analgesia	_	_	O
133	.	_	_	O

134	The	_	_	O
135	analysis	_	_	O
136	included	_	_	O
137	46	_	_	O
138	patients	_	_	O
139	in	_	_	O
140	the	_	_	O
141	ERP	_	_	O
142	group	_	_	O
143	and	_	_	O
144	45	_	_	O
145	in	_	_	O
146	the	_	_	O
147	standard	_	_	O
148	care	_	_	O
149	group	_	_	O
150	.	_	_	O

151	Median	_	_	B-Premise
152	MFD	_	_	I-Premise
153	time	_	_	I-Premise
154	was	_	_	I-Premise
155	reduced	_	_	I-Premise
156	in	_	_	I-Premise
157	the	_	_	I-Premise
158	ERP	_	_	I-Premise
159	group	_	_	I-Premise
160	(	_	_	I-Premise
161	3	_	_	I-Premise
162	days	_	_	I-Premise
163	versus	_	_	I-Premise
164	6	_	_	I-Premise
165	days	_	_	I-Premise
166	with	_	_	I-Premise
167	standard	_	_	I-Premise
168	care	_	_	I-Premise
169	;	_	_	I-Premise
170	P	_	_	I-Premise
171	<	_	_	I-Premise
172	0	_	_	I-Premise
173	·	_	_	I-Premise
174	001	_	_	I-Premise
175	)	_	_	I-Premise
176	,	_	_	I-Premise
177	as	_	_	I-Premise
178	was	_	_	I-Premise
179	LOS	_	_	I-Premise
180	(	_	_	I-Premise
181	4	_	_	I-Premise
182	days	_	_	I-Premise
183	versus	_	_	I-Premise
184	7	_	_	I-Premise
185	days	_	_	I-Premise
186	;	_	_	I-Premise
187	P	_	_	I-Premise
188	<	_	_	I-Premise
189	0	_	_	I-Premise
190	·	_	_	I-Premise
191	001	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	The	_	_	B-Premise
195	ERP	_	_	I-Premise
196	significantly	_	_	I-Premise
197	reduced	_	_	I-Premise
198	the	_	_	I-Premise
199	rate	_	_	I-Premise
200	of	_	_	I-Premise
201	medical	_	_	I-Premise
202	complications	_	_	I-Premise
203	(	_	_	I-Premise
204	7	_	_	I-Premise
205	versus	_	_	I-Premise
206	27	_	_	I-Premise
207	per	_	_	I-Premise
208	cent	_	_	I-Premise
209	;	_	_	I-Premise
210	P	_	_	I-Premise
211	=	_	_	I-Premise
212	0	_	_	I-Premise
213	·	_	_	I-Premise
214	020	_	_	I-Premise
215	)	_	_	I-Premise
216	,	_	_	I-Premise
217	but	_	_	B-Premise
218	not	_	_	I-Premise
219	surgical	_	_	I-Premise
220	complications	_	_	I-Premise
221	(	_	_	I-Premise
222	15	_	_	I-Premise
223	versus	_	_	I-Premise
224	11	_	_	I-Premise
225	per	_	_	I-Premise
226	cent	_	_	I-Premise
227	;	_	_	I-Premise
228	P	_	_	I-Premise
229	=	_	_	I-Premise
230	0	_	_	I-Premise
231	·	_	_	I-Premise
232	612	_	_	I-Premise
233	)	_	_	I-Premise
234	,	_	_	I-Premise
235	readmissions	_	_	I-Premise
236	(	_	_	I-Premise
237	4	_	_	I-Premise
238	versus	_	_	I-Premise
239	0	_	_	I-Premise
240	per	_	_	I-Premise
241	cent	_	_	I-Premise
242	;	_	_	I-Premise
243	P	_	_	I-Premise
244	=	_	_	I-Premise
245	0	_	_	I-Premise
246	·	_	_	I-Premise
247	153	_	_	I-Premise
248	)	_	_	I-Premise
249	or	_	_	I-Premise
250	mortality	_	_	I-Premise
251	(	_	_	I-Premise
252	both	_	_	I-Premise
253	2	_	_	I-Premise
254	per	_	_	I-Premise
255	cent	_	_	I-Premise
256	;	_	_	I-Premise
257	P	_	_	I-Premise
258	=	_	_	I-Premise
259	0	_	_	I-Premise
260	·	_	_	I-Premise
261	987	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	QoL	_	_	B-Premise
265	over	_	_	I-Premise
266	28	_	_	I-Premise
267	days	_	_	I-Premise
268	was	_	_	I-Premise
269	significantly	_	_	I-Premise
270	better	_	_	I-Premise
271	in	_	_	I-Premise
272	the	_	_	I-Premise
273	ERP	_	_	I-Premise
274	group	_	_	I-Premise
275	(	_	_	I-Premise
276	P	_	_	I-Premise
277	=	_	_	I-Premise
278	0	_	_	I-Premise
279	·	_	_	I-Premise
280	002	_	_	I-Premise
281	)	_	_	I-Premise
282	.	_	_	I-Premise

283	There	_	_	B-Premise
284	was	_	_	I-Premise
285	no	_	_	I-Premise
286	difference	_	_	I-Premise
287	in	_	_	I-Premise
288	patient	_	_	I-Premise
289	satisfaction	_	_	I-Premise
290	.	_	_	I-Premise

291	ERPs	_	_	B-Claim
292	for	_	_	I-Claim
293	open	_	_	I-Claim
294	liver	_	_	I-Claim
295	resection	_	_	I-Claim
296	surgery	_	_	I-Claim
297	are	_	_	I-Claim
298	safe	_	_	I-Claim
299	and	_	_	I-Claim
300	effective	_	_	I-Claim
301	.	_	_	I-Claim

302	Patients	_	_	B-Claim
303	treated	_	_	I-Claim
304	in	_	_	I-Claim
305	the	_	_	I-Claim
306	ERP	_	_	I-Claim
307	recovered	_	_	I-Claim
308	faster	_	_	I-Claim
309	,	_	_	I-Claim
310	were	_	_	I-Claim
311	discharged	_	_	I-Claim
312	sooner	_	_	I-Claim
313	,	_	_	I-Claim
314	and	_	_	I-Claim
315	had	_	_	I-Claim
316	fewer	_	_	I-Claim
317	medical	_	_	I-Claim
318	-	_	_	I-Claim
319	related	_	_	I-Claim
320	complications	_	_	I-Claim
321	and	_	_	I-Claim
322	improved	_	_	I-Claim
323	QoL	_	_	I-Claim
324	.	_	_	I-Claim


0	In	_	_	O
1	the	_	_	O
2	Gynecologic	_	_	O
3	Cancer	_	_	O
4	Intergroup	_	_	O
5	International	_	_	O
6	Collaboration	_	_	O
7	on	_	_	O
8	Ovarian	_	_	O
9	Neoplasms	_	_	O
10	7	_	_	O
11	(	_	_	O
12	ICON7	_	_	O
13	)	_	_	O
14	trial	_	_	O
15	,	_	_	O
16	bevacizumab	_	_	O
17	improved	_	_	O
18	progression	_	_	O
19	-	_	_	O
20	free	_	_	O
21	survival	_	_	O
22	in	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	ovarian	_	_	O
26	cancer	_	_	O
27	when	_	_	O
28	used	_	_	O
29	in	_	_	O
30	combination	_	_	O
31	with	_	_	O
32	first	_	_	O
33	-	_	_	O
34	line	_	_	O
35	chemotherapy	_	_	O
36	and	_	_	O
37	as	_	_	O
38	a	_	_	O
39	single	_	_	O
40	-	_	_	O
41	drug	_	_	O
42	continuation	_	_	O
43	treatment	_	_	O
44	for	_	_	O
45	18	_	_	O
46	cycles	_	_	O
47	.	_	_	O

48	In	_	_	O
49	a	_	_	O
50	preliminary	_	_	O
51	analysis	_	_	O
52	of	_	_	O
53	a	_	_	O
54	high	_	_	O
55	-	_	_	O
56	risk	_	_	O
57	subset	_	_	O
58	of	_	_	O
59	patients	_	_	O
60	,	_	_	O
61	there	_	_	O
62	was	_	_	O
63	also	_	_	O
64	an	_	_	O
65	improvement	_	_	O
66	in	_	_	O
67	overall	_	_	O
68	survival	_	_	O
69	.	_	_	O

70	This	_	_	O
71	study	_	_	O
72	aims	_	_	O
73	to	_	_	O
74	describe	_	_	O
75	the	_	_	O
76	health	_	_	O
77	-	_	_	O
78	related	_	_	O
79	quality	_	_	O
80	-	_	_	O
81	of	_	_	O
82	-	_	_	O
83	life	_	_	O
84	(	_	_	O
85	QoL	_	_	O
86	)	_	_	O
87	outcomes	_	_	O
88	from	_	_	O
89	ICON7	_	_	O
90	.	_	_	O

91	ICON7	_	_	O
92	is	_	_	O
93	a	_	_	O
94	randomised	_	_	O
95	,	_	_	O
96	multicentre	_	_	O
97	,	_	_	O
98	open	_	_	O
99	-	_	_	O
100	label	_	_	O
101	phase	_	_	O
102	3	_	_	O
103	trial	_	_	O
104	.	_	_	O

105	Between	_	_	O
106	Dec	_	_	O
107	18	_	_	O
108	,	_	_	O
109	2006	_	_	O
110	,	_	_	O
111	and	_	_	O
112	Feb	_	_	O
113	16	_	_	O
114	,	_	_	O
115	2009	_	_	O
116	,	_	_	O
117	after	_	_	O
118	a	_	_	O
119	surgical	_	_	O
120	procedure	_	_	O
121	aiming	_	_	O
122	to	_	_	O
123	debulk	_	_	O
124	the	_	_	O
125	disease	_	_	O
126	,	_	_	O
127	women	_	_	O
128	with	_	_	O
129	International	_	_	O
130	Federation	_	_	O
131	of	_	_	O
132	Gynecology	_	_	O
133	and	_	_	O
134	Obstetrics	_	_	O
135	(	_	_	O
136	FIGO	_	_	O
137	)	_	_	O
138	high	_	_	O
139	-	_	_	O
140	risk	_	_	O
141	stage	_	_	O
142	I	_	_	O
143	-	_	_	O
144	IV	_	_	O
145	epithelial	_	_	O
146	ovarian	_	_	O
147	cancer	_	_	O
148	were	_	_	O
149	randomly	_	_	O
150	allocated	_	_	O
151	(	_	_	O
152	1	_	_	O
153	:	_	_	O
154	1	_	_	O
155	)	_	_	O
156	by	_	_	O
157	computer	_	_	O
158	program	_	_	O
159	and	_	_	O
160	block	_	_	O
161	randomisation	_	_	O
162	to	_	_	O
163	receive	_	_	O
164	either	_	_	O
165	six	_	_	O
166	cycles	_	_	O
167	of	_	_	O
168	standard	_	_	O
169	chemotherapy	_	_	O
170	(	_	_	O
171	total	_	_	O
172	18	_	_	O
173	weeks	_	_	O
174	)	_	_	O
175	with	_	_	O
176	carboplatin	_	_	O
177	(	_	_	O
178	area	_	_	O
179	under	_	_	O
180	the	_	_	O
181	curve	_	_	O
182	5	_	_	O
183	or	_	_	O
184	6	_	_	O
185	)	_	_	O
186	and	_	_	O
187	paclitaxel	_	_	O
188	(	_	_	O
189	175	_	_	O
190	mg	_	_	O
191	/	_	_	O
192	m	_	_	O
193	(	_	_	O
194	2	_	_	O
195	)	_	_	O
196	)	_	_	O
197	alone	_	_	O
198	or	_	_	O
199	with	_	_	O
200	bevacizumab	_	_	O
201	(	_	_	O
202	7	_	_	O
203	·	_	_	O
204	5	_	_	O
205	mg	_	_	O
206	/	_	_	O
207	kg	_	_	O
208	)	_	_	O
209	given	_	_	O
210	intravenously	_	_	O
211	with	_	_	O
212	chemotherapy	_	_	O
213	and	_	_	O
214	continued	_	_	O
215	as	_	_	O
216	a	_	_	O
217	single	_	_	O
218	drug	_	_	O
219	thereafter	_	_	O
220	(	_	_	O
221	total	_	_	O
222	54	_	_	O
223	weeks	_	_	O
224	)	_	_	O
225	.	_	_	O

226	The	_	_	O
227	primary	_	_	O
228	QoL	_	_	O
229	endpoint	_	_	O
230	was	_	_	O
231	global	_	_	O
232	QoL	_	_	O
233	from	_	_	O
234	the	_	_	O
235	European	_	_	O
236	Organisation	_	_	O
237	for	_	_	O
238	Research	_	_	O
239	and	_	_	O
240	Treatment	_	_	O
241	of	_	_	O
242	Cancer	_	_	O
243	quality	_	_	O
244	-	_	_	O
245	of	_	_	O
246	-	_	_	O
247	life	_	_	O
248	questionnaire	_	_	O
249	-	_	_	O
250	core	_	_	O
251	30	_	_	O
252	at	_	_	O
253	week	_	_	O
254	54	_	_	O
255	,	_	_	O
256	analysed	_	_	O
257	by	_	_	O
258	ANOVA	_	_	O
259	and	_	_	O
260	adjusted	_	_	O
261	for	_	_	O
262	baseline	_	_	O
263	score	_	_	O
264	.	_	_	O

265	Analyses	_	_	O
266	were	_	_	O
267	by	_	_	O
268	intention	_	_	O
269	to	_	_	O
270	treat	_	_	O
271	.	_	_	O

272	The	_	_	O
273	ICON7	_	_	O
274	trial	_	_	O
275	has	_	_	O
276	completed	_	_	O
277	recruitment	_	_	O
278	and	_	_	O
279	remains	_	_	O
280	in	_	_	O
281	follow	_	_	O
282	-	_	_	O
283	up	_	_	O
284	.	_	_	O

285	This	_	_	O
286	study	_	_	O
287	is	_	_	O
288	registered	_	_	O
289	,	_	_	O
290	number	_	_	O
291	ISRCTN91273375	_	_	O
292	.	_	_	O

293	764	_	_	O
294	women	_	_	O
295	were	_	_	O
296	randomly	_	_	O
297	assigned	_	_	O
298	to	_	_	O
299	the	_	_	O
300	standard	_	_	O
301	chemotherapy	_	_	O
302	group	_	_	O
303	and	_	_	O
304	764	_	_	O
305	to	_	_	O
306	the	_	_	O
307	bevacizumab	_	_	O
308	group	_	_	O
309	.	_	_	O

310	At	_	_	O
311	baseline	_	_	O
312	,	_	_	O
313	684	_	_	O
314	(	_	_	O
315	90	_	_	O
316	%	_	_	O
317	)	_	_	O
318	of	_	_	O
319	women	_	_	O
320	in	_	_	O
321	the	_	_	O
322	standard	_	_	O
323	chemotherapy	_	_	O
324	group	_	_	O
325	and	_	_	O
326	691	_	_	O
327	(	_	_	O
328	90	_	_	O
329	%	_	_	O
330	)	_	_	O
331	of	_	_	O
332	those	_	_	O
333	in	_	_	O
334	the	_	_	O
335	bevacizumab	_	_	O
336	group	_	_	O
337	had	_	_	O
338	completed	_	_	O
339	QoL	_	_	O
340	questionnaires	_	_	O
341	.	_	_	O

342	At	_	_	O
343	week	_	_	O
344	54	_	_	O
345	,	_	_	O
346	502	_	_	O
347	(	_	_	O
348	66	_	_	O
349	%	_	_	O
350	)	_	_	O
351	women	_	_	O
352	in	_	_	O
353	the	_	_	O
354	bevacizumab	_	_	O
355	group	_	_	O
356	and	_	_	O
357	388	_	_	O
358	(	_	_	O
359	51	_	_	O
360	%	_	_	O
361	)	_	_	O
362	women	_	_	O
363	in	_	_	O
364	the	_	_	O
365	standard	_	_	O
366	chemotherapy	_	_	O
367	group	_	_	O
368	provided	_	_	O
369	QoL	_	_	O
370	data	_	_	O
371	.	_	_	O

372	Overall	_	_	B-Premise
373	,	_	_	I-Premise
374	the	_	_	I-Premise
375	mean	_	_	I-Premise
376	global	_	_	I-Premise
377	QoL	_	_	I-Premise
378	score	_	_	I-Premise
379	improved	_	_	I-Premise
380	during	_	_	I-Premise
381	chemotherapy	_	_	I-Premise
382	by	_	_	I-Premise
383	7	_	_	I-Premise
384	·	_	_	I-Premise
385	2	_	_	I-Premise
386	points	_	_	I-Premise
387	(	_	_	I-Premise
388	SD	_	_	I-Premise
389	24	_	_	I-Premise
390	·	_	_	I-Premise
391	4	_	_	I-Premise
392	)	_	_	I-Premise
393	when	_	_	I-Premise
394	analysed	_	_	I-Premise
395	for	_	_	I-Premise
396	all	_	_	I-Premise
397	women	_	_	I-Premise
398	with	_	_	I-Premise
399	data	_	_	I-Premise
400	at	_	_	I-Premise
401	baseline	_	_	I-Premise
402	and	_	_	I-Premise
403	week	_	_	I-Premise
404	18	_	_	I-Premise
405	.	_	_	I-Premise

406	The	_	_	B-Premise
407	mean	_	_	I-Premise
408	global	_	_	I-Premise
409	QoL	_	_	I-Premise
410	score	_	_	I-Premise
411	at	_	_	I-Premise
412	54	_	_	I-Premise
413	weeks	_	_	I-Premise
414	was	_	_	I-Premise
415	higher	_	_	I-Premise
416	in	_	_	I-Premise
417	the	_	_	I-Premise
418	standard	_	_	I-Premise
419	chemotherapy	_	_	I-Premise
420	group	_	_	I-Premise
421	than	_	_	I-Premise
422	in	_	_	I-Premise
423	the	_	_	I-Premise
424	bevacizumab	_	_	I-Premise
425	group	_	_	I-Premise
426	(	_	_	I-Premise
427	76	_	_	I-Premise
428	·	_	_	I-Premise
429	1	_	_	I-Premise
430	[	_	_	I-Premise
431	SD	_	_	I-Premise
432	18	_	_	I-Premise
433	·	_	_	I-Premise
434	2	_	_	I-Premise
435	]	_	_	I-Premise
436	vs	_	_	I-Premise
437	69	_	_	I-Premise
438	·	_	_	I-Premise
439	7	_	_	I-Premise
440	[	_	_	I-Premise
441	19	_	_	I-Premise
442	·	_	_	I-Premise
443	1	_	_	I-Premise
444	]	_	_	I-Premise
445	points	_	_	I-Premise
446	;	_	_	I-Premise
447	difference	_	_	I-Premise
448	6	_	_	I-Premise
449	·	_	_	I-Premise
450	4	_	_	I-Premise
451	points	_	_	I-Premise
452	,	_	_	I-Premise
453	95	_	_	I-Premise
454	%	_	_	I-Premise
455	CI	_	_	I-Premise
456	3	_	_	I-Premise
457	·	_	_	I-Premise
458	7	_	_	I-Premise
459	-	_	_	I-Premise
460	9	_	_	I-Premise
461	·	_	_	I-Premise
462	0	_	_	I-Premise
463	,	_	_	I-Premise
464	p	_	_	I-Premise
465	<	_	_	I-Premise
466	0	_	_	I-Premise
467	·	_	_	I-Premise
468	0001	_	_	I-Premise
469	)	_	_	I-Premise
470	.	_	_	I-Premise

471	Bevacizumab	_	_	B-Claim
472	continuation	_	_	I-Claim
473	treatment	_	_	I-Claim
474	seems	_	_	I-Claim
475	to	_	_	I-Claim
476	be	_	_	I-Claim
477	associated	_	_	I-Claim
478	with	_	_	I-Claim
479	a	_	_	I-Claim
480	small	_	_	I-Claim
481	but	_	_	I-Claim
482	clinically	_	_	I-Claim
483	significant	_	_	I-Claim
484	decrement	_	_	I-Claim
485	in	_	_	I-Claim
486	QoL	_	_	I-Claim
487	compared	_	_	I-Claim
488	with	_	_	I-Claim
489	standard	_	_	I-Claim
490	treatment	_	_	I-Claim
491	for	_	_	I-Claim
492	women	_	_	I-Claim
493	with	_	_	I-Claim
494	ovarian	_	_	I-Claim
495	cancer	_	_	I-Claim
496	.	_	_	I-Claim

497	The	_	_	O
498	trade	_	_	O
499	-	_	_	O
500	off	_	_	O
501	between	_	_	O
502	the	_	_	O
503	prolongation	_	_	O
504	of	_	_	O
505	progression	_	_	O
506	-	_	_	O
507	free	_	_	O
508	survival	_	_	O
509	and	_	_	O
510	the	_	_	O
511	quality	_	_	O
512	of	_	_	O
513	that	_	_	O
514	period	_	_	O
515	of	_	_	O
516	time	_	_	O
517	needs	_	_	O
518	to	_	_	O
519	be	_	_	O
520	considered	_	_	O
521	in	_	_	O
522	clinical	_	_	O
523	practice	_	_	O
524	when	_	_	O
525	making	_	_	O
526	treatment	_	_	O
527	decisions	_	_	O
528	.	_	_	O


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	combination	_	_	O
4	of	_	_	O
5	the	_	_	O
6	gastrin	_	_	O
7	antagonist	_	_	O
8	Z	_	_	O
9	-	_	_	O
10	360	_	_	O
11	and	_	_	O
12	gemcitabine	_	_	O
13	for	_	_	O
14	advanced	_	_	O
15	pancreatic	_	_	O
16	cancer	_	_	O
17	.	_	_	O

18	Previously	_	_	O
19	untreated	_	_	O
20	patients	_	_	O
21	with	_	_	O
22	PC	_	_	O
23	were	_	_	O
24	randomly	_	_	O
25	allocated	_	_	O
26	to	_	_	O
27	Z	_	_	O
28	-	_	_	O
29	360	_	_	O
30	120	_	_	O
31	mg	_	_	O
32	,	_	_	O
33	240	_	_	O
34	mg	_	_	O
35	or	_	_	O
36	placebo	_	_	O
37	.	_	_	O

38	Z	_	_	O
39	-	_	_	O
40	360	_	_	O
41	/	_	_	O
42	placebo	_	_	O
43	was	_	_	O
44	given	_	_	O
45	on	_	_	O
46	day	_	_	O
47	-	_	_	O
48	3	_	_	O
49	and	_	_	O
50	gemcitabine	_	_	O
51	1000	_	_	O
52	mg	_	_	O
53	/	_	_	O
54	m	_	_	O
55	(	_	_	O
56	2	_	_	O
57	)	_	_	O
58	commenced	_	_	O
59	on	_	_	O
60	day	_	_	O
61	1	_	_	O
62	followed	_	_	O
63	by	_	_	O
64	Z	_	_	O
65	-	_	_	O
66	360	_	_	O
67	on	_	_	O
68	day	_	_	O
69	2	_	_	O
70	.	_	_	O

71	Thereafter	_	_	O
72	Z	_	_	O
73	-	_	_	O
74	360	_	_	O
75	/	_	_	O
76	placebo	_	_	O
77	was	_	_	O
78	given	_	_	O
79	twice	_	_	O
80	daily	_	_	O
81	concurrently	_	_	O
82	with	_	_	O
83	standard	_	_	O
84	dose	_	_	O
85	of	_	_	O
86	gemcitabine	_	_	O
87	.	_	_	O

88	Pharmacokinetics	_	_	O
89	for	_	_	O
90	both	_	_	O
91	drugs	_	_	O
92	was	_	_	O
93	measured	_	_	O
94	alone	_	_	O
95	and	_	_	O
96	in	_	_	O
97	combination	_	_	O
98	.	_	_	O

99	Toxicity	_	_	O
100	,	_	_	O
101	response	_	_	O
102	and	_	_	O
103	quality	_	_	O
104	of	_	_	O
105	life	_	_	O
106	were	_	_	O
107	also	_	_	O
108	recorded	_	_	O
109	.	_	_	O

110	Thirty	_	_	O
111	-	_	_	O
112	three	_	_	O
113	patients	_	_	O
114	with	_	_	O
115	a	_	_	O
116	median	_	_	O
117	age	_	_	O
118	of	_	_	O
119	62	_	_	O
120	years	_	_	O
121	were	_	_	O
122	randomised	_	_	O
123	of	_	_	O
124	which	_	_	O
125	six	_	_	O
126	had	_	_	O
127	locally	_	_	O
128	advanced	_	_	O
129	disease	_	_	O
130	and	_	_	O
131	26	_	_	O
132	had	_	_	O
133	metastatic	_	_	O
134	disease	_	_	O
135	.	_	_	O

136	Analysis	_	_	O
137	of	_	_	O
138	the	_	_	O
139	area	_	_	O
140	under	_	_	O
141	the	_	_	O
142	plasma	_	_	O
143	concentration	_	_	O
144	versus	_	_	O
145	time	_	_	O
146	curve	_	_	O
147	(	_	_	O
148	AUC	_	_	O
149	)	_	_	O
150	,	_	_	O
151	the	_	_	O
152	maximum	_	_	O
153	observed	_	_	O
154	concentration	_	_	O
155	(	_	_	O
156	Cmax	_	_	O
157	(	_	_	O
158	obs	_	_	O
159	)	_	_	O
160	)	_	_	O
161	and	_	_	O
162	the	_	_	O
163	time	_	_	O
164	of	_	_	O
165	the	_	_	O
166	maximum	_	_	O
167	observed	_	_	O
168	concentration	_	_	O
169	(	_	_	O
170	Tmax	_	_	O
171	(	_	_	O
172	obs	_	_	O
173	)	_	_	O
174	)	_	_	O
175	for	_	_	O
176	Z	_	_	O
177	-	_	_	O
178	360	_	_	O
179	,	_	_	O
180	gemcitabine	_	_	O
181	and	_	_	O
182	2	_	_	O
183	,	_	_	O
184	2	_	_	O
185	-	_	_	O
186	difluorodeoxyuridine	_	_	O
187	(	_	_	O
188	dFdU	_	_	O
189	)	_	_	O
190	,	_	_	O
191	could	_	_	O
192	not	_	_	O
193	exclude	_	_	O
194	an	_	_	O
195	effect	_	_	O
196	on	_	_	O
197	the	_	_	O
198	systemic	_	_	O
199	exposure	_	_	O
200	to	_	_	O
201	Z	_	_	O
202	-	_	_	O
203	360	_	_	O
204	,	_	_	O
205	gemcitabine	_	_	O
206	and	_	_	O
207	dFdU	_	_	O
208	when	_	_	O
209	co	_	_	O
210	-	_	_	O
211	administration	_	_	O
212	of	_	_	O
213	Z	_	_	O
214	-	_	_	O
215	360	_	_	O
216	and	_	_	O
217	gemcitabine	_	_	O
218	was	_	_	O
219	compared	_	_	O
220	with	_	_	O
221	single	_	_	O
222	agent	_	_	O
223	administration	_	_	O
224	.	_	_	O

225	The	_	_	B-Premise
226	most	_	_	I-Premise
227	commonly	_	_	I-Premise
228	reported	_	_	I-Premise
229	adverse	_	_	I-Premise
230	events	_	_	I-Premise
231	were	_	_	I-Premise
232	nausea	_	_	I-Premise
233	,	_	_	I-Premise
234	abdominal	_	_	I-Premise
235	pain	_	_	I-Premise
236	,	_	_	I-Premise
237	vomiting	_	_	I-Premise
238	and	_	_	I-Premise
239	fatigue	_	_	I-Premise
240	.	_	_	I-Premise

241	At	_	_	B-Premise
242	the	_	_	I-Premise
243	end	_	_	I-Premise
244	of	_	_	I-Premise
245	the	_	_	I-Premise
246	study	_	_	I-Premise
247	,	_	_	I-Premise
248	62	_	_	I-Premise
249	.	_	_	I-Premise

250	5	_	_	I-Premise
251	%	_	_	I-Premise
252	,	_	_	I-Premise
253	25	_	_	I-Premise
254	%	_	_	I-Premise
255	and	_	_	I-Premise
256	60	_	_	I-Premise
257	%	_	_	I-Premise
258	had	_	_	I-Premise
259	stable	_	_	I-Premise
260	disease	_	_	I-Premise
261	in	_	_	I-Premise
262	the	_	_	I-Premise
263	120	_	_	I-Premise
264	mg	_	_	I-Premise
265	,	_	_	I-Premise
266	240	_	_	I-Premise
267	mg	_	_	I-Premise
268	and	_	_	I-Premise
269	placebo	_	_	I-Premise
270	group	_	_	I-Premise
271	,	_	_	I-Premise
272	respectively	_	_	I-Premise
273	.	_	_	I-Premise

274	A	_	_	B-Premise
275	higher	_	_	I-Premise
276	proportion	_	_	I-Premise
277	of	_	_	I-Premise
278	patients	_	_	I-Premise
279	in	_	_	I-Premise
280	Z	_	_	I-Premise
281	-	_	_	I-Premise
282	360	_	_	I-Premise
283	groups	_	_	I-Premise
284	reported	_	_	I-Premise
285	improvement	_	_	I-Premise
286	in	_	_	I-Premise
287	pain	_	_	I-Premise
288	.	_	_	I-Premise

289	Z	_	_	B-Claim
290	-	_	_	I-Claim
291	360	_	_	I-Claim
292	is	_	_	I-Claim
293	safe	_	_	I-Claim
294	and	_	_	I-Claim
295	well	_	_	I-Claim
296	tolerated	_	_	I-Claim
297	when	_	_	I-Claim
298	combined	_	_	I-Claim
299	with	_	_	I-Claim
300	gemcitabine	_	_	I-Claim
301	.	_	_	I-Claim

302	A	_	_	O
303	Phase	_	_	O
304	III	_	_	O
305	trial	_	_	O
306	is	_	_	O
307	needed	_	_	O
308	to	_	_	O
309	determine	_	_	O
310	whether	_	_	O
311	the	_	_	O
312	combination	_	_	O
313	of	_	_	O
314	Z	_	_	O
315	-	_	_	O
316	360	_	_	O
317	and	_	_	O
318	gemcitabine	_	_	O
319	is	_	_	O
320	superior	_	_	O
321	to	_	_	O
322	gemcitabine	_	_	O
323	alone	_	_	O
324	in	_	_	O
325	advanced	_	_	O
326	PC	_	_	O
327	.	_	_	O


0	Intermittent	_	_	O
1	dosing	_	_	O
2	may	_	_	O
3	reduce	_	_	O
4	the	_	_	O
5	adverse	_	_	O
6	events	_	_	O
7	(	_	_	O
8	AEs	_	_	O
9	)	_	_	O
10	of	_	_	O
11	androgen	_	_	O
12	-	_	_	O
13	deprivation	_	_	O
14	therapy	_	_	O
15	(	_	_	O
16	ADT	_	_	O
17	)	_	_	O
18	.	_	_	O

19	To	_	_	O
20	compare	_	_	O
21	intermittent	_	_	O
22	androgen	_	_	O
23	deprivation	_	_	O
24	(	_	_	O
25	IAD	_	_	O
26	)	_	_	O
27	and	_	_	O
28	continuous	_	_	O
29	androgen	_	_	O
30	deprivation	_	_	O
31	(	_	_	O
32	CAD	_	_	O
33	)	_	_	O
34	with	_	_	O
35	regard	_	_	O
36	to	_	_	O
37	health	_	_	O
38	-	_	_	O
39	related	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	(	_	_	O
44	QoL	_	_	O
45	)	_	_	O
46	.	_	_	O

47	A	_	_	O
48	total	_	_	O
49	of	_	_	O
50	852	_	_	O
51	men	_	_	O
52	with	_	_	O
53	advanced	_	_	O
54	prostate	_	_	O
55	cancer	_	_	O
56	(	_	_	O
57	PCa	_	_	O
58	)	_	_	O
59	were	_	_	O
60	enrolled	_	_	O
61	to	_	_	O
62	receive	_	_	O
63	goserelin	_	_	O
64	acetate	_	_	O
65	3	_	_	O
66	.	_	_	O

67	6	_	_	O
68	mg	_	_	O
69	every	_	_	O
70	28	_	_	O
71	d	_	_	O
72	for	_	_	O
73	24	_	_	O
74	wk	_	_	O
75	.	_	_	O

76	A	_	_	O
77	total	_	_	O
78	of	_	_	O
79	554	_	_	O
80	patients	_	_	O
81	whose	_	_	O
82	prostate	_	_	O
83	-	_	_	O
84	specific	_	_	O
85	antigen	_	_	O
86	(	_	_	O
87	PSA	_	_	O
88	)	_	_	O
89	decreased	_	_	O
90	to	_	_	O
91	<	_	_	O
92	10	_	_	O
93	ng	_	_	O
94	/	_	_	O
95	ml	_	_	O
96	or	_	_	O
97	by	_	_	O
98	≥	_	_	O
99	50	_	_	O
100	%	_	_	O
101	(	_	_	O
102	<	_	_	O
103	20	_	_	O
104	ng	_	_	O
105	/	_	_	O
106	ml	_	_	O
107	at	_	_	O
108	baseline	_	_	O
109	)	_	_	O
110	were	_	_	O
111	randomised	_	_	O
112	to	_	_	O
113	IAD	_	_	O
114	or	_	_	O
115	CAD	_	_	O
116	.	_	_	O

117	In	_	_	O
118	the	_	_	O
119	IAD	_	_	O
120	arm	_	_	O
121	,	_	_	O
122	ADT	_	_	O
123	was	_	_	O
124	resumed	_	_	O
125	for	_	_	O
126	at	_	_	O
127	least	_	_	O
128	24	_	_	O
129	wk	_	_	O
130	whenever	_	_	O
131	PSA	_	_	O
132	increased	_	_	O
133	>	_	_	O
134	20	_	_	O
135	ng	_	_	O
136	/	_	_	O
137	ml	_	_	O
138	or	_	_	O
139	above	_	_	O
140	baseline	_	_	O
141	.	_	_	O

142	QoL	_	_	O
143	was	_	_	O
144	monitored	_	_	O
145	with	_	_	O
146	a	_	_	O
147	validated	_	_	O
148	Cleary	_	_	O
149	30	_	_	O
150	-	_	_	O
151	item	_	_	O
152	questionnaire	_	_	O
153	and	_	_	O
154	analysed	_	_	O
155	by	_	_	O
156	the	_	_	O
157	Mann	_	_	O
158	-	_	_	O
159	Whitney	_	_	O
160	U	_	_	O
161	test	_	_	O
162	,	_	_	O
163	0	_	_	O
164	.	_	_	O

165	5	_	_	O
166	standard	_	_	O
167	deviation	_	_	O
168	rule	_	_	O
169	,	_	_	O
170	and	_	_	O
171	repeated	_	_	O
172	measures	_	_	O
173	analysis	_	_	O
174	of	_	_	O
175	variance	_	_	O
176	.	_	_	O

177	AEs	_	_	O
178	and	_	_	O
179	adverse	_	_	O
180	drug	_	_	O
181	reactions	_	_	O
182	(	_	_	O
183	ADRs	_	_	O
184	)	_	_	O
185	were	_	_	O
186	analysed	_	_	O
187	by	_	_	O
188	the	_	_	O
189	chi	_	_	O
190	-	_	_	O
191	square	_	_	O
192	test	_	_	O
193	.	_	_	O

194	Median	_	_	O
195	follow	_	_	O
196	-	_	_	O
197	up	_	_	O
198	was	_	_	O
199	65	_	_	O
200	mo	_	_	O
201	.	_	_	O

202	Significant	_	_	B-Premise
203	differences	_	_	I-Premise
204	in	_	_	I-Premise
205	QoL	_	_	I-Premise
206	emerged	_	_	I-Premise
207	in	_	_	I-Premise
208	activity	_	_	I-Premise
209	limitation	_	_	I-Premise
210	,	_	_	I-Premise
211	physical	_	_	I-Premise
212	capacity	_	_	I-Premise
213	,	_	_	I-Premise
214	and	_	_	I-Premise
215	sexual	_	_	I-Premise
216	functioning	_	_	I-Premise
217	,	_	_	I-Premise
218	favouring	_	_	I-Premise
219	IAD	_	_	I-Premise
220	.	_	_	I-Premise

221	No	_	_	B-Premise
222	significant	_	_	I-Premise
223	differences	_	_	I-Premise
224	emerged	_	_	I-Premise
225	in	_	_	I-Premise
226	the	_	_	I-Premise
227	prevalence	_	_	I-Premise
228	of	_	_	I-Premise
229	AEs	_	_	I-Premise
230	:	_	_	I-Premise
231	87	_	_	I-Premise
232	patients	_	_	I-Premise
233	in	_	_	I-Premise
234	the	_	_	I-Premise
235	IAD	_	_	I-Premise
236	arm	_	_	I-Premise
237	(	_	_	I-Premise
238	31	_	_	I-Premise
239	.	_	_	I-Premise

240	8	_	_	I-Premise
241	%	_	_	I-Premise
242	)	_	_	I-Premise
243	and	_	_	I-Premise
244	95	_	_	I-Premise
245	in	_	_	I-Premise
246	the	_	_	I-Premise
247	CAD	_	_	I-Premise
248	arm	_	_	I-Premise
249	(	_	_	I-Premise
250	33	_	_	I-Premise
251	.	_	_	I-Premise

252	9	_	_	I-Premise
253	%	_	_	I-Premise
254	)	_	_	I-Premise
255	had	_	_	I-Premise
256	cardiovascular	_	_	I-Premise
257	(	_	_	I-Premise
258	CV	_	_	I-Premise
259	)	_	_	I-Premise
260	AEs	_	_	I-Premise
261	(	_	_	I-Premise
262	p	_	_	I-Premise
263	=	_	_	I-Premise
264	0	_	_	I-Premise
265	.	_	_	I-Premise

266	59	_	_	I-Premise
267	)	_	_	I-Premise
268	,	_	_	I-Premise
269	with	_	_	I-Premise
270	25	_	_	I-Premise
271	(	_	_	I-Premise
272	9	_	_	I-Premise
273	.	_	_	I-Premise

274	1	_	_	I-Premise
275	%	_	_	I-Premise
276	)	_	_	I-Premise
277	and	_	_	I-Premise
278	29	_	_	I-Premise
279	(	_	_	I-Premise
280	10	_	_	I-Premise
281	.	_	_	I-Premise

282	4	_	_	I-Premise
283	%	_	_	I-Premise
284	)	_	_	I-Premise
285	withdrawn	_	_	I-Premise
286	(	_	_	I-Premise
287	p	_	_	I-Premise
288	=	_	_	I-Premise
289	0	_	_	I-Premise
290	.	_	_	I-Premise

291	62	_	_	I-Premise
292	)	_	_	I-Premise
293	,	_	_	I-Premise
294	and	_	_	I-Premise
295	21	_	_	I-Premise
296	(	_	_	I-Premise
297	7	_	_	I-Premise
298	.	_	_	I-Premise

299	7	_	_	I-Premise
300	%	_	_	I-Premise
301	)	_	_	I-Premise
302	and	_	_	I-Premise
303	24	_	_	I-Premise
304	(	_	_	I-Premise
305	8	_	_	I-Premise
306	.	_	_	I-Premise

307	6	_	_	I-Premise
308	%	_	_	I-Premise
309	)	_	_	I-Premise
310	dying	_	_	I-Premise
311	because	_	_	I-Premise
312	of	_	_	I-Premise
313	a	_	_	I-Premise
314	CV	_	_	I-Premise
315	event	_	_	I-Premise
316	(	_	_	I-Premise
317	p	_	_	I-Premise
318	=	_	_	I-Premise
319	0	_	_	I-Premise
320	.	_	_	I-Premise

321	70	_	_	I-Premise
322	)	_	_	I-Premise
323	,	_	_	I-Premise
324	respectively	_	_	I-Premise
325	;	_	_	I-Premise
326	bone	_	_	B-Premise
327	fractures	_	_	I-Premise
328	occurred	_	_	I-Premise
329	in	_	_	I-Premise
330	19	_	_	I-Premise
331	(	_	_	I-Premise
332	6	_	_	I-Premise
333	.	_	_	I-Premise

334	9	_	_	I-Premise
335	%	_	_	I-Premise
336	)	_	_	I-Premise
337	and	_	_	I-Premise
338	15	_	_	I-Premise
339	(	_	_	I-Premise
340	5	_	_	I-Premise
341	.	_	_	I-Premise

342	4	_	_	I-Premise
343	%	_	_	I-Premise
344	)	_	_	I-Premise
345	patients	_	_	I-Premise
346	(	_	_	I-Premise
347	p	_	_	I-Premise
348	=	_	_	I-Premise
349	0	_	_	I-Premise
350	.	_	_	I-Premise

351	44	_	_	I-Premise
352	)	_	_	I-Premise
353	,	_	_	I-Premise
354	respectively	_	_	I-Premise
355	.	_	_	I-Premise

356	Hot	_	_	B-Premise
357	flushes	_	_	I-Premise
358	or	_	_	I-Premise
359	night	_	_	I-Premise
360	sweats	_	_	I-Premise
361	were	_	_	I-Premise
362	the	_	_	I-Premise
363	most	_	_	I-Premise
364	common	_	_	I-Premise
365	ADRs	_	_	I-Premise
366	(	_	_	I-Premise
367	47	_	_	I-Premise
368	.	_	_	I-Premise

369	1	_	_	I-Premise
370	%	_	_	I-Premise
371	vs	_	_	I-Premise
372	50	_	_	I-Premise
373	.	_	_	I-Premise

374	4	_	_	I-Premise
375	%	_	_	I-Premise
376	;	_	_	I-Premise
377	p	_	_	I-Premise
378	=	_	_	I-Premise
379	0	_	_	I-Premise
380	.	_	_	I-Premise

381	44	_	_	I-Premise
382	)	_	_	I-Premise
383	.	_	_	I-Premise

384	Erectile	_	_	B-Premise
385	dysfunction	_	_	I-Premise
386	(	_	_	I-Premise
387	15	_	_	I-Premise
388	.	_	_	I-Premise

389	7	_	_	I-Premise
390	%	_	_	I-Premise
391	vs	_	_	I-Premise
392	7	_	_	I-Premise
393	.	_	_	I-Premise

394	9	_	_	I-Premise
395	%	_	_	I-Premise
396	;	_	_	I-Premise
397	p	_	_	I-Premise
398	=	_	_	I-Premise
399	0	_	_	I-Premise
400	.	_	_	I-Premise

401	042	_	_	I-Premise
402	)	_	_	I-Premise
403	and	_	_	I-Premise
404	depressed	_	_	I-Premise
405	mood	_	_	I-Premise
406	(	_	_	I-Premise
407	2	_	_	I-Premise
408	.	_	_	I-Premise

409	2	_	_	I-Premise
410	vs	_	_	I-Premise
411	0	_	_	I-Premise
412	%	_	_	I-Premise
413	;	_	_	I-Premise
414	p	_	_	I-Premise
415	=	_	_	I-Premise
416	0	_	_	I-Premise
417	.	_	_	I-Premise

418	032	_	_	I-Premise
419	)	_	_	I-Premise
420	were	_	_	I-Premise
421	more	_	_	I-Premise
422	common	_	_	I-Premise
423	in	_	_	I-Premise
424	the	_	_	I-Premise
425	IAD	_	_	I-Premise
426	arm	_	_	I-Premise
427	.	_	_	I-Premise

428	IAD	_	_	B-Claim
429	showed	_	_	I-Claim
430	benefits	_	_	I-Claim
431	in	_	_	I-Claim
432	the	_	_	I-Claim
433	treatment	_	_	I-Claim
434	of	_	_	I-Claim
435	advanced	_	_	I-Claim
436	PCa	_	_	I-Claim
437	with	_	_	I-Claim
438	respect	_	_	I-Claim
439	to	_	_	I-Claim
440	QoL	_	_	I-Claim
441	.	_	_	I-Claim

442	The	_	_	B-Claim
443	prevalence	_	_	I-Claim
444	of	_	_	I-Claim
445	AEs	_	_	I-Claim
446	was	_	_	I-Claim
447	not	_	_	I-Claim
448	significantly	_	_	I-Claim
449	lower	_	_	I-Claim
450	with	_	_	I-Claim
451	IAD	_	_	I-Claim
452	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	whether	_	_	O
3	treatment	_	_	O
4	with	_	_	O
5	single	_	_	O
6	-	_	_	O
7	agent	_	_	O
8	docetaxel	_	_	O
9	would	_	_	O
10	result	_	_	O
11	in	_	_	O
12	longer	_	_	O
13	survival	_	_	O
14	than	_	_	O
15	would	_	_	O
16	best	_	_	O
17	supportive	_	_	O
18	care	_	_	O
19	in	_	_	O
20	patients	_	_	O
21	with	_	_	O
22	non	_	_	O
23	-	_	_	O
24	small	_	_	O
25	-	_	_	O
26	cell	_	_	O
27	lung	_	_	O
28	cancer	_	_	O
29	who	_	_	O
30	had	_	_	O
31	previously	_	_	O
32	been	_	_	O
33	treated	_	_	O
34	with	_	_	O
35	platinum	_	_	O
36	-	_	_	O
37	based	_	_	O
38	chemotherapy	_	_	O
39	.	_	_	O

40	Secondary	_	_	O
41	end	_	_	O
42	points	_	_	O
43	included	_	_	O
44	assessment	_	_	O
45	of	_	_	O
46	response	_	_	O
47	(	_	_	O
48	docetaxel	_	_	O
49	arm	_	_	O
50	only	_	_	O
51	)	_	_	O
52	,	_	_	O
53	toxicity	_	_	O
54	,	_	_	O
55	and	_	_	O
56	quality	_	_	O
57	of	_	_	O
58	life	_	_	O
59	.	_	_	O

60	Patients	_	_	O
61	with	_	_	O
62	performance	_	_	O
63	statuses	_	_	O
64	of	_	_	O
65	0	_	_	O
66	to	_	_	O
67	2	_	_	O
68	and	_	_	O
69	stage	_	_	O
70	IIIB	_	_	O
71	/	_	_	O
72	IV	_	_	O
73	non	_	_	O
74	-	_	_	O
75	small	_	_	O
76	-	_	_	O
77	cell	_	_	O
78	lung	_	_	O
79	cancer	_	_	O
80	with	_	_	O
81	either	_	_	O
82	measurable	_	_	O
83	or	_	_	O
84	evaluable	_	_	O
85	lesions	_	_	O
86	were	_	_	O
87	eligible	_	_	O
88	for	_	_	O
89	entry	_	_	O
90	onto	_	_	O
91	the	_	_	O
92	study	_	_	O
93	if	_	_	O
94	they	_	_	O
95	had	_	_	O
96	undergone	_	_	O
97	one	_	_	O
98	or	_	_	O
99	more	_	_	O
100	platinum	_	_	O
101	-	_	_	O
102	based	_	_	O
103	chemotherapy	_	_	O
104	regimens	_	_	O
105	and	_	_	O
106	if	_	_	O
107	they	_	_	O
108	had	_	_	O
109	adequate	_	_	O
110	hematology	_	_	O
111	and	_	_	O
112	biochemistry	_	_	O
113	parameters	_	_	O
114	.	_	_	O

115	They	_	_	O
116	were	_	_	O
117	excluded	_	_	O
118	if	_	_	O
119	they	_	_	O
120	had	_	_	O
121	symptomatic	_	_	O
122	brain	_	_	O
123	metastases	_	_	O
124	or	_	_	O
125	if	_	_	O
126	they	_	_	O
127	had	_	_	O
128	previously	_	_	O
129	been	_	_	O
130	treated	_	_	O
131	with	_	_	O
132	paclitaxel	_	_	O
133	.	_	_	O

134	Patients	_	_	O
135	were	_	_	O
136	stratified	_	_	O
137	by	_	_	O
138	performance	_	_	O
139	status	_	_	O
140	and	_	_	O
141	best	_	_	O
142	response	_	_	O
143	to	_	_	O
144	cisplatin	_	_	O
145	chemotherapy	_	_	O
146	and	_	_	O
147	were	_	_	O
148	then	_	_	O
149	randomized	_	_	O
150	to	_	_	O
151	treatment	_	_	O
152	with	_	_	O
153	docetaxel	_	_	O
154	100	_	_	O
155	mg	_	_	O
156	/	_	_	O
157	m	_	_	O
158	(	_	_	O
159	2	_	_	O
160	)	_	_	O
161	(	_	_	O
162	49	_	_	O
163	patients	_	_	O
164	)	_	_	O
165	or	_	_	O
166	75	_	_	O
167	mg	_	_	O
168	/	_	_	O
169	m	_	_	O
170	(	_	_	O
171	2	_	_	O
172	)	_	_	O
173	(	_	_	O
174	55	_	_	O
175	patients	_	_	O
176	)	_	_	O
177	or	_	_	O
178	best	_	_	O
179	supportive	_	_	O
180	care	_	_	O
181	.	_	_	O

182	Patients	_	_	O
183	in	_	_	O
184	both	_	_	O
185	arms	_	_	O
186	were	_	_	O
187	assessed	_	_	O
188	every	_	_	O
189	3	_	_	O
190	weeks	_	_	O
191	.	_	_	O

192	One	_	_	O
193	hundred	_	_	O
194	four	_	_	O
195	patients	_	_	O
196	(	_	_	O
197	103	_	_	O
198	of	_	_	O
199	whom	_	_	O
200	were	_	_	O
201	eligible	_	_	O
202	for	_	_	O
203	entry	_	_	O
204	onto	_	_	O
205	the	_	_	O
206	study	_	_	O
207	)	_	_	O
208	were	_	_	O
209	well	_	_	O
210	balanced	_	_	O
211	for	_	_	O
212	prognostic	_	_	O
213	factors	_	_	O
214	.	_	_	O

215	Of	_	_	O
216	84	_	_	O
217	patients	_	_	O
218	with	_	_	O
219	measurable	_	_	O
220	lesions	_	_	O
221	,	_	_	O
222	six	_	_	O
223	(	_	_	O
224	7	_	_	O
225	.	_	_	O

226	1	_	_	O
227	%	_	_	O
228	)	_	_	O
229	achieved	_	_	O
230	partial	_	_	O
231	responses	_	_	O
232	(	_	_	O
233	three	_	_	O
234	patients	_	_	O
235	at	_	_	O
236	each	_	_	O
237	dose	_	_	O
238	level	_	_	O
239	)	_	_	O
240	.	_	_	O

241	Time	_	_	B-Premise
242	to	_	_	I-Premise
243	progression	_	_	I-Premise
244	was	_	_	I-Premise
245	longer	_	_	I-Premise
246	for	_	_	I-Premise
247	docetaxel	_	_	I-Premise
248	patients	_	_	I-Premise
249	than	_	_	I-Premise
250	for	_	_	I-Premise
251	best	_	_	I-Premise
252	supportive	_	_	I-Premise
253	care	_	_	I-Premise
254	patients	_	_	I-Premise
255	(	_	_	I-Premise
256	10	_	_	I-Premise
257	.	_	_	I-Premise

258	6	_	_	I-Premise
259	v	_	_	I-Premise
260	6	_	_	I-Premise
261	.	_	_	I-Premise

262	7	_	_	I-Premise
263	weeks	_	_	I-Premise
264	,	_	_	I-Premise
265	respectively	_	_	I-Premise
266	;	_	_	I-Premise
267	P	_	_	I-Premise
268	<	_	_	I-Premise
269	.	_	_	I-Premise

270	001	_	_	I-Premise
271	)	_	_	I-Premise
272	,	_	_	I-Premise
273	as	_	_	I-Premise
274	was	_	_	I-Premise
275	median	_	_	I-Premise
276	survival	_	_	I-Premise
277	(	_	_	I-Premise
278	7	_	_	I-Premise
279	.	_	_	I-Premise

280	0	_	_	I-Premise
281	v	_	_	I-Premise
282	4	_	_	I-Premise
283	.	_	_	I-Premise

284	6	_	_	I-Premise
285	months	_	_	I-Premise
286	;	_	_	I-Premise
287	log	_	_	I-Premise
288	-	_	_	I-Premise
289	rank	_	_	I-Premise
290	test	_	_	I-Premise
291	,	_	_	I-Premise
292	P	_	_	I-Premise
293	=	_	_	I-Premise
294	.	_	_	I-Premise

295	047	_	_	I-Premise
296	)	_	_	I-Premise
297	.	_	_	I-Premise

298	The	_	_	B-Premise
299	difference	_	_	I-Premise
300	was	_	_	I-Premise
301	more	_	_	I-Premise
302	significant	_	_	I-Premise
303	for	_	_	I-Premise
304	docetaxel	_	_	I-Premise
305	75	_	_	I-Premise
306	mg	_	_	I-Premise
307	/	_	_	I-Premise
308	m	_	_	I-Premise
309	(	_	_	I-Premise
310	2	_	_	I-Premise
311	)	_	_	I-Premise
312	patients	_	_	I-Premise
313	,	_	_	I-Premise
314	compared	_	_	I-Premise
315	with	_	_	I-Premise
316	corresponding	_	_	I-Premise
317	best	_	_	I-Premise
318	supportive	_	_	I-Premise
319	care	_	_	I-Premise
320	patients	_	_	I-Premise
321	(	_	_	I-Premise
322	7	_	_	I-Premise
323	.	_	_	I-Premise

324	5	_	_	I-Premise
325	v	_	_	I-Premise
326	4	_	_	I-Premise
327	.	_	_	I-Premise

328	6	_	_	I-Premise
329	months	_	_	I-Premise
330	;	_	_	I-Premise
331	log	_	_	I-Premise
332	-	_	_	I-Premise
333	rank	_	_	I-Premise
334	test	_	_	I-Premise
335	,	_	_	I-Premise
336	P	_	_	I-Premise
337	=	_	_	I-Premise
338	.	_	_	I-Premise

339	010	_	_	I-Premise
340	;	_	_	I-Premise
341	1	_	_	I-Premise
342	-	_	_	I-Premise
343	year	_	_	I-Premise
344	survival	_	_	I-Premise
345	,	_	_	I-Premise
346	37	_	_	I-Premise
347	%	_	_	I-Premise
348	v	_	_	I-Premise
349	11	_	_	I-Premise
350	%	_	_	I-Premise
351	;	_	_	I-Premise
352	chi	_	_	I-Premise
353	(	_	_	I-Premise
354	2	_	_	I-Premise
355	)	_	_	I-Premise
356	test	_	_	I-Premise
357	,	_	_	I-Premise
358	P	_	_	I-Premise
359	=	_	_	I-Premise
360	.	_	_	I-Premise

361	003	_	_	I-Premise
362	)	_	_	I-Premise
363	.	_	_	I-Premise

364	Febrile	_	_	B-Premise
365	neutropenia	_	_	I-Premise
366	occurred	_	_	I-Premise
367	in	_	_	I-Premise
368	11	_	_	I-Premise
369	patients	_	_	I-Premise
370	treated	_	_	I-Premise
371	with	_	_	I-Premise
372	docetaxel	_	_	I-Premise
373	100	_	_	I-Premise
374	mg	_	_	I-Premise
375	/	_	_	I-Premise
376	m	_	_	I-Premise
377	(	_	_	I-Premise
378	2	_	_	I-Premise
379	)	_	_	I-Premise
380	,	_	_	I-Premise
381	three	_	_	I-Premise
382	of	_	_	I-Premise
383	whom	_	_	I-Premise
384	died	_	_	I-Premise
385	,	_	_	I-Premise
386	and	_	_	I-Premise
387	in	_	_	I-Premise
388	one	_	_	I-Premise
389	patient	_	_	I-Premise
390	treated	_	_	I-Premise
391	with	_	_	I-Premise
392	docetaxel	_	_	I-Premise
393	75	_	_	I-Premise
394	mg	_	_	I-Premise
395	/	_	_	I-Premise
396	m	_	_	I-Premise
397	(	_	_	I-Premise
398	2	_	_	I-Premise
399	)	_	_	I-Premise
400	.	_	_	I-Premise

401	Grade	_	_	B-Premise
402	3	_	_	I-Premise
403	or	_	_	I-Premise
404	4	_	_	I-Premise
405	nonhematologic	_	_	I-Premise
406	toxicity	_	_	I-Premise
407	,	_	_	I-Premise
408	with	_	_	I-Premise
409	the	_	_	I-Premise
410	exception	_	_	I-Premise
411	of	_	_	I-Premise
412	diarrhea	_	_	I-Premise
413	,	_	_	I-Premise
414	occurred	_	_	I-Premise
415	at	_	_	I-Premise
416	a	_	_	I-Premise
417	similar	_	_	I-Premise
418	rate	_	_	I-Premise
419	in	_	_	I-Premise
420	both	_	_	I-Premise
421	the	_	_	I-Premise
422	docetaxel	_	_	I-Premise
423	and	_	_	I-Premise
424	best	_	_	I-Premise
425	supportive	_	_	I-Premise
426	care	_	_	I-Premise
427	groups	_	_	I-Premise
428	.	_	_	I-Premise

429	Treatment	_	_	B-Claim
430	with	_	_	I-Claim
431	docetaxel	_	_	I-Claim
432	is	_	_	I-Claim
433	associated	_	_	I-Claim
434	with	_	_	I-Claim
435	significant	_	_	I-Claim
436	prolongation	_	_	I-Claim
437	of	_	_	I-Claim
438	survival	_	_	I-Claim
439	,	_	_	I-Claim
440	and	_	_	O
441	at	_	_	B-Claim
442	a	_	_	I-Claim
443	dose	_	_	I-Claim
444	of	_	_	I-Claim
445	75	_	_	I-Claim
446	mg	_	_	I-Claim
447	/	_	_	I-Claim
448	m	_	_	I-Claim
449	(	_	_	I-Claim
450	2	_	_	I-Claim
451	)	_	_	I-Claim
452	,	_	_	I-Claim
453	the	_	_	I-Claim
454	benefits	_	_	I-Claim
455	of	_	_	I-Claim
456	docetaxel	_	_	I-Claim
457	therapy	_	_	I-Claim
458	outweigh	_	_	I-Claim
459	the	_	_	I-Claim
460	risks	_	_	I-Claim
461	.	_	_	I-Claim


0	Suramin	_	_	B-Claim
1	is	_	_	I-Claim
2	a	_	_	I-Claim
3	novel	_	_	I-Claim
4	agent	_	_	I-Claim
5	that	_	_	I-Claim
6	has	_	_	I-Claim
7	demonstrated	_	_	I-Claim
8	preliminary	_	_	I-Claim
9	evidence	_	_	I-Claim
10	of	_	_	I-Claim
11	antitumor	_	_	I-Claim
12	activity	_	_	I-Claim
13	in	_	_	I-Claim
14	hormone	_	_	I-Claim
15	-	_	_	I-Claim
16	refractory	_	_	I-Claim
17	prostate	_	_	I-Claim
18	cancer	_	_	I-Claim
19	(	_	_	I-Claim
20	HRPC	_	_	I-Claim
21	)	_	_	I-Claim
22	.	_	_	I-Claim

23	A	_	_	O
24	prospective	_	_	O
25	randomized	_	_	O
26	clinical	_	_	O
27	trial	_	_	O
28	was	_	_	O
29	designed	_	_	O
30	to	_	_	O
31	evaluate	_	_	O
32	pain	_	_	O
33	and	_	_	O
34	opioid	_	_	O
35	analgesic	_	_	O
36	intake	_	_	O
37	as	_	_	O
38	surrogates	_	_	O
39	for	_	_	O
40	antitumor	_	_	O
41	response	_	_	O
42	in	_	_	O
43	HRPC	_	_	O
44	patients	_	_	O
45	with	_	_	O
46	significant	_	_	O
47	,	_	_	O
48	opioid	_	_	O
49	analgesic	_	_	O
50	-	_	_	O
51	dependent	_	_	O
52	pain	_	_	O
53	.	_	_	O

54	A	_	_	O
55	double	_	_	O
56	-	_	_	O
57	blind	_	_	O
58	,	_	_	O
59	placebo	_	_	O
60	-	_	_	O
61	controlled	_	_	O
62	trial	_	_	O
63	randomized	_	_	O
64	patients	_	_	O
65	to	_	_	O
66	receive	_	_	O
67	a	_	_	O
68	78	_	_	O
69	-	_	_	O
70	day	_	_	O
71	,	_	_	O
72	outpatient	_	_	O
73	regimen	_	_	O
74	of	_	_	O
75	either	_	_	O
76	suramin	_	_	O
77	plus	_	_	O
78	hydrocortisone	_	_	O
79	(	_	_	O
80	HC	_	_	O
81	,	_	_	O
82	40	_	_	O
83	mg	_	_	O
84	/	_	_	O
85	d	_	_	O
86	)	_	_	O
87	or	_	_	O
88	placebo	_	_	O
89	plus	_	_	O
90	HC	_	_	O
91	.	_	_	O

92	Treatment	_	_	O
93	assignment	_	_	O
94	was	_	_	O
95	unblinded	_	_	O
96	when	_	_	O
97	either	_	_	O
98	disease	_	_	O
99	progression	_	_	O
100	or	_	_	O
101	dose	_	_	O
102	-	_	_	O
103	limiting	_	_	O
104	toxicity	_	_	O
105	occurred	_	_	O
106	;	_	_	O
107	placebo	_	_	O
108	patients	_	_	O
109	were	_	_	O
110	allowed	_	_	O
111	to	_	_	O
112	cross	_	_	O
113	-	_	_	O
114	over	_	_	O
115	to	_	_	O
116	open	_	_	O
117	-	_	_	O
118	label	_	_	O
119	suramin	_	_	O
120	plus	_	_	O
121	HC	_	_	O
122	.	_	_	O

123	In	_	_	O
124	addition	_	_	O
125	to	_	_	O
126	pain	_	_	O
127	and	_	_	O
128	opioid	_	_	O
129	analgesic	_	_	O
130	intake	_	_	O
131	,	_	_	O
132	prostate	_	_	O
133	-	_	_	O
134	specific	_	_	O
135	antigen	_	_	O
136	(	_	_	O
137	PSA	_	_	O
138	)	_	_	O
139	response	_	_	O
140	,	_	_	O
141	time	_	_	O
142	to	_	_	O
143	disease	_	_	O
144	progression	_	_	O
145	,	_	_	O
146	quality	_	_	O
147	of	_	_	O
148	life	_	_	O
149	,	_	_	O
150	performance	_	_	O
151	status	_	_	O
152	,	_	_	O
153	and	_	_	O
154	survival	_	_	O
155	were	_	_	O
156	compared	_	_	O
157	.	_	_	O

158	Overall	_	_	B-Premise
159	mean	_	_	I-Premise
160	reductions	_	_	I-Premise
161	in	_	_	I-Premise
162	combined	_	_	I-Premise
163	pain	_	_	I-Premise
164	and	_	_	I-Premise
165	opioid	_	_	I-Premise
166	analgesic	_	_	I-Premise
167	intake	_	_	I-Premise
168	were	_	_	I-Premise
169	greater	_	_	I-Premise
170	for	_	_	I-Premise
171	suramin	_	_	I-Premise
172	plus	_	_	I-Premise
173	HC	_	_	I-Premise
174	(	_	_	I-Premise
175	rank	_	_	I-Premise
176	sum	_	_	I-Premise
177	P	_	_	I-Premise
178	=	_	_	I-Premise
179	.	_	_	I-Premise

180	0001	_	_	I-Premise
181	)	_	_	I-Premise
182	.	_	_	I-Premise

183	Pain	_	_	B-Premise
184	response	_	_	I-Premise
185	was	_	_	I-Premise
186	achieved	_	_	I-Premise
187	in	_	_	I-Premise
188	a	_	_	I-Premise
189	higher	_	_	I-Premise
190	proportion	_	_	I-Premise
191	of	_	_	I-Premise
192	patients	_	_	I-Premise
193	receiving	_	_	I-Premise
194	suramin	_	_	I-Premise
195	than	_	_	I-Premise
196	placebo	_	_	I-Premise
197	(	_	_	I-Premise
198	43	_	_	I-Premise
199	%	_	_	I-Premise
200	v	_	_	I-Premise
201	28	_	_	I-Premise
202	%	_	_	I-Premise
203	;	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	.	_	_	I-Premise

207	001	_	_	I-Premise
208	)	_	_	I-Premise
209	,	_	_	I-Premise
210	and	_	_	O
211	duration	_	_	B-Premise
212	of	_	_	I-Premise
213	response	_	_	I-Premise
214	was	_	_	I-Premise
215	longer	_	_	I-Premise
216	for	_	_	I-Premise
217	suramin	_	_	I-Premise
218	responders	_	_	I-Premise
219	(	_	_	I-Premise
220	median	_	_	I-Premise
221	,	_	_	I-Premise
222	240	_	_	I-Premise
223	v	_	_	I-Premise
224	69	_	_	I-Premise
225	days	_	_	I-Premise
226	;	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	.	_	_	I-Premise

230	0027	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	Time	_	_	B-Premise
234	to	_	_	I-Premise
235	disease	_	_	I-Premise
236	progression	_	_	I-Premise
237	was	_	_	I-Premise
238	longer	_	_	I-Premise
239	(	_	_	I-Premise
240	relative	_	_	I-Premise
241	risk	_	_	I-Premise
242	=	_	_	I-Premise
243	1	_	_	I-Premise
244	.	_	_	I-Premise

245	5	_	_	I-Premise
246	;	_	_	I-Premise
247	95	_	_	I-Premise
248	%	_	_	I-Premise
249	confidence	_	_	I-Premise
250	interval	_	_	I-Premise
251	,	_	_	I-Premise
252	1	_	_	I-Premise
253	.	_	_	I-Premise

254	2	_	_	I-Premise
255	to	_	_	I-Premise
256	1	_	_	I-Premise
257	.	_	_	I-Premise

258	9	_	_	I-Premise
259	)	_	_	I-Premise
260	and	_	_	O
261	the	_	_	B-Premise
262	proportion	_	_	I-Premise
263	of	_	_	I-Premise
264	patients	_	_	I-Premise
265	with	_	_	I-Premise
266	a	_	_	I-Premise
267	greater	_	_	I-Premise
268	than	_	_	I-Premise
269	50	_	_	I-Premise
270	%	_	_	I-Premise
271	decline	_	_	I-Premise
272	in	_	_	I-Premise
273	PSA	_	_	I-Premise
274	was	_	_	I-Premise
275	higher	_	_	I-Premise
276	(	_	_	I-Premise
277	33	_	_	I-Premise
278	%	_	_	I-Premise
279	v	_	_	I-Premise
280	16	_	_	I-Premise
281	%	_	_	I-Premise
282	;	_	_	I-Premise
283	P	_	_	I-Premise
284	=	_	_	I-Premise
285	.	_	_	I-Premise

286	01	_	_	I-Premise
287	)	_	_	I-Premise
288	in	_	_	I-Premise
289	patients	_	_	I-Premise
290	who	_	_	I-Premise
291	received	_	_	I-Premise
292	suramin	_	_	I-Premise
293	.	_	_	I-Premise

294	Neither	_	_	B-Premise
295	quality	_	_	I-Premise
296	of	_	_	I-Premise
297	life	_	_	I-Premise
298	nor	_	_	I-Premise
299	performance	_	_	I-Premise
300	status	_	_	I-Premise
301	was	_	_	I-Premise
302	decreased	_	_	I-Premise
303	by	_	_	I-Premise
304	suramin	_	_	I-Premise
305	treatment	_	_	I-Premise
306	,	_	_	I-Premise
307	and	_	_	O
308	overall	_	_	B-Premise
309	survival	_	_	I-Premise
310	was	_	_	I-Premise
311	similar	_	_	I-Premise
312	.	_	_	I-Premise

313	Most	_	_	B-Premise
314	adverse	_	_	I-Premise
315	events	_	_	I-Premise
316	were	_	_	I-Premise
317	of	_	_	I-Premise
318	mild	_	_	I-Premise
319	or	_	_	I-Premise
320	moderate	_	_	I-Premise
321	intensity	_	_	I-Premise
322	and	_	_	I-Premise
323	were	_	_	I-Premise
324	easily	_	_	I-Premise
325	managed	_	_	I-Premise
326	medically	_	_	I-Premise
327	.	_	_	I-Premise

328	Outpatient	_	_	B-Claim
329	treatment	_	_	I-Claim
330	with	_	_	I-Claim
331	suramin	_	_	I-Claim
332	plus	_	_	I-Claim
333	HC	_	_	I-Claim
334	is	_	_	I-Claim
335	well	_	_	I-Claim
336	tolerated	_	_	I-Claim
337	and	_	_	I-Claim
338	provides	_	_	I-Claim
339	moderate	_	_	I-Claim
340	palliative	_	_	I-Claim
341	benefit	_	_	I-Claim
342	and	_	_	I-Claim
343	delay	_	_	I-Claim
344	in	_	_	I-Claim
345	disease	_	_	I-Claim
346	progression	_	_	I-Claim
347	for	_	_	I-Claim
348	patients	_	_	I-Claim
349	with	_	_	I-Claim
350	symptomatic	_	_	I-Claim
351	HRPC	_	_	I-Claim
352	.	_	_	I-Claim


0	To	_	_	O
1	analyze	_	_	O
2	the	_	_	O
3	clinical	_	_	O
4	course	_	_	O
5	,	_	_	O
6	treatment	_	_	O
7	,	_	_	O
8	complications	_	_	O
9	,	_	_	O
10	outcome	_	_	O
11	,	_	_	O
12	and	_	_	O
13	quality	_	_	O
14	of	_	_	O
15	life	_	_	O
16	(	_	_	O
17	QOL	_	_	O
18	)	_	_	O
19	in	_	_	O
20	patients	_	_	O
21	with	_	_	O
22	perineal	_	_	O
23	/	_	_	O
24	perianal	_	_	O
25	rhabdomyosarcoma	_	_	O
26	(	_	_	O
27	PRMS	_	_	O
28	)	_	_	O
29	treated	_	_	O
30	within	_	_	O
31	the	_	_	O
32	CWS	_	_	O
33	-	_	_	O
34	86	_	_	O
35	,	_	_	O
36	-	_	_	O
37	91	_	_	O
38	,	_	_	O
39	-	_	_	O
40	96	_	_	O
41	,	_	_	O
42	and	_	_	O
43	-	_	_	O
44	2002P	_	_	O
45	trials	_	_	O
46	.	_	_	O

47	Although	_	_	O
48	multiple	_	_	O
49	international	_	_	O
50	study	_	_	O
51	trials	_	_	O
52	exist	_	_	O
53	for	_	_	O
54	the	_	_	O
55	treatment	_	_	O
56	of	_	_	O
57	rhabdomyosarcoma	_	_	O
58	,	_	_	O
59	only	_	_	O
60	very	_	_	O
61	limited	_	_	O
62	information	_	_	O
63	is	_	_	O
64	given	_	_	O
65	on	_	_	O
66	treatment	_	_	O
67	,	_	_	O
68	outcome	_	_	O
69	,	_	_	O
70	and	_	_	O
71	QOL	_	_	O
72	in	_	_	O
73	PRMS	_	_	O
74	.	_	_	O

75	A	_	_	O
76	total	_	_	O
77	of	_	_	O
78	35	_	_	O
79	patients	_	_	O
80	suffering	_	_	O
81	from	_	_	O
82	PRMS	_	_	O
83	were	_	_	O
84	treated	_	_	O
85	with	_	_	O
86	neoadjuvant	_	_	O
87	chemotherapy	_	_	O
88	.	_	_	O

89	Local	_	_	O
90	therapy	_	_	O
91	with	_	_	O
92	radiation	_	_	O
93	and	_	_	O
94	/	_	_	O
95	or	_	_	O
96	surgery	_	_	O
97	was	_	_	O
98	performed	_	_	O
99	,	_	_	O
100	followed	_	_	O
101	by	_	_	O
102	adjuvant	_	_	O
103	chemotherapy	_	_	O
104	.	_	_	O

105	Functional	_	_	O
106	long	_	_	O
107	-	_	_	O
108	term	_	_	O
109	follow	_	_	O
110	-	_	_	O
111	up	_	_	O
112	was	_	_	O
113	evaluated	_	_	O
114	by	_	_	O
115	a	_	_	O
116	gastrointestinal	_	_	O
117	/	_	_	O
118	QOL	_	_	O
119	survey	_	_	O
120	.	_	_	O

121	Thirty	_	_	O
122	-	_	_	O
123	two	_	_	O
124	patients	_	_	O
125	were	_	_	O
126	evaluated	_	_	O
127	(	_	_	O
128	exclusion	_	_	O
129	n	_	_	O
130	=	_	_	O
131	3	_	_	O
132	)	_	_	O
133	.	_	_	O

134	Eight	_	_	O
135	patients	_	_	O
136	had	_	_	O
137	embryonal	_	_	O
138	histology	_	_	O
139	,	_	_	O
140	and	_	_	O
141	24	_	_	O
142	patients	_	_	O
143	had	_	_	O
144	alveolar	_	_	O
145	histology	_	_	O
146	.	_	_	O

147	The	_	_	O
148	median	_	_	O
149	age	_	_	O
150	was	_	_	O
151	108	_	_	O
152	months	_	_	O
153	(	_	_	O
154	median	_	_	O
155	follow	_	_	O
156	-	_	_	O
157	up	_	_	O
158	:	_	_	O
159	5	_	_	O
160	.	_	_	O

161	8	_	_	O
162	years	_	_	O
163	)	_	_	O
164	.	_	_	O

165	The	_	_	O
166	5	_	_	O
167	-	_	_	O
168	year	_	_	O
169	overall	_	_	O
170	survival	_	_	O
171	was	_	_	O
172	47	_	_	O
173	%	_	_	O
174	(	_	_	O
175	95	_	_	O
176	%	_	_	O
177	confidence	_	_	O
178	interval	_	_	O
179	:	_	_	O
180	29	_	_	O
181	-	_	_	O
182	64	_	_	O
183	)	_	_	O
184	.	_	_	O

185	Sixteen	_	_	O
186	IRS	_	_	O
187	(	_	_	O
188	Intergroup	_	_	O
189	Rhabdomyosarcoma	_	_	O
190	Study	_	_	O
191	)	_	_	O
192	III	_	_	O
193	and	_	_	O
194	IV	_	_	O
195	patients	_	_	O
196	had	_	_	O
197	locoregional	_	_	O
198	lymph	_	_	O
199	node	_	_	O
200	involvement	_	_	O
201	at	_	_	O
202	diagnosis	_	_	O
203	.	_	_	O

204	Seven	_	_	O
205	patients	_	_	O
206	were	_	_	O
207	treated	_	_	O
208	with	_	_	O
209	chemotherapy	_	_	O
210	/	_	_	O
211	surgery	_	_	O
212	alone	_	_	O
213	[	_	_	O
214	5	_	_	O
215	-	_	_	O
216	year	_	_	O
217	event	_	_	O
218	-	_	_	O
219	free	_	_	O
220	survival	_	_	O
221	(	_	_	O
222	EFS	_	_	O
223	)	_	_	O
224	:	_	_	O
225	85	_	_	O
226	.	_	_	O

227	7	_	_	O
228	%	_	_	O
229	]	_	_	O
230	.	_	_	O

231	Eleven	_	_	O
232	patients	_	_	O
233	received	_	_	O
234	only	_	_	O
235	radiochemotherapy	_	_	O
236	(	_	_	O
237	5	_	_	O
238	-	_	_	O
239	year	_	_	O
240	EFS	_	_	O
241	:	_	_	O
242	27	_	_	O
243	.	_	_	O

244	3	_	_	O
245	%	_	_	O
246	)	_	_	O
247	.	_	_	O

248	Combined	_	_	O
249	radiochemotherapy	_	_	O
250	/	_	_	O
251	surgery	_	_	O
252	was	_	_	O
253	used	_	_	O
254	in	_	_	O
255	12	_	_	O
256	patients	_	_	O
257	(	_	_	O
258	5	_	_	O
259	-	_	_	O
260	year	_	_	O
261	EFS	_	_	O
262	:	_	_	O
263	63	_	_	O
264	.	_	_	O

265	6	_	_	O
266	%	_	_	O
267	)	_	_	O
268	.	_	_	O

269	Two	_	_	O
270	patients	_	_	O
271	were	_	_	O
272	treated	_	_	O
273	only	_	_	O
274	with	_	_	O
275	chemotherapy	_	_	O
276	and	_	_	O
277	they	_	_	O
278	died	_	_	O
279	.	_	_	O

280	Patients	_	_	B-Premise
281	with	_	_	I-Premise
282	embryonal	_	_	I-Premise
283	histology	_	_	I-Premise
284	had	_	_	I-Premise
285	a	_	_	I-Premise
286	significantly	_	_	I-Premise
287	better	_	_	I-Premise
288	5	_	_	I-Premise
289	-	_	_	I-Premise
290	year	_	_	I-Premise
291	EFS	_	_	I-Premise
292	(	_	_	I-Premise
293	87	_	_	I-Premise
294	.	_	_	I-Premise

295	5	_	_	I-Premise
296	%	_	_	I-Premise
297	)	_	_	I-Premise
298	than	_	_	I-Premise
299	patients	_	_	I-Premise
300	with	_	_	I-Premise
301	alveolar	_	_	I-Premise
302	histology	_	_	I-Premise
303	(	_	_	I-Premise
304	39	_	_	I-Premise
305	.	_	_	I-Premise

306	1	_	_	I-Premise
307	%	_	_	I-Premise
308	;	_	_	I-Premise
309	P	_	_	I-Premise
310	=	_	_	I-Premise
311	0	_	_	I-Premise
312	.	_	_	I-Premise

313	013	_	_	I-Premise
314	)	_	_	I-Premise
315	.	_	_	I-Premise

316	Some	_	_	B-Premise
317	patients	_	_	I-Premise
318	reported	_	_	I-Premise
319	symptoms	_	_	I-Premise
320	of	_	_	I-Premise
321	fecal	_	_	I-Premise
322	incontinence	_	_	I-Premise
323	.	_	_	I-Premise

324	The	_	_	B-Premise
325	median	_	_	I-Premise
326	Wexner	_	_	I-Premise
327	fecal	_	_	I-Premise
328	incontinence	_	_	I-Premise
329	score	_	_	I-Premise
330	was	_	_	I-Premise
331	9	_	_	I-Premise
332	(	_	_	I-Premise
333	possible	_	_	I-Premise
334	range	_	_	I-Premise
335	:	_	_	I-Premise
336	0	_	_	I-Premise
337	-	_	_	I-Premise
338	20	_	_	I-Premise
339	)	_	_	I-Premise
340	,	_	_	I-Premise
341	and	_	_	I-Premise
342	the	_	_	I-Premise
343	median	_	_	I-Premise
344	QOL	_	_	I-Premise
345	score	_	_	I-Premise
346	was	_	_	I-Premise
347	90	_	_	I-Premise
348	.	_	_	I-Premise

349	5	_	_	I-Premise
350	(	_	_	I-Premise
351	applicable	_	_	I-Premise
352	range	_	_	I-Premise
353	:	_	_	I-Premise
354	0	_	_	I-Premise
355	-	_	_	I-Premise
356	144	_	_	I-Premise
357	)	_	_	I-Premise
358	.	_	_	I-Premise

359	The	_	_	B-Claim
360	outcome	_	_	I-Claim
361	of	_	_	I-Claim
362	these	_	_	I-Claim
363	patients	_	_	I-Claim
364	remains	_	_	I-Claim
365	unsatisfactory	_	_	I-Claim
366	.	_	_	I-Claim

367	Prognostic	_	_	B-Premise
368	factors	_	_	I-Premise
369	for	_	_	I-Premise
370	a	_	_	I-Premise
371	favorable	_	_	I-Premise
372	outcome	_	_	I-Premise
373	are	_	_	I-Premise
374	tumor	_	_	I-Premise
375	size	_	_	I-Premise
376	of	_	_	I-Premise
377	smaller	_	_	I-Premise
378	than	_	_	I-Premise
379	5	_	_	I-Premise
380	cm	_	_	I-Premise
381	,	_	_	I-Premise
382	negative	_	_	I-Premise
383	locoregional	_	_	I-Premise
384	lymph	_	_	I-Premise
385	nodes	_	_	I-Premise
386	,	_	_	I-Premise
387	age	_	_	I-Premise
388	less	_	_	I-Premise
389	than	_	_	I-Premise
390	10	_	_	I-Premise
391	years	_	_	I-Premise
392	,	_	_	I-Premise
393	low	_	_	I-Premise
394	IRS	_	_	I-Premise
395	group	_	_	I-Premise
396	,	_	_	I-Premise
397	and	_	_	I-Premise
398	embryonal	_	_	I-Premise
399	histology	_	_	I-Premise
400	.	_	_	I-Premise

401	Fecal	_	_	B-Claim
402	incontinence	_	_	I-Claim
403	seems	_	_	I-Claim
404	to	_	_	I-Claim
405	be	_	_	I-Claim
406	a	_	_	I-Claim
407	problem	_	_	I-Claim
408	.	_	_	I-Claim


0	This	_	_	O
1	randomised	_	_	O
2	,	_	_	O
3	placebo	_	_	O
4	-	_	_	O
5	controlled	_	_	O
6	single	_	_	O
7	-	_	_	O
8	blind	_	_	O
9	trial	_	_	O
10	investigated	_	_	O
11	the	_	_	O
12	safety	_	_	O
13	and	_	_	O
14	efficacy	_	_	O
15	of	_	_	O
16	SAMITAL	_	_	O
17	®	_	_	O
18	,	_	_	O
19	a	_	_	O
20	formulation	_	_	O
21	of	_	_	O
22	highly	_	_	O
23	standardised	_	_	O
24	botanical	_	_	O
25	extracts	_	_	O
26	,	_	_	O
27	in	_	_	O
28	the	_	_	O
29	treatment	_	_	O
30	of	_	_	O
31	chemo	_	_	O
32	/	_	_	O
33	radiotherapy	_	_	O
34	-	_	_	O
35	induced	_	_	O
36	oral	_	_	O
37	mucositis	_	_	O
38	(	_	_	O
39	OM	_	_	O
40	)	_	_	O
41	in	_	_	O
42	patients	_	_	O
43	with	_	_	O
44	head	_	_	O
45	and	_	_	O
46	neck	_	_	O
47	cancer	_	_	O
48	.	_	_	O

49	Patients	_	_	O
50	received	_	_	O
51	SAMITAL	_	_	O
52	®	_	_	O
53	or	_	_	O
54	placebo	_	_	O
55	four	_	_	O
56	times	_	_	O
57	daily	_	_	O
58	for	_	_	O
59	up	_	_	O
60	to	_	_	O
61	50	_	_	O
62	days	_	_	O
63	during	_	_	O
64	scheduled	_	_	O
65	chemo	_	_	O
66	/	_	_	O
67	radiotherapy	_	_	O
68	.	_	_	O

69	Severity	_	_	O
70	of	_	_	O
71	OM	_	_	O
72	was	_	_	O
73	monitored	_	_	O
74	according	_	_	O
75	to	_	_	O
76	a	_	_	O
77	modified	_	_	O
78	WHO	_	_	O
79	severity	_	_	O
80	scale	_	_	O
81	,	_	_	O
82	and	_	_	O
83	pain	_	_	O
84	and	_	_	O
85	quality	_	_	O
86	-	_	_	O
87	of	_	_	O
88	-	_	_	O
89	life	_	_	O
90	assessments	_	_	O
91	were	_	_	O
92	based	_	_	O
93	on	_	_	O
94	the	_	_	O
95	effect	_	_	O
96	of	_	_	O
97	symptoms	_	_	O
98	of	_	_	O
99	OM	_	_	O
100	on	_	_	O
101	relevant	_	_	O
102	daily	_	_	O
103	activities	_	_	O
104	,	_	_	O
105	according	_	_	O
106	to	_	_	O
107	a	_	_	O
108	visual	_	_	O
109	analogue	_	_	O
110	scale	_	_	O
111	.	_	_	O

112	Mean	_	_	B-Premise
113	scores	_	_	I-Premise
114	for	_	_	I-Premise
115	the	_	_	I-Premise
116	severity	_	_	I-Premise
117	of	_	_	I-Premise
118	OM	_	_	I-Premise
119	were	_	_	I-Premise
120	significantly	_	_	I-Premise
121	(	_	_	I-Premise
122	p	_	_	I-Premise
123	<	_	_	I-Premise
124	0	_	_	I-Premise
125	.	_	_	I-Premise

126	05	_	_	I-Premise
127	versus	_	_	I-Premise
128	baseline	_	_	I-Premise
129	)	_	_	I-Premise
130	reduced	_	_	I-Premise
131	from	_	_	I-Premise
132	day	_	_	I-Premise
133	31	_	_	I-Premise
134	until	_	_	I-Premise
135	the	_	_	I-Premise
136	end	_	_	I-Premise
137	of	_	_	I-Premise
138	treatment	_	_	I-Premise
139	in	_	_	I-Premise
140	patients	_	_	I-Premise
141	treated	_	_	I-Premise
142	with	_	_	I-Premise
143	SAMITAL	_	_	I-Premise
144	®	_	_	I-Premise
145	(	_	_	I-Premise
146	n	_	_	I-Premise
147	=	_	_	I-Premise
148	20	_	_	I-Premise
149	)	_	_	I-Premise
150	.	_	_	I-Premise

151	No	_	_	B-Premise
152	significant	_	_	I-Premise
153	improvement	_	_	I-Premise
154	was	_	_	I-Premise
155	observed	_	_	I-Premise
156	in	_	_	I-Premise
157	the	_	_	I-Premise
158	placebo	_	_	I-Premise
159	group	_	_	I-Premise
160	(	_	_	I-Premise
161	n	_	_	I-Premise
162	=	_	_	I-Premise
163	10	_	_	I-Premise
164	)	_	_	I-Premise
165	.	_	_	I-Premise

166	Pain	_	_	B-Premise
167	reduction	_	_	I-Premise
168	was	_	_	I-Premise
169	significant	_	_	I-Premise
170	from	_	_	I-Premise
171	day	_	_	I-Premise
172	4	_	_	I-Premise
173	till	_	_	I-Premise
174	end	_	_	I-Premise
175	of	_	_	I-Premise
176	treatment	_	_	I-Premise
177	with	_	_	I-Premise
178	SAMITAL	_	_	I-Premise
179	®	_	_	I-Premise
180	and	_	_	I-Premise
181	from	_	_	I-Premise
182	days	_	_	I-Premise
183	7	_	_	I-Premise
184	to	_	_	I-Premise
185	21	_	_	I-Premise
186	in	_	_	I-Premise
187	placebo	_	_	I-Premise
188	patients	_	_	I-Premise
189	.	_	_	I-Premise

190	SAMITAL	_	_	B-Premise
191	®	_	_	I-Premise
192	also	_	_	I-Premise
193	significantly	_	_	I-Premise
194	improved	_	_	I-Premise
195	quality	_	_	I-Premise
196	of	_	_	I-Premise
197	life	_	_	I-Premise
198	,	_	_	I-Premise
199	as	_	_	I-Premise
200	shown	_	_	I-Premise
201	by	_	_	I-Premise
202	improvements	_	_	I-Premise
203	in	_	_	I-Premise
204	scores	_	_	I-Premise
205	for	_	_	I-Premise
206	relevant	_	_	I-Premise
207	daily	_	_	I-Premise
208	activities	_	_	I-Premise
209	including	_	_	I-Premise
210	eating	_	_	I-Premise
211	,	_	_	I-Premise
212	drinking	_	_	I-Premise
213	and	_	_	I-Premise
214	sleeping	_	_	I-Premise
215	.	_	_	I-Premise

216	All	_	_	O
217	SAMITAL	_	_	O
218	®	_	_	O
219	patients	_	_	O
220	completed	_	_	O
221	the	_	_	O
222	treatment	_	_	O
223	period	_	_	O
224	,	_	_	O
225	but	_	_	O
226	no	_	_	O
227	placebo	_	_	O
228	recipients	_	_	O
229	completed	_	_	O
230	treatment	_	_	O
231	.	_	_	O

232	No	_	_	B-Premise
233	severe	_	_	I-Premise
234	adverse	_	_	I-Premise
235	events	_	_	I-Premise
236	were	_	_	I-Premise
237	observed	_	_	I-Premise
238	with	_	_	I-Premise
239	SAMITAL	_	_	I-Premise
240	®	_	_	I-Premise
241	,	_	_	I-Premise
242	and	_	_	I-Premise
243	systemic	_	_	I-Premise
244	absorption	_	_	I-Premise
245	of	_	_	I-Premise
246	relevant	_	_	I-Premise
247	active	_	_	I-Premise
248	ingredients	_	_	I-Premise
249	was	_	_	I-Premise
250	undetectable	_	_	I-Premise
251	.	_	_	I-Premise

252	SAMITAL	_	_	B-Claim
253	®	_	_	I-Claim
254	significantly	_	_	I-Claim
255	decreased	_	_	I-Claim
256	the	_	_	I-Claim
257	severity	_	_	I-Claim
258	of	_	_	I-Claim
259	chemo	_	_	I-Claim
260	/	_	_	I-Claim
261	radiotherapy	_	_	I-Claim
262	-	_	_	I-Claim
263	induced	_	_	I-Claim
264	OM	_	_	I-Claim
265	in	_	_	I-Claim
266	patients	_	_	I-Claim
267	with	_	_	I-Claim
268	head	_	_	I-Claim
269	and	_	_	I-Claim
270	neck	_	_	I-Claim
271	cancer	_	_	I-Claim
272	,	_	_	I-Claim
273	with	_	_	I-Claim
274	no	_	_	I-Claim
275	treatment	_	_	I-Claim
276	-	_	_	I-Claim
277	related	_	_	I-Claim
278	adverse	_	_	I-Claim
279	events	_	_	I-Claim
280	.	_	_	I-Claim

281	Pain	_	_	B-Claim
282	relief	_	_	I-Claim
283	lasted	_	_	I-Claim
284	through	_	_	I-Claim
285	the	_	_	I-Claim
286	treatment	_	_	I-Claim
287	period	_	_	I-Claim
288	,	_	_	I-Claim
289	and	_	_	I-Claim
290	improvements	_	_	I-Claim
291	in	_	_	I-Claim
292	quality	_	_	I-Claim
293	of	_	_	I-Claim
294	life	_	_	I-Claim
295	were	_	_	I-Claim
296	reflected	_	_	I-Claim
297	by	_	_	I-Claim
298	the	_	_	I-Claim
299	significant	_	_	I-Claim
300	benefits	_	_	I-Claim
301	of	_	_	I-Claim
302	SAMITAL	_	_	I-Claim
303	®	_	_	I-Claim
304	on	_	_	I-Claim
305	activities	_	_	I-Claim
306	like	_	_	I-Claim
307	drinking	_	_	I-Claim
308	,	_	_	I-Claim
309	eating	_	_	I-Claim
310	and	_	_	I-Claim
311	speaking	_	_	I-Claim
312	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	first	_	_	O
8	-	_	_	O
9	line	_	_	O
10	,	_	_	O
11	single	_	_	O
12	-	_	_	O
13	agent	_	_	O
14	trastuzumab	_	_	O
15	in	_	_	O
16	women	_	_	O
17	with	_	_	O
18	HER2	_	_	O
19	-	_	_	O
20	overexpressing	_	_	O
21	metastatic	_	_	O
22	breast	_	_	O
23	cancer	_	_	O
24	.	_	_	O

25	One	_	_	O
26	hundred	_	_	O
27	fourteen	_	_	O
28	women	_	_	O
29	with	_	_	O
30	HER2	_	_	O
31	-	_	_	O
32	overexpressing	_	_	O
33	metastatic	_	_	O
34	breast	_	_	O
35	cancer	_	_	O
36	were	_	_	O
37	randomized	_	_	O
38	to	_	_	O
39	receive	_	_	O
40	first	_	_	O
41	-	_	_	O
42	line	_	_	O
43	treatment	_	_	O
44	with	_	_	O
45	trastuzumab	_	_	O
46	4	_	_	O
47	mg	_	_	O
48	/	_	_	O
49	kg	_	_	O
50	loading	_	_	O
51	dose	_	_	O
52	,	_	_	O
53	followed	_	_	O
54	by	_	_	O
55	2	_	_	O
56	mg	_	_	O
57	/	_	_	O
58	kg	_	_	O
59	weekly	_	_	O
60	,	_	_	O
61	or	_	_	O
62	a	_	_	O
63	higher	_	_	O
64	8	_	_	O
65	mg	_	_	O
66	/	_	_	O
67	kg	_	_	O
68	loading	_	_	O
69	dose	_	_	O
70	,	_	_	O
71	followed	_	_	O
72	by	_	_	O
73	4	_	_	O
74	mg	_	_	O
75	/	_	_	O
76	kg	_	_	O
77	weekly	_	_	O
78	.	_	_	O

79	The	_	_	B-Premise
80	objective	_	_	I-Premise
81	response	_	_	I-Premise
82	rate	_	_	I-Premise
83	was	_	_	I-Premise
84	26	_	_	I-Premise
85	%	_	_	I-Premise
86	(	_	_	I-Premise
87	95	_	_	I-Premise
88	%	_	_	I-Premise
89	confidence	_	_	I-Premise
90	interval	_	_	I-Premise
91	[	_	_	I-Premise
92	CI	_	_	I-Premise
93	]	_	_	I-Premise
94	,	_	_	I-Premise
95	18	_	_	I-Premise
96	.	_	_	I-Premise

97	2	_	_	I-Premise
98	%	_	_	I-Premise
99	to	_	_	I-Premise
100	34	_	_	I-Premise
101	.	_	_	I-Premise

102	4	_	_	I-Premise
103	%	_	_	I-Premise
104	)	_	_	I-Premise
105	,	_	_	I-Premise
106	with	_	_	I-Premise
107	seven	_	_	I-Premise
108	complete	_	_	I-Premise
109	and	_	_	I-Premise
110	23	_	_	I-Premise
111	partial	_	_	I-Premise
112	responses	_	_	I-Premise
113	.	_	_	I-Premise

114	Response	_	_	B-Premise
115	rates	_	_	I-Premise
116	in	_	_	I-Premise
117	111	_	_	I-Premise
118	assessable	_	_	I-Premise
119	patients	_	_	I-Premise
120	with	_	_	I-Premise
121	3	_	_	I-Premise
122	+	_	_	I-Premise
123	and	_	_	I-Premise
124	2	_	_	I-Premise
125	+	_	_	I-Premise
126	HER2	_	_	I-Premise
127	overexpression	_	_	I-Premise
128	by	_	_	I-Premise
129	immunohistochemistry	_	_	I-Premise
130	(	_	_	I-Premise
131	IHC	_	_	I-Premise
132	)	_	_	I-Premise
133	were	_	_	I-Premise
134	35	_	_	I-Premise
135	%	_	_	I-Premise
136	(	_	_	I-Premise
137	95	_	_	I-Premise
138	%	_	_	I-Premise
139	CI	_	_	I-Premise
140	,	_	_	I-Premise
141	24	_	_	I-Premise
142	.	_	_	I-Premise

143	4	_	_	I-Premise
144	%	_	_	I-Premise
145	to	_	_	I-Premise
146	44	_	_	I-Premise
147	.	_	_	I-Premise

148	7	_	_	I-Premise
149	%	_	_	I-Premise
150	)	_	_	I-Premise
151	and	_	_	I-Premise
152	none	_	_	I-Premise
153	(	_	_	I-Premise
154	95	_	_	I-Premise
155	%	_	_	I-Premise
156	CI	_	_	I-Premise
157	,	_	_	I-Premise
158	0	_	_	I-Premise
159	%	_	_	I-Premise
160	to	_	_	I-Premise
161	15	_	_	I-Premise
162	.	_	_	I-Premise

163	5	_	_	I-Premise
164	%	_	_	I-Premise
165	)	_	_	I-Premise
166	,	_	_	I-Premise
167	respectively	_	_	I-Premise
168	.	_	_	I-Premise

169	The	_	_	B-Premise
170	clinical	_	_	I-Premise
171	benefit	_	_	I-Premise
172	rates	_	_	I-Premise
173	in	_	_	I-Premise
174	assessable	_	_	I-Premise
175	patients	_	_	I-Premise
176	with	_	_	I-Premise
177	3	_	_	I-Premise
178	+	_	_	I-Premise
179	and	_	_	I-Premise
180	2	_	_	I-Premise
181	+	_	_	I-Premise
182	HER2	_	_	I-Premise
183	overexpression	_	_	I-Premise
184	were	_	_	I-Premise
185	48	_	_	I-Premise
186	%	_	_	I-Premise
187	and	_	_	I-Premise
188	7	_	_	I-Premise
189	%	_	_	I-Premise
190	,	_	_	I-Premise
191	respectively	_	_	I-Premise
192	.	_	_	I-Premise

193	The	_	_	B-Premise
194	response	_	_	I-Premise
195	rates	_	_	I-Premise
196	in	_	_	I-Premise
197	108	_	_	I-Premise
198	assessable	_	_	I-Premise
199	patients	_	_	I-Premise
200	with	_	_	I-Premise
201	and	_	_	I-Premise
202	without	_	_	I-Premise
203	HER2	_	_	I-Premise
204	gene	_	_	I-Premise
205	amplification	_	_	I-Premise
206	by	_	_	I-Premise
207	fluorescence	_	_	I-Premise
208	in	_	_	I-Premise
209	situ	_	_	I-Premise
210	hybridization	_	_	I-Premise
211	(	_	_	I-Premise
212	FISH	_	_	I-Premise
213	)	_	_	I-Premise
214	analysis	_	_	I-Premise
215	were	_	_	I-Premise
216	34	_	_	I-Premise
217	%	_	_	I-Premise
218	(	_	_	I-Premise
219	95	_	_	I-Premise
220	%	_	_	I-Premise
221	CI	_	_	I-Premise
222	,	_	_	I-Premise
223	23	_	_	I-Premise
224	.	_	_	I-Premise

225	9	_	_	I-Premise
226	%	_	_	I-Premise
227	to	_	_	I-Premise
228	45	_	_	I-Premise
229	.	_	_	I-Premise

230	7	_	_	I-Premise
231	%	_	_	I-Premise
232	)	_	_	I-Premise
233	and	_	_	I-Premise
234	7	_	_	I-Premise
235	%	_	_	I-Premise
236	(	_	_	I-Premise
237	95	_	_	I-Premise
238	%	_	_	I-Premise
239	CI	_	_	I-Premise
240	,	_	_	I-Premise
241	0	_	_	I-Premise
242	.	_	_	I-Premise

243	8	_	_	I-Premise
244	%	_	_	I-Premise
245	to	_	_	I-Premise
246	22	_	_	I-Premise
247	.	_	_	I-Premise

248	8	_	_	I-Premise
249	%	_	_	I-Premise
250	)	_	_	I-Premise
251	,	_	_	I-Premise
252	respectively	_	_	I-Premise
253	.	_	_	I-Premise

254	Seventeen	_	_	B-Premise
255	(	_	_	I-Premise
256	57	_	_	I-Premise
257	%	_	_	I-Premise
258	)	_	_	I-Premise
259	of	_	_	I-Premise
260	30	_	_	I-Premise
261	patients	_	_	I-Premise
262	with	_	_	I-Premise
263	an	_	_	I-Premise
264	objective	_	_	I-Premise
265	response	_	_	I-Premise
266	and	_	_	I-Premise
267	22	_	_	I-Premise
268	(	_	_	I-Premise
269	51	_	_	I-Premise
270	%	_	_	I-Premise
271	)	_	_	I-Premise
272	of	_	_	I-Premise
273	43	_	_	I-Premise
274	patients	_	_	I-Premise
275	with	_	_	I-Premise
276	clinical	_	_	I-Premise
277	benefit	_	_	I-Premise
278	had	_	_	I-Premise
279	not	_	_	I-Premise
280	experienced	_	_	I-Premise
281	disease	_	_	I-Premise
282	progression	_	_	I-Premise
283	at	_	_	I-Premise
284	follow	_	_	I-Premise
285	-	_	_	I-Premise
286	up	_	_	I-Premise
287	at	_	_	I-Premise
288	12	_	_	I-Premise
289	months	_	_	I-Premise
290	or	_	_	I-Premise
291	later	_	_	I-Premise
292	.	_	_	I-Premise

293	The	_	_	B-Premise
294	most	_	_	I-Premise
295	common	_	_	I-Premise
296	treatment	_	_	I-Premise
297	-	_	_	I-Premise
298	related	_	_	I-Premise
299	adverse	_	_	I-Premise
300	events	_	_	I-Premise
301	were	_	_	I-Premise
302	chills	_	_	I-Premise
303	(	_	_	I-Premise
304	25	_	_	I-Premise
305	%	_	_	I-Premise
306	of	_	_	I-Premise
307	patients	_	_	I-Premise
308	)	_	_	I-Premise
309	,	_	_	I-Premise
310	asthenia	_	_	I-Premise
311	(	_	_	I-Premise
312	23	_	_	I-Premise
313	%	_	_	I-Premise
314	)	_	_	I-Premise
315	,	_	_	I-Premise
316	fever	_	_	I-Premise
317	(	_	_	I-Premise
318	22	_	_	I-Premise
319	%	_	_	I-Premise
320	)	_	_	I-Premise
321	,	_	_	I-Premise
322	pain	_	_	I-Premise
323	(	_	_	I-Premise
324	18	_	_	I-Premise
325	%	_	_	I-Premise
326	)	_	_	I-Premise
327	,	_	_	I-Premise
328	and	_	_	I-Premise
329	nausea	_	_	I-Premise
330	(	_	_	I-Premise
331	14	_	_	I-Premise
332	%	_	_	I-Premise
333	)	_	_	I-Premise
334	.	_	_	I-Premise

335	Cardiac	_	_	B-Premise
336	dysfunction	_	_	I-Premise
337	occurred	_	_	I-Premise
338	in	_	_	I-Premise
339	two	_	_	I-Premise
340	patients	_	_	I-Premise
341	(	_	_	I-Premise
342	2	_	_	I-Premise
343	%	_	_	I-Premise
344	)	_	_	I-Premise
345	;	_	_	I-Premise
346	both	_	_	I-Premise
347	had	_	_	I-Premise
348	histories	_	_	I-Premise
349	of	_	_	I-Premise
350	cardiac	_	_	I-Premise
351	disease	_	_	I-Premise
352	and	_	_	I-Premise
353	did	_	_	I-Premise
354	not	_	_	I-Premise
355	require	_	_	I-Premise
356	additional	_	_	I-Premise
357	intervention	_	_	I-Premise
358	after	_	_	I-Premise
359	discontinuation	_	_	I-Premise
360	of	_	_	I-Premise
361	trastuzumab	_	_	I-Premise
362	.	_	_	I-Premise

363	There	_	_	B-Claim
364	was	_	_	I-Claim
365	no	_	_	I-Claim
366	clear	_	_	I-Claim
367	evidence	_	_	I-Claim
368	of	_	_	I-Claim
369	a	_	_	I-Claim
370	dose	_	_	I-Claim
371	-	_	_	I-Claim
372	response	_	_	I-Claim
373	relationship	_	_	I-Claim
374	for	_	_	I-Claim
375	response	_	_	I-Claim
376	,	_	_	I-Claim
377	survival	_	_	I-Claim
378	,	_	_	I-Claim
379	or	_	_	I-Claim
380	adverse	_	_	I-Claim
381	events	_	_	I-Claim
382	.	_	_	I-Claim

383	Single	_	_	B-Claim
384	-	_	_	I-Claim
385	agent	_	_	I-Claim
386	trastuzumab	_	_	I-Claim
387	is	_	_	I-Claim
388	active	_	_	I-Claim
389	and	_	_	I-Claim
390	well	_	_	I-Claim
391	tolerated	_	_	I-Claim
392	as	_	_	I-Claim
393	first	_	_	I-Claim
394	-	_	_	I-Claim
395	line	_	_	I-Claim
396	treatment	_	_	I-Claim
397	of	_	_	I-Claim
398	women	_	_	I-Claim
399	with	_	_	I-Claim
400	metastatic	_	_	I-Claim
401	breast	_	_	I-Claim
402	cancer	_	_	I-Claim
403	with	_	_	I-Claim
404	HER2	_	_	I-Claim
405	3	_	_	I-Claim
406	+	_	_	I-Claim
407	overexpression	_	_	I-Claim
408	by	_	_	I-Claim
409	IHC	_	_	I-Claim
410	or	_	_	I-Claim
411	gene	_	_	I-Claim
412	amplification	_	_	I-Claim
413	by	_	_	I-Claim
414	FISH	_	_	I-Claim
415	.	_	_	I-Claim


0	Phase	_	_	B-Claim
1	II	_	_	I-Claim
2	and	_	_	I-Claim
3	III	_	_	I-Claim
4	studies	_	_	I-Claim
5	have	_	_	I-Claim
6	shown	_	_	I-Claim
7	that	_	_	I-Claim
8	the	_	_	I-Claim
9	addition	_	_	I-Claim
10	of	_	_	I-Claim
11	interleukin	_	_	I-Claim
12	-	_	_	I-Claim
13	2	_	_	I-Claim
14	(	_	_	I-Claim
15	IL	_	_	I-Claim
16	-	_	_	I-Claim
17	2	_	_	I-Claim
18	)	_	_	I-Claim
19	and	_	_	I-Claim
20	interferon	_	_	I-Claim
21	alpha	_	_	I-Claim
22	-	_	_	I-Claim
23	2b	_	_	I-Claim
24	(	_	_	I-Claim
25	IFN	_	_	I-Claim
26	alpha	_	_	I-Claim
27	-	_	_	I-Claim
28	2b	_	_	I-Claim
29	)	_	_	I-Claim
30	in	_	_	I-Claim
31	multiagent	_	_	I-Claim
32	chemotherapy	_	_	I-Claim
33	(	_	_	I-Claim
34	CT	_	_	I-Claim
35	)	_	_	I-Claim
36	for	_	_	I-Claim
37	advanced	_	_	I-Claim
38	melanoma	_	_	I-Claim
39	increases	_	_	I-Claim
40	overall	_	_	I-Claim
41	response	_	_	I-Claim
42	(	_	_	I-Claim
43	OR	_	_	I-Claim
44	)	_	_	I-Claim
45	,	_	_	I-Claim
46	albeit	_	_	I-Claim
47	without	_	_	I-Claim
48	clear	_	_	I-Claim
49	evidence	_	_	I-Claim
50	of	_	_	I-Claim
51	an	_	_	I-Claim
52	improvement	_	_	I-Claim
53	in	_	_	I-Claim
54	overall	_	_	I-Claim
55	survival	_	_	I-Claim
56	(	_	_	I-Claim
57	OS	_	_	I-Claim
58	)	_	_	I-Claim
59	.	_	_	I-Claim

60	Treatment	_	_	B-Claim
61	with	_	_	I-Claim
62	high	_	_	I-Claim
63	-	_	_	I-Claim
64	dose	_	_	I-Claim
65	IL	_	_	I-Claim
66	-	_	_	I-Claim
67	2	_	_	I-Claim
68	can	_	_	I-Claim
69	cause	_	_	I-Claim
70	severe	_	_	I-Claim
71	toxicity	_	_	I-Claim
72	and	_	_	I-Claim
73	is	_	_	I-Claim
74	normally	_	_	I-Claim
75	administered	_	_	I-Claim
76	in	_	_	I-Claim
77	an	_	_	I-Claim
78	inpatient	_	_	I-Claim
79	setting	_	_	I-Claim
80	.	_	_	I-Claim

81	We	_	_	O
82	conducted	_	_	O
83	a	_	_	O
84	multicenter	_	_	O
85	prospective	_	_	O
86	randomized	_	_	O
87	clinical	_	_	O
88	trial	_	_	O
89	in	_	_	O
90	outpatients	_	_	O
91	with	_	_	O
92	metastatic	_	_	O
93	melanoma	_	_	O
94	to	_	_	O
95	compare	_	_	O
96	CT	_	_	O
97	with	_	_	O
98	biochemotherapy	_	_	O
99	(	_	_	O
100	bioCT	_	_	O
101	)	_	_	O
102	using	_	_	O
103	immunomodulant	_	_	O
104	doses	_	_	O
105	of	_	_	O
106	IL	_	_	O
107	-	_	_	O
108	2	_	_	O
109	and	_	_	O
110	IFN	_	_	O
111	alpha	_	_	O
112	-	_	_	O
113	2b	_	_	O
114	.	_	_	O

115	One	_	_	O
116	hundred	_	_	O
117	seventy	_	_	O
118	-	_	_	O
119	six	_	_	O
120	eligible	_	_	O
121	patients	_	_	O
122	with	_	_	O
123	advanced	_	_	O
124	melanoma	_	_	O
125	were	_	_	O
126	randomized	_	_	O
127	to	_	_	O
128	receive	_	_	O
129	CT	_	_	O
130	(	_	_	O
131	cisplatin	_	_	O
132	and	_	_	O
133	dacarbazine	_	_	O
134	with	_	_	O
135	or	_	_	O
136	without	_	_	O
137	carmustine	_	_	O
138	every	_	_	O
139	21	_	_	O
140	days	_	_	O
141	)	_	_	O
142	or	_	_	O
143	bioCT	_	_	O
144	comprising	_	_	O
145	the	_	_	O
146	same	_	_	O
147	CT	_	_	O
148	regimen	_	_	O
149	followed	_	_	O
150	by	_	_	O
151	low	_	_	O
152	-	_	_	O
153	dose	_	_	O
154	subcutaneous	_	_	O
155	IL	_	_	O
156	-	_	_	O
157	2	_	_	O
158	for	_	_	O
159	8	_	_	O
160	days	_	_	O
161	and	_	_	O
162	IFN	_	_	O
163	alpha	_	_	O
164	-	_	_	O
165	2b	_	_	O
166	three	_	_	O
167	times	_	_	O
168	a	_	_	O
169	week	_	_	O
170	,	_	_	O
171	both	_	_	O
172	for	_	_	O
173	six	_	_	O
174	cycles	_	_	O
175	.	_	_	O

176	At	_	_	B-Premise
177	a	_	_	I-Premise
178	median	_	_	I-Premise
179	follow	_	_	I-Premise
180	-	_	_	I-Premise
181	up	_	_	I-Premise
182	of	_	_	I-Premise
183	18	_	_	I-Premise
184	(	_	_	I-Premise
185	CT	_	_	I-Premise
186	)	_	_	I-Premise
187	and	_	_	I-Premise
188	16	_	_	I-Premise
189	(	_	_	I-Premise
190	bioCT	_	_	I-Premise
191	)	_	_	I-Premise
192	months	_	_	I-Premise
193	,	_	_	I-Premise
194	median	_	_	I-Premise
195	OS	_	_	I-Premise
196	was	_	_	I-Premise
197	9	_	_	I-Premise
198	.	_	_	I-Premise

199	5	_	_	I-Premise
200	versus	_	_	I-Premise
201	11	_	_	I-Premise
202	.	_	_	I-Premise

203	0	_	_	I-Premise
204	months	_	_	I-Premise
205	(	_	_	I-Premise
206	P	_	_	I-Premise
207	=	_	_	I-Premise
208	.	_	_	I-Premise

209	51	_	_	I-Premise
210	)	_	_	I-Premise
211	,	_	_	I-Premise
212	respectively	_	_	I-Premise
213	.	_	_	I-Premise

214	In	_	_	B-Premise
215	the	_	_	I-Premise
216	89	_	_	I-Premise
217	CT	_	_	I-Premise
218	-	_	_	I-Premise
219	arm	_	_	I-Premise
220	patients	_	_	I-Premise
221	,	_	_	I-Premise
222	18	_	_	I-Premise
223	ORs	_	_	I-Premise
224	(	_	_	I-Premise
225	20	_	_	I-Premise
226	.	_	_	I-Premise

227	2	_	_	I-Premise
228	%	_	_	I-Premise
229	)	_	_	I-Premise
230	(	_	_	I-Premise
231	three	_	_	I-Premise
232	complete	_	_	I-Premise
233	responders	_	_	I-Premise
234	[	_	_	I-Premise
235	CRs	_	_	I-Premise
236	]	_	_	I-Premise
237	and	_	_	I-Premise
238	15	_	_	I-Premise
239	partial	_	_	I-Premise
240	responders	_	_	I-Premise
241	[	_	_	I-Premise
242	PRs	_	_	I-Premise
243	]	_	_	I-Premise
244	)	_	_	I-Premise
245	were	_	_	I-Premise
246	observed	_	_	I-Premise
247	according	_	_	I-Premise
248	to	_	_	I-Premise
249	World	_	_	I-Premise
250	Health	_	_	I-Premise
251	Organization	_	_	I-Premise
252	criteria	_	_	I-Premise
253	.	_	_	I-Premise

254	In	_	_	B-Premise
255	the	_	_	I-Premise
256	87	_	_	I-Premise
257	bioCT	_	_	I-Premise
258	-	_	_	I-Premise
259	arm	_	_	I-Premise
260	patients	_	_	I-Premise
261	,	_	_	I-Premise
262	22	_	_	I-Premise
263	ORs	_	_	I-Premise
264	(	_	_	I-Premise
265	25	_	_	I-Premise
266	.	_	_	I-Premise

267	3	_	_	I-Premise
268	%	_	_	I-Premise
269	)	_	_	I-Premise
270	(	_	_	I-Premise
271	three	_	_	I-Premise
272	CRs	_	_	I-Premise
273	and	_	_	I-Premise
274	19	_	_	I-Premise
275	PRs	_	_	I-Premise
276	)	_	_	I-Premise
277	(	_	_	I-Premise
278	P	_	_	I-Premise
279	=	_	_	I-Premise
280	.	_	_	I-Premise

281	70	_	_	I-Premise
282	)	_	_	I-Premise
283	were	_	_	I-Premise
284	recorded	_	_	I-Premise
285	.	_	_	I-Premise

286	Treatment	_	_	B-Premise
287	-	_	_	I-Premise
288	related	_	_	I-Premise
289	toxicity	_	_	I-Premise
290	was	_	_	I-Premise
291	fairly	_	_	I-Premise
292	similar	_	_	I-Premise
293	in	_	_	I-Premise
294	both	_	_	I-Premise
295	arms	_	_	I-Premise
296	.	_	_	I-Premise

297	The	_	_	B-Claim
298	addition	_	_	I-Claim
299	of	_	_	I-Claim
300	low	_	_	I-Claim
301	-	_	_	I-Claim
302	dose	_	_	I-Claim
303	immunotherapy	_	_	I-Claim
304	did	_	_	I-Claim
305	not	_	_	I-Claim
306	produce	_	_	I-Claim
307	a	_	_	I-Claim
308	statistically	_	_	I-Claim
309	significant	_	_	I-Claim
310	advantage	_	_	I-Claim
311	in	_	_	I-Claim
312	OS	_	_	I-Claim
313	,	_	_	I-Claim
314	time	_	_	I-Claim
315	to	_	_	I-Claim
316	progression	_	_	I-Claim
317	,	_	_	I-Claim
318	or	_	_	I-Claim
319	OR	_	_	I-Claim
320	.	_	_	I-Claim

321	However	_	_	B-Claim
322	,	_	_	I-Claim
323	the	_	_	I-Claim
324	11	_	_	I-Claim
325	-	_	_	I-Claim
326	month	_	_	I-Claim
327	median	_	_	I-Claim
328	OS	_	_	I-Claim
329	in	_	_	I-Claim
330	the	_	_	I-Claim
331	bioCT	_	_	I-Claim
332	arm	_	_	I-Claim
333	does	_	_	I-Claim
334	not	_	_	I-Claim
335	differ	_	_	I-Claim
336	greatly	_	_	I-Claim
337	from	_	_	I-Claim
338	the	_	_	I-Claim
339	best	_	_	I-Claim
340	results	_	_	I-Claim
341	with	_	_	I-Claim
342	high	_	_	I-Claim
343	-	_	_	I-Claim
344	dose	_	_	I-Claim
345	IL	_	_	I-Claim
346	-	_	_	I-Claim
347	2	_	_	I-Claim
348	-	_	_	I-Claim
349	containing	_	_	I-Claim
350	regimens	_	_	I-Claim
351	reported	_	_	I-Claim
352	in	_	_	I-Claim
353	the	_	_	I-Claim
354	literature	_	_	I-Claim
355	.	_	_	I-Claim

356	Furthermore	_	_	O
357	,	_	_	O
358	our	_	_	B-Claim
359	treatment	_	_	I-Claim
360	schedule	_	_	I-Claim
361	was	_	_	I-Claim
362	carried	_	_	I-Claim
363	out	_	_	I-Claim
364	on	_	_	I-Claim
365	outpatients	_	_	I-Claim
366	and	_	_	I-Claim
367	had	_	_	I-Claim
368	an	_	_	I-Claim
369	acceptable	_	_	I-Claim
370	level	_	_	I-Claim
371	of	_	_	I-Claim
372	toxicity	_	_	I-Claim
373	.	_	_	I-Claim


0	In	_	_	B-Claim
1	a	_	_	I-Claim
2	randomized	_	_	I-Claim
3	clinical	_	_	I-Claim
4	trial	_	_	I-Claim
5	in	_	_	I-Claim
6	patients	_	_	I-Claim
7	with	_	_	I-Claim
8	advanced	_	_	I-Claim
9	non	_	_	I-Claim
10	-	_	_	I-Claim
11	small	_	_	I-Claim
12	-	_	_	I-Claim
13	cell	_	_	I-Claim
14	lung	_	_	I-Claim
15	cancer	_	_	I-Claim
16	(	_	_	I-Claim
17	NSCLC	_	_	I-Claim
18	)	_	_	I-Claim
19	,	_	_	I-Claim
20	infusion	_	_	I-Claim
21	with	_	_	I-Claim
22	adenosine	_	_	I-Claim
23	5	_	_	I-Claim
24	'	_	_	I-Claim
25	-	_	_	I-Claim
26	triphosphate	_	_	I-Claim
27	(	_	_	I-Claim
28	ATP	_	_	I-Claim
29	)	_	_	I-Claim
30	inhibited	_	_	I-Claim
31	loss	_	_	I-Claim
32	of	_	_	I-Claim
33	body	_	_	I-Claim
34	weight	_	_	I-Claim
35	and	_	_	I-Claim
36	quality	_	_	I-Claim
37	of	_	_	I-Claim
38	life	_	_	I-Claim
39	.	_	_	I-Claim

40	In	_	_	O
41	the	_	_	O
42	present	_	_	O
43	article	_	_	O
44	,	_	_	O
45	the	_	_	O
46	effects	_	_	O
47	of	_	_	O
48	ATP	_	_	O
49	on	_	_	O
50	body	_	_	O
51	composition	_	_	O
52	,	_	_	O
53	energy	_	_	O
54	intake	_	_	O
55	,	_	_	O
56	and	_	_	O
57	energy	_	_	O
58	expenditure	_	_	O
59	as	_	_	O
60	secondary	_	_	O
61	outcome	_	_	O
62	measures	_	_	O
63	in	_	_	O
64	the	_	_	O
65	same	_	_	O
66	patients	_	_	O
67	are	_	_	O
68	reported	_	_	O
69	.	_	_	O

70	Patients	_	_	O
71	with	_	_	O
72	NSCLC	_	_	O
73	,	_	_	O
74	stage	_	_	O
75	IIIB	_	_	O
76	or	_	_	O
77	IV	_	_	O
78	,	_	_	O
79	were	_	_	O
80	randomized	_	_	O
81	to	_	_	O
82	receive	_	_	O
83	either	_	_	O
84	10	_	_	O
85	intravenous	_	_	O
86	,	_	_	O
87	30	_	_	O
88	-	_	_	O
89	hour	_	_	O
90	ATP	_	_	O
91	infusions	_	_	O
92	every	_	_	O
93	2	_	_	O
94	to	_	_	O
95	4	_	_	O
96	weeks	_	_	O
97	or	_	_	O
98	no	_	_	O
99	ATP	_	_	O
100	.	_	_	O

101	Fat	_	_	O
102	mass	_	_	O
103	(	_	_	O
104	FM	_	_	O
105	)	_	_	O
106	,	_	_	O
107	fat	_	_	O
108	-	_	_	O
109	free	_	_	O
110	mass	_	_	O
111	(	_	_	O
112	FFM	_	_	O
113	)	_	_	O
114	,	_	_	O
115	and	_	_	O
116	arm	_	_	O
117	muscle	_	_	O
118	area	_	_	O
119	were	_	_	O
120	assessed	_	_	O
121	at	_	_	O
122	4	_	_	O
123	-	_	_	O
124	week	_	_	O
125	intervals	_	_	O
126	for	_	_	O
127	28	_	_	O
128	weeks	_	_	O
129	.	_	_	O

130	Food	_	_	O
131	intake	_	_	O
132	,	_	_	O
133	body	_	_	O
134	cell	_	_	O
135	mass	_	_	O
136	(	_	_	O
137	BCM	_	_	O
138	)	_	_	O
139	,	_	_	O
140	and	_	_	O
141	resting	_	_	O
142	energy	_	_	O
143	expenditure	_	_	O
144	(	_	_	O
145	REE	_	_	O
146	)	_	_	O
147	were	_	_	O
148	assessed	_	_	O
149	at	_	_	O
150	8	_	_	O
151	-	_	_	O
152	week	_	_	O
153	intervals	_	_	O
154	for	_	_	O
155	16	_	_	O
156	weeks	_	_	O
157	.	_	_	O

158	Between	_	_	O
159	-	_	_	O
160	group	_	_	O
161	differences	_	_	O
162	were	_	_	O
163	tested	_	_	O
164	for	_	_	O
165	statistical	_	_	O
166	significance	_	_	O
167	by	_	_	O
168	repeated	_	_	O
169	-	_	_	O
170	measures	_	_	O
171	analysis	_	_	O
172	of	_	_	O
173	covariance	_	_	O
174	.	_	_	O

175	Fifty	_	_	O
176	-	_	_	O
177	eight	_	_	O
178	patients	_	_	O
179	were	_	_	O
180	randomized	_	_	O
181	(	_	_	O
182	28	_	_	O
183	ATP	_	_	O
184	,	_	_	O
185	30	_	_	O
186	control	_	_	O
187	)	_	_	O
188	.	_	_	O

189	No	_	_	B-Premise
190	change	_	_	I-Premise
191	in	_	_	I-Premise
192	body	_	_	I-Premise
193	composition	_	_	I-Premise
194	over	_	_	I-Premise
195	the	_	_	I-Premise
196	28	_	_	I-Premise
197	-	_	_	I-Premise
198	week	_	_	I-Premise
199	follow	_	_	I-Premise
200	-	_	_	I-Premise
201	up	_	_	I-Premise
202	period	_	_	I-Premise
203	was	_	_	I-Premise
204	found	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	ATP	_	_	I-Premise
208	group	_	_	I-Premise
209	,	_	_	I-Premise
210	whereas	_	_	I-Premise
211	,	_	_	I-Premise
212	per	_	_	I-Premise
213	4	_	_	I-Premise
214	weeks	_	_	I-Premise
215	,	_	_	I-Premise
216	the	_	_	I-Premise
217	control	_	_	I-Premise
218	group	_	_	I-Premise
219	lost	_	_	I-Premise
220	0	_	_	I-Premise
221	.	_	_	I-Premise

222	6	_	_	I-Premise
223	kg	_	_	I-Premise
224	of	_	_	I-Premise
225	FM	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	.	_	_	I-Premise

230	004	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	0	_	_	I-Premise
234	.	_	_	I-Premise

235	5	_	_	I-Premise
236	kg	_	_	I-Premise
237	of	_	_	I-Premise
238	FFM	_	_	I-Premise
239	(	_	_	I-Premise
240	P	_	_	I-Premise
241	=	_	_	I-Premise
242	.	_	_	I-Premise

243	02	_	_	I-Premise
244	)	_	_	I-Premise
245	,	_	_	I-Premise
246	1	_	_	I-Premise
247	.	_	_	I-Premise

248	8	_	_	I-Premise
249	%	_	_	I-Premise
250	of	_	_	I-Premise
251	arm	_	_	I-Premise
252	muscle	_	_	I-Premise
253	area	_	_	I-Premise
254	(	_	_	I-Premise
255	P	_	_	I-Premise
256	=	_	_	I-Premise
257	.	_	_	I-Premise

258	02	_	_	I-Premise
259	)	_	_	I-Premise
260	,	_	_	I-Premise
261	and	_	_	I-Premise
262	0	_	_	I-Premise
263	.	_	_	I-Premise

264	6	_	_	I-Premise
265	%	_	_	I-Premise
266	of	_	_	I-Premise
267	BCM	_	_	I-Premise
268	/	_	_	I-Premise
269	kg	_	_	I-Premise
270	body	_	_	I-Premise
271	weight	_	_	I-Premise
272	(	_	_	I-Premise
273	P	_	_	I-Premise
274	=	_	_	I-Premise
275	.	_	_	I-Premise

276	054	_	_	I-Premise
277	)	_	_	I-Premise
278	and	_	_	I-Premise
279	decreased	_	_	I-Premise
280	568	_	_	I-Premise
281	KJ	_	_	I-Premise
282	/	_	_	I-Premise
283	d	_	_	I-Premise
284	in	_	_	I-Premise
285	energy	_	_	I-Premise
286	intake	_	_	I-Premise
287	(	_	_	I-Premise
288	P	_	_	I-Premise
289	=	_	_	I-Premise
290	.	_	_	I-Premise

291	0001	_	_	I-Premise
292	)	_	_	I-Premise
293	.	_	_	I-Premise

294	Appetite	_	_	B-Premise
295	also	_	_	I-Premise
296	remained	_	_	I-Premise
297	stable	_	_	I-Premise
298	in	_	_	I-Premise
299	the	_	_	I-Premise
300	ATP	_	_	I-Premise
301	group	_	_	I-Premise
302	but	_	_	I-Premise
303	decreased	_	_	I-Premise
304	significantly	_	_	I-Premise
305	in	_	_	I-Premise
306	the	_	_	I-Premise
307	control	_	_	I-Premise
308	group	_	_	I-Premise
309	(	_	_	I-Premise
310	P	_	_	I-Premise
311	=	_	_	I-Premise
312	.	_	_	I-Premise

313	0004	_	_	I-Premise
314	)	_	_	I-Premise
315	.	_	_	I-Premise

316	No	_	_	B-Premise
317	significant	_	_	I-Premise
318	differences	_	_	I-Premise
319	in	_	_	I-Premise
320	REE	_	_	I-Premise
321	between	_	_	I-Premise
322	the	_	_	I-Premise
323	ATP	_	_	I-Premise
324	and	_	_	I-Premise
325	control	_	_	I-Premise
326	groups	_	_	I-Premise
327	were	_	_	I-Premise
328	observed	_	_	I-Premise
329	.	_	_	I-Premise

330	The	_	_	B-Claim
331	inhibition	_	_	I-Claim
332	of	_	_	I-Claim
333	weight	_	_	I-Claim
334	loss	_	_	I-Claim
335	by	_	_	I-Claim
336	ATP	_	_	I-Claim
337	infusions	_	_	I-Claim
338	in	_	_	I-Claim
339	patients	_	_	I-Claim
340	with	_	_	I-Claim
341	advanced	_	_	I-Claim
342	NSCLC	_	_	I-Claim
343	is	_	_	I-Claim
344	attributed	_	_	I-Claim
345	to	_	_	I-Claim
346	counteracting	_	_	I-Claim
347	the	_	_	I-Claim
348	loss	_	_	I-Claim
349	of	_	_	I-Claim
350	both	_	_	I-Claim
351	metabolically	_	_	I-Claim
352	active	_	_	I-Claim
353	and	_	_	I-Claim
354	inactive	_	_	I-Claim
355	tissues	_	_	I-Claim
356	.	_	_	I-Claim

357	These	_	_	B-Premise
358	effects	_	_	I-Premise
359	are	_	_	I-Premise
360	partly	_	_	I-Premise
361	ascribed	_	_	I-Premise
362	to	_	_	I-Premise
363	maintenance	_	_	I-Premise
364	of	_	_	I-Premise
365	energy	_	_	I-Premise
366	intake	_	_	I-Premise
367	.	_	_	I-Premise


0	Menopausal	_	_	O
1	hormone	_	_	O
2	therapy	_	_	O
3	continues	_	_	O
4	in	_	_	O
5	clinical	_	_	O
6	use	_	_	O
7	but	_	_	O
8	questions	_	_	O
9	remain	_	_	O
10	regarding	_	_	O
11	its	_	_	O
12	risks	_	_	O
13	and	_	_	O
14	benefits	_	_	O
15	for	_	_	O
16	chronic	_	_	O
17	disease	_	_	O
18	prevention	_	_	O
19	.	_	_	O

20	To	_	_	O
21	report	_	_	O
22	a	_	_	O
23	comprehensive	_	_	O
24	,	_	_	O
25	integrated	_	_	O
26	overview	_	_	O
27	of	_	_	O
28	findings	_	_	O
29	from	_	_	O
30	the	_	_	O
31	2	_	_	O
32	Women	_	_	O
33	'	_	_	O
34	s	_	_	O
35	Health	_	_	O
36	Initiative	_	_	O
37	(	_	_	O
38	WHI	_	_	O
39	)	_	_	O
40	hormone	_	_	O
41	therapy	_	_	O
42	trials	_	_	O
43	with	_	_	O
44	extended	_	_	O
45	postintervention	_	_	O
46	follow	_	_	O
47	-	_	_	O
48	up	_	_	O
49	.	_	_	O

50	A	_	_	O
51	total	_	_	O
52	of	_	_	O
53	27	_	_	O
54	,	_	_	O
55	347	_	_	O
56	postmenopausal	_	_	O
57	women	_	_	O
58	aged	_	_	O
59	50	_	_	O
60	to	_	_	O
61	79	_	_	O
62	years	_	_	O
63	were	_	_	O
64	enrolled	_	_	O
65	at	_	_	O
66	40	_	_	O
67	US	_	_	O
68	centers	_	_	O
69	.	_	_	O

70	Women	_	_	O
71	with	_	_	O
72	an	_	_	O
73	intact	_	_	O
74	uterus	_	_	O
75	received	_	_	O
76	conjugated	_	_	O
77	equine	_	_	O
78	estrogens	_	_	O
79	(	_	_	O
80	CEE	_	_	O
81	;	_	_	O
82	0	_	_	O
83	.	_	_	O

84	625	_	_	O
85	mg	_	_	O
86	/	_	_	O
87	d	_	_	O
88	)	_	_	O
89	plus	_	_	O
90	medroxyprogesterone	_	_	O
91	acetate	_	_	O
92	(	_	_	O
93	MPA	_	_	O
94	;	_	_	O
95	2	_	_	O
96	.	_	_	O

97	5	_	_	O
98	mg	_	_	O
99	/	_	_	O
100	d	_	_	O
101	)	_	_	O
102	(	_	_	O
103	n	_	_	O
104	=	_	_	O
105	8506	_	_	O
106	)	_	_	O
107	or	_	_	O
108	placebo	_	_	O
109	(	_	_	O
110	n	_	_	O
111	=	_	_	O
112	8102	_	_	O
113	)	_	_	O
114	.	_	_	O

115	Women	_	_	O
116	with	_	_	O
117	prior	_	_	O
118	hysterectomy	_	_	O
119	received	_	_	O
120	CEE	_	_	O
121	alone	_	_	O
122	(	_	_	O
123	0	_	_	O
124	.	_	_	O

125	625	_	_	O
126	mg	_	_	O
127	/	_	_	O
128	d	_	_	O
129	)	_	_	O
130	(	_	_	O
131	n	_	_	O
132	=	_	_	O
133	5310	_	_	O
134	)	_	_	O
135	or	_	_	O
136	placebo	_	_	O
137	(	_	_	O
138	n	_	_	O
139	=	_	_	O
140	5429	_	_	O
141	)	_	_	O
142	.	_	_	O

143	The	_	_	O
144	intervention	_	_	O
145	lasted	_	_	O
146	a	_	_	O
147	median	_	_	O
148	of	_	_	O
149	5	_	_	O
150	.	_	_	O

151	6	_	_	O
152	years	_	_	O
153	in	_	_	O
154	CEE	_	_	O
155	plus	_	_	O
156	MPA	_	_	O
157	trial	_	_	O
158	and	_	_	O
159	7	_	_	O
160	.	_	_	O

161	2	_	_	O
162	years	_	_	O
163	in	_	_	O
164	CEE	_	_	O
165	alone	_	_	O
166	trial	_	_	O
167	with	_	_	O
168	13	_	_	O
169	years	_	_	O
170	of	_	_	O
171	cumulative	_	_	O
172	follow	_	_	O
173	-	_	_	O
174	up	_	_	O
175	until	_	_	O
176	September	_	_	O
177	30	_	_	O
178	,	_	_	O
179	2010	_	_	O
180	.	_	_	O

181	Primary	_	_	O
182	efficacy	_	_	O
183	and	_	_	O
184	safety	_	_	O
185	outcomes	_	_	O
186	were	_	_	O
187	coronary	_	_	O
188	heart	_	_	O
189	disease	_	_	O
190	(	_	_	O
191	CHD	_	_	O
192	)	_	_	O
193	and	_	_	O
194	invasive	_	_	O
195	breast	_	_	O
196	cancer	_	_	O
197	,	_	_	O
198	respectively	_	_	O
199	.	_	_	O

200	A	_	_	O
201	global	_	_	O
202	index	_	_	O
203	also	_	_	O
204	included	_	_	O
205	stroke	_	_	O
206	,	_	_	O
207	pulmonary	_	_	O
208	embolism	_	_	O
209	,	_	_	O
210	colorectal	_	_	O
211	cancer	_	_	O
212	,	_	_	O
213	endometrial	_	_	O
214	cancer	_	_	O
215	,	_	_	O
216	hip	_	_	O
217	fracture	_	_	O
218	,	_	_	O
219	and	_	_	O
220	death	_	_	O
221	.	_	_	O

222	During	_	_	B-Premise
223	the	_	_	I-Premise
224	CEE	_	_	I-Premise
225	plus	_	_	I-Premise
226	MPA	_	_	I-Premise
227	intervention	_	_	I-Premise
228	phase	_	_	I-Premise
229	,	_	_	I-Premise
230	the	_	_	I-Premise
231	numbers	_	_	I-Premise
232	of	_	_	I-Premise
233	CHD	_	_	I-Premise
234	cases	_	_	I-Premise
235	were	_	_	I-Premise
236	196	_	_	I-Premise
237	for	_	_	I-Premise
238	CEE	_	_	I-Premise
239	plus	_	_	I-Premise
240	MPA	_	_	I-Premise
241	vs	_	_	I-Premise
242	159	_	_	I-Premise
243	for	_	_	I-Premise
244	placebo	_	_	I-Premise
245	(	_	_	I-Premise
246	hazard	_	_	I-Premise
247	ratio	_	_	I-Premise
248	[	_	_	I-Premise
249	HR	_	_	I-Premise
250	]	_	_	I-Premise
251	,	_	_	I-Premise
252	1	_	_	I-Premise
253	.	_	_	I-Premise

254	18	_	_	I-Premise
255	;	_	_	I-Premise
256	95	_	_	I-Premise
257	%	_	_	I-Premise
258	CI	_	_	I-Premise
259	,	_	_	I-Premise
260	0	_	_	I-Premise
261	.	_	_	I-Premise

262	95	_	_	I-Premise
263	-	_	_	I-Premise
264	1	_	_	I-Premise
265	.	_	_	I-Premise

266	45	_	_	I-Premise
267	)	_	_	I-Premise
268	and	_	_	I-Premise
269	206	_	_	I-Premise
270	vs	_	_	I-Premise
271	155	_	_	I-Premise
272	,	_	_	I-Premise
273	respectively	_	_	I-Premise
274	,	_	_	I-Premise
275	for	_	_	I-Premise
276	invasive	_	_	I-Premise
277	breast	_	_	I-Premise
278	cancer	_	_	I-Premise
279	(	_	_	I-Premise
280	HR	_	_	I-Premise
281	,	_	_	I-Premise
282	1	_	_	I-Premise
283	.	_	_	I-Premise

284	24	_	_	I-Premise
285	;	_	_	I-Premise
286	95	_	_	I-Premise
287	%	_	_	I-Premise
288	CI	_	_	I-Premise
289	,	_	_	I-Premise
290	1	_	_	I-Premise
291	.	_	_	I-Premise

292	01	_	_	I-Premise
293	-	_	_	I-Premise
294	1	_	_	I-Premise
295	.	_	_	I-Premise

296	53	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	Other	_	_	B-Premise
300	risks	_	_	I-Premise
301	included	_	_	I-Premise
302	increased	_	_	I-Premise
303	stroke	_	_	I-Premise
304	,	_	_	I-Premise
305	pulmonary	_	_	I-Premise
306	embolism	_	_	I-Premise
307	,	_	_	I-Premise
308	dementia	_	_	I-Premise
309	(	_	_	I-Premise
310	in	_	_	I-Premise
311	women	_	_	I-Premise
312	aged	_	_	I-Premise
313	≥	_	_	I-Premise
314	65	_	_	I-Premise
315	years	_	_	I-Premise
316	)	_	_	I-Premise
317	,	_	_	I-Premise
318	gallbladder	_	_	I-Premise
319	disease	_	_	I-Premise
320	,	_	_	I-Premise
321	and	_	_	I-Premise
322	urinary	_	_	I-Premise
323	incontinence	_	_	I-Premise
324	;	_	_	I-Premise
325	benefits	_	_	I-Premise
326	included	_	_	I-Premise
327	decreased	_	_	I-Premise
328	hip	_	_	I-Premise
329	fractures	_	_	I-Premise
330	,	_	_	I-Premise
331	diabetes	_	_	I-Premise
332	,	_	_	I-Premise
333	and	_	_	I-Premise
334	vasomotor	_	_	I-Premise
335	symptoms	_	_	I-Premise
336	.	_	_	I-Premise

337	Most	_	_	B-Premise
338	risks	_	_	I-Premise
339	and	_	_	I-Premise
340	benefits	_	_	I-Premise
341	dissipated	_	_	I-Premise
342	postintervention	_	_	I-Premise
343	,	_	_	I-Premise
344	although	_	_	B-Premise
345	some	_	_	I-Premise
346	elevation	_	_	I-Premise
347	in	_	_	I-Premise
348	breast	_	_	I-Premise
349	cancer	_	_	I-Premise
350	risk	_	_	I-Premise
351	persisted	_	_	I-Premise
352	during	_	_	I-Premise
353	cumulative	_	_	I-Premise
354	follow	_	_	I-Premise
355	-	_	_	I-Premise
356	up	_	_	I-Premise
357	(	_	_	I-Premise
358	434	_	_	I-Premise
359	cases	_	_	I-Premise
360	for	_	_	I-Premise
361	CEE	_	_	I-Premise
362	plus	_	_	I-Premise
363	MPA	_	_	I-Premise
364	vs	_	_	I-Premise
365	323	_	_	I-Premise
366	for	_	_	I-Premise
367	placebo	_	_	I-Premise
368	;	_	_	I-Premise
369	HR	_	_	I-Premise
370	,	_	_	I-Premise
371	1	_	_	I-Premise
372	.	_	_	I-Premise

373	28	_	_	I-Premise
374	[	_	_	I-Premise
375	95	_	_	I-Premise
376	%	_	_	I-Premise
377	CI	_	_	I-Premise
378	,	_	_	I-Premise
379	1	_	_	I-Premise
380	.	_	_	I-Premise

381	11	_	_	I-Premise
382	-	_	_	I-Premise
383	1	_	_	I-Premise
384	.	_	_	I-Premise

385	48	_	_	I-Premise
386	]	_	_	I-Premise
387	)	_	_	I-Premise
388	.	_	_	I-Premise

389	The	_	_	B-Premise
390	risks	_	_	I-Premise
391	and	_	_	I-Premise
392	benefits	_	_	I-Premise
393	were	_	_	I-Premise
394	more	_	_	I-Premise
395	balanced	_	_	I-Premise
396	during	_	_	I-Premise
397	the	_	_	I-Premise
398	CEE	_	_	I-Premise
399	alone	_	_	I-Premise
400	intervention	_	_	I-Premise
401	with	_	_	I-Premise
402	204	_	_	I-Premise
403	CHD	_	_	I-Premise
404	cases	_	_	I-Premise
405	for	_	_	I-Premise
406	CEE	_	_	I-Premise
407	alone	_	_	I-Premise
408	vs	_	_	I-Premise
409	222	_	_	I-Premise
410	cases	_	_	I-Premise
411	for	_	_	I-Premise
412	placebo	_	_	I-Premise
413	(	_	_	I-Premise
414	HR	_	_	I-Premise
415	,	_	_	I-Premise
416	0	_	_	I-Premise
417	.	_	_	I-Premise

418	94	_	_	I-Premise
419	;	_	_	I-Premise
420	95	_	_	I-Premise
421	%	_	_	I-Premise
422	CI	_	_	I-Premise
423	,	_	_	I-Premise
424	0	_	_	I-Premise
425	.	_	_	I-Premise

426	78	_	_	I-Premise
427	-	_	_	I-Premise
428	1	_	_	I-Premise
429	.	_	_	I-Premise

430	14	_	_	I-Premise
431	)	_	_	I-Premise
432	and	_	_	I-Premise
433	104	_	_	I-Premise
434	vs	_	_	I-Premise
435	135	_	_	I-Premise
436	,	_	_	I-Premise
437	respectively	_	_	I-Premise
438	,	_	_	I-Premise
439	for	_	_	I-Premise
440	invasive	_	_	I-Premise
441	breast	_	_	I-Premise
442	cancer	_	_	I-Premise
443	(	_	_	I-Premise
444	HR	_	_	I-Premise
445	,	_	_	I-Premise
446	0	_	_	I-Premise
447	.	_	_	I-Premise

448	79	_	_	I-Premise
449	;	_	_	I-Premise
450	95	_	_	I-Premise
451	%	_	_	I-Premise
452	CI	_	_	I-Premise
453	,	_	_	I-Premise
454	0	_	_	I-Premise
455	.	_	_	I-Premise

456	61	_	_	I-Premise
457	-	_	_	I-Premise
458	1	_	_	I-Premise
459	.	_	_	I-Premise

460	02	_	_	I-Premise
461	)	_	_	I-Premise
462	;	_	_	I-Premise
463	cumulatively	_	_	I-Premise
464	,	_	_	I-Premise
465	there	_	_	I-Premise
466	were	_	_	I-Premise
467	168	_	_	I-Premise
468	vs	_	_	I-Premise
469	216	_	_	I-Premise
470	,	_	_	I-Premise
471	respectively	_	_	I-Premise
472	,	_	_	I-Premise
473	cases	_	_	I-Premise
474	of	_	_	I-Premise
475	breast	_	_	I-Premise
476	cancer	_	_	I-Premise
477	diagnosed	_	_	I-Premise
478	(	_	_	I-Premise
479	HR	_	_	I-Premise
480	,	_	_	I-Premise
481	0	_	_	I-Premise
482	.	_	_	I-Premise

483	79	_	_	I-Premise
484	;	_	_	I-Premise
485	95	_	_	I-Premise
486	%	_	_	I-Premise
487	CI	_	_	I-Premise
488	,	_	_	I-Premise
489	0	_	_	I-Premise
490	.	_	_	I-Premise

491	65	_	_	I-Premise
492	-	_	_	I-Premise
493	0	_	_	I-Premise
494	.	_	_	I-Premise

495	97	_	_	I-Premise
496	)	_	_	I-Premise
497	.	_	_	I-Premise

498	Results	_	_	O
499	for	_	_	O
500	other	_	_	O
501	outcomes	_	_	O
502	were	_	_	O
503	similar	_	_	O
504	to	_	_	O
505	CEE	_	_	O
506	plus	_	_	O
507	MPA	_	_	O
508	.	_	_	O

509	Neither	_	_	O
510	regimen	_	_	O
511	affected	_	_	O
512	all	_	_	O
513	-	_	_	O
514	cause	_	_	O
515	mortality	_	_	O
516	.	_	_	O

517	For	_	_	B-Premise
518	CEE	_	_	I-Premise
519	alone	_	_	I-Premise
520	,	_	_	I-Premise
521	younger	_	_	I-Premise
522	women	_	_	I-Premise
523	(	_	_	I-Premise
524	aged	_	_	I-Premise
525	50	_	_	I-Premise
526	-	_	_	I-Premise
527	59	_	_	I-Premise
528	years	_	_	I-Premise
529	)	_	_	I-Premise
530	had	_	_	I-Premise
531	more	_	_	I-Premise
532	favorable	_	_	I-Premise
533	results	_	_	I-Premise
534	for	_	_	I-Premise
535	all	_	_	I-Premise
536	-	_	_	I-Premise
537	cause	_	_	I-Premise
538	mortality	_	_	I-Premise
539	,	_	_	I-Premise
540	myocardial	_	_	I-Premise
541	infarction	_	_	I-Premise
542	,	_	_	I-Premise
543	and	_	_	I-Premise
544	the	_	_	I-Premise
545	global	_	_	I-Premise
546	index	_	_	I-Premise
547	(	_	_	I-Premise
548	nominal	_	_	I-Premise
549	P	_	_	I-Premise
550	<	_	_	I-Premise
551	.	_	_	I-Premise

552	05	_	_	I-Premise
553	for	_	_	I-Premise
554	trend	_	_	I-Premise
555	by	_	_	I-Premise
556	age	_	_	I-Premise
557	)	_	_	I-Premise
558	.	_	_	I-Premise

559	Absolute	_	_	B-Premise
560	risks	_	_	I-Premise
561	of	_	_	I-Premise
562	adverse	_	_	I-Premise
563	events	_	_	I-Premise
564	(	_	_	I-Premise
565	measured	_	_	I-Premise
566	by	_	_	I-Premise
567	the	_	_	I-Premise
568	global	_	_	I-Premise
569	index	_	_	I-Premise
570	)	_	_	I-Premise
571	per	_	_	I-Premise
572	10	_	_	I-Premise
573	,	_	_	I-Premise
574	000	_	_	I-Premise
575	women	_	_	I-Premise
576	annually	_	_	I-Premise
577	taking	_	_	I-Premise
578	CEE	_	_	I-Premise
579	plus	_	_	I-Premise
580	MPA	_	_	I-Premise
581	ranged	_	_	I-Premise
582	from	_	_	I-Premise
583	12	_	_	I-Premise
584	excess	_	_	I-Premise
585	cases	_	_	I-Premise
586	for	_	_	I-Premise
587	ages	_	_	I-Premise
588	of	_	_	I-Premise
589	50	_	_	I-Premise
590	-	_	_	I-Premise
591	59	_	_	I-Premise
592	years	_	_	I-Premise
593	to	_	_	I-Premise
594	38	_	_	I-Premise
595	for	_	_	I-Premise
596	ages	_	_	I-Premise
597	of	_	_	I-Premise
598	70	_	_	I-Premise
599	-	_	_	I-Premise
600	79	_	_	I-Premise
601	years	_	_	I-Premise
602	;	_	_	I-Premise
603	for	_	_	I-Premise
604	women	_	_	I-Premise
605	taking	_	_	I-Premise
606	CEE	_	_	I-Premise
607	alone	_	_	I-Premise
608	,	_	_	I-Premise
609	from	_	_	I-Premise
610	19	_	_	I-Premise
611	fewer	_	_	I-Premise
612	cases	_	_	I-Premise
613	for	_	_	I-Premise
614	ages	_	_	I-Premise
615	of	_	_	I-Premise
616	50	_	_	I-Premise
617	-	_	_	I-Premise
618	59	_	_	I-Premise
619	years	_	_	I-Premise
620	to	_	_	I-Premise
621	51	_	_	I-Premise
622	excess	_	_	I-Premise
623	cases	_	_	I-Premise
624	for	_	_	I-Premise
625	ages	_	_	I-Premise
626	of	_	_	I-Premise
627	70	_	_	I-Premise
628	-	_	_	I-Premise
629	79	_	_	I-Premise
630	years	_	_	I-Premise
631	.	_	_	I-Premise

632	Quality	_	_	O
633	-	_	_	O
634	of	_	_	O
635	-	_	_	O
636	life	_	_	O
637	outcomes	_	_	O
638	had	_	_	O
639	mixed	_	_	O
640	results	_	_	O
641	in	_	_	O
642	both	_	_	O
643	trials	_	_	O
644	.	_	_	O

645	Menopausal	_	_	B-Claim
646	hormone	_	_	I-Claim
647	therapy	_	_	I-Claim
648	has	_	_	I-Claim
649	a	_	_	I-Claim
650	complex	_	_	I-Claim
651	pattern	_	_	I-Claim
652	of	_	_	I-Claim
653	risks	_	_	I-Claim
654	and	_	_	I-Claim
655	benefits	_	_	I-Claim
656	.	_	_	I-Claim

657	Findings	_	_	B-Claim
658	from	_	_	I-Claim
659	the	_	_	I-Claim
660	intervention	_	_	I-Claim
661	and	_	_	I-Claim
662	extended	_	_	I-Claim
663	postintervention	_	_	I-Claim
664	follow	_	_	I-Claim
665	-	_	_	I-Claim
666	up	_	_	I-Claim
667	of	_	_	I-Claim
668	the	_	_	I-Claim
669	2	_	_	I-Claim
670	WHI	_	_	I-Claim
671	hormone	_	_	I-Claim
672	therapy	_	_	I-Claim
673	trials	_	_	I-Claim
674	do	_	_	I-Claim
675	not	_	_	I-Claim
676	support	_	_	I-Claim
677	use	_	_	I-Claim
678	of	_	_	I-Claim
679	this	_	_	I-Claim
680	therapy	_	_	I-Claim
681	for	_	_	I-Claim
682	chronic	_	_	I-Claim
683	disease	_	_	I-Claim
684	prevention	_	_	I-Claim
685	,	_	_	I-Claim
686	although	_	_	B-Claim
687	it	_	_	I-Claim
688	is	_	_	I-Claim
689	appropriate	_	_	I-Claim
690	for	_	_	I-Claim
691	symptom	_	_	I-Claim
692	management	_	_	I-Claim
693	in	_	_	I-Claim
694	some	_	_	I-Claim
695	women	_	_	I-Claim
696	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	two	_	_	O
6	doses	_	_	O
7	of	_	_	O
8	megestrol	_	_	O
9	acetate	_	_	O
10	(	_	_	O
11	MA	_	_	O
12	)	_	_	O
13	compared	_	_	O
14	with	_	_	O
15	placebo	_	_	O
16	on	_	_	O
17	quality	_	_	O
18	of	_	_	O
19	life	_	_	O
20	(	_	_	O
21	QoL	_	_	O
22	)	_	_	O
23	and	_	_	O
24	nutritional	_	_	O
25	status	_	_	O
26	(	_	_	O
27	NS	_	_	O
28	)	_	_	O
29	in	_	_	O
30	patients	_	_	O
31	with	_	_	O
32	advanced	_	_	O
33	endocrine	_	_	O
34	-	_	_	O
35	insensitive	_	_	O
36	cancer	_	_	O
37	.	_	_	O

38	Two	_	_	O
39	hundred	_	_	O
40	forty	_	_	O
41	patients	_	_	O
42	were	_	_	O
43	randomised	_	_	O
44	to	_	_	O
45	double	_	_	O
46	-	_	_	O
47	blind	_	_	O
48	MA	_	_	O
49	480	_	_	O
50	mg	_	_	O
51	/	_	_	O
52	day	_	_	O
53	,	_	_	O
54	MA	_	_	O
55	160	_	_	O
56	mg	_	_	O
57	/	_	_	O
58	day	_	_	O
59	,	_	_	O
60	or	_	_	O
61	matching	_	_	O
62	placebo	_	_	O
63	for	_	_	O
64	12	_	_	O
65	weeks	_	_	O
66	.	_	_	O

67	Nutritional	_	_	O
68	status	_	_	O
69	(	_	_	O
70	including	_	_	O
71	weight	_	_	O
72	,	_	_	O
73	skinfold	_	_	O
74	thickness	_	_	O
75	and	_	_	O
76	midarm	_	_	O
77	circumference	_	_	O
78	)	_	_	O
79	and	_	_	O
80	QoL	_	_	O
81	(	_	_	O
82	using	_	_	O
83	6	_	_	O
84	linear	_	_	O
85	analogue	_	_	O
86	self	_	_	O
87	-	_	_	O
88	assessment	_	_	O
89	(	_	_	O
90	LASA	_	_	O
91	)	_	_	O
92	scales	_	_	O
93	)	_	_	O
94	were	_	_	O
95	assessed	_	_	O
96	at	_	_	O
97	randomisation	_	_	O
98	and	_	_	O
99	after	_	_	O
100	four	_	_	O
101	,	_	_	O
102	eight	_	_	O
103	and	_	_	O
104	12	_	_	O
105	weeks	_	_	O
106	.	_	_	O

107	A	_	_	O
108	QoL	_	_	O
109	ranking	_	_	O
110	incorporating	_	_	O
111	QoL	_	_	O
112	and	_	_	O
113	death	_	_	O
114	was	_	_	O
115	also	_	_	O
116	used	_	_	O
117	ranging	_	_	O
118	from	_	_	O
119	1	_	_	O
120	=	_	_	O
121	dead	_	_	O
122	to	_	_	O
123	5	_	_	O
124	=	_	_	O
125	much	_	_	O
126	better	_	_	O
127	QoL	_	_	O
128	.	_	_	O

129	One	_	_	O
130	hundred	_	_	O
131	seventy	_	_	O
132	-	_	_	O
133	four	_	_	O
134	patients	_	_	O
135	were	_	_	O
136	assessable	_	_	O
137	at	_	_	O
138	week	_	_	O
139	four	_	_	O
140	,	_	_	O
141	136	_	_	O
142	at	_	_	O
143	week	_	_	O
144	eight	_	_	O
145	and	_	_	O
146	103	_	_	O
147	patients	_	_	O
148	at	_	_	O
149	week	_	_	O
150	12	_	_	O
151	.	_	_	O

152	Patients	_	_	B-Premise
153	receiving	_	_	I-Premise
154	MA	_	_	I-Premise
155	reported	_	_	I-Premise
156	substantially	_	_	I-Premise
157	better	_	_	I-Premise
158	appetite	_	_	I-Premise
159	(	_	_	I-Premise
160	P	_	_	I-Premise
161	=	_	_	I-Premise
162	0	_	_	I-Premise
163	.	_	_	I-Premise

164	001	_	_	I-Premise
165	)	_	_	I-Premise
166	,	_	_	I-Premise
167	mood	_	_	I-Premise
168	(	_	_	I-Premise
169	P	_	_	I-Premise
170	=	_	_	I-Premise
171	0	_	_	I-Premise
172	.	_	_	I-Premise

173	001	_	_	I-Premise
174	)	_	_	I-Premise
175	and	_	_	I-Premise
176	overall	_	_	I-Premise
177	quality	_	_	I-Premise
178	of	_	_	I-Premise
179	life	_	_	I-Premise
180	(	_	_	I-Premise
181	P	_	_	I-Premise
182	<	_	_	I-Premise
183	0	_	_	I-Premise
184	.	_	_	I-Premise

185	001	_	_	I-Premise
186	)	_	_	I-Premise
187	,	_	_	I-Premise
188	and	_	_	I-Premise
189	possibly	_	_	I-Premise
190	less	_	_	I-Premise
191	nausea	_	_	I-Premise
192	and	_	_	I-Premise
193	vomiting	_	_	I-Premise
194	(	_	_	I-Premise
195	P	_	_	I-Premise
196	=	_	_	I-Premise
197	0	_	_	I-Premise
198	.	_	_	I-Premise

199	08	_	_	I-Premise
200	)	_	_	I-Premise
201	than	_	_	I-Premise
202	patients	_	_	I-Premise
203	receiving	_	_	I-Premise
204	placebo	_	_	I-Premise
205	,	_	_	I-Premise
206	based	_	_	I-Premise
207	on	_	_	I-Premise
208	a	_	_	I-Premise
209	test	_	_	I-Premise
210	for	_	_	I-Premise
211	trend	_	_	I-Premise
212	.	_	_	I-Premise

213	A	_	_	B-Premise
214	larger	_	_	I-Premise
215	benefit	_	_	I-Premise
216	was	_	_	I-Premise
217	seen	_	_	I-Premise
218	with	_	_	I-Premise
219	the	_	_	I-Premise
220	higher	_	_	I-Premise
221	dose	_	_	I-Premise
222	which	_	_	I-Premise
223	(	_	_	I-Premise
224	unlike	_	_	I-Premise
225	the	_	_	I-Premise
226	lower	_	_	I-Premise
227	dose	_	_	I-Premise
228	)	_	_	I-Premise
229	was	_	_	I-Premise
230	significantly	_	_	I-Premise
231	better	_	_	I-Premise
232	in	_	_	I-Premise
233	pairwise	_	_	I-Premise
234	comparisons	_	_	I-Premise
235	with	_	_	I-Premise
236	placebo	_	_	I-Premise
237	for	_	_	I-Premise
238	appetite	_	_	I-Premise
239	,	_	_	I-Premise
240	mood	_	_	I-Premise
241	and	_	_	I-Premise
242	overall	_	_	I-Premise
243	QoL	_	_	I-Premise
244	(	_	_	I-Premise
245	each	_	_	I-Premise
246	P	_	_	I-Premise
247	<	_	_	I-Premise
248	or	_	_	I-Premise
249	=	_	_	I-Premise
250	0	_	_	I-Premise
251	.	_	_	I-Premise

252	001	_	_	I-Premise
253	)	_	_	I-Premise
254	.	_	_	I-Premise

255	Despite	_	_	B-Premise
256	some	_	_	I-Premise
257	missing	_	_	I-Premise
258	data	_	_	I-Premise
259	on	_	_	I-Premise
260	QoL	_	_	I-Premise
261	scores	_	_	I-Premise
262	,	_	_	I-Premise
263	QoL	_	_	I-Premise
264	ranking	_	_	I-Premise
265	was	_	_	I-Premise
266	available	_	_	I-Premise
267	on	_	_	I-Premise
268	227	_	_	I-Premise
269	(	_	_	I-Premise
270	95	_	_	I-Premise
271	%	_	_	I-Premise
272	)	_	_	I-Premise
273	of	_	_	I-Premise
274	patients	_	_	I-Premise
275	with	_	_	I-Premise
276	significantly	_	_	I-Premise
277	higher	_	_	I-Premise
278	QoL	_	_	I-Premise
279	ranking	_	_	I-Premise
280	associated	_	_	I-Premise
281	with	_	_	I-Premise
282	MA	_	_	I-Premise
283	(	_	_	I-Premise
284	P	_	_	I-Premise
285	=	_	_	I-Premise
286	0	_	_	I-Premise
287	.	_	_	I-Premise

288	002	_	_	I-Premise
289	)	_	_	I-Premise
290	.	_	_	I-Premise

291	Improvements	_	_	B-Premise
292	in	_	_	I-Premise
293	QoL	_	_	I-Premise
294	occurred	_	_	I-Premise
295	early	_	_	I-Premise
296	within	_	_	I-Premise
297	four	_	_	I-Premise
298	weeks	_	_	I-Premise
299	and	_	_	I-Premise
300	were	_	_	I-Premise
301	sustained	_	_	I-Premise
302	.	_	_	I-Premise

303	No	_	_	B-Premise
304	statistically	_	_	I-Premise
305	significant	_	_	I-Premise
306	differences	_	_	I-Premise
307	were	_	_	I-Premise
308	observed	_	_	I-Premise
309	in	_	_	I-Premise
310	NS	_	_	I-Premise
311	measurements	_	_	I-Premise
312	,	_	_	I-Premise
313	including	_	_	I-Premise
314	weight	_	_	I-Premise
315	(	_	_	I-Premise
316	P	_	_	I-Premise
317	=	_	_	I-Premise
318	0	_	_	I-Premise
319	.	_	_	I-Premise

320	29	_	_	I-Premise
321	)	_	_	I-Premise
322	.	_	_	I-Premise

323	Side	_	_	B-Premise
324	effects	_	_	I-Premise
325	of	_	_	I-Premise
326	therapy	_	_	I-Premise
327	were	_	_	I-Premise
328	minor	_	_	I-Premise
329	and	_	_	I-Premise
330	did	_	_	I-Premise
331	not	_	_	I-Premise
332	differ	_	_	I-Premise
333	significantly	_	_	I-Premise
334	across	_	_	I-Premise
335	treatments	_	_	I-Premise
336	.	_	_	I-Premise

337	Megestrol	_	_	B-Claim
338	acetate	_	_	I-Claim
339	given	_	_	I-Claim
340	at	_	_	I-Claim
341	480	_	_	I-Claim
342	mg	_	_	I-Claim
343	/	_	_	I-Claim
344	day	_	_	I-Claim
345	is	_	_	I-Claim
346	useful	_	_	I-Claim
347	palliation	_	_	I-Claim
348	in	_	_	I-Claim
349	patients	_	_	I-Claim
350	with	_	_	I-Claim
351	endocrine	_	_	I-Claim
352	-	_	_	I-Claim
353	insensitive	_	_	I-Claim
354	advanced	_	_	I-Claim
355	cancer	_	_	I-Claim
356	.	_	_	I-Claim

357	It	_	_	B-Claim
358	improves	_	_	I-Claim
359	appetite	_	_	I-Claim
360	,	_	_	I-Claim
361	mood	_	_	I-Claim
362	and	_	_	I-Claim
363	overall	_	_	I-Claim
364	quality	_	_	I-Claim
365	of	_	_	I-Claim
366	life	_	_	I-Claim
367	in	_	_	I-Claim
368	these	_	_	I-Claim
369	patients	_	_	I-Claim
370	,	_	_	I-Claim
371	although	_	_	B-Claim
372	not	_	_	I-Claim
373	through	_	_	I-Claim
374	a	_	_	I-Claim
375	direct	_	_	I-Claim
376	effect	_	_	I-Claim
377	on	_	_	I-Claim
378	nutritional	_	_	I-Claim
379	status	_	_	I-Claim
380	.	_	_	I-Claim


0	SIR	_	_	O
1	-	_	_	O
2	Spheres	_	_	O
3	are	_	_	O
4	radioactive	_	_	O
5	yttrium90	_	_	O
6	microspheres	_	_	O
7	(	_	_	O
8	SIR	_	_	O
9	-	_	_	O
10	Spheres	_	_	O
11	,	_	_	O
12	Sirtex	_	_	O
13	Medical	_	_	O
14	Limited	_	_	O
15	,	_	_	O
16	Australia	_	_	O
17	)	_	_	O
18	used	_	_	O
19	to	_	_	O
20	selectively	_	_	O
21	target	_	_	O
22	high	_	_	O
23	levels	_	_	O
24	of	_	_	O
25	ionising	_	_	O
26	radiation	_	_	O
27	to	_	_	O
28	tumors	_	_	O
29	within	_	_	O
30	the	_	_	O
31	liver	_	_	O
32	.	_	_	O

33	This	_	_	O
34	trial	_	_	O
35	was	_	_	O
36	designed	_	_	O
37	to	_	_	O
38	measure	_	_	O
39	any	_	_	O
40	increased	_	_	O
41	patient	_	_	O
42	benefit	_	_	O
43	by	_	_	O
44	adding	_	_	O
45	a	_	_	O
46	single	_	_	O
47	administration	_	_	O
48	of	_	_	O
49	SIR	_	_	O
50	-	_	_	O
51	Spheres	_	_	O
52	to	_	_	O
53	a	_	_	O
54	regimen	_	_	O
55	of	_	_	O
56	regional	_	_	O
57	hepatic	_	_	O
58	artery	_	_	O
59	chemotherapy	_	_	O
60	(	_	_	O
61	HAC	_	_	O
62	)	_	_	O
63	administered	_	_	O
64	as	_	_	O
65	a	_	_	O
66	12	_	_	O
67	day	_	_	O
68	infusion	_	_	O
69	of	_	_	O
70	floxuridine	_	_	O
71	and	_	_	O
72	repeated	_	_	O
73	at	_	_	O
74	monthly	_	_	O
75	intervals	_	_	O
76	,	_	_	O
77	vs	_	_	O
78	.	_	_	O

79	the	_	_	O
80	same	_	_	O
81	chemotherapy	_	_	O
82	alone	_	_	O
83	.	_	_	O

84	A	_	_	O
85	phase	_	_	O
86	III	_	_	O
87	randomised	_	_	O
88	clinical	_	_	O
89	trial	_	_	O
90	entering	_	_	O
91	74	_	_	O
92	patients	_	_	O
93	was	_	_	O
94	undertaken	_	_	O
95	on	_	_	O
96	patients	_	_	O
97	with	_	_	O
98	bi	_	_	O
99	-	_	_	O
100	lobar	_	_	O
101	non	_	_	O
102	-	_	_	O
103	resectable	_	_	O
104	liver	_	_	O
105	metastases	_	_	O
106	from	_	_	O
107	primary	_	_	O
108	adenocarcinoma	_	_	O
109	of	_	_	O
110	the	_	_	O
111	large	_	_	O
112	bowel	_	_	O
113	.	_	_	O

114	Patient	_	_	O
115	benefit	_	_	O
116	criteria	_	_	O
117	assessed	_	_	O
118	in	_	_	O
119	the	_	_	O
120	trial	_	_	O
121	were	_	_	O
122	tumor	_	_	O
123	response	_	_	O
124	,	_	_	O
125	time	_	_	O
126	to	_	_	O
127	disease	_	_	O
128	progression	_	_	O
129	in	_	_	O
130	the	_	_	O
131	liver	_	_	O
132	,	_	_	O
133	overall	_	_	O
134	survival	_	_	O
135	,	_	_	O
136	quality	_	_	O
137	of	_	_	O
138	life	_	_	O
139	,	_	_	O
140	and	_	_	O
141	treatment	_	_	O
142	related	_	_	O
143	toxicity	_	_	O
144	.	_	_	O

145	Tumor	_	_	O
146	response	_	_	O
147	was	_	_	O
148	measured	_	_	O
149	by	_	_	O
150	serial	_	_	O
151	changes	_	_	O
152	in	_	_	O
153	both	_	_	O
154	cross	_	_	O
155	-	_	_	O
156	sectional	_	_	O
157	tumor	_	_	O
158	areas	_	_	O
159	and	_	_	O
160	total	_	_	O
161	tumor	_	_	O
162	volumes	_	_	O
163	,	_	_	O
164	provided	_	_	O
165	any	_	_	O
166	response	_	_	O
167	lasted	_	_	O
168	not	_	_	O
169	less	_	_	O
170	than	_	_	O
171	three	_	_	O
172	months	_	_	O
173	as	_	_	O
174	well	_	_	O
175	as	_	_	O
176	changes	_	_	O
177	in	_	_	O
178	serum	_	_	O
179	carcino	_	_	O
180	-	_	_	O
181	embryonic	_	_	O
182	antigen	_	_	O
183	(	_	_	O
184	CEA	_	_	O
185	)	_	_	O
186	.	_	_	O

187	The	_	_	B-Premise
188	partial	_	_	I-Premise
189	and	_	_	I-Premise
190	complete	_	_	I-Premise
191	response	_	_	I-Premise
192	rate	_	_	I-Premise
193	(	_	_	I-Premise
194	PR	_	_	I-Premise
195	+	_	_	I-Premise
196	CR	_	_	I-Premise
197	)	_	_	I-Premise
198	was	_	_	I-Premise
199	significantly	_	_	I-Premise
200	greater	_	_	I-Premise
201	for	_	_	I-Premise
202	patients	_	_	I-Premise
203	receiving	_	_	I-Premise
204	SIR	_	_	I-Premise
205	-	_	_	I-Premise
206	Spheres	_	_	I-Premise
207	when	_	_	I-Premise
208	measured	_	_	I-Premise
209	by	_	_	I-Premise
210	tumor	_	_	I-Premise
211	areas	_	_	I-Premise
212	(	_	_	I-Premise
213	44	_	_	I-Premise
214	%	_	_	I-Premise
215	)	_	_	I-Premise
216	vs	_	_	I-Premise
217	.	_	_	I-Premise

218	17	_	_	I-Premise
219	.	_	_	I-Premise

220	6	_	_	I-Premise
221	%	_	_	I-Premise
222	,	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	0	_	_	I-Premise
226	.	_	_	I-Premise

227	01	_	_	I-Premise
228	)	_	_	I-Premise
229	tumor	_	_	I-Premise
230	volumes	_	_	I-Premise
231	(	_	_	I-Premise
232	50	_	_	I-Premise
233	%	_	_	I-Premise
234	vs	_	_	I-Premise
235	.	_	_	I-Premise

236	24	_	_	I-Premise
237	%	_	_	I-Premise
238	,	_	_	I-Premise
239	P	_	_	I-Premise
240	=	_	_	I-Premise
241	0	_	_	I-Premise
242	.	_	_	I-Premise

243	03	_	_	I-Premise
244	)	_	_	I-Premise
245	and	_	_	I-Premise
246	CEA	_	_	I-Premise
247	(	_	_	I-Premise
248	72	_	_	I-Premise
249	%	_	_	I-Premise
250	vs	_	_	I-Premise
251	.	_	_	I-Premise

252	47	_	_	I-Premise
253	%	_	_	I-Premise
254	,	_	_	I-Premise
255	P	_	_	I-Premise
256	=	_	_	I-Premise
257	0	_	_	I-Premise
258	.	_	_	I-Premise

259	004	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	The	_	_	B-Premise
263	median	_	_	I-Premise
264	time	_	_	I-Premise
265	to	_	_	I-Premise
266	disease	_	_	I-Premise
267	progression	_	_	I-Premise
268	in	_	_	I-Premise
269	the	_	_	I-Premise
270	liver	_	_	I-Premise
271	was	_	_	I-Premise
272	significantly	_	_	I-Premise
273	longer	_	_	I-Premise
274	for	_	_	I-Premise
275	patients	_	_	I-Premise
276	receiving	_	_	I-Premise
277	SIR	_	_	I-Premise
278	-	_	_	I-Premise
279	Spheres	_	_	I-Premise
280	in	_	_	I-Premise
281	comparison	_	_	I-Premise
282	to	_	_	I-Premise
283	patients	_	_	I-Premise
284	receiving	_	_	I-Premise
285	HAC	_	_	I-Premise
286	alone	_	_	I-Premise
287	when	_	_	I-Premise
288	measured	_	_	I-Premise
289	by	_	_	I-Premise
290	either	_	_	I-Premise
291	tumor	_	_	I-Premise
292	areas	_	_	I-Premise
293	(	_	_	I-Premise
294	9	_	_	I-Premise
295	.	_	_	I-Premise

296	7	_	_	I-Premise
297	vs	_	_	I-Premise
298	.	_	_	I-Premise

299	15	_	_	I-Premise
300	.	_	_	I-Premise

301	9	_	_	I-Premise
302	months	_	_	I-Premise
303	,	_	_	I-Premise
304	P	_	_	I-Premise
305	=	_	_	I-Premise
306	0	_	_	I-Premise
307	.	_	_	I-Premise

308	001	_	_	I-Premise
309	)	_	_	I-Premise
310	,	_	_	I-Premise
311	tumor	_	_	I-Premise
312	volumes	_	_	I-Premise
313	(	_	_	I-Premise
314	7	_	_	I-Premise
315	.	_	_	I-Premise

316	6	_	_	I-Premise
317	vs	_	_	I-Premise
318	.	_	_	I-Premise

319	12	_	_	I-Premise
320	.	_	_	I-Premise

321	0	_	_	I-Premise
322	months	_	_	I-Premise
323	,	_	_	I-Premise
324	P	_	_	I-Premise
325	=	_	_	I-Premise
326	0	_	_	I-Premise
327	.	_	_	I-Premise

328	04	_	_	I-Premise
329	)	_	_	I-Premise
330	or	_	_	I-Premise
331	CEA	_	_	I-Premise
332	(	_	_	I-Premise
333	5	_	_	I-Premise
334	.	_	_	I-Premise

335	7	_	_	I-Premise
336	vs	_	_	I-Premise
337	.	_	_	I-Premise

338	6	_	_	I-Premise
339	.	_	_	I-Premise

340	7	_	_	I-Premise
341	months	_	_	I-Premise
342	,	_	_	I-Premise
343	P	_	_	I-Premise
344	=	_	_	I-Premise
345	0	_	_	I-Premise
346	.	_	_	I-Premise

347	06	_	_	I-Premise
348	)	_	_	I-Premise
349	.	_	_	I-Premise

350	The	_	_	B-Premise
351	one	_	_	I-Premise
352	,	_	_	I-Premise
353	two	_	_	I-Premise
354	,	_	_	I-Premise
355	three	_	_	I-Premise
356	and	_	_	I-Premise
357	five	_	_	I-Premise
358	-	_	_	I-Premise
359	year	_	_	I-Premise
360	survival	_	_	I-Premise
361	for	_	_	I-Premise
362	patients	_	_	I-Premise
363	receiving	_	_	I-Premise
364	SIR	_	_	I-Premise
365	-	_	_	I-Premise
366	Spheres	_	_	I-Premise
367	was	_	_	I-Premise
368	72	_	_	I-Premise
369	%	_	_	I-Premise
370	,	_	_	I-Premise
371	39	_	_	I-Premise
372	%	_	_	I-Premise
373	,	_	_	I-Premise
374	17	_	_	I-Premise
375	%	_	_	I-Premise
376	and	_	_	I-Premise
377	3	_	_	I-Premise
378	.	_	_	I-Premise

379	5	_	_	I-Premise
380	%	_	_	I-Premise
381	,	_	_	I-Premise
382	compared	_	_	I-Premise
383	to	_	_	I-Premise
384	68	_	_	I-Premise
385	%	_	_	I-Premise
386	,	_	_	I-Premise
387	29	_	_	I-Premise
388	%	_	_	I-Premise
389	,	_	_	I-Premise
390	6	_	_	I-Premise
391	.	_	_	I-Premise

392	5	_	_	I-Premise
393	%	_	_	I-Premise
394	and	_	_	I-Premise
395	0	_	_	I-Premise
396	%	_	_	I-Premise
397	for	_	_	I-Premise
398	HAC	_	_	I-Premise
399	alone	_	_	I-Premise
400	.	_	_	I-Premise

401	Cox	_	_	B-Premise
402	regression	_	_	I-Premise
403	analysis	_	_	I-Premise
404	suggests	_	_	I-Premise
405	an	_	_	I-Premise
406	improvement	_	_	I-Premise
407	in	_	_	I-Premise
408	survival	_	_	I-Premise
409	for	_	_	I-Premise
410	patients	_	_	I-Premise
411	treated	_	_	I-Premise
412	with	_	_	I-Premise
413	SIR	_	_	I-Premise
414	-	_	_	I-Premise
415	Spheres	_	_	I-Premise
416	who	_	_	I-Premise
417	survive	_	_	I-Premise
418	more	_	_	I-Premise
419	than	_	_	I-Premise
420	15	_	_	I-Premise
421	months	_	_	I-Premise
422	(	_	_	I-Premise
423	P	_	_	I-Premise
424	=	_	_	I-Premise
425	0	_	_	I-Premise
426	.	_	_	I-Premise

427	06	_	_	I-Premise
428	)	_	_	I-Premise
429	.	_	_	I-Premise

430	There	_	_	B-Premise
431	was	_	_	I-Premise
432	no	_	_	I-Premise
433	increase	_	_	I-Premise
434	in	_	_	I-Premise
435	grade	_	_	I-Premise
436	3	_	_	I-Premise
437	-	_	_	I-Premise
438	4	_	_	I-Premise
439	treatment	_	_	I-Premise
440	related	_	_	I-Premise
441	toxicity	_	_	I-Premise
442	and	_	_	I-Premise
443	no	_	_	I-Premise
444	loss	_	_	I-Premise
445	of	_	_	I-Premise
446	quality	_	_	I-Premise
447	of	_	_	I-Premise
448	life	_	_	I-Premise
449	for	_	_	I-Premise
450	patients	_	_	I-Premise
451	receiving	_	_	I-Premise
452	SIR	_	_	I-Premise
453	-	_	_	I-Premise
454	Spheres	_	_	I-Premise
455	in	_	_	I-Premise
456	comparison	_	_	I-Premise
457	to	_	_	I-Premise
458	patients	_	_	I-Premise
459	receiving	_	_	I-Premise
460	HAC	_	_	I-Premise
461	alone	_	_	I-Premise
462	.	_	_	I-Premise

463	The	_	_	B-Claim
464	combination	_	_	I-Claim
465	of	_	_	I-Claim
466	a	_	_	I-Claim
467	single	_	_	I-Claim
468	injection	_	_	I-Claim
469	of	_	_	I-Claim
470	SIR	_	_	I-Claim
471	-	_	_	I-Claim
472	Spheres	_	_	I-Claim
473	plus	_	_	I-Claim
474	HAC	_	_	I-Claim
475	is	_	_	I-Claim
476	substantially	_	_	I-Claim
477	more	_	_	I-Claim
478	effective	_	_	I-Claim
479	in	_	_	I-Claim
480	increasing	_	_	I-Claim
481	tumor	_	_	I-Claim
482	responses	_	_	I-Claim
483	and	_	_	I-Claim
484	progression	_	_	I-Claim
485	free	_	_	I-Claim
486	survival	_	_	I-Claim
487	than	_	_	I-Claim
488	the	_	_	I-Claim
489	same	_	_	I-Claim
490	regimen	_	_	I-Claim
491	of	_	_	I-Claim
492	HAC	_	_	I-Claim
493	alone	_	_	I-Claim
494	.	_	_	I-Claim


